file,set_id,spl_version,title,ingredient_rx_cui,ingredient_name,pt_meddra_id,pt_meddra_term,cohort_id,condition_name,positive_controls,label,cohort_id_right,drug_concept_id,affect,reference
./data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,f47d4365-40a8-445b-99cd-49edad6a8ffc,15,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only",35827,ketorolac,10069339,acute kidney injury,500000401,acute kidney injury,6,1,500000401,1136980,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_84428af5-ab7d-4822-a40e-3cf6e3fb9fee.json,84428af5-ab7d-4822-a40e-3cf6e3fb9fee,9,"Hydrochlorothiazide Capsules USP, 12.5 mg",5487,hydrochlorothiazide,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,974166,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_0a2a1310-0a57-4fb0-a2e6-6fdb21cda9c7.json,0a2a1310-0a57-4fb0-a2e6-6fdb21cda9c7,7,"Buspirone Hydrochloride Tablets, USP",1827,buspirone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231215_8ded0773-3aec-4e89-9836-d22a5a84abf0.json,8ded0773-3aec-4e89-9836-d22a5a84abf0,17,Quinapril Tablets USP,35208,quinapril,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_f9feb925-e1b8-41bc-b9c5-89198f07c0e9.json,f9feb925-e1b8-41bc-b9c5-89198f07c0e9,11,"Caffeine Citrate Injection, USP",1886,caffeine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011",25480,gabapentin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,7652adc6-1aad-4422-b85c-0c6b11c23b73,7,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993",25480,gabapentin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_7d655d6d-01da-488c-bd4e-c7fbe0ace38c.json,7d655d6d-01da-488c-bd4e-c7fbe0ace38c,5,"These highlights do not include all the information needed to use TESTOSTERONE GEL, 1% safely and effectively.  See full prescribing information for TESTOSTERONE GEL, 1%.

 TESTOSTERONE gel 1%, for topical use, CIII Initial U.S. Approval: 1953",10379,testosterone,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,56d64558-1fad-420e-8fcd-7103cd073127,1,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998",140587,celecoxib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,56d64558-1fad-420e-8fcd-7103cd073127,1,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998",140587,celecoxib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987",2551,ciprofloxacin,10019692,hepatic necrosis,500000301,acute liver injury,15,1,500000301,1797513,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987",2551,ciprofloxacin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987",2551,ciprofloxacin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_13abdafb-71a8-40a1-ba5a-7c2b2573e53e.json,13abdafb-71a8-40a1-ba5a-7c2b2573e53e,12,"Amitriptyline Hydrochloride Tablets, USP",704,amitriptyline,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,42f49299-7ae5-4d30-86eb-66b739c0e95d,5,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988",29046,lisinopril,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_f34c08e6-fe74-4de3-9e36-a82c3c1c183b.json,f34c08e6-fe74-4de3-9e36-a82c3c1c183b,9,"These highlights do not include all the information needed to use MOXIFLOXACIN TABLETS safely and effectively. See full prescribing information for MOXIFLOXACIN TABLETS.
 MOXIFLOXACIN tablets, for oral use Initial U.S. Approval: 1999",139462,moxifloxacin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,9678a98e-4aab-4d87-b5e1-37c3109e378e,16,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996",57258,tizanidine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,ccd95dfc-9236-4707-a715-6a12c91519ff,6,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976",7258,naproxen,10024690,liver function test abnormal,500000301,acute liver injury,15,1,500000301,1115008,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_b72ca065-6396-41b9-a195-a8819688f471.json,b72ca065-6396-41b9-a195-a8819688f471,9,"These highlights do not include all the information needed to use SPIRONOLACTONE TABLETS safely and effectively. See full prescribing information for SPIRONOLACTONE TABLETS.
 



SPIRONOLACTONE tablets for oral use
 



Initial U.S. Approval: 1960",9997,spironolactone,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_4260d746-bb58-4e10-9ffe-fc414f22b591.json,4260d746-bb58-4e10-9ffe-fc414f22b591,11,"Gemfibrozil Tablets, USP 600 mg",4719,gemfibrozil,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240218_726b1e63-437a-4b3b-b773-3ac47a5c0f38.json,726b1e63-437a-4b3b-b773-3ac47a5c0f38,8,"These highlights do not include all the information needed to use EZETIMIBE TABLETS safely and effectively. See full prescribing information for EZETIMIBE TABLETS.
 EZETIMIBE tablets, for oral use Initial U.S. Approval: 2002",341248,ezetimibe,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240126_1fffe88d-50c8-45cf-ac7c-a62b665c89a8.json,1fffe88d-50c8-45cf-ac7c-a62b665c89a8,16,SULINDAC TABLETS USP,10237,sulindac,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20141007_144067b2-0532-476a-996e-e4a0a9d09b05.json,144067b2-0532-476a-996e-e4a0a9d09b05,1,"These highlights do not include all the information needed to use STRIBILD safely and effectively. See full prescribing information for STRIBILD.
 STRIBILD® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral useInitial U.S. Approval: 2012",300195,tenofovir disoproxil,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_6296e2ed-334c-b9af-e053-2991aa0aae0c.json,6296e2ed-334c-b9af-e053-2991aa0aae0c,5,"Erythromycin Ophthalmic Ointment, USP 0.5% (Sterile)",4053,erythromycin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_56370be6-42a2-4962-acdc-22b7c6e0e7fe.json,56370be6-42a2-4962-acdc-22b7c6e0e7fe,8,"These highlights do not include all the information needed to use ZIPRASIDONE CAPSULES safely and effectively. See full prescribing information for ZIPRASIDONE CAPSULES.


ZIPRASIDONE capsules, for oral use

Initial U.S. Approval: 2001",115698,ziprasidone,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_eb354221-c476-41cb-ad87-52423f81d698.json,eb354221-c476-41cb-ad87-52423f81d698,3,"Cefdinir Capsules, USP
 
Rx only",25037,cefdinir,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240119_00aa81c2-73c7-4bf8-94e9-f644381b631f.json,00aa81c2-73c7-4bf8-94e9-f644381b631f,4,"These highlights do not include all the information needed to use ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES.
 

ESOMEPRAZOLE MAGNESIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989 (omeprazole)",283742,esomeprazole,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_b6b1d427-e19a-4fc1-b518-f58bacc46736.json,b6b1d427-e19a-4fc1-b518-f58bacc46736,8,"Guanfacine Tablets, USP 


Rx only",40114,guanfacine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,113558e6-8b45-cdbd-e063-6394a90ac036,2,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only",24605,etodolac,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1195492,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,"IBUPROFEN Tablets, USP",5640,ibuprofen,10019692,hepatic necrosis,500000301,acute liver injury,15,1,500000301,1177480,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240201_d79a4b28-ef2b-4f0f-baec-002df7d06dd4.json,d79a4b28-ef2b-4f0f-baec-002df7d06dd4,10,Cefaclor Capsules USP,2176,cefaclor,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_09c6c750-ae05-459f-83e8-4a9e4fd85212.json,09c6c750-ae05-459f-83e8-4a9e4fd85212,28,"These highlights do not include all the information needed to use ATORVASTATIN CALCIUM TABLETS safely and effectively. See full prescribing information for ATORVASTATIN CALCIUM TABLETS.
 

ATORVASTATIN CALCIUM tablets, for oral use
 

Initial U.S. Approval: 1996",83367,atorvastatin,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_41c095b6-acd9-4627-a813-bbca7ecafee5.json,41c095b6-acd9-4627-a813-bbca7ecafee5,10,"These highlights do not include all the information needed to use DONEPEZIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for DONEPEZIL HYDROCHLORIDE TABLETS.
 

DONEPEZIL HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1996",135447,donepezil,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_0f672b76-f673-4cba-99d2-818a9e2e6d7f.json,0f672b76-f673-4cba-99d2-818a9e2e6d7f,7,"These highlights do not include all the information needed to use LOSARTAN POTASSIUM TABLETS safely and effectively. see full prescribing information for LOSARTAN POTASSIUM TABLETS.
 



LOSARTAN POTASSIUM tablets, for oral use
 

Initial U.S. Approval: 1995",52175,losartan,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_fedbffa7-087d-4448-85c9-0350a3947080.json,fedbffa7-087d-4448-85c9-0350a3947080,10,"HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use LINEZOLID INJECTION safely and effectively. See full prescribing information for LINEZOLID INJECTION.




LINEZOLID injection, for intravenous use

Initial U.S. Approval: 2000",190376,linezolid,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_bc737938-ae36-460b-a2a8-609f3fe59156.json,bc737938-ae36-460b-a2a8-609f3fe59156,2,"These highlights do not include all the information needed to use VANCOMYCIN HYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for VANCOMYCIN HYDROCHLORIDE CAPSULES.  VANCOMYCIN HYDROCHLORIDE capsules, for oral use Initial U.S. Approval: 1986 To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin hydrochloride capsules and other antibacterial drugs, vancomycin hydrochloride capsules should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.",11124,vancomycin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_11fad602-16c2-4c1f-bdf1-867d95f063ca.json,11fad602-16c2-4c1f-bdf1-867d95f063ca,10,"These highlights do not include all the information needed to use ROSUVASTATIN TABLETS safely and effectively. See full prescribing information for ROSUVASTATIN TABLETS.
 

ROSUVASTATIN tablets, for oral use
 
Initial U.S. Approval: 2003",301542,rosuvastatin,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230713_740a0f37-aa95-4558-b415-be516b8c40a3.json,740a0f37-aa95-4558-b415-be516b8c40a3,2,"Tolmetin Sodium Capsules, USP 400 mg
 Rx only",10636,tolmetin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1102917,1,1
./data/2024_latest_labels/latest_labels_ingredients/20120323_8bc2ddf8-d695-46b3-bf76-9f85ce6027e3.json,8bc2ddf8-d695-46b3-bf76-9f85ce6027e3,4,Ganite® (gallium nitrate injection),1310124,gallium,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,5108ca9c-b307-4cb2-8ea1-6553764f375a,13,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002",321988,escitalopram,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_726daf35-4c03-464f-a814-cc0a715d6031.json,726daf35-4c03-464f-a814-cc0a715d6031,1,"Fluconazole Tablets USP
 
Rx only",4450,fluconazole,10019837,hepatocellular injury,500000301,acute liver injury,3,1,500000301,1754994,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231111_3c52dddd-0457-41cd-99e0-d30d4fd00ec5.json,3c52dddd-0457-41cd-99e0-d30d4fd00ec5,4,"These highlights do not include all the information needed to use SELZENTRY safely and effectively. See full prescribing information for SELZENTRY.
SELZENTRY (maraviroc) tablets, for oral useSELZENTRY (maraviroc) oral solutionInitial U.S. Approval: 2007",620216,maraviroc,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_a26cfa07-14a7-4468-8eed-3529f3d613f4.json,a26cfa07-14a7-4468-8eed-3529f3d613f4,6,"These highlights do not include all the information needed to use EFAVIRENZ CAPSULES safely and effectively. See full prescribing information for EFAVIRENZ CAPSULES.
 EFAVIRENZ capsules for oral use Initial U.S. Approval: 1998",195085,efavirenz,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1738135,1,1
./data/2024_latest_labels/latest_labels_ingredients/20230221_87768fbf-7c63-47da-8925-0316f343d6ef.json,87768fbf-7c63-47da-8925-0316f343d6ef,16,"These highlights do not include all the information needed to use PERINDOPRIL ERBUMINE TABLETS safely and effectively. See full prescribing information for PERINDOPRIL ERBUMINE TABLETS.
 PERINDOPRIL erbumine tablets, for oral use Initial U.S. Approval: 1993",54552,perindopril,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_0be243c6-de02-45dd-8210-cab1bbc8dfa7.json,0be243c6-de02-45dd-8210-cab1bbc8dfa7,28,"These highlights do not include all the information needed to use CLARITHROMYCIN TABLETS safely and effectively. See full prescribing information for CLARITHROMYCIN TABLETS.
 

CLARITHROMYCIN tablets, for oral use
 
Initial U.S. Approval: 1991",21212,clarithromycin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240202_e2e576e6-6181-4178-b989-61d0e795e559.json,e2e576e6-6181-4178-b989-61d0e795e559,13,"These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. 
JANUVIA® (sitagliptin) tablets, for oral useInitial U.S. Approval: 2006",593411,sitagliptin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_c394914b-2334-418e-bf86-9f9100323717.json,c394914b-2334-418e-bf86-9f9100323717,6,KETOCONAZOLE CREAM 2%,6135,ketoconazole,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230912_4031017d-d768-46de-8081-476bcb883f5e.json,4031017d-d768-46de-8081-476bcb883f5e,5,"These highlights do not include all the information needed to use GEMCITABINE INJECTION safely and effectively. See full prescribing information for GEMCITABINE INJECTION.
 



GEMCITABINE injection, for intravenous use
 

Initial U.S. Approval: 1996",12574,gemcitabine,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1314924,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231117_8512d0c6-db4e-4673-b3b4-28975c18413f.json,8512d0c6-db4e-4673-b3b4-28975c18413f,12,"",32385,olsalazine,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_53bdb79c-c4cf-4818-b1f0-225e67a14536.json,53bdb79c-c4cf-4818-b1f0-225e67a14536,24,"These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
 
CLOZAPINE tablets, for oral use
 
Initial U.S. Approval: 1989",2626,clozapine,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,800878,0,1
./data/2024_latest_labels/latest_labels_ingredients/20240220_e2dbbdf9-ddfd-4d6d-ad42-6e658969f11e.json,e2dbbdf9-ddfd-4d6d-ad42-6e658969f11e,1,"Pyrazinamide Tablets, USP
  
Rx Only
  
8478901/0923F",8987,pyrazinamide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20160806_77d619f8-05a3-408a-a6f8-1511694b6a24.json,77d619f8-05a3-408a-a6f8-1511694b6a24,3,TICLOPIDINE HYDROCHLORIDE TABLETS USP 0154 Rx only,10594,ticlopidine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,9803db35-2600-4f42-80c1-43216fd1ba3d,4,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004",82819,acamprosate,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_22477d77-3369-43cf-a444-dfc7ea69cacf.json,22477d77-3369-43cf-a444-dfc7ea69cacf,2,"BACLOFEN TABLETS USP

Rx only",1292,baclofen,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_f299b2d2-86ed-4fb8-822e-65455a0bb75a.json,f299b2d2-86ed-4fb8-822e-65455a0bb75a,6,"These highlights do not include all the information needed to use OXALIPLATIN INJECTION safely and effectively. See full prescribing information for OXALIPLATIN INJECTION.OXALIPLATIN injection, for intravenous useInitial U.S. Approval: 2002",32592,oxaliplatin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240117_852f013f-6759-4438-83c1-8ff48133dc85.json,852f013f-6759-4438-83c1-8ff48133dc85,4,"HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALBENDAZOLE TABLETS safely and effectively. See full prescribing information for ALBENDAZOLE TABLETS.  ALBENDAZOLE tablets, for oral use  Initial U.S. Approval: 1996",430,albendazole,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_8e99d6fe-42ab-44c1-8b51-e4ac7406dbe4.json,8e99d6fe-42ab-44c1-8b51-e4ac7406dbe4,2,"Oxacillin for Injection, USP
 

For Intramuscular or Intravenous Injection",7773,oxacillin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_8e99d6fe-42ab-44c1-8b51-e4ac7406dbe4.json,8e99d6fe-42ab-44c1-8b51-e4ac7406dbe4,2,"Oxacillin for Injection, USP
 

For Intramuscular or Intravenous Injection",7773,oxacillin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988",5657,ifosfamide,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230620_20e5acf0-90b7-45c8-be78-91eaf77c9ac0.json,20e5acf0-90b7-45c8-be78-91eaf77c9ac0,2,"These highlights do not include all the information needed to use FLUDARABINE phosphate injection safely and effectively. See full prescribing information for FLUDARABINE phosphate injection.
FLUDARABINE phosphate injection, for intravenous use onlyInitial U.S. Approval: 1991",24698,fludarabine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_bc737938-ae36-460b-a2a8-609f3fe59156.json,bc737938-ae36-460b-a2a8-609f3fe59156,2,"These highlights do not include all the information needed to use VANCOMYCIN HYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for VANCOMYCIN HYDROCHLORIDE CAPSULES.  VANCOMYCIN HYDROCHLORIDE capsules, for oral use Initial U.S. Approval: 1986 To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin hydrochloride capsules and other antibacterial drugs, vancomycin hydrochloride capsules should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.",11124,vancomycin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230916_2cab8dd1-3a10-48e6-86ce-0e5275ed49e5.json,2cab8dd1-3a10-48e6-86ce-0e5275ed49e5,10,"These highlights do not include all the information needed to use FARESTON® safely and effectively. See full prescribing information for FARESTON®.


FARESTON® (toremifene citrate) 60 mg Tablets oral administration

Initial U.S. Approval: 1997",38409,toremifene,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20231004_63df5af3-b8ac-4e76-9830-2dbb340af922.json,63df5af3-b8ac-4e76-9830-2dbb340af922,27,"These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspensionInitial U.S. Approval: 2013",1433868,dolutegravir,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231205_4afb20ee-eb3f-1937-ffa4-5d3228e82688.json,4afb20ee-eb3f-1937-ffa4-5d3228e82688,3,Penicillamine Capsules,7975,penicillamine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210106_dd367eec-359a-4065-b5c3-7c0107c823fe.json,dd367eec-359a-4065-b5c3-7c0107c823fe,7,"Tolcapone Tablets

100 mg",72937,tolcapone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information",3008,cyclosporine,10067125,liver injury,500000301,acute liver injury,6,1,500000301,19010482,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240125_da1ce22b-6a8e-40a2-afbb-011fa3ed3a8b.json,da1ce22b-6a8e-40a2-afbb-011fa3ed3a8b,10,"These highlights do not include all the information needed to use ROPIVACAINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for ROPIVACAINE HYDROCHLORIDE INJECTION.



ROPIVACAINE HYDROCHLORIDE injection, for epidural, perineural, or infiltration use 

Initial U.S. Approval: 1996",35780,ropivacaine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_dc8d68d1-0c5c-4004-b71d-22b83daf4270.json,dc8d68d1-0c5c-4004-b71d-22b83daf4270,6,"These highlights do not include all the information needed to use BEXAROTENE CAPSULES safely and effectively.  See full prescribing information for BEXAROTENE CAPSULES.BEXAROTENE capsules, for oral useInitial U.S. Approval: 1999",233272,bexarotene,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005",614373,deferasirox,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240201_bcc81df2-20e3-4738-bfcf-301da883c1d9.json,bcc81df2-20e3-4738-bfcf-301da883c1d9,10,Ceftazidime for Injection,2191,ceftazidime,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/train_xml/20231205_3d0c9554-eaeb-4694-8089-00133fcadce3.json,3d0c9554-eaeb-4694-8089-00133fcadce3,16,"These highlights do not include all the information needed to use APTIOM safely and effectively.  See full prescribing information for APTIOM.  
APTIOM® (eslicarbazepine acetate) tablets, for oral useInitial U.S. Approval: 2013",1482502,eslicarbazepine,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_918d0e2a-3af3-46e8-ad06-528263e03ba0.json,918d0e2a-3af3-46e8-ad06-528263e03ba0,11,"These highlights do not include all the information needed to use fentanyl buccal tablet safely and effectively.  See full prescribing information for fentanyl buccal tablet. 
 Fentanyl Buccal Tablet, CII    Initial U.S. Approval: 1968",4337,fentanyl,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_dd47a015-ff90-d7a7-8dcb-4e6e31a68071.json,dd47a015-ff90-d7a7-8dcb-4e6e31a68071,1,"These highlights do not include all the information needed to use DABIGATRAN 
ETEXILATE CAPSULES
 safely and effectively. See full prescribing information for 
DABIGATRAN
 ETEXILATE CAPSULES.


DABIGATRAN E
TEXILATE capsules, for oral use 

Initial U.S. Approval: 2010",1037042,dabigatran etexilate,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210729_1b97bd3a-1040-4511-b0e6-4758e8083ae5.json,1b97bd3a-1040-4511-b0e6-4758e8083ae5,3,"These highlights do not include all the information needed to use FARYDAK safely and effectively. See full prescribing information for FARYDAK.


FARYDAK® (panobinostat) capsules, for oral use

Initial U.S. Approval: 2015",1603350,panobinostat,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,0772eb61-ca42-39de-e063-6294a90a6632,1,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006",357977,sunitinib,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_88f28338-9a64-42aa-a4e9-b1ad3fd073fe.json,88f28338-9a64-42aa-a4e9-b1ad3fd073fe,9,"BETAMETHASONE VALERATE CREAM USP, 0.1%

BETAMETHASONE VALERATE OINTMENT USP, 0.1%

BETAMETHASONE VALERATE LOTION USP, 0.1%

(Potency expressed as betamethasone)",1514,betamethasone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20211124_75c0c785-38e0-4049-a6fb-b77581f5b35c.json,75c0c785-38e0-4049-a6fb-b77581f5b35c,6,"These highlights do not include all the information needed to use FETROJA® safely and effectively. See full prescribing information for FETROJA. 
 FETROJA (cefiderocol) for injection, for intravenous use  Initial U.S. Approval: 2019",2265702,cefiderocol,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,b6465b44-a6dd-f99c-d009-6851cf05169c,11,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab).",224905,trastuzumab,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_a26cfa07-14a7-4468-8eed-3529f3d613f4.json,a26cfa07-14a7-4468-8eed-3529f3d613f4,6,"These highlights do not include all the information needed to use EFAVIRENZ CAPSULES safely and effectively. See full prescribing information for EFAVIRENZ CAPSULES.
 EFAVIRENZ capsules for oral use Initial U.S. Approval: 1998",195085,efavirenz,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1738135,1,1
./data/2024_latest_labels/latest_labels_ingredients/20220218_47547f93-489c-4298-aeea-d6a37ca6cb1d.json,47547f93-489c-4298-aeea-d6a37ca6cb1d,5,"These highlights do not include all the information needed to use COPIKTRA safely and effectively. See full prescribing information for COPIKTRA.
  



COPIKTRA (duvelisib), capsules for oral use
  

Initial U.S. Approval: 2018",2058509,duvelisib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221214_de61685e-2b8c-4e22-84bb-869e13600440.json,de61685e-2b8c-4e22-84bb-869e13600440,38,"These highlights do not include all the information needed to use PEGASYS safely and effectively. See full prescribing information for PEGASYS. 
 PEGASYS® (peginterferon alfa-2a) injection, for subcutaneous use  Initial U.S. Approval: 2002",120608,peginterferon alfa-2a,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221214_de61685e-2b8c-4e22-84bb-869e13600440.json,de61685e-2b8c-4e22-84bb-869e13600440,38,"These highlights do not include all the information needed to use PEGASYS safely and effectively. See full prescribing information for PEGASYS. 
 PEGASYS® (peginterferon alfa-2a) injection, for subcutaneous use  Initial U.S. Approval: 2002",120608,peginterferon alfa-2a,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,2150f73a-179b-4afc-b8ce-67c85cc72f04,60,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009",141704,everolimus,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,2150f73a-179b-4afc-b8ce-67c85cc72f04,60,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009",141704,everolimus,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_5f01e40a-b6f6-40fb-b37c-3d06f1428e86.json,5f01e40a-b6f6-40fb-b37c-3d06f1428e86,27,"These highlights do not include all the information needed to use GLATOPA safely and effectively. See full prescribing information for GLATOPA.
GLATOPA® (glatiramer acetate injection), for subcutaneous useInitial U.S. Approval: 1996",214582,glatiramer,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,c98fb504-76d0-4c25-9c0b-412885828a7a,7,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005",342369,lenalidomide,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_d35193e4-0b0e-4a0a-acd8-aa90cc075a2b.json,d35193e4-0b0e-4a0a-acd8-aa90cc075a2b,16,"These highlights do not include all the information needed to use METHOTREXATE TABLETS safely and effectively. See full prescribing information for METHOTREXATE TABLETS.
 

METHOTREXATE tablets, for oral use
 
Initial U.S. Approval: 1953",6851,methotrexate,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,d5929f91-6496-4c0e-97e8-0bd524e15763,3,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220826_de77155c-ecf2-4f15-9758-21d271449d83.json,de77155c-ecf2-4f15-9758-21d271449d83,2,"These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. 
FOTIVDA® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021",2534233,tivozanib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/gold_xml/20231129_83a504ef-cf92-467d-9ecf-d251194a3484.json,83a504ef-cf92-467d-9ecf-d251194a3484,20,"These highlights do not include all the information needed to use SYNRIBO safely and effectively.  See full prescribing information for SYNRIBO. 
SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous useInitial U.S. Approval: 2012",27100,omacetaxine mepesuccinate,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012",1302966,carfilzomib,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_2e32d778-54ca-4bd8-b61a-236208f36e98.json,2e32d778-54ca-4bd8-b61a-236208f36e98,4,"These highlights do not include all the information needed to use STEGLATRO safely and effectively. See full prescribing information for STEGLATRO.
STEGLATRO® (ertugliflozin) tablets, for oral useInitial U.S. Approval: 2017",1992672,ertugliflozin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_cc4da2c3-f939-444d-9b5b-a57b6051c190.json,cc4da2c3-f939-444d-9b5b-a57b6051c190,11,"LEVOCARNITINE INJECTION, USP1 g per 5 mL vial and 4 g per 20 mL vialFOR INTRAVENOUS USE ONLYRx Only",42955,levocarnitine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20221214_8b6261f6-4bdc-462e-8af1-4064664c62f3.json,8b6261f6-4bdc-462e-8af1-4064664c62f3,2,"These highlights do not include all the information
needed to use JARDIANCE safely and effectively.  See full prescribing
information for JARDIANCE.
 JARDIANCE® (empagliflozin) tablets, for oral use Initial U.S. Approval: 2014",1545653,empagliflozin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240103_21149cc3-049b-43e2-b141-c9499160556c.json,21149cc3-049b-43e2-b141-c9499160556c,9,"These highlights do not include all the information needed to use TAVALISSE® safely and effectively.  See full prescribing information for TAVALISSE. 
TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for oral useInitial U.S. Approval: 2018",2044896,fostamatinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221230_2ef0cf38-101c-4681-98fe-c05dc9ead443.json,2ef0cf38-101c-4681-98fe-c05dc9ead443,3,"These highlights do not include all the information needed to use LUNSUMIO safely and effectively. See full prescribing information for LUNSUMIO. LUNSUMIO™ (mosunetuzumab-axgb) injection, for intravenous use Initial U.S. Approval: 2022",2625122,mosunetuzumab,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010",612865,tocilizumab,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230106_74a611bc-9977-46bb-b626-0370b3031628.json,74a611bc-9977-46bb-b626-0370b3031628,8,"These highlights do not include all the information needed to use FEXINIDAZOLE TABLETS safely and effectively. See full prescribing information for FEXINIDAZOLE TABLETS.
 



FEXINIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2021",2564146,fexinidazole,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_cee4cdd0-58c5-4704-9fb6-d4bffb1764a8.json,cee4cdd0-58c5-4704-9fb6-d4bffb1764a8,2,"Midazolam Injection, USP

 CIV

 (For Intravenous or Intramuscular Use Only)

 Rx only

 NOT FOR USE IN NEONATES

 CONTAINS BENZYL ALCOHOL",6960,midazolam,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230202_49596de6-ab18-49d1-9e5b-30968fc21c36.json,49596de6-ab18-49d1-9e5b-30968fc21c36,26,"VinCRIStine Sulfate 

Injection, USP",11202,vincristine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230203_0b1332a1-0581-4707-9bf6-1eccfa39bef4.json,0b1332a1-0581-4707-9bf6-1eccfa39bef4,2,"These highlights do not include all the information needed to use LYTGOBI safely and effectively. See full prescribing information for LYTGOBI.
LYTGOBI® (futibatinib) tablets, for oral use
Initial U.S. Approval: 2022",2628190,futibatinib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230908_2b34d62d-e02a-4af3-bc0d-1571dd4ee76d.json,2b34d62d-e02a-4af3-bc0d-1571dd4ee76d,7,"These highlights do not include all the information needed to use LORBRENA safely and effectively. See full prescribing information for LORBRENA.
 LORBRENA® (lorlatinib) tablets, for oral use Initial U.S. Approval: 2018",2103164,lorlatinib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230331_4a0c7c8b-b95f-455d-9600-b7351e4397fe.json,4a0c7c8b-b95f-455d-9600-b7351e4397fe,2,"These highlights do not include all the information needed to use REZLIDHIA safely and effectively. See full prescribing information for REZLIDHIA.
REZLIDHIA™ (olutasidenib) capsules, for oral useInitial U.S. Approval: 2022",2623641,olutasidenib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,2eda833b-1357-4ed4-a093-194524fcb061,25,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998",10432,thalidomide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,2eda833b-1357-4ed4-a093-194524fcb061,25,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998",10432,thalidomide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013",1369713,pomalidomide,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013",1369713,pomalidomide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230526_d7836711-b677-412d-bf2d-0f7c8444103a.json,d7836711-b677-412d-bf2d-0f7c8444103a,3,"These highlights do not include all the information needed to use EPKINLY safely and effectively. See full prescribing information for EPKINLY.
 EPKINLY™ (epcoritamab-bysp) injection, for subcutaneous use Initial U.S. Approval: 2023",2637392,epcoritamab,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230613_c387579e-cee0-4334-bd1e-73f93ac1bde6.json,c387579e-cee0-4334-bd1e-73f93ac1bde6,18,"These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.
COTELLIC®  (cobimetinib) tablets, for oral useInitial U.S. Approval: 2015",1722365,cobimetinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_6690679c-be2f-4588-a2e4-89fff74dd6be.json,6690679c-be2f-4588-a2e4-89fff74dd6be,9,"These highlights do not include all the information needed to use IMJUDO safely and effectively. See full prescribing information for IMJUDO.IMJUDO® (tremelimumab-actl) injection, for intravenous useInitial U.S. Approval: 2022",2619313,tremelimumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230628_8bc6397e-4bd8-4d37-a007-a327e4da34d9.json,8bc6397e-4bd8-4d37-a007-a327e4da34d9,56,"These highlights do not include all the information needed to use ERBITUX safely and effectively. See full prescribing information for ERBITUX.ERBITUX® (cetuximab) injection, for intravenous useInitial U.S. Approval: 2004",318341,cetuximab,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/train_xml/20230720_de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa.json,de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,24,"These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA.
 JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010",996051,cabazitaxel,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230816_5c4841b4-fbc0-4163-8ee1-cb28629cbfbf.json,5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,13,"These highlights do not include all the information needed to use PHOTOFRIN 
 ® safely and effectively. See full prescribing information for PHOTOFRIN.
 



PHOTOFRIN (porfimer sodium) for injection, for intravenous useInitial U.S. Approval: 1995",23066,dihematoporphyrin ether,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_467cd83f-d695-4040-9434-10e80b4271da.json,467cd83f-d695-4040-9434-10e80b4271da,2,"These highlights do not include all the information needed to use GLOPERBA® safely and effectively. See full prescribing information for GLOPERBA®. 
 GLOPERBA® (colchicine) Oral Solution Initial U.S. Approval: 1961",2683,colchicine,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_4034fb6d-f55d-4df0-b500-d6a413591f6e.json,4034fb6d-f55d-4df0-b500-d6a413591f6e,39,"These highlights do not include all the information needed to use DOXAZOSIN TABLETS safely and effectively. See full prescribing information for DOXAZOSIN TABLETS.




DOXAZOSIN tablets, for oral use 




Initial U.S. Approval: 1990",49276,doxazosin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230908_bb9a3820-f31a-4dd9-bef4-97094c01a398.json,bb9a3820-f31a-4dd9-bef4-97094c01a398,7,"These highlights do not include all the information needed to use LEUKINE safely and effectively. See full prescribing information for LEUKINE.
		
LEUKINE® (sargramostim) for injection, for subcutaneous or intravenous use
		Initial U.S. Approval: 1991",69634,sargramostim,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012",1363268,cabozantinib,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,84137882-e000-47da-bd5b-fa76ab3c76f9,20,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012",1242999,axitinib,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231018_1534c9ae-4948-4cf4-9f66-222a99db6d0e.json,1534c9ae-4948-4cf4-9f66-222a99db6d0e,26,"These highlights do not include all the information needed to use SIRTURO safely and effectively. See full prescribing information for SIRTURO.
 

SIRTURO 
 ®(bedaquiline) tablets, for oral use
 
Initial U.S. Approval: 2012",1364504,bedaquiline,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231019_6c3408ac-d401-4925-8a03-26591afbc240.json,6c3408ac-d401-4925-8a03-26591afbc240,10,"These highlights do not include all the information needed to use MEKTOVI safely and effectively. See full prescribing information for MEKTOVI.
MEKTOVI® (binimetinib) tablets, for oral useInitial U.S. Approval: 2018",2049122,binimetinib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_61c3d6c7-0d9c-4e46-b091-88d84893e14a.json,61c3d6c7-0d9c-4e46-b091-88d84893e14a,11,"These highlights do not include all the information needed to use ZOLPIDEM TARTRATE TABLETS safely and effectively. See full prescribing information for ZOLPIDEM TARTRATE TABLETS.
 



ZOLPIDEM TARTRATE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1992",39993,zolpidem,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_a74239bf-4684-424c-ba4e-6087e363265b.json,a74239bf-4684-424c-ba4e-6087e363265b,14,"These highlights do not include all the information needed to use amlodipine besylate tablets safely and effectively. See full prescribing information for amlodipine besylate tablets. 
AMLODIPINE besylate tablets, USP for oral administration
Initial U.S. Approval: 1987",17767,amlodipine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1332418,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240217_0becbde8-6ec5-4830-a0d9-cfdb7b15eb84.json,0becbde8-6ec5-4830-a0d9-cfdb7b15eb84,11,"Minocycline Hydrochloride Capsules, USP
 

Rx only",6980,minocycline,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20080508_d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee.json,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,1,INNOHEP®(tinzaparin sodium injection),69646,tinzaparin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_c89e8f4d-96c0-44c6-906a-b803141920b1.json,c89e8f4d-96c0-44c6-906a-b803141920b1,27,"These highlights do not include all the information needed to use CEFUROXIME AXETIL TABLETS safely and effectively. See full prescribing information for CEFUROXIME AXETIL TABLETS.  CEFUROXIME AXETIL tablets, for oral use  Initial U.S. Approval: 1987",2194,cefuroxime,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_e55f3dc2-c754-4550-a2c0-c304471a8791.json,e55f3dc2-c754-4550-a2c0-c304471a8791,2,"Nitrofurantoin Capsules, USP (monohydrate/macrocrystals)

Rx Only",7454,nitrofurantoin,10019692,hepatic necrosis,500000301,acute liver injury,15,1,500000301,920293,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231215_8ded0773-3aec-4e89-9836-d22a5a84abf0.json,8ded0773-3aec-4e89-9836-d22a5a84abf0,17,Quinapril Tablets USP,35208,quinapril,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_584abe73-8290-4484-ff8e-5890831c095e.json,584abe73-8290-4484-ff8e-5890831c095e,21,"These highlights do not include all the information needed to use IMITREX safely and effectively. See full prescribing information for IMITREX.IMITREX (sumatriptan) tablets, for oral useInitial U.S. Approval: 1992",37418,sumatriptan,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1140643,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,"IBUPROFEN Tablets, USP",5640,ibuprofen,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1177480,1,1
./data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011",25480,gabapentin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_0be26591-e0dd-429d-a4c7-b2e39aab13dd.json,0be26591-e0dd-429d-a4c7-b2e39aab13dd,9,"These highlights do not include all the information needed to use TERBINAFINE TABLETS safely and effectively. See full prescribing information for TERBINAFINE TABLETS
 

TERBINAFINE tablets, for oral use
 
Initial U.S. Approval: 1992",37801,terbinafine,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1741309,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,51635427-fb13-45ee-813d-a40b0405d14f,7,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information",3355,diclofenac,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_4314da8a-40e5-4aba-a32b-57b4166ade30.json,4314da8a-40e5-4aba-a32b-57b4166ade30,12,"These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.  AZITHROMYCIN tablets, for oral use Initial U.S. Approval: 1991",18631,azithromycin,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992",32613,oxaprozin,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1118045,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998",2556,citalopram,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,797617,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,76e1839b-7462-4344-b319-001a5f57d67a,12,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000",40790,pantoprazole,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,"Venlafaxine Tablets, USP
 
Rx only",39786,venlafaxine,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240120_c522c860-84ce-4c61-ab72-077de73195df.json,c522c860-84ce-4c61-ab72-077de73195df,1,"Tetracycline Hydrochloride Tablets, USP For Oral Use",10395,tetracycline,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,ccd95dfc-9236-4707-a715-6a12c91519ff,6,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976",7258,naproxen,10018830,haematemesis,500001001,gi bleed,11,1,500001001,1115008,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,575da603-b038-421f-9894-6796d9ac33cc,11,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991",36437,sertraline,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,52781229-ee82-43f9-a113-4419a611978d,1,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000",183379,rivastigmine,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,24926986-7552-4f1a-8366-f035bbd07104,7,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987",4493,fluoxetine,10018830,haematemesis,500001001,gi bleed,11,1,500001001,755695,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240217_4dd14728-02b4-4e75-b9c6-227be7816d5b.json,4dd14728-02b4-4e75-b9c6-227be7816d5b,9,"These highlights do not include all the information needed to use ABACAVIR TABLETS safely and effectively. See full prescribing information for ABACAVIR TABLETS.
 



ABACAVIR tablets, for oral use
 

Initial U.S. Approval: 1998",190521,abacavir,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,8345d55e-ad02-4726-a04b-1a46e3337a4b,13,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998",194000,capecitabine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_1a309416-bd6a-45b1-982f-b689b097453d.json,1a309416-bd6a-45b1-982f-b689b097453d,13,"These highlights do not include all the information needed to use MODAFINIL TABLETS safely and effectively.  See full prescribing information for MODAFINIL TABLETS.
 MODAFINIL tablets, for oral use, C-IV  Initial U.S. Approval: 1998",30125,modafinil,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_55ae23ff-60f5-4de6-bd1b-472243b8636b.json,55ae23ff-60f5-4de6-bd1b-472243b8636b,8,"These highlights do not include all the information needed to use PIOGLITAZONE TABLETS safely and effectively. See full prescribing information for PIOGLITAZONE TABLETS
 







PIOGLITAZONE tablets, for oral use
 



Initial U.S. Approval: 1999",33738,pioglitazone,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1525215,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,f47d4365-40a8-445b-99cd-49edad6a8ffc,15,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only",35827,ketorolac,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,500000301,1136980,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_09c6c750-ae05-459f-83e8-4a9e4fd85212.json,09c6c750-ae05-459f-83e8-4a9e4fd85212,28,"These highlights do not include all the information needed to use ATORVASTATIN CALCIUM TABLETS safely and effectively. See full prescribing information for ATORVASTATIN CALCIUM TABLETS.
 

ATORVASTATIN CALCIUM tablets, for oral use
 

Initial U.S. Approval: 1996",83367,atorvastatin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_41c095b6-acd9-4627-a813-bbca7ecafee5.json,41c095b6-acd9-4627-a813-bbca7ecafee5,10,"These highlights do not include all the information needed to use DONEPEZIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for DONEPEZIL HYDROCHLORIDE TABLETS.
 

DONEPEZIL HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1996",135447,donepezil,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_8c065559-bd35-4dda-ac8f-624eea0641ae.json,8c065559-bd35-4dda-ac8f-624eea0641ae,9,"These highlights do not include all the information needed to use ZIDOVUDINE TABLETS safely and effectively. See full prescribing information for ZIDOVUDINE TABLETS.
 



ZIDOVUDINE tablets, for oral use
 



Initial U.S. Approval: 1987",11413,zidovudine,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1710612,1,1
./data/2024_latest_labels/gold_xml/20220909_69ea2d58-5353-4222-b61f-cab976fa7e5e.json,69ea2d58-5353-4222-b61f-cab976fa7e5e,2,"These highlights do not include all the information needed to use EFFIENT safely and effectively. See full prescribing information for EFFIENT.
 



EFFIENT 
 ® (prasugrel) tablets, for oral use
 

Initial U.S. Approval: 2009",613391,prasugrel,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_baac91ad-f8ee-4694-89f8-5c47a8eda39a.json,baac91ad-f8ee-4694-89f8-5c47a8eda39a,10,"Moexipril Hydrochloride Tablets USP

7.5 mg and 15 mg",30131,moexipril,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1310756,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995",68149,mycophenolate mofetil,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_f9ca2ef5-46d8-475a-a26e-f7c8becd6db7.json,f9ca2ef5-46d8-475a-a26e-f7c8becd6db7,8,"These highlights do not include all the information needed to use HYDROMORPHONE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for HYDROMORPHONE HYDROCHLORIDE INJECTION.
HYDROMORPHONE HYDROCHLORIDE injection, for intravenous, intramuscular, or subcutaneous use, CII
Initial U.S. Approval: 1984",3423,hydromorphone,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_3a404db2-7a7d-476f-81cf-979a67d37f66.json,3a404db2-7a7d-476f-81cf-979a67d37f66,7,"These highlights do not include all the information needed to use ALYQ™ safely and effectively.  See full prescribing information for ALYQ™. 


ALYQ™ (tadalafil) tablets for oral administration

Initial U.S. Approval: 2003",358263,tadalafil,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231230_b1739aa5-69d8-4a69-be58-6d789ea2a516.json,b1739aa5-69d8-4a69-be58-6d789ea2a516,10,"Clomipramine Hydrochloride Capsules, USP

(25 mg, 50 mg, and 75 mg)
 


Rx only",2597,clomipramine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231230_cb960074-99c1-4a73-941f-f0644a7ec219.json,cb960074-99c1-4a73-941f-f0644a7ec219,40,"These highlights do not include all the information needed to use AGRYLIN safely and effectively. See full prescribing information for AGRYLIN.
AGRYLIN® (anagrelide) capsules, for oral useInitial U.S. Approval: 1997",596724,anagrelide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231215_fc2a08dd-4fb6-4ac4-9082-f99552fae25c.json,fc2a08dd-4fb6-4ac4-9082-f99552fae25c,11,Parlodel Capsules and Tablets,1760,bromocriptine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,730548,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240220_42e99112-c402-4662-877f-9e3a84dff9f2.json,42e99112-c402-4662-877f-9e3a84dff9f2,9,"These highlights do not include all the information needed to use CINACALCET TABLETS safely and effectively. See full prescribing information for CINACALCET TABLETS. 
 CINACALCET tablets, for oral use  Initial U.S. Approval: 2004",407990,cinacalcet,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_55ae23ff-60f5-4de6-bd1b-472243b8636b.json,55ae23ff-60f5-4de6-bd1b-472243b8636b,8,"These highlights do not include all the information needed to use PIOGLITAZONE TABLETS safely and effectively. See full prescribing information for PIOGLITAZONE TABLETS
 







PIOGLITAZONE tablets, for oral use
 



Initial U.S. Approval: 1999",33738,pioglitazone,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1525215,1,1
./data/2024_latest_labels/latest_labels_ingredients/20160810_63f60426-e27f-4258-9bfc-b4a15ebdca83.json,63f60426-e27f-4258-9bfc-b4a15ebdca83,3,"FACTIVE ®
 (gemifloxacin mesylate) Tablets",138099,gemifloxacin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/gold_xml/20231205_5359b759-db7c-4672-9e8a-59c93869bd91.json,5359b759-db7c-4672-9e8a-59c93869bd91,5,"These highlights do not include all the information needed to use VIBATIV® (telavancin) safely and effectively. See full prescribing information for VIBATIV. 
VIBATIV® (telavancin) for injection, for intravenous use Initial U.S. Approval: 2009",473837,telavancin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231117_8512d0c6-db4e-4673-b3b4-28975c18413f.json,8512d0c6-db4e-4673-b3b4-28975c18413f,12,"",32385,olsalazine,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_d9db3882-a7b5-435b-9d5a-a5e4ef7c2537.json,d9db3882-a7b5-435b-9d5a-a5e4ef7c2537,2,"Fluphenazine Hydrochloride Tablets, USPRx only",4496,fluphenazine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_cac4f544-536c-4886-a379-99eed2d35240.json,cac4f544-536c-4886-a379-99eed2d35240,8,"These highlights do not include all the information needed to use SILDENAFIL TABLETS safely and effectively. See full prescribing information for SILDENAFIL TABLETS.
 







SILDENAFIL tablets, for oral use
 







Initial U.S. Approval:1998",136411,sildenafil,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20151015_4c2a1403-3862-1efd-0a91-444989222b37.json,4c2a1403-3862-1efd-0a91-444989222b37,6,"These highlights do not include all the information needed to use DURLAZA™ safely and effectively.  See full prescribing information for DURLAZA.
DURLAZA (aspirin) Extended Release Capsules, for oral useInitial U.S. Approval:2015",1191,aspirin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_b0075b72-c3cc-f844-e053-2a95a90a417f.json,b0075b72-c3cc-f844-e053-2a95a90a417f,5,"These highlights do not include all the information needed to use MEROPENEM FOR INJECTION safely and effectively. See full prescribing information for MEROPENEM FOR INJECTION
 







MEROPENEM for injection, for intravenous use
 







Initial U.S. Approval: 1996",29561,meropenem,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_5721b46a-4a9f-46c2-8804-a9bad4d5f80a.json,5721b46a-4a9f-46c2-8804-a9bad4d5f80a,5,FLUCYTOSINE Capsules USPRx only,4451,flucytosine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_02e2aa54-1ed8-445a-a082-ac2c64b339fe.json,02e2aa54-1ed8-445a-a082-ac2c64b339fe,16,"These highlights do not include all the information needed to use SOLIFENACIN SUCCINATE TABLETS safely and effectively. See full prescribing information for SOLIFENACIN SUCCINATE TABLETS.


SOLIFENACIN SUCCINATE tablets for oral use 

Initial U.S. Approval: 2004",322167,solifenacin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240213_a60c5173-6bc0-4c9d-9674-b3f4d68f79ba.json,a60c5173-6bc0-4c9d-9674-b3f4d68f79ba,4,"These highlights do not include all the information needed to use CISPLATIN INJECTION, USP safely and effectively. See full prescribing information for CISPLATIN INJECTION, USP.
 



CISPLATIN injection USP, for intravenous use
 



Initial U.S. Approval: 1978",2555,cisplatin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_29ba0172-7ca3-4122-af1b-f0da522318cb.json,29ba0172-7ca3-4122-af1b-f0da522318cb,6,"These highlights do not include all the information needed to use HYDROXYCHLOROQUINE SULFATE TABLETS safely and effectively. See full prescribing information for HYDROXYCHLOROQUINE SULFATE TABLETS.
HYDROXYCHLOROQUINE SULFATE Tablets, for oral use
Initial U.S. Approval: 1955",5521,hydroxychloroquine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_b1bd0d02-eccb-4449-82b9-9b552835029e.json,b1bd0d02-eccb-4449-82b9-9b552835029e,10,"These highlights do not include all the information needed to use WARFARIN SODIUM TABLETS safely and effectively. See full prescribing information for WARFARIN SODIUM TABLETS.
 



WARFARIN SODIUM tablets, for oral use
 

Initial U.S. Approval: 1954",11289,warfarin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_b31ff20a-c363-4be0-9bc0-3081c163b63c.json,b31ff20a-c363-4be0-9bc0-3081c163b63c,7,"These highlights do not include all the information needed to use ATOVAQUONE ORAL SUSPENSION safely and effectively. See full prescribing information for ATOVAQUONE ORAL SUSPENSION.


ATOVAQUONE oral suspension, for oral use


Initial U.S. Approval: 1992",60212,atovaquone,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_106b33e3-b199-e555-e063-6294a90a5af5.json,106b33e3-b199-e555-e063-6294a90a5af5,1,"Diltiazem Hydrochloride Tablets, USP


Tablets",3443,diltiazem,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002",121243,voriconazole,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1714277,1,1
./data/2024_latest_labels/latest_labels_ingredients/20230916_2cab8dd1-3a10-48e6-86ce-0e5275ed49e5.json,2cab8dd1-3a10-48e6-86ce-0e5275ed49e5,10,"These highlights do not include all the information needed to use FARESTON® safely and effectively. See full prescribing information for FARESTON®.


FARESTON® (toremifene citrate) 60 mg Tablets oral administration

Initial U.S. Approval: 1997",38409,toremifene,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_86766b51-4443-4cec-97a2-c483b07681de.json,86766b51-4443-4cec-97a2-c483b07681de,8,"Tobramycin

Ophthalmic Solution, USP

0.3%

(Sterile)
 
Rx only",10627,tobramycin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240126_04fb6cd5-3c21-433e-a053-623b73218bd6.json,04fb6cd5-3c21-433e-a053-623b73218bd6,2,"Niacin Tablets, USP 500 mg",7393,niacin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,500000301,1517824,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992",70223,aldesleukin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_a4978a54-1799-43d6-85dd-05fa9de0a5d7.json,a4978a54-1799-43d6-85dd-05fa9de0a5d7,8,"These highlights do not include all the information needed to use AMBRISENTAN TABLETS safely and effectively. See full prescribing information for AMBRISENTAN TABLETS.  AMBRISENTAN tablets, for oral use  Initial U.S. Approval: 2007",358274,ambrisentan,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,b605b541-4bfd-db3e-9710-11c27f6dee6c,2,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003",358258,bortezomib,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,b605b541-4bfd-db3e-9710-11c27f6dee6c,2,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003",358258,bortezomib,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1336825,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240220_a3b50576-cd40-4f7e-9506-bd0a61988424.json,a3b50576-cd40-4f7e-9506-bd0a61988424,3,"These highlights do not include all the information needed to use FAMOTIDINE TABLETS safely and effectively. See full prescribing information for FAMOTIDINE TABLETS.
 
FAMOTIDINE tablets, for oral use
 
Initial U.S. Approval: 1986",4278,famotidine,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230420_5736aecc-cc1d-47dd-86c0-5fb2e9d70f61.json,5736aecc-cc1d-47dd-86c0-5fb2e9d70f61,5,CLADRIBINE INJECTION,44157,cladribine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005",614373,deferasirox,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_454f092e-dcd0-47bd-a521-b07400403dad.json,454f092e-dcd0-47bd-a521-b07400403dad,5,"These highlights do not include all the information needed to use BRONCHITOL safely and effectively. See full prescribing information for BRONCHITOL.BRONCHITOL® (mannitol) inhalation powder, for oral inhalation useInitial U.S. Approval: 1964",6628,mannitol,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231118_4c61e68e-f2d1-4998-aae7-62997971dab7.json,4c61e68e-f2d1-4998-aae7-62997971dab7,4,"FOSCAVIR 
 ® 


(foscarnet sodium) INJECTION",33562,foscarnet,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_dbf738c4-3fac-4422-a9d8-51d9c83a8789.json,dbf738c4-3fac-4422-a9d8-51d9c83a8789,3,"These highlights do not include all the information needed to use RENFLEXIS® safely and effectively. See full prescribing information for RENFLEXIS. 
RENFLEXIS (infliximab-abda) for injection, for intravenous use Initial U.S. Approval: 2017 RENFLEXIS (infliximab-abda) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of RENFLEXIS has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to REMICADE (infliximab).",191831,infliximab,10000804,acute hepatic failure,500000301,acute liver injury,5,1,500000301,937368,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995",68149,mycophenolate mofetil,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/gold_xml/20231213_c488fb7c-0a5b-487c-b452-996809d1cb99.json,c488fb7c-0a5b-487c-b452-996809d1cb99,65,"These highlights do not include all the information needed to use RELISTOR safely and effectively. See full prescribing information for RELISTOR.
 

RELISTOR 
 ®(methylnaltrexone bromide) tablets, for oral use
 
RELISTOR 
 ®(methylnaltrexone bromide) injection, for subcutaneous use
 
Initial U.S. Approval: 2008",29899,methylnaltrexone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_1793e218-7b49-497d-879f-1020de6e6d68.json,1793e218-7b49-497d-879f-1020de6e6d68,8,Prednisolone Sodium Phosphate Oral Solution,8638,prednisolone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221214_de61685e-2b8c-4e22-84bb-869e13600440.json,de61685e-2b8c-4e22-84bb-869e13600440,38,"These highlights do not include all the information needed to use PEGASYS safely and effectively. See full prescribing information for PEGASYS. 
 PEGASYS® (peginterferon alfa-2a) injection, for subcutaneous use  Initial U.S. Approval: 2002",120608,peginterferon alfa-2a,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009",141704,everolimus,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/train_xml/20221029_39d53698-57fa-7c99-fc5b-f52a55684826.json,39d53698-57fa-7c99-fc5b-f52a55684826,26,"These highlights do not include all the information needed to use TREANDA safely and effectively. See full prescribing information for TREANDA.
TREANDA® (bendamustine hydrochloride) injection, for intravenous useTREANDA® (bendamustine hydrochloride) for injection, for intravenous useInitial U.S. Approval: 2008",134547,bendamustine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220623_08982e49-d2eb-4b25-b01a-1be52fd669ef.json,08982e49-d2eb-4b25-b01a-1be52fd669ef,16,"These highlights do not include all the information needed to use APTIVUS safely and effectively.  See full prescribing information for APTIVUS. 
APTIVUS® (tipranavir) capsules, for oral use APTIVUS® (tipranavir) oral solution Initial U.S. Approval: 2005",190548,tipranavir,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1736999,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,c98fb504-76d0-4c25-9c0b-412885828a7a,7,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005",342369,lenalidomide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231108_c01906fa-2c73-4c13-9765-2fd06628d263.json,c01906fa-2c73-4c13-9765-2fd06628d263,26,"Lincocin®


 lincomycin injection, USP",6398,lincomycin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_4b4674d8-4d1e-4728-8465-d42ada33fa5c.json,4b4674d8-4d1e-4728-8465-d42ada33fa5c,23,"These highlights do not include all the information needed to use 
DALVANCE

®

 
safely and effectively.  
See full prescribing information for 
DALVANCE
.  

   

DALVANCE
 (
dalbavancin
)
 
for 
injection
,
 
for 
intravenous 
use 

Initial U.S. Approval: 
2014",1539239,dalbavancin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231129_cd86ee78-2781-468b-930c-3c4677bcc092.json,cd86ee78-2781-468b-930c-3c4677bcc092,25,"These highlights do not include all the information needed to use ZOLINZA safely and effectively. See full prescribing information for ZOLINZA. 
ZOLINZA® (vorinostat capsules, for oral use) Initial U.S. Approval: 2006",194337,vorinostat,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240127_08ce9fdd-1e84-4043-b085-91053f975b64.json,08ce9fdd-1e84-4043-b085-91053f975b64,101,"®

Tablets",16818,acitretin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231128_dd966338-c820-4270-b704-09ef75fa3ceb.json,dd966338-c820-4270-b704-09ef75fa3ceb,19,"These highlights do not include all the information needed to use DIFICID safely and effectively. See full prescribing information for DIFICID. 
DIFICID® (fidaxomicin) tablets, for oral use DIFICID® (fidaxomicin) for oral suspension Initial U.S. Approval: 2011",1111103,fidaxomicin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221118_a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330.json,a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330,4,"These highlights do not include all the information needed to use Cleviprex safely and effectively. See full prescribing information for Cleviprex.
 



Cleviprex (clevidipine) injectable emulsion, for intravenous use
 

Initial U.S. Approval: 2008",233603,clevidipine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231101_f5a010cf-5954-4e6d-acfa-fb414efdf471.json,f5a010cf-5954-4e6d-acfa-fb414efdf471,1,"Mitomycin for Injection, USP Rx only",632,mitomycin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/train_xml/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012",1302966,carfilzomib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231117_a3e4c8e5-bff0-4a8f-8401-e9866c846ee2.json,a3e4c8e5-bff0-4a8f-8401-e9866c846ee2,3,"These highlights do not include all the information needed to use Suprane (desflurane, USP) safely and effectively. See full prescribing information for Suprane (desflurane, USP).Suprane (desflurane, USP) Volatile Liquid for InhalationInitial U.S. Approval:  1992",27340,desflurane,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_7499fc35-fae8-44ad-bbab-9a1a589bf3ee.json,7499fc35-fae8-44ad-bbab-9a1a589bf3ee,20,"These highlights do not include all the information needed to use ETOPOPHOS safely and effectively. See full prescribing information for ETOPOPHOS.
ETOPOPHOS® (etoposide phosphate) for injection, for intravenous useInitial U.S. Approval: 1983",4179,etoposide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20231216_8d5f892b-e4f3-4a9e-9a91-95e2fca34144.json,8d5f892b-e4f3-4a9e-9a91-95e2fca34144,9,"These highlights do not include all the information needed to use INVOKANA safely and effectively. See full prescribing information for INVOKANA.
 

INVOKANA 
 ®(canagliflozin) tablets, for oral use
 
Initial U.S. Approval: 2013",1373458,canagliflozin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_b3ecc533-dd55-4a2f-84c4-ecd454aae766.json,b3ecc533-dd55-4a2f-84c4-ecd454aae766,14,"These highlights do not include all the information needed to use BALSALAZIDE DISODIUM CAPSULES safely and effectively. See full prescribing information for BALSALAZIDE DISODIUM CAPSULES.
 

BALSALAZIDE DISODIUM capsules, for oral use
 
Initial U.S. Approval: 2000",18747,balsalazide,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231209_6585bd0d-bd78-4341-9e87-0f7664821f05.json,6585bd0d-bd78-4341-9e87-0f7664821f05,11,"These highlights do not include all the information needed to use ASPARLAS safely and effectively. See full prescribing information for ASPARLAS.
 ASPARLAS® (calaspargase pegol-mknl) injection, for intravenous use  Initial U.S. Approval: 2018",2121416,calaspargase pegol,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221230_f1906fc9-cb3c-4e13-8a4a-da76100c1bf3.json,f1906fc9-cb3c-4e13-8a4a-da76100c1bf3,10,"These highlights do not include all the information needed to use PRETOMANID TABLETS safely and effectively.  See full prescribing information for PRETOMANID TABLETS. 
PRETOMANID tablets, for oral use
Initial U.S. Approval: 2019LIMITED POPULATION",2198359,pretomanid,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230202_241f0b1e-8b95-470d-876f-bf1804daaf18.json,241f0b1e-8b95-470d-876f-bf1804daaf18,11,"These highlights do not include all the information needed to use IXEMPRA 
 ® safely and effectively. See full prescribing information for IXEMPRA 
 ®.
 



IXEMPRA 
 ® 
Kit (ixabepilone) for Injection, for intravenous infusion only
 



Initial U.S. Approval: 2007",337523,ixabepilone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_246d42e5-5418-42ba-aff9-ae399b166c69.json,246d42e5-5418-42ba-aff9-ae399b166c69,4,"These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS.
 







TERIFLUNOMIDE tablets, for oral use
 



Initial U.S. Approval: 2012",1310520,teriflunomide,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231111_8983d6a0-f63f-4f8e-bba4-38223f39e29b.json,8983d6a0-f63f-4f8e-bba4-38223f39e29b,11,"These highlights do not include all the information needed to use BENZNIDAZOLE TABLETS safely and effectively. See full prescribing information for BENZNIDAZOLE TABLETS.
 



BENZNIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2017",18994,benznidazole,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230223_4764f37b-c9e6-4ede-bcc2-8a03b7c521df.json,4764f37b-c9e6-4ede-bcc2-8a03b7c521df,46,"These highlights do not include all the information needed to use SPRYCEL® safely and effectively. See full prescribing information for SPRYCEL.

SPRYCEL (dasatinib) tablets, for oral useInitial U.S. Approval: 2006",475342,dasatinib,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_b1274d78-1096-4ae3-8299-a2e94eaa0ea5.json,b1274d78-1096-4ae3-8299-a2e94eaa0ea5,16,Itraconazole Capsules,28031,itraconazole,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230322_866e9f35-9035-4581-a4b1-75a621ab55cf.json,866e9f35-9035-4581-a4b1-75a621ab55cf,22,"These highlights do not include all the information needed to use OLUMIANT safely and effectively. See full prescribing information for OLUMIANT.
OLUMIANT (baricitinib) tablets, for oral useInitial U.S. Approval: 2018",2047232,baricitinib,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/gold_xml/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013",1369713,pomalidomide,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240118_d1cda4f7-cb33-46ea-b9ac-431f6452b1a5.json,d1cda4f7-cb33-46ea-b9ac-431f6452b1a5,23,"These highlights do not include all the information needed to use ERLEADA safely and effectively. See full prescribing information for ERLEADA.
 



ERLEADA 
 ®(apalutamide) tablets, for oral use
 

Initial U.S. Approval – 2018",1999574,apalutamide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230505_99e5a37a-930c-4641-bcdd-7013ec1c15fe.json,99e5a37a-930c-4641-bcdd-7013ec1c15fe,2,"These highlights do not include all the information needed to use VOWST™ safely and effectively. See full prescribing information for VOWST.
 VOWST (fecal microbiota spores, live-brpk) capsules, for oral administration Initial U.S. Approval:  2023",2636537,"fecal microbiota spores, live",10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_be4bc0de-0fdc-4d46-8d25-be43c79e6a06.json,be4bc0de-0fdc-4d46-8d25-be43c79e6a06,22,"These highlights do not include all the information needed to use VERZENIO safely and effectively. See full prescribing information for VERZENIO.
VERZENIO® (abemaciclib) tablets, for oral useInitial U.S. Approval: 2017",1946825,abemaciclib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230510_ad965f38-dd22-4607-a673-2fb92f3b527a.json,ad965f38-dd22-4607-a673-2fb92f3b527a,8,"These highlights do not include all the information needed to use ARCALYST safely and effectively. See full prescribing information for ARCALYST. 
ARCALYST® (rilonacept) for injection, for subcutaneous use Initial U.S. Approval: 2008",763450,rilonacept,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/train_xml/20230516_2e8ef36b-71fa-4492-a16f-577d5f7d111d.json,2e8ef36b-71fa-4492-a16f-577d5f7d111d,7,"These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ.
 BELEODAQ® (belinostat) for injection, for intravenous use Initial U.S. Approval: 2014",1543543,belinostat,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_d138ab10-1ed9-44be-8d81-49dda1e434ac.json,d138ab10-1ed9-44be-8d81-49dda1e434ac,2,"These highlights do not include all the information needed to use ERAXIS safely and effectively. See full prescribing information for ERAXIS. 
ERAXIS® (anidulafungin) for injection, for intravenous use Initial U.S. Approval: 2006",341018,anidulafungin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,6fa682c9-a312-4932-9831-f286908660ee,34,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016",1792776,atezolizumab,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230524_d11fba31-0a6c-11e3-8ffd-0800200c9a66.json,d11fba31-0a6c-11e3-8ffd-0800200c9a66,16,"These highlights do not include all the information needed to use NATPARA safely and effectively. See full prescribing information for NATPARA. 
 NATPARA® (parathyroid hormone) for injection, for subcutaneous use  Initial U.S. Approval: 2015",1427222,parathyroid hormone,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230527_11fa3fc9-6776-49a6-b1c1-653f627c3e58.json,11fa3fc9-6776-49a6-b1c1-653f627c3e58,11,"These highlights do not include all the information needed to use RYDAPT safely and effectively. See full prescribing information for RYDAPT.
RYDAPT® (midostaurin) capsules, for oral useInitial U.S. Approval: 2017",1919083,midostaurin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230607_f3bc9031-0620-4a50-b440-f661cadfeb1d.json,f3bc9031-0620-4a50-b440-f661cadfeb1d,10,"These highlights do not include all the information needed to use CERVIDIL safely and effectively. See full prescribing information for CERVIDIL. 
CERVIDIL® (dinoprostone) vaginal insert Initial U.S. Approval: 1977",3478,dinoprostone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,2265ef30-253e-11df-8a39-0800200c9a66,42,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011",1094833,ipilimumab,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20240220_38b482a8-960b-4591-9857-5031ecb830aa.json,38b482a8-960b-4591-9857-5031ecb830aa,35,"These highlights do not include all the information needed to use BLINCYTO® safely and effectively. See full prescribing information for BLINCYTO.  
BLINCYTO® (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014",1597258,blinatumomab,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/train_xml/20240220_38b482a8-960b-4591-9857-5031ecb830aa.json,38b482a8-960b-4591-9857-5031ecb830aa,35,"These highlights do not include all the information needed to use BLINCYTO® safely and effectively. See full prescribing information for BLINCYTO.  
BLINCYTO® (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014",1597258,blinatumomab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_81a33cfa-262f-4432-a05d-7dd260928437.json,81a33cfa-262f-4432-a05d-7dd260928437,7,"These highlights do not include all the information needed to use ABRILADA safely and effectively. See full prescribing information for ABRILADA.
ABRILADA™ (adalimumab-afzb) injection, for subcutaneous useInitial U.S. Approval: 2019
ABRILADA (adalimumab-afzb) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ABRILADA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA (adalimumab).",797541,isopropyl alcohol,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230908_bb9a3820-f31a-4dd9-bef4-97094c01a398.json,bb9a3820-f31a-4dd9-bef4-97094c01a398,7,"These highlights do not include all the information needed to use LEUKINE safely and effectively. See full prescribing information for LEUKINE.
		
LEUKINE® (sargramostim) for injection, for subcutaneous or intravenous use
		Initial U.S. Approval: 1991",69634,sargramostim,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230908_c0978fa8-53ff-4ca2-82a7-567fd3e958ca.json,c0978fa8-53ff-4ca2-82a7-567fd3e958ca,16,"These highlights do not include all the information needed to use VEKLURY safely and effectively. See full prescribing information for VEKLURY.
 VEKLURY® (remdesivir) for injection, for intravenous use  VEKLURY® (remdesivir) injection, for intravenous use Initial U.S. Approval: 2020",2284718,remdesivir,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,3850cce2-6137-42e5-a792-d318c4a4b3b5,14,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012",1363268,cabozantinib,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,3850cce2-6137-42e5-a792-d318c4a4b3b5,14,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012",1363268,cabozantinib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,84137882-e000-47da-bd5b-fa76ab3c76f9,20,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012",1242999,axitinib,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231019_235dfc38-0f0b-4037-b501-7a9f4294740c.json,235dfc38-0f0b-4037-b501-7a9f4294740c,16,"These highlights do not include all the information needed to use BRAFTOVI safely and effectively. See full prescribing information for BRAFTOVI.
BRAFTOVI® (encorafenib) capsules, for oral useInitial U.S. Approval: 2018",2049106,encorafenib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,4911f343-68e6-71b0-e054-00144ff8d46c,5,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000",41493,meloxicam,10018830,haematemesis,500001001,gi bleed,11,1,500001001,1150345,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_9d88f915-13dd-5463-e053-2a95a90a09bf.json,9d88f915-13dd-5463-e053-2a95a90a09bf,3,ENALAPRILAT INJECTION 1.25mg/mL 1mL VIAL,3829,enalaprilat,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1342001,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_9d88f915-13dd-5463-e053-2a95a90a09bf.json,9d88f915-13dd-5463-e053-2a95a90a09bf,3,ENALAPRILAT INJECTION 1.25mg/mL 1mL VIAL,3829,enalaprilat,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1342001,1,1
./data/2024_latest_labels/latest_labels_ingredients/20080508_d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee.json,d3e5fbbf-4a1f-4aa2-8e80-9729f6cf04ee,1,INNOHEP®(tinzaparin sodium injection),69646,tinzaparin,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_584abe73-8290-4484-ff8e-5890831c095e.json,584abe73-8290-4484-ff8e-5890831c095e,21,"These highlights do not include all the information needed to use IMITREX safely and effectively. See full prescribing information for IMITREX.IMITREX (sumatriptan) tablets, for oral useInitial U.S. Approval: 1992",37418,sumatriptan,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,"IBUPROFEN Tablets, USP",5640,ibuprofen,10069339,acute kidney injury,500000401,acute kidney injury,6,1,500000401,1177480,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240202_a3d68763-95e0-4ad6-89c2-c4b1c0b43948.json,a3d68763-95e0-4ad6-89c2-c4b1c0b43948,1,"Torsemide Tablets, USP
 


These highlights do not include all the information needed to use TORSEMIDE TABLETS safely and effectively. See full prescribing information for TORSEMIDE TABLETS
 

TORSEMIDE tablets, for oral use
 
Initial U.S. Approval: 1993",38413,torsemide,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,56d64558-1fad-420e-8fcd-7103cd073127,1,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998",140587,celecoxib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_64b7df84-c990-49f7-bc04-0cccfd7d2019.json,64b7df84-c990-49f7-bc04-0cccfd7d2019,14,"These highlights do not include all the information needed to use TRAMADOL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAMADOL HYDROCHLORIDE TABLETS.
 



TRAMADOL HYDROCHLORIDE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1995",10689,tramadol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_13abdafb-71a8-40a1-ba5a-7c2b2573e53e.json,13abdafb-71a8-40a1-ba5a-7c2b2573e53e,12,"Amitriptyline Hydrochloride Tablets, USP",704,amitriptyline,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,42f49299-7ae5-4d30-86eb-66b739c0e95d,5,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988",29046,lisinopril,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1308216,1,1
./data/2024_latest_labels/train_xml/20231208_df918ec2-0907-443f-a52a-b72866959644.json,df918ec2-0907-443f-a52a-b72866959644,22,"These highlights do not include all the information needed to use GRANIX safely and effectively.  See full prescribing information for GRANIX.GRANIX® (tbo-filgrastim) injection, for subcutaneous use Initial U.S. Approval: 2012",68442,filgrastim,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,304a3059-4f7f-4ec4-839d-86492bb5e07b,6,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003",6719,memantine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_b6737b25-0c4f-4131-ba23-b0f2252a18ea.json,b6737b25-0c4f-4131-ba23-b0f2252a18ea,9,"These highlights do not include all the information needed to use SIMVASTATIN TABLETS safely and effectively. See full prescribing information for SIMVASTATIN TABLETS.








SIMVASTATIN tablets, for oral use








Initial U.S. Approval:
1991",36567,simvastatin,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240119_6d1c87df-b319-4c63-9f19-6584d7c4ff8e.json,6d1c87df-b319-4c63-9f19-6584d7c4ff8e,8,Rifampin Capsules USP,9384,rifampin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,500000301,1763204,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240221_6fc9c8e2-6f34-aa43-e053-2a91aa0ac377.json,6fc9c8e2-6f34-aa43-e053-2a91aa0ac377,10,"QUETIAPINE TABLETS. These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
 

Quetiapine tablets, for oral use
 

Initial U.S. Approval: 1997",51272,quetiapine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_116f4f0d-66c5-49dd-e063-6394a90ab2b5.json,116f4f0d-66c5-49dd-e063-6394a90ab2b5,1,"Acyclovir Tablets, USP",281,acyclovir,10062237,renal impairment,500000401,acute kidney injury,8,1,500000401,1703687,1,1
./data/2024_latest_labels/train_xml/20230816_6a9cbc29-9f15-4b24-8d86-206b82887f3d.json,6a9cbc29-9f15-4b24-8d86-206b82887f3d,24,"These highlights do not include all the information needed to use INTELENCE safely and effectively. See full prescribing information for INTELENCE.
 





INTELENCE 
 ®(etravirine) tablets, for oral use
 

Initial U.S. Approval: 2008",475969,etravirine,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_eb354221-c476-41cb-ad87-52423f81d698.json,eb354221-c476-41cb-ad87-52423f81d698,3,"Cefdinir Capsules, USP
 
Rx only",25037,cefdinir,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_0d976866-81b3-5db8-e063-6294a90a39f9.json,0d976866-81b3-5db8-e063-6294a90a39f9,3,"",8727,progesterone,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993",8703,fenofibrate,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240119_00aa81c2-73c7-4bf8-94e9-f644381b631f.json,00aa81c2-73c7-4bf8-94e9-f644381b631f,4,"These highlights do not include all the information needed to use ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES.
 

ESOMEPRAZOLE MAGNESIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989 (omeprazole)",283742,esomeprazole,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_8b365514-c859-ff93-e053-2a95a90ac698.json,8b365514-c859-ff93-e053-2a95a90ac698,4,"LEFLUNOMIDE TABLETS
   

Rx Only
   

These highlights do not include all the information needed to use
   

See full prescribing information for
   

Initial U.S. Approval",27169,leflunomide,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_9e5c0ef3-3179-4d7b-bc76-901473c73ce8.json,9e5c0ef3-3179-4d7b-bc76-901473c73ce8,20,"These highlights do not include all the information needed to use VARENICLINE TABLETS safely and effectively. See full prescribing information for VARENICLINE TABLETS.



VARENICLINE tablets, for oral use 

Initial U.S. Approval: 2006",591622,varenicline,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_9e5c0ef3-3179-4d7b-bc76-901473c73ce8.json,9e5c0ef3-3179-4d7b-bc76-901473c73ce8,20,"These highlights do not include all the information needed to use VARENICLINE TABLETS safely and effectively. See full prescribing information for VARENICLINE TABLETS.



VARENICLINE tablets, for oral use 

Initial U.S. Approval: 2006",591622,varenicline,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,"IBUPROFEN Tablets, USP",5640,ibuprofen,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,500000301,1177480,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994",28439,lamotrigine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994",28439,lamotrigine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009",73689,febuxostat,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_b3ecc533-dd55-4a2f-84c4-ecd454aae766.json,b3ecc533-dd55-4a2f-84c4-ecd454aae766,14,"These highlights do not include all the information needed to use BALSALAZIDE DISODIUM CAPSULES safely and effectively. See full prescribing information for BALSALAZIDE DISODIUM CAPSULES.
 

BALSALAZIDE DISODIUM capsules, for oral use
 
Initial U.S. Approval: 2000",18747,balsalazide,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_b3ecc533-dd55-4a2f-84c4-ecd454aae766.json,b3ecc533-dd55-4a2f-84c4-ecd454aae766,14,"These highlights do not include all the information needed to use BALSALAZIDE DISODIUM CAPSULES safely and effectively. See full prescribing information for BALSALAZIDE DISODIUM CAPSULES.
 

BALSALAZIDE DISODIUM capsules, for oral use
 
Initial U.S. Approval: 2000",18747,balsalazide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_666f89b4-fd81-420a-a390-eb1cd4014f61.json,666f89b4-fd81-420a-a390-eb1cd4014f61,10,Rx only,3393,diflunisal,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1126128,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240217_0f15cb50-5917-c928-e063-6294a90ab284.json,0f15cb50-5917-c928-e063-6294a90ab284,2,"Cevimeline Hydrochloride Capsules
 
Rx only",44281,cevimeline,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_69301126-c901-4d0d-9acb-91ba1a87cd21.json,69301126-c901-4d0d-9acb-91ba1a87cd21,26,"HIGHLIGHTS OF PRESCRIBING INFORMATION
 

These highlights do not include all the information needed to use valacyclovir hydrochloride safely and effectively. See full prescribing information for valacyclovir hydrochloride.
 

Valacyclovir Tablets, USP
 

Initial U.S. Approval:1995",73645,valacyclovir,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_029a90b6-0722-49be-8400-3ec29526aafd.json,029a90b6-0722-49be-8400-3ec29526aafd,6,"These highlights do not include all the information needed to use IRBESARTAN TABLETS safely and effectively. See full prescribing information for IRBESARTAN TABLETS.
 



IRBESARTAN tablets, for oral use
 

Initial U.S. Approval: 1997",83818,irbesartan,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,c35e019d-ec34-4e61-9400-a7ae7913e025,3,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004",337525,erlotinib,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_8ea61d0d-4403-4d9f-a946-85a459cc0aa0.json,8ea61d0d-4403-4d9f-a946-85a459cc0aa0,5,"These highlights do not include all the information needed to use FONDAPARINUX SODIUM INJECTION safely and effectively. See full prescribing information for FONDAPARINUX SODIUM INJECTION.
 FONDAPARINUX SODIUM injection, for subcutaneous use Initial U.S. Approval: 2001",321208,fondaparinux,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240127_6aec72b5-a9f4-45a3-82a6-7d3de64ba5e5.json,6aec72b5-a9f4-45a3-82a6-7d3de64ba5e5,100,"Probenecid Tablets, USP500 mg
Rx Only",8698,probenecid,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,5108ca9c-b307-4cb2-8ea1-6553764f375a,13,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002",321988,escitalopram,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230223_4764f37b-c9e6-4ede-bcc2-8a03b7c521df.json,4764f37b-c9e6-4ede-bcc2-8a03b7c521df,46,"These highlights do not include all the information needed to use SPRYCEL® safely and effectively. See full prescribing information for SPRYCEL.

SPRYCEL (dasatinib) tablets, for oral useInitial U.S. Approval: 2006",475342,dasatinib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230115_c94e51d9-beef-4b06-e053-2a95a90a754a.json,c94e51d9-beef-4b06-e053-2a95a90a754a,3,Steritalc,10323,talc,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,88441a9f-b4f9-455d-a355-46fb30699a7b,10,"Sulfasalazine Tablets, USP",9524,sulfasalazine,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/gold_xml/20231205_5359b759-db7c-4672-9e8a-59c93869bd91.json,5359b759-db7c-4672-9e8a-59c93869bd91,5,"These highlights do not include all the information needed to use VIBATIV® (telavancin) safely and effectively. See full prescribing information for VIBATIV. 
VIBATIV® (telavancin) for injection, for intravenous use Initial U.S. Approval: 2009",473837,telavancin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,9678a98e-4aab-4d87-b5e1-37c3109e378e,16,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996",57258,tizanidine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,"Venlafaxine Tablets, USP
 
Rx only",39786,venlafaxine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_0e98593a-8424-48c8-acc0-671f4b566aee.json,0e98593a-8424-48c8-acc0-671f4b566aee,9,"These highlights do not include all the information needed to use CARVEDILOL TABLETS safely and effectively. See full prescribing information for CARVEDILOL TABLETS.
 

CARVEDILOL tablets, for oral use
 
Initial U.S. Approval: 1995",20352,carvedilol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231115_f9c6fd52-6e28-482c-8b76-bd111760a34c.json,f9c6fd52-6e28-482c-8b76-bd111760a34c,10,"These highlights do not include all the information needed to use NALFON safely and effectively. See full prescribing information for NALFON.
 



NALFON (fenoprofen calcium, USP) capsules, for oral use
 

Initial U.S. Approval: 1982",4331,fenoprofen,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1153928,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240214_a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243.json,a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243,9,"These highlights do not include all the information needed to use GALANTAMINE TABLETS safely and effectively. See full prescribing information for GALANTAMINE TABLETS.
 GALANTAMINE tablets, for oral use Initial U.S. Approval: 2001",4637,galantamine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_49873158-5c0a-41da-86a2-369ef6b0cbc8.json,49873158-5c0a-41da-86a2-369ef6b0cbc8,2,"These highlights do not include all the information needed to use RANOLAZINE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for RANOLAZINE EXTENDED-RELEASE TABLETS.
 RANOLAZINE extended-release tablets, for oral use Initial U.S. Approval: 2006",35829,ranolazine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_b1274d78-1096-4ae3-8299-a2e94eaa0ea5.json,b1274d78-1096-4ae3-8299-a2e94eaa0ea5,16,Itraconazole Capsules,28031,itraconazole,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1703653,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240223_b1274d78-1096-4ae3-8299-a2e94eaa0ea5.json,b1274d78-1096-4ae3-8299-a2e94eaa0ea5,16,Itraconazole Capsules,28031,itraconazole,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240102_7036c6df-6527-4701-b484-6b962914b52a.json,7036c6df-6527-4701-b484-6b962914b52a,7,Tiagabine Hydrochloride Tablets,31914,tiagabine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,8345d55e-ad02-4726-a04b-1a46e3337a4b,13,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998",194000,capecitabine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_1738a682-5903-b675-3a7a-61d299a6f248.json,1738a682-5903-b675-3a7a-61d299a6f248,19,"These highlights do not include all the information needed to use ZOLEDRONIC ACID INJECTION safely and effectively. See full prescribing information for ZOLEDRONIC ACID INJECTION. ZOLEDRONIC ACID injection, for intravenous use 
Initial U.S. Approval: 2001",77655,zoledronic acid,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240117_79eec27d-ac63-4996-8b1a-c2cd52ad2b2c.json,79eec27d-ac63-4996-8b1a-c2cd52ad2b2c,5,"These highlights do not include all the information needed to use ARGATROBAN INJECTION safely and effectively. See full prescribing information for ARGATROBAN INJECTION.


ARGATROBAN INJECTION, for intravenous infusion only 

Initial U.S. Approval: 2000",15202,argatroban,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992",32613,oxaprozin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1118045,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,52781229-ee82-43f9-a113-4419a611978d,1,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000",183379,rivastigmine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231117_0c8ca614-58b2-4aa4-83d3-0387a8f782fd.json,0c8ca614-58b2-4aa4-83d3-0387a8f782fd,9,"These highlights do not include all the information needed to use VITRAKVI safely and effectively.  See full prescribing information for VITRAKVI.
VITRAKVI® (larotrectinib) capsules, for oral use VITRAKVI® (larotrectinib) oral solutionInitial U.S. Approval: 2018",2105628,larotrectinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231205_4afb20ee-eb3f-1937-ffa4-5d3228e82688.json,4afb20ee-eb3f-1937-ffa4-5d3228e82688,3,Penicillamine Capsules,7975,penicillamine,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,19028050,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240217_0becbde8-6ec5-4830-a0d9-cfdb7b15eb84.json,0becbde8-6ec5-4830-a0d9-cfdb7b15eb84,11,"Minocycline Hydrochloride Capsules, USP
 

Rx only",6980,minocycline,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/gold_xml/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,7e9ab975-db2f-423c-a089-bc5a73313609,11,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011",1114195,rivaroxaban,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240124_00fd1905-27e4-420e-8dc5-a69e4ddc1526.json,00fd1905-27e4-420e-8dc5-a69e4ddc1526,11,"These highlights do not include all the information needed to use NITYR safely and effectively. See full prescribing information for NITYR.
NITYR® (nitisinone) tablets, for oral useInitial U.S. Approval: 2002",61805,nitisinone,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220420_accf9569-4b57-4e83-a7db-4e890a75d1ba.json,accf9569-4b57-4e83-a7db-4e890a75d1ba,23,"MitoXANTRONE Injection, USP (concentrate)",7005,mitoxantrone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220420_accf9569-4b57-4e83-a7db-4e890a75d1ba.json,accf9569-4b57-4e83-a7db-4e890a75d1ba,23,"MitoXANTRONE Injection, USP (concentrate)",7005,mitoxantrone,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/gold_xml/20240110_4650d12c-b9c8-4525-b07f-a2d773eca155.json,4650d12c-b9c8-4525-b07f-a2d773eca155,26,"These highlights do not include all the information needed to use AUBAGIO® safely and effectively. See full prescribing information for AUBAGIO. 
AUBAGIO (teriflunomide) tablets, for oral use Initial U.S. Approval: 2012",1310520,teriflunomide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230321_f7573809-7741-04c9-e053-6294a90ab193.json,f7573809-7741-04c9-e053-6294a90ab193,1,"ZILEUTON EXTENDED-RELEASE TABLETS. These highlights do not include all the information needed to use ZILEUTON EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for ZILEUTON EXTENDED-RELEASE TABLETS.
 

ZILEUTON extended-release tablets, for oral use
 

Initial U.S. Approval: 1996",40575,zileuton,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_a99335d0-1e87-4180-bde3-cbb12bf91a52.json,a99335d0-1e87-4180-bde3-cbb12bf91a52,1,"These highlights do not include all the information needed to use DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION.
DEXMEDETOMIDINE HYDROCHLORIDE in 0.9% SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 1999",48937,dexmedetomidine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231205_a64a50ba-e3da-4227-9bce-87101d60409e.json,a64a50ba-e3da-4227-9bce-87101d60409e,2,"These highlights do not include all the information needed to use SAPROPTERIN DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SAPROPTERIN DIHYDROCHLORIDE TABLETS.
 
SAPROPTERIN DIHYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2007",753340,sapropterin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959""",3002,cyclophosphamide,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_21002702-422b-1402-73b8-670314d8e579.json,21002702-422b-1402-73b8-670314d8e579,3,"These highlights do not include all the information needed to use LIOTHYRONINE SODIUM TABLETS safely and effectively. See full prescribing information for LIOTHYRONINE SODIUM TABLETS.
LIOTHYRONINE SODIUM tablets, for oral useInitial U.S. Approval: 1956",10814,liothyronine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b.json,3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b,13,"These highlights do not include all the information needed to use MICAFUNGIN FOR INJECTION safely and effectively. See full prescribing information for MICAFUNGIN FOR INJECTION.
 MICAFUNGIN for Injection, for intravenous infusion only Initial U.S. Approval: 2005",325887,micafungin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993",8703,fenofibrate,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230325_294b168b-6e5f-4db9-bf70-d599271458b3.json,294b168b-6e5f-4db9-bf70-d599271458b3,6,These highlights do not include all the information needed to use ZOLADEX safely and effectively. See full prescribing information for ZOLADEX.ZOLADEX® (goserelin implant) 3.6 mgInitial U.S. Approval: 1989,50610,goserelin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231206_06a0322b-eb28-44e2-9925-88bebd8fa91b.json,06a0322b-eb28-44e2-9925-88bebd8fa91b,9,"These highlights do not include all the information needed to use carmustine for injection, USP safely and effectively. See full prescribing information for carmustine for injection, USP.
Carmustine for injection, USP, for intravenous use Initial U.S. Approval: 1977",2105,carmustine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_a3087a39-f218-4f16-a1e7-17c39bb2eb69.json,a3087a39-f218-4f16-a1e7-17c39bb2eb69,5,"HYDROXOCOBALAMIN INJECTION USP
Rx Only",5514,hydroxocobalamin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_dbf738c4-3fac-4422-a9d8-51d9c83a8789.json,dbf738c4-3fac-4422-a9d8-51d9c83a8789,3,"These highlights do not include all the information needed to use RENFLEXIS® safely and effectively. See full prescribing information for RENFLEXIS. 
RENFLEXIS (infliximab-abda) for injection, for intravenous use Initial U.S. Approval: 2017 RENFLEXIS (infliximab-abda) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of RENFLEXIS has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to REMICADE (infliximab).",191831,infliximab,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,937368,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240110_dbf738c4-3fac-4422-a9d8-51d9c83a8789.json,dbf738c4-3fac-4422-a9d8-51d9c83a8789,3,"These highlights do not include all the information needed to use RENFLEXIS® safely and effectively. See full prescribing information for RENFLEXIS. 
RENFLEXIS (infliximab-abda) for injection, for intravenous use Initial U.S. Approval: 2017 RENFLEXIS (infliximab-abda) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of RENFLEXIS has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to REMICADE (infliximab).",191831,infliximab,10067125,liver injury,500000301,acute liver injury,6,1,500000301,937368,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240104_f941fc61-f7a3-4e4a-ab7c-87c1667fa05b.json,f941fc61-f7a3-4e4a-ab7c-87c1667fa05b,5,"These highlights do not include all the information needed to use RUXIENCE safely and effectively. See full prescribing information for RUXIENCE. 
RUXIENCE® (rituximab-pvvr) injection, for intravenous use Initial U.S. Approval: 2019 
RUXIENCE (rituximab-pvvr) is biosimilar
Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of RUXIENCE has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.
 to RITUXAN (rituximab)",121191,rituximab,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_19880f51-badb-4846-a02a-592a210690ab.json,19880f51-badb-4846-a02a-592a210690ab,10,"These highlights do not include all the information needed to use SIROLIMUS ORAL SOLUTION safely and effectively. See full prescribing information for SIROLIMUS ORAL SOLUTION.


SIROLIMUS oral solutionInitial U.S. Approval: 1999",35302,sirolimus,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231216_d9fd11d0-4269-12fb-95cf-b3c11d75e479.json,d9fd11d0-4269-12fb-95cf-b3c11d75e479,6,"These highlights do not include all the information needed to use TOLVAPTAN TABLETS safely and effectively. See full prescribing information for TOLVAPTAN TABLETS.

TOLVAPTAN tablets, for oral use

Initial U.S. Approval: 2009",358257,tolvaptan,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_f8b01c77-620d-4734-a771-b8524b65bcca.json,f8b01c77-620d-4734-a771-b8524b65bcca,3,"These highlights do not include all the information needed to use KETAMINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for KETAMINE HYDROCHLORIDE INJECTION. KETAMINE HYDROCHLORIDE injection, for intravenous or intramuscular use, CIII Initial U.S. Approval: 1970",6130,ketamine,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,2150f73a-179b-4afc-b8ce-67c85cc72f04,60,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009",141704,everolimus,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,f47d4365-40a8-445b-99cd-49edad6a8ffc,15,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only",35827,ketorolac,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1136980,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240110_f2feda53-54b9-4e40-8a01-9e7b45cb3d8c.json,f2feda53-54b9-4e40-8a01-9e7b45cb3d8c,9,"These highlights do not include all the information needed to use ARFORMOTEROL TARTRATE INHALATION SOLUTION safely and effectively. See full prescribing information for ARFORMOTEROL TARTRATE INHALATION SOLUTION.
 ARFORMOTEROL TARTRATE inhalation solution Initial U.S. Approval: 2006",304962,arformoterol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_10e39d3b-8621-16f8-e063-6294a90a254e.json,10e39d3b-8621-16f8-e063-6294a90a254e,1,"ALVIMOPAN CAPSULES. These highlights do not include all the information needed to use ALVIMOPAN CAPSULES safely and effectively. See full prescribing information for ALVIMOPAN CAPSULES.
 

ALVIMOPAN capsules, for oral use
 
Initial U.S. Approval: 2008",480639,alvimopan,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/train_xml/20221029_39d53698-57fa-7c99-fc5b-f52a55684826.json,39d53698-57fa-7c99-fc5b-f52a55684826,26,"These highlights do not include all the information needed to use TREANDA safely and effectively. See full prescribing information for TREANDA.
TREANDA® (bendamustine hydrochloride) injection, for intravenous useTREANDA® (bendamustine hydrochloride) for injection, for intravenous useInitial U.S. Approval: 2008",134547,bendamustine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_766b73e2-49bb-47f9-bbb1-44cfa1a3197e.json,766b73e2-49bb-47f9-bbb1-44cfa1a3197e,4,"These highlights do not include all the information needed to use BENDAMUSTINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for BENDAMUSTINE HYDROCHLORIDE INJECTION. 
	BENDAMUSTINE HYDROCHLORIDE injection,	 for intravenous use. 	Initial U.S. Approval: 2008",134547,bendamustine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/train_xml/20220723_fd638e5e-8032-e7ca-0179-95e96ab5d387.json,fd638e5e-8032-e7ca-0179-95e96ab5d387,18,"These highlights do not include all the information needed to use GILOTRIF safely and effectively.  See full prescribing information for GILOTRIF. 
GILOTRIF® (afatinib tablets), for oral use Initial U.S. Approval: 2013",1430438,afatinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_2ecc0f15-1d46-4b87-a6ae-aebb7b38bc73.json,2ecc0f15-1d46-4b87-a6ae-aebb7b38bc73,2,"These highlights do not include all the information needed to use CAPLYTA safely and effectively. See full prescribing information for CAPLYTA.


CAPLYTA 
  ® (lumateperone) capsules, for oral use 
 

Initial U.S. Approval: 2019",2275602,lumateperone,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220928_88b434fa-8891-4fd5-9d86-7ea64667c08f.json,88b434fa-8891-4fd5-9d86-7ea64667c08f,7,"These highlights do not include all the information needed to use KENGREAL safely and effectively.  See full prescribing information for KENGREAL.

KENGREAL® (
c
angrelor) for injection, for intravenous use

Initial U.S. Approval:  201
5",1656052,cangrelor,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6.json,a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6,10,"These highlights do not include all the information needed to use IDHIFA safely and effectively. See full prescribing information for IDHIFA. 
IDHIFA® (enasidenib) tablets, for oral use Initial U.S. Approval: 2017",1940332,enasidenib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221103_03880372-2c68-45c6-a53a-f420c49541d6.json,03880372-2c68-45c6-a53a-f420c49541d6,21,"These highlights do not include all the information needed to use EDURANT safely and effectively. See full prescribing information for EDURANT. 
EDURANT® (rilpivirine) tablets for oral useInitial U.S. Approval: 2011",1102270,rilpivirine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221118_3ecde48b-75a2-4beb-9999-369f3f61bb8a.json,3ecde48b-75a2-4beb-9999-369f3f61bb8a,37,"These highlights do not include all the information needed to use
 
T
EFLARO 
safely and effectively. See full prescribing information for 
TE
FLARO
.

    

TE
FLARO

®

 (ceftaroline fosamil) 
for 
injection
,
 for intravenous use

Initial U.S. Approval: 
2010",1040004,ceftaroline fosamil,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231118_31ce4750-ded5-4a0b-95e9-f229fa6bc822.json,31ce4750-ded5-4a0b-95e9-f229fa6bc822,66,"These highlights do not include all the information needed to use HALAVEN safely and effectively.  See full prescribing information for HALAVEN.

 

HALAVEN

®

 (eribulin mesylate) injection, for intravenous use

Initial U.S. Approval: 2010",1045453,eribulin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20231213_58353438-3236-4596-9324-62fed9615cb7.json,58353438-3236-4596-9324-62fed9615cb7,12,"These highlights do not include all the information needed to use TRULICITY safely and effectively. See full prescribing information for TRULICITY.
TRULICITY (dulaglutide) injection, for subcutaneous useInitial U.S. Approval: 2014",1551291,dulaglutide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/gold_xml/20231202_824f19c9-0546-4a8a-8d8f-c4055c04f7c7.json,824f19c9-0546-4a8a-8d8f-c4055c04f7c7,33,"These highlights do not include all the information needed to use STIVARGA safely and effectively.  See full prescribing information for STIVARGA.STIVARGA® (regorafenib) tablets, for oral useInitial U.S. Approval: 2012",1312397,regorafenib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_a6d46c03-bb1d-417b-b8e5-3bffe352fe29.json,a6d46c03-bb1d-417b-b8e5-3bffe352fe29,14,"These highlights do not include all the information needed to use RUBRACA safely and effectively. See full prescribing information for RUBRACA.
 
RUBRACA 
 ®(rucaparib) tablets, for oral use
 
Initial U.S. Approval: 2016",1862579,rucaparib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008",709271,certolizumab pegol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/gold_xml/20231104_f7b3f443-e83d-4bf2-0e96-023448fed9a8.json,f7b3f443-e83d-4bf2-0e96-023448fed9a8,49,"These highlights do not include all the information needed to use BRILINTA safely and effectively. See full prescribing information for BRILINTA.
BRILINTA® (ticagrelor) tablets, for oral useInitial U.S. Approval: 2011",1116632,ticagrelor,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230125_80686b7e-f6f4-4154-b5c0-c846425e2d91.json,80686b7e-f6f4-4154-b5c0-c846425e2d91,12,"These highlights do not include all the information needed to use EMPLICITI safely and effectively. See full prescribing information for EMPLICITI.
EMPLICITI
®
 (elotuzumab) for injection, for intravenous useInitial U.S. Approval: 2015",1726104,elotuzumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_c5116390-e0fe-4969-94cb-e9de5165fbab.json,c5116390-e0fe-4969-94cb-e9de5165fbab,23,"These highlights do not include all the information needed to use ONGLYZA safely and effectively. See full prescribing information for ONGLYZA.
ONGLYZA® (saxagliptin) tablets, for oral useInitial U.S. Approval: 2009",857974,saxagliptin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_38eea320-7e0c-485a-bc30-98c3c45e2763.json,38eea320-7e0c-485a-bc30-98c3c45e2763,24,"These highlights do not include all the information needed to use ZELBORAF safely and effectively. See full prescribing information for ZELBORAF. 
 ZELBORAF® (vemurafenib) tablet for oral use  Initial U.S. Approval: 2011",1147220,vemurafenib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240125_077a92f6-9f1b-479a-87c7-c92b5db6aa9c.json,077a92f6-9f1b-479a-87c7-c92b5db6aa9c,10,"These highlights do not include all the information needed to use ORGOVYX safely and effectively. See full prescribing information for ORGOVYX.
 



ORGOVYX (relugolix) tablets, for oral use
 

Initial U.S. Approval: 2020",2472778,relugolix,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/gold_xml/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013",1369713,pomalidomide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013",1369713,pomalidomide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_48aa32cb-047a-414a-822e-82a5f26d8817.json,48aa32cb-047a-414a-822e-82a5f26d8817,17,"Diazepam Tablets, USP, CIV


Rx only",3322,diazepam,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_fb973a8d-7fea-4a7a-963f-2a8e67a46e55.json,fb973a8d-7fea-4a7a-963f-2a8e67a46e55,6,"These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.
		

		PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use
		
		Initial U.S. Approval: 2022",2597054,vipivotide tetraxetan,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_be4bc0de-0fdc-4d46-8d25-be43c79e6a06.json,be4bc0de-0fdc-4d46-8d25-be43c79e6a06,22,"These highlights do not include all the information needed to use VERZENIO safely and effectively. See full prescribing information for VERZENIO.
VERZENIO® (abemaciclib) tablets, for oral useInitial U.S. Approval: 2017",1946825,abemaciclib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_be4bc0de-0fdc-4d46-8d25-be43c79e6a06.json,be4bc0de-0fdc-4d46-8d25-be43c79e6a06,22,"These highlights do not include all the information needed to use VERZENIO safely and effectively. See full prescribing information for VERZENIO.
VERZENIO® (abemaciclib) tablets, for oral useInitial U.S. Approval: 2017",1946825,abemaciclib,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,6fa682c9-a312-4932-9831-f286908660ee,34,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016",1792776,atezolizumab,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20230803_5429f134-839f-4ffc-9944-55f51238def8.json,5429f134-839f-4ffc-9944-55f51238def8,17,"These highlights do not include all the information needed to use SAPHRIS (asenapine) 
sublingual tablets 
safely and effectively. See full prescribing information for SAPHRIS.

  

SAPHRIS

®

 (asenapine) sublingual tablets

Initial U.S. Approval: 2009",784649,asenapine,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/gold_xml/20230615_1e484a50-55db-4b85-8c57-6cd1b0353abd.json,1e484a50-55db-4b85-8c57-6cd1b0353abd,32,"These highlights do not include all the information needed to use OPSUMIT safely and effectively. See full prescribing information for OPSUMIT.
 



OPSUMIT 
 ® (macitentan) tablets, for oral use
 

Initial U.S. Approval: 2013",1442132,macitentan,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230627_3904f8dd-1aef-3490-e48f-bd55f32ed67f.json,3904f8dd-1aef-3490-e48f-bd55f32ed67f,34,"These highlights do not include all the information needed to use ADCETRIS safely and effectively. See full prescribing information for ADCETRIS. 
ADCETRIS® (brentuximab vedotin) for injection, for intravenous use Initial U.S. approval: 2011",1147320,brentuximab vedotin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,2265ef30-253e-11df-8a39-0800200c9a66,42,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011",1094833,ipilimumab,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_38b482a8-960b-4591-9857-5031ecb830aa.json,38b482a8-960b-4591-9857-5031ecb830aa,35,"These highlights do not include all the information needed to use BLINCYTO® safely and effectively. See full prescribing information for BLINCYTO.  
BLINCYTO® (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014",1597258,blinatumomab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_81a33cfa-262f-4432-a05d-7dd260928437.json,81a33cfa-262f-4432-a05d-7dd260928437,7,"These highlights do not include all the information needed to use ABRILADA safely and effectively. See full prescribing information for ABRILADA.
ABRILADA™ (adalimumab-afzb) injection, for subcutaneous useInitial U.S. Approval: 2019
ABRILADA (adalimumab-afzb) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ABRILADA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA (adalimumab).",797541,isopropyl alcohol,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_58d80bc6-bdfb-4908-93e7-aace447c8d1a.json,58d80bc6-bdfb-4908-93e7-aace447c8d1a,1,"These highlights do not include all the information needed to use MYCAPSSA® safely and effectively. See full prescribing information for MYCAPSSA.
 MYCAPSSA (octreotide) delayed-release capsules, for oral use Initial U.S. Approval: 1988",7617,octreotide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240213_a60c5173-6bc0-4c9d-9674-b3f4d68f79ba.json,a60c5173-6bc0-4c9d-9674-b3f4d68f79ba,4,"These highlights do not include all the information needed to use CISPLATIN INJECTION, USP safely and effectively. See full prescribing information for CISPLATIN INJECTION, USP.
 



CISPLATIN injection USP, for intravenous use
 



Initial U.S. Approval: 1978",2555,cisplatin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230811_632bb50c-3bcb-4c85-9056-fc33410550ae.json,632bb50c-3bcb-4c85-9056-fc33410550ae,5,"These highlights do not include all the information needed to use ZEPZELCA safely and effectively.  See full prescribing information for ZEPZELCA.

ZEPZELCA® (lurbinectedin) for injection, for intravenous use
Initial U.S. Approval: 2020",2374729,lurbinectedin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230817_5be69660-738c-4db7-b0d4-517aa873dc41.json,5be69660-738c-4db7-b0d4-517aa873dc41,9,"These highlights do not include all the information needed to use PONVORY safely and effectively. See full prescribing information for PONVORY.
 

PONVORY 
 ®(ponesimod) tablets, for oral use
 
Initial U.S. Approval: 2021",2532300,ponesimod,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230907_82f4d266-3f52-41eb-86ba-0abf3cf468e8.json,82f4d266-3f52-41eb-86ba-0abf3cf468e8,18,"These highlights do not include all the information needed to use REBLOZYL safely and effectively. See full prescribing information for REBLOZYL.
 REBLOZYL® (luspatercept-aamt) for injection, for subcutaneous use Initial U.S. Approval:  2019",2262544,luspatercept,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/gold_xml/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,0002ad27-779d-42ab-83b5-bc65453412a1,22,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013",1425099,trametinib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012",1363268,cabozantinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,84137882-e000-47da-bd5b-fa76ab3c76f9,20,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012",1242999,axitinib,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231024_61e025f1-a38e-4af2-9e18-13ea12977cf5.json,61e025f1-a38e-4af2-9e18-13ea12977cf5,2,"These highlights do not include all the information needed to use INTRALIPID® safely and effectively. See full prescribing information for INTRALIPID.
INTRALIPID 20% (lipid injectable emulsion), for intravenous useInitial U.S. Approval: 1975",9949,soybean oil,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,4911f343-68e6-71b0-e054-00144ff8d46c,5,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000",41493,meloxicam,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1150345,1,1
./data/2024_latest_labels/latest_labels_ingredients/20230914_31e79459-107f-4d69-a163-90014f1c4772.json,31e79459-107f-4d69-a163-90014f1c4772,3,Disopyramide phosphate capsules,3541,disopyramide,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231215_8ded0773-3aec-4e89-9836-d22a5a84abf0.json,8ded0773-3aec-4e89-9836-d22a5a84abf0,17,Quinapril Tablets USP,35208,quinapril,10024690,liver function test abnormal,500000301,acute liver injury,15,1,500000301,1331235,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240222_584abe73-8290-4484-ff8e-5890831c095e.json,584abe73-8290-4484-ff8e-5890831c095e,21,"These highlights do not include all the information needed to use IMITREX safely and effectively. See full prescribing information for IMITREX.IMITREX (sumatriptan) tablets, for oral useInitial U.S. Approval: 1992",37418,sumatriptan,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_101b2d4d-4740-4225-94bc-aecc05d82c6b.json,101b2d4d-4740-4225-94bc-aecc05d82c6b,10,"These highlights do not include all the information needed to use RISPERIDONE TABLETS safely and effectively. See full prescribing information for RISPERIDONE TABLETS.
 

RISPERIDONE tablets, for oral use
 



Initial U.S. Approval: 1993",35636,risperidone,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_fbac3b4f-dc23-4359-ac3f-2b3fdde41af2.json,fbac3b4f-dc23-4359-ac3f-2b3fdde41af2,32,"These highlights do not include all the information needed to use ALLOPURINOL TABLETS safely and effectively. See full prescribing information for ALLOPURINOL TABLETS.


ALLOPURINOL tablets for oral use 

Initial U.S. Approval:1966",519,allopurinol,10019692,hepatic necrosis,500000301,acute liver injury,15,1,500000301,1167322,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_4314da8a-40e5-4aba-a32b-57b4166ade30.json,4314da8a-40e5-4aba-a32b-57b4166ade30,12,"These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.  AZITHROMYCIN tablets, for oral use Initial U.S. Approval: 1991",18631,azithromycin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231221_9f416ce0-012f-4194-9382-74ac71e4b2a9.json,9f416ce0-012f-4194-9382-74ac71e4b2a9,6,"Ranitidine Tablets, USP

(150 mg and 300 mg)

Rx Only",9143,ranitidine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_f34c08e6-fe74-4de3-9e36-a82c3c1c183b.json,f34c08e6-fe74-4de3-9e36-a82c3c1c183b,9,"These highlights do not include all the information needed to use MOXIFLOXACIN TABLETS safely and effectively. See full prescribing information for MOXIFLOXACIN TABLETS.
 MOXIFLOXACIN tablets, for oral use Initial U.S. Approval: 1999",139462,moxifloxacin,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_fdbcc274-c343-4461-9db9-6ff1be15d727.json,fdbcc274-c343-4461-9db9-6ff1be15d727,10,"These highlights do not include all the information needed to use 
  BUPROPIONHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for 
  BUPROPIONHYDROCHLORIDE TABLETS. 
 


BUPROPION HYDROCHLORIDE tablets, for oral use
  
Initial U.S. Approval: 1985",42347,bupropion,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,"Venlafaxine Tablets, USP
 
Rx only",39786,venlafaxine,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,ccd95dfc-9236-4707-a715-6a12c91519ff,6,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976",7258,naproxen,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,22174520-4b78-4841-96f7-530ba12d2cf1,8,"Paroxetine Tablets USP, film coated for oral use",32937,paroxetine,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,22174520-4b78-4841-96f7-530ba12d2cf1,8,"Paroxetine Tablets USP, film coated for oral use",32937,paroxetine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)",52582,mesalamine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,52781229-ee82-43f9-a113-4419a611978d,1,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000",183379,rivastigmine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999",21107,cilostazol,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_41ab333a-fafb-4647-844e-f3b2a76723cb.json,41ab333a-fafb-4647-844e-f3b2a76723cb,5,"Cefadroxil Capsules, USP Rx only",2177,cefadroxil,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_ff3b5265-f533-4332-a861-d8c9c1664ffd.json,ff3b5265-f533-4332-a861-d8c9c1664ffd,15,"These highlights do not include all the information needed to use LAMIVUDINE TABLETS safely and effectively. See full prescribing information for LAMIVUDINE TABLETS.LAMIVUDINE tablets, for oral useInitial U.S. Approval: 1995",68244,lamivudine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231221_f567d5c7-ea5d-49a7-a035-b47208135f73.json,f567d5c7-ea5d-49a7-a035-b47208135f73,9,"These highlights do not include all the information needed to use 
QUININE SULFATE CAPSULES safely and effectively. See full prescribing information for
 QUININE SULFATE CAPSULES.


QUININE sulfate capsules, for oral use

Initial U.S. Approval: 2005",9071,quinine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240118_99fb821a-fe33-4468-9026-9729a8deff08.json,99fb821a-fe33-4468-9026-9729a8deff08,5,CYPROHEPTADINE HYDROCHLORIDE TABLETS USPRx only,3013,cyproheptadine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd.json,3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd,8,"These highlights do not include all the information needed to use LEVETIRACETAM INJECTION safely and effectively. See full prescribing information for LEVETIRACETAM INJECTION.
 LEVETIRACETAM injection, for intravenous use Initial U.S. Approval: 1999",114477,levetiracetam,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240119_6d1c87df-b319-4c63-9f19-6584d7c4ff8e.json,6d1c87df-b319-4c63-9f19-6584d7c4ff8e,8,Rifampin Capsules USP,9384,rifampin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_81d9e47e-ae81-4755-a5ee-546a038fadb4.json,81d9e47e-ae81-4755-a5ee-546a038fadb4,7,"These highlights do not include all the information needed to use MIRTAZAPINE TABLETS safely and effectively. See full prescribing information for MIRTAZAPINE TABLETS.
 

MIRTAZAPINE tablets, for oral use
 
Initial U.S. Approval: 1996",15996,mirtazapine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993",8703,fenofibrate,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_2a7300d3-95e3-427e-bf37-55fa654cc90a.json,2a7300d3-95e3-427e-bf37-55fa654cc90a,9,"These highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS.


OLANZAPINE
 tablets, for oral use 


Initial U.S. Approval: 1996",61381,olanzapine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20120508_829e744d-7bd4-43dc-9b58-ffb016cb8e67.json,829e744d-7bd4-43dc-9b58-ffb016cb8e67,1,These highlights do not include all the information needed to use didanosine delayed-release capsules safely and effectively. See full prescribing information for didanosine delayed-release capsules. Initial U.S. Approval: 1991,3364,didanosine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1724869,1,1
./data/2024_latest_labels/latest_labels_ingredients/20120618_83aeddf8-6fed-487c-858b-2240f0a0e8af.json,83aeddf8-6fed-487c-858b-2240f0a0e8af,1,"CRIXIVAN®
(INDINAVIR SULFATE)CAPSULES",114289,indinavir,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)",52582,mesalamine,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_06c0a509-026f-44e0-9975-a94a8de51d43.json,06c0a509-026f-44e0-9975-a94a8de51d43,11,"",2541,cimetidine,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210804_ed23b6bc-32c7-4c50-a53d-313ae78e5623.json,ed23b6bc-32c7-4c50-a53d-313ae78e5623,13,"CEFOTAXIME FOR INJECTION, USP",2186,cefotaxime,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_b6b1d427-e19a-4fc1-b518-f58bacc46736.json,b6b1d427-e19a-4fc1-b518-f58bacc46736,8,"Guanfacine Tablets, USP 


Rx only",40114,guanfacine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_51a88e8e-da02-4b97-9e7e-442fbffd908d.json,51a88e8e-da02-4b97-9e7e-442fbffd908d,8,"These highlights do not include all the information needed to use AMIODARONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for AMIODARONE HYDROCHLORIDE TABLETS.
 

AMIODARONE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1985",703,amiodarone,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,11344047-7ed4-61e7-e063-6394a90a332d,1,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995",17128,lansoprazole,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231231_1e87a81a-7084-4436-918b-a50451534307.json,1e87a81a-7084-4436-918b-a50451534307,11,"These highlights do not include all the information needed to use PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION.  

PILOCARPINE
 hydrochloride ophthalmic solution 

Initial U.S. Approval: 1974",8328,pilocarpine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231231_1e87a81a-7084-4436-918b-a50451534307.json,1e87a81a-7084-4436-918b-a50451534307,11,"These highlights do not include all the information needed to use PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION.  

PILOCARPINE
 hydrochloride ophthalmic solution 

Initial U.S. Approval: 1974",8328,pilocarpine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006,134748,rasagiline,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994",28439,lamotrigine,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_cac4f544-536c-4886-a379-99eed2d35240.json,cac4f544-536c-4886-a379-99eed2d35240,8,"These highlights do not include all the information needed to use SILDENAFIL TABLETS safely and effectively. See full prescribing information for SILDENAFIL TABLETS.
 







SILDENAFIL tablets, for oral use
 







Initial U.S. Approval:1998",136411,sildenafil,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009",73689,febuxostat,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009",73689,febuxostat,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_b7b679a9-6823-4ef8-8d31-3ab5058ffcfc.json,b7b679a9-6823-4ef8-8d31-3ab5058ffcfc,11,"These highlights do not include all the information needed to use ELIGARD
®
 safely and effectively. See full prescribing information for ELIGARD.
ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002",42375,leuprolide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_fdbcc274-c343-4461-9db9-6ff1be15d727.json,fdbcc274-c343-4461-9db9-6ff1be15d727,10,"These highlights do not include all the information needed to use 
  BUPROPIONHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for 
  BUPROPIONHYDROCHLORIDE TABLETS. 
 


BUPROPION HYDROCHLORIDE tablets, for oral use
  
Initial U.S. Approval: 1985",42347,bupropion,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240111_907c965e-8faf-53db-e053-2995a90a8cd1.json,907c965e-8faf-53db-e053-2995a90a8cd1,5,ZONISAMIDE,39998,zonisamide,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240202_596c923d-db8d-4b96-bf31-52186a38c30d.json,596c923d-db8d-4b96-bf31-52186a38c30d,11,"These highlights do not include all the information needed to use PRASUGREL TABLETS safely and effectively. See full prescribing information for PRASUGREL TABLETS.
 PRASUGREL tablets, for oral use Initial U.S. Approval: 2009",613391,prasugrel,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_b3ecc533-dd55-4a2f-84c4-ecd454aae766.json,b3ecc533-dd55-4a2f-84c4-ecd454aae766,14,"These highlights do not include all the information needed to use BALSALAZIDE DISODIUM CAPSULES safely and effectively. See full prescribing information for BALSALAZIDE DISODIUM CAPSULES.
 

BALSALAZIDE DISODIUM capsules, for oral use
 
Initial U.S. Approval: 2000",18747,balsalazide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_1d3a45f3-3854-4d0c-9241-770aa24063fd.json,1d3a45f3-3854-4d0c-9241-770aa24063fd,5,"These highlights do not include all the information needed to use DULOXETINE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DULOXETINE DELAYED-RELEASE CAPSULES.
 
DULOXETINE delayed-release capsules for oral use.
 
Initial U.S. Approval: 2004",72625,duloxetine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_b8d657ac-dbda-4455-8bb5-3896951c3b67.json,b8d657ac-dbda-4455-8bb5-3896951c3b67,4,"These highlights do not include all the information needed to use ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS safely and effectively. See full prescribing information for ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS.
 ZOLMITRIPTAN orally disintegrating tablets Initial U.S. Approval: 1997",135775,zolmitriptan,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240201_8d731e7e-3b04-49a2-a0f6-3779422174cc.json,8d731e7e-3b04-49a2-a0f6-3779422174cc,11,"Tamoxifen Citrate Tablets, USP


Rx 
O
nly",10324,tamoxifen,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_34f83d9d-2c64-463e-8a90-9a460fedfead.json,34f83d9d-2c64-463e-8a90-9a460fedfead,22,"These highlights do not include all the information needed to use LATISSE safely and effectively. See full prescribing information for LATISSE. 

       

LATISSE

®

 (bimatoprost ophthalmic solution) 0.03%
, for topical ophthalmic use
  

Initial U.S. Approval: 2001",283810,bimatoprost,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/train_xml/20111230_236d4549-f44b-4677-b857-acedd10b9920.json,236d4549-f44b-4677-b857-acedd10b9920,2,These highlights do not include all the information needed to use MULTAQ safely and effectively. See full prescribing information for MULTAQ. MULTAQ (dronedarone) TabletsInitial U.S. Approval: 2009,233698,dronedarone,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993",8703,fenofibrate,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,c35e019d-ec34-4e61-9400-a7ae7913e025,3,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004",337525,erlotinib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_caad4ada-2cf9-4e12-99df-6ca4388cf0f6.json,caad4ada-2cf9-4e12-99df-6ca4388cf0f6,100,"These highlights do not include all the information needed to use DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES.


DEXLANSOPRAZOLE delayed-release capsules, for oral use 

Initial U.S. Approval: 1995 (lansoprazole)",816346,dexlansoprazole,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240203_453a5759-2f0d-421d-be78-81ab97c8ce77.json,453a5759-2f0d-421d-be78-81ab97c8ce77,1,"These highlights do not include all the information needed to use DESVENLAFAXINE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DESVENLAFAXINE EXTENDED-RELEASE TABLETS.DESVENLAFAXINE extended-release tablets, for oral useInitial U.S. Approval: 2008",734064,desvenlafaxine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231102_0c721ba4-ae19-417f-aae1-221ed1a0866a.json,0c721ba4-ae19-417f-aae1-221ed1a0866a,29,"These highlights do not include all the information needed to use PROCRIT safely and effectively. See full prescribing information for PROCRIT.
 

PROCRIT 
 ®(epoetin alfa) injection, for intravenous or subcutaneous use
 
Initial U.S. Approval: 1989",105694,epoetin alfa,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1301125,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231231_b9bc3907-bfa7-4d9f-90d9-c2097230f7e4.json,b9bc3907-bfa7-4d9f-90d9-c2097230f7e4,5,"Ethacrynic Acid Tablets, USP 

(25 mg)


Rx Only",62349,ethacrynate,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_64b7df84-c990-49f7-bc04-0cccfd7d2019.json,64b7df84-c990-49f7-bc04-0cccfd7d2019,14,"These highlights do not include all the information needed to use TRAMADOL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAMADOL HYDROCHLORIDE TABLETS.
 



TRAMADOL HYDROCHLORIDE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1995",10689,tramadol,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,51635427-fb13-45ee-813d-a40b0405d14f,7,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information",3355,diclofenac,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231228_67e3ba3c-77e1-43b5-a93c-5bf5e3855780.json,67e3ba3c-77e1-43b5-a93c-5bf5e3855780,2,"GRISEOFULVIN ORAL SUSPENSION, USP


Microsize


125 mg/5 mL




Rx only",5021,griseofulvin,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,500000301,1763779,0,1
./data/2024_latest_labels/latest_labels_ingredients/20231228_040a97e5-efd1-4a2f-b737-2f13e5366d70.json,040a97e5-efd1-4a2f-b737-2f13e5366d70,7,Selegiline Hydrochloride Tablets USP 5 mg,9639,selegiline,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,4911f343-68e6-71b0-e054-00144ff8d46c,5,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000",41493,meloxicam,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20160806_77d619f8-05a3-408a-a6f8-1511694b6a24.json,77d619f8-05a3-408a-a6f8-1511694b6a24,3,TICLOPIDINE HYDROCHLORIDE TABLETS USP 0154 Rx only,10594,ticlopidine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20160806_77d619f8-05a3-408a-a6f8-1511694b6a24.json,77d619f8-05a3-408a-a6f8-1511694b6a24,3,TICLOPIDINE HYDROCHLORIDE TABLETS USP 0154 Rx only,10594,ticlopidine,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240201_f06d1bb3-83f1-4d84-8004-4c6681ad8a5a.json,f06d1bb3-83f1-4d84-8004-4c6681ad8a5a,4,"These highlights do not include all the information needed to use PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND) safely and effectively. See full prescribing information for PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND).
PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND), for intravenous use Initial U.S. Approval: 2005",56946,paclitaxel,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_22477d77-3369-43cf-a444-dfc7ea69cacf.json,22477d77-3369-43cf-a444-dfc7ea69cacf,2,"BACLOFEN TABLETS USP

Rx only",1292,baclofen,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_fee3bd4a-ade3-41fa-839a-48e9af69bcf4.json,fee3bd4a-ade3-41fa-839a-48e9af69bcf4,5,"Diprivan® (Propofol) Injectable Emulsion, USP",8782,propofol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20211217_52fea941-0b47-41c1-b00d-f88150e8ab93.json,52fea941-0b47-41c1-b00d-f88150e8ab93,13,WARNING,10502,thioridazine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240202_86c0b4ae-5e38-4efe-88af-50ac560e294f.json,86c0b4ae-5e38-4efe-88af-50ac560e294f,8,"These highlights do not include all the information needed to use IBANDRONATE SODIUM TABLETS safely and effectively. See full prescribing information for IBANDRONATE SODIUM TABLETS.
 IBANDRONATE SODIUM tablets, for oral use Initial U.S. Approval: 2003",115264,ibandronate,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988",5657,ifosfamide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988",5657,ifosfamide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230620_20e5acf0-90b7-45c8-be78-91eaf77c9ac0.json,20e5acf0-90b7-45c8-be78-91eaf77c9ac0,2,"These highlights do not include all the information needed to use FLUDARABINE phosphate injection safely and effectively. See full prescribing information for FLUDARABINE phosphate injection.
FLUDARABINE phosphate injection, for intravenous use onlyInitial U.S. Approval: 1991",24698,fludarabine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,a1787fad-3612-43e1-98fa-ce62361e0b3c,13,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001",282388,imatinib,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240201_b17679e8-88c8-4b8d-bfae-246fab6eead9.json,b17679e8-88c8-4b8d-bfae-246fab6eead9,13,"These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, for intravenous use
Initial U.S. Approval: 1996",72962,docetaxel,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210106_dd367eec-359a-4065-b5c3-7c0107c823fe.json,dd367eec-359a-4065-b5c3-7c0107c823fe,7,"Tolcapone Tablets

100 mg",72937,tolcapone,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_749e42fb-2fe0-45dd-9268-b43bb3f4081c.json,749e42fb-2fe0-45dd-9268-b43bb3f4081c,32,"These highlights do not include all the information needed to use TRACLEER safely and effectively. See full prescribing information for TRACLEER.
 



TRACLEER 
 ®(bosentan) tablets, for oral use
 

TRACLEER 
 ®(bosentan) tablets for oral suspension
 

Initial U.S. Approval: 2001",75207,bosentan,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1321636,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240222_918d0e2a-3af3-46e8-ad06-528263e03ba0.json,918d0e2a-3af3-46e8-ad06-528263e03ba0,11,"These highlights do not include all the information needed to use fentanyl buccal tablet safely and effectively.  See full prescribing information for fentanyl buccal tablet. 
 Fentanyl Buccal Tablet, CII    Initial U.S. Approval: 1968",4337,fentanyl,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240117_8c5d6067-16a1-43ab-9e52-a33c600a5c44.json,8c5d6067-16a1-43ab-9e52-a33c600a5c44,2,"These highlights do not include all the information needed to use DECITABINE FOR INJECTION safely and effectively. See full prescribing information for DECITABINE FOR INJECTION.
DECITABINE for injection, for intravenous useInitial U.S. Approval: 2006",15657,decitabine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240202_819207a2-0c37-b275-e053-2a91aa0afb36.json,819207a2-0c37-b275-e053-2a91aa0afb36,7,"AMINOPHYLLINE INJ., USP 500mg (25mg/mL) 20mL VIAL",689,aminophylline,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240202_b2ab70e4-ca0c-4a73-9c98-974bf94e890c.json,b2ab70e4-ca0c-4a73-9c98-974bf94e890c,14,"LEVORPHANOL TARTRATE TABLETS USP, CII

Rx Only",6378,levorphanol,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b.json,3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b,13,"These highlights do not include all the information needed to use MICAFUNGIN FOR INJECTION safely and effectively. See full prescribing information for MICAFUNGIN FOR INJECTION.
 MICAFUNGIN for Injection, for intravenous infusion only Initial U.S. Approval: 2005",325887,micafungin,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/train_xml/20211231_ca70b23e-6f02-43a8-9c88-9550c0d230cf.json,ca70b23e-6f02-43a8-9c88-9550c0d230cf,100,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012",1364430,apixaban,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240118_b471eb51-488e-5312-e053-2a95a90a8116.json,b471eb51-488e-5312-e053-2a95a90a8116,5,"These highlights do not include all the information needed to use FULVESTRANT INJECTION safely and effectively. See full prescribing information for FULVESTRANT INJECTION.
 
FULVESTRANT injection, for intramuscular use
 
Initial U.S. Approval: 2002",282357,fulvestrant,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)",52582,mesalamine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_7b11f6ac-4c27-4748-9e65-22d4cf3adfb4.json,7b11f6ac-4c27-4748-9e65-22d4cf3adfb4,6,"These highlights do not include all the information needed to use SAXENDA® safely and effectively.  See full prescribing information for SAXENDA.SAXENDA (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010",475968,liraglutide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/gold_xml/20230715_5a9ef4ea-c76a-4d34-a604-27c5b505f5a4.json,5a9ef4ea-c76a-4d34-a604-27c5b505f5a4,27,"These highlights do not include all the information needed to use VICTOZA safely and effectively. See full prescribing information for VICTOZA.VICTOZA® (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010",475968,liraglutide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231118_4c61e68e-f2d1-4998-aae7-62997971dab7.json,4c61e68e-f2d1-4998-aae7-62997971dab7,4,"FOSCAVIR 
 ® 


(foscarnet sodium) INJECTION",33562,foscarnet,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/train_xml/20141007_144067b2-0532-476a-996e-e4a0a9d09b05.json,144067b2-0532-476a-996e-e4a0a9d09b05,1,"These highlights do not include all the information needed to use STRIBILD safely and effectively. See full prescribing information for STRIBILD.
 STRIBILD® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral useInitial U.S. Approval: 2012",1306284,cobicistat,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_a3087a39-f218-4f16-a1e7-17c39bb2eb69.json,a3087a39-f218-4f16-a1e7-17c39bb2eb69,5,"HYDROXOCOBALAMIN INJECTION USP
Rx Only",5514,hydroxocobalamin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20211014_96f19af4-de8f-4fd7-90d8-55fe6ebdd81d.json,96f19af4-de8f-4fd7-90d8-55fe6ebdd81d,15,"",588003,meclofenamate,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231222_674e0e6d-46ed-4868-9196-04019d667716.json,674e0e6d-46ed-4868-9196-04019d667716,24,"",8011,pentostatin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_d4500795-3b07-4a7d-b432-73cafbb3dbc6.json,d4500795-3b07-4a7d-b432-73cafbb3dbc6,2,"Aztreonam for Injection, USP",1272,aztreonam,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_7a7974c7-8b6c-41ae-9a48-a08a1439087a.json,7a7974c7-8b6c-41ae-9a48-a08a1439087a,100,"These highlights do not include all the information needed to use TRETINOIN CAPSULES safely and effectively. See full prescribing information for TRETINOIN CAPSULES
.



TRETINOIN 
capsules, for oral use 

Initial U.S. Approval: 1995",10753,tretinoin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009",141704,everolimus,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/gold_xml/20240223_8d663642-f52e-49c0-a023-2da083fdfc0b.json,8d663642-f52e-49c0-a023-2da083fdfc0b,6,"These highlights do not include all the information needed to use SYLVANT 
 ®safely and effectively. See full prescribing information for SYLVANT.
 

SYLVANT (siltuximab) for injection, for intravenous use
 
Initial U.S. Approval: 2014",1535218,siltuximab,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_5f01e40a-b6f6-40fb-b37c-3d06f1428e86.json,5f01e40a-b6f6-40fb-b37c-3d06f1428e86,27,"These highlights do not include all the information needed to use GLATOPA safely and effectively. See full prescribing information for GLATOPA.
GLATOPA® (glatiramer acetate injection), for subcutaneous useInitial U.S. Approval: 1996",214582,glatiramer,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_5f01e40a-b6f6-40fb-b37c-3d06f1428e86.json,5f01e40a-b6f6-40fb-b37c-3d06f1428e86,27,"These highlights do not include all the information needed to use GLATOPA safely and effectively. See full prescribing information for GLATOPA.
GLATOPA® (glatiramer acetate injection), for subcutaneous useInitial U.S. Approval: 1996",214582,glatiramer,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231129_d1e41dcf-e82a-47c2-a0ad-6c6eef621834.json,d1e41dcf-e82a-47c2-a0ad-6c6eef621834,16,"These highlights do not include all the information needed to use NERLYNX safely and effectively. See full prescribing information for NERLYNX.
 



NERLYNX 
 ®(neratinib) tablets, for oral use
 

Initial U.S. Approval: 2017",1940643,neratinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_458e043d-6584-4503-b398-2032d3cce2f1.json,458e043d-6584-4503-b398-2032d3cce2f1,22,"Clindamycin Injection, USP",2582,clindamycin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/train_xml/20221029_39d53698-57fa-7c99-fc5b-f52a55684826.json,39d53698-57fa-7c99-fc5b-f52a55684826,26,"These highlights do not include all the information needed to use TREANDA safely and effectively. See full prescribing information for TREANDA.
TREANDA® (bendamustine hydrochloride) injection, for intravenous useTREANDA® (bendamustine hydrochloride) for injection, for intravenous useInitial U.S. Approval: 2008",134547,bendamustine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_fedfd1db-7e32-44b2-89e9-7bb00ee6810d.json,fedfd1db-7e32-44b2-89e9-7bb00ee6810d,24,"Sojourn®
 
Sevoflurane, USP
 
Volatile Liquid for Inhalation",36453,sevoflurane,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220727_551e43d5-f700-4d6e-8029-026f8a8932ff.json,551e43d5-f700-4d6e-8029-026f8a8932ff,14,These highlights do not include all the information needed to use SOLOSEC® safely and effectively. See full prescribing information for SOLOSEC.SOLOSEC® (secnidazole) oral granulesInitial U.S. Approval: 2017,36314,secnidazole,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,d5929f91-6496-4c0e-97e8-0bd524e15763,3,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231129_cd86ee78-2781-468b-930c-3c4677bcc092.json,cd86ee78-2781-468b-930c-3c4677bcc092,25,"These highlights do not include all the information needed to use ZOLINZA safely and effectively. See full prescribing information for ZOLINZA. 
ZOLINZA® (vorinostat capsules, for oral use) Initial U.S. Approval: 2006",194337,vorinostat,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221021_cdfbe0cd-eb15-45a1-ac17-531bcda21aec.json,cdfbe0cd-eb15-45a1-ac17-531bcda21aec,11,"These highlights do not include all the information needed to use OCALIVA® safely and effectively.  See full prescribing information for OCALIVA. 
OCALIVA® (obeticholic acid) tablets, for oral use Initial U.S. Approval: 2016",1798288,obeticholic acid,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/gold_xml/20221119_5526617c-c7b9-4556-886d-729bbabbc566.json,5526617c-c7b9-4556-886d-729bbabbc566,21,"These highlights do not include all the information needed to use SAMSCA safely and effectively. See full prescribing information for SAMSCA.
 SAMSCA® (tolvaptan) tablets, for oral use Initial U.S. Approval: 2009",358257,tolvaptan,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231229_4b4725eb-95f1-45cc-852f-152beb5f1e2c.json,4b4725eb-95f1-45cc-852f-152beb5f1e2c,4,"These highlights do not include all the information needed to use THIOTEPA FOR INJECTION safely and effectively. See full prescribing information for THIOTEPA FOR INJECTION.THIOTEPA for injection, for intravenous, intracavitary, or intravesical useInitial U.S. Approval: 1959",10473,thiotepa,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/gold_xml/20230607_5e4cf15b-bf7b-4b83-863e-e9ef27741a51.json,5e4cf15b-bf7b-4b83-863e-e9ef27741a51,25,"These highlights do not include all the information needed to use FOLOTYN® safely and effectively. See full prescribing information for FOLOTYN. FOLOTYN (pralatrexate injection), for intravenous use   Initial U.S. Approval: 2009",662019,pralatrexate,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_7499fc35-fae8-44ad-bbab-9a1a589bf3ee.json,7499fc35-fae8-44ad-bbab-9a1a589bf3ee,20,"These highlights do not include all the information needed to use ETOPOPHOS safely and effectively. See full prescribing information for ETOPOPHOS.
ETOPOPHOS® (etoposide phosphate) for injection, for intravenous useInitial U.S. Approval: 1983",4179,etoposide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221201_857e53aa-1098-4dad-b654-0276cdd43e03.json,857e53aa-1098-4dad-b654-0276cdd43e03,4,"These highlights do not include all the information needed to use RYLAZE safely and effectively. See full prescribing information for RYLAZE.
RYLAZE® (asparaginase erwinia chrysanthemi (recombinant)-rywn) injection, for intramuscular useInitial U.S. Approval: 2021",1156,asparaginase,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231117_a3e4c8e5-bff0-4a8f-8401-e9866c846ee2.json,a3e4c8e5-bff0-4a8f-8401-e9866c846ee2,3,"These highlights do not include all the information needed to use Suprane (desflurane, USP) safely and effectively. See full prescribing information for Suprane (desflurane, USP).Suprane (desflurane, USP) Volatile Liquid for InhalationInitial U.S. Approval:  1992",27340,desflurane,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_a398400e-bd31-41a9-9696-4f7c06569ede.json,a398400e-bd31-41a9-9696-4f7c06569ede,14,"These highlights do not include all the information needed to use XOFIGO safely and effectively.  See full prescribing information for XOFIGO.
XOFIGO (radium Ra 223 dichloride) injection, for intravenous useInitial U.S. Approval: 2013",1546450,radium,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231122_faf3dd6a-9cd0-39c2-0d2e-232cb3f67565.json,faf3dd6a-9cd0-39c2-0d2e-232cb3f67565,26,"These highlights do not include all the information needed to use JARDIANCE safely and effectively.  See full prescribing information for JARDIANCE. 
JARDIANCE® (empagliflozin tablets), for oral useInitial U.S. Approval: 2014",1545653,empagliflozin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221217_2c3db989-d7ad-41ed-9ebf-698dcf6c24ec.json,2c3db989-d7ad-41ed-9ebf-698dcf6c24ec,7,"These highlights do not include all the information needed to use DEFITELIO safely and effectively.  See full prescribing information for DEFITELIO.
DEFITELIO (defibrotide sodium) injection, for intravenous useInitial U.S. Approval: 2016",1311089,defibrotide,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/train_xml/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008",709271,certolizumab pegol,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008",709271,certolizumab pegol,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,"FORANE (isoflurane, USP) liquid for inhalation",6026,isoflurane,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230125_c16ac648-d5d2-9f7d-8637-e2328572754e.json,c16ac648-d5d2-9f7d-8637-e2328572754e,15,"These highlights do not include all the information needed to use NULOJIX safely and effectively. See full prescribing information for NULOJIX.
NULOJIX (belatacept) for injection, for intravenous useInitial U.S. Approval: 2011",1112973,belatacept,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231111_8983d6a0-f63f-4f8e-bba4-38223f39e29b.json,8983d6a0-f63f-4f8e-bba4-38223f39e29b,11,"These highlights do not include all the information needed to use BENZNIDAZOLE TABLETS safely and effectively. See full prescribing information for BENZNIDAZOLE TABLETS.
 



BENZNIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2017",18994,benznidazole,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230225_d7354af1-f304-f4d9-e053-2995a90ab219.json,d7354af1-f304-f4d9-e053-2995a90ab219,2,"These highlights do not include all the information needed to use FILSPARITM safely and effectively. See full prescribing information for FILSPARITM.
FILSPARITM (sparsentan) tablets, for oral useInitial U.S. Approval: 2023",2630535,sparsentan,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231229_a161f9d4-70f1-4097-957a-eafb35d3274f.json,a161f9d4-70f1-4097-957a-eafb35d3274f,8,"These highlights do not include all the information needed to use BAFIERTAM safely and effectively. See full prescribing information for BAFIERTAM. BAFIERTAM® (monomethyl fumarate) delayed-release capsules, for oral use Initial U.S. Approval:  2013",1546433,monomethyl fumarate,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230329_64000394-1ef6-4e76-8ba8-11f25ba1b167.json,64000394-1ef6-4e76-8ba8-11f25ba1b167,6,"These highlights do not include all the information needed to use LIVMARLI safely and effectively. See full prescribing information for LIVMARLI. 
 LIVMARLI® (maralixibat) oral solution  Initial U.S. Approval:  2021",2571074,maralixibat,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240125_077a92f6-9f1b-479a-87c7-c92b5db6aa9c.json,077a92f6-9f1b-479a-87c7-c92b5db6aa9c,10,"These highlights do not include all the information needed to use ORGOVYX safely and effectively. See full prescribing information for ORGOVYX.
 



ORGOVYX (relugolix) tablets, for oral use
 

Initial U.S. Approval: 2020",2472778,relugolix,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013",1369713,pomalidomide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/gold_xml/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013",1369713,pomalidomide,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230426_a2523317-e071-4e04-9d9f-9053286e0ce2.json,a2523317-e071-4e04-9d9f-9053286e0ce2,8,"AMYTAL® SODIUM CII

(amobarbital sodium)

FOR INJECTION, USP

Vials



CAUTION: These products are to be used under the direction of a physician.

The intravenous administration of AMYTAL® SODIUM

(amobarbital sodium) FOR INJECTION, USP carries with it the potential dangers

inherent in the intravenous use of any potent hypnotic.",719,amobarbital,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_fb973a8d-7fea-4a7a-963f-2a8e67a46e55.json,fb973a8d-7fea-4a7a-963f-2a8e67a46e55,6,"These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.
		

		PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use
		
		Initial U.S. Approval: 2022",2597054,vipivotide tetraxetan,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230803_cf94c7fc-13a0-4ac9-bb85-9c38aa704d35.json,cf94c7fc-13a0-4ac9-bb85-9c38aa704d35,5,"These highlights do not include all the information needed to use FERUMOXYTOL INJECTION safely and effectively. See full prescribing information for FERUMOXYTOL INJECTION. 
	FERUMOXYTOL injection, for intravenous use 	Initial U.S. Approval: 2009",473387,ferumoxytol,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,"IBUPROFEN Tablets, USP",5640,ibuprofen,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1177480,1,1
./data/2024_latest_labels/latest_labels_ingredients/20230527_11fa3fc9-6776-49a6-b1c1-653f627c3e58.json,11fa3fc9-6776-49a6-b1c1-653f627c3e58,11,"These highlights do not include all the information needed to use RYDAPT safely and effectively. See full prescribing information for RYDAPT.
RYDAPT® (midostaurin) capsules, for oral useInitial U.S. Approval: 2017",1919083,midostaurin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230528_645c887c-8cd4-4623-8da9-ac223d71a8b9.json,645c887c-8cd4-4623-8da9-ac223d71a8b9,8,"These highlights do not include all the information needed to use AYVAKIT safely and effectively. See full prescribing information for AYVAKIT.
 AYVAKIT® (avapritinib) tablets, for oral use Initial U.S. Approval: 2020",2272107,avapritinib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230613_c387579e-cee0-4334-bd1e-73f93ac1bde6.json,c387579e-cee0-4334-bd1e-73f93ac1bde6,18,"These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.
COTELLIC®  (cobimetinib) tablets, for oral useInitial U.S. Approval: 2015",1722365,cobimetinib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230613_c387579e-cee0-4334-bd1e-73f93ac1bde6.json,c387579e-cee0-4334-bd1e-73f93ac1bde6,18,"These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.
COTELLIC®  (cobimetinib) tablets, for oral useInitial U.S. Approval: 2015",1722365,cobimetinib,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_b7b679a9-6823-4ef8-8d31-3ab5058ffcfc.json,b7b679a9-6823-4ef8-8d31-3ab5058ffcfc,11,"These highlights do not include all the information needed to use ELIGARD
®
 safely and effectively. See full prescribing information for ELIGARD.
ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002",42375,leuprolide,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231216_d66bdf0d-9d65-45de-ae5b-a58617c27492.json,d66bdf0d-9d65-45de-ae5b-a58617c27492,9,"These highlights do not include all the information needed to use UNITUXIN safely and effectively.  See Full Prescribing Information for UNITUXIN. 
UNITUXIN® (dinutuximab) injection, for intravenous use Initial U.S. Approval:  2015",1606274,dinutuximab,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/train_xml/20230720_de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa.json,de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,24,"These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA.
 JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010",996051,cabazitaxel,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230802_1af01887-b69d-444b-91ed-ebfe12784440.json,1af01887-b69d-444b-91ed-ebfe12784440,13,"Simulect

®


(basiliximab)


For Injection


Rx only



	Prescribing Information",196102,basiliximab,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_fff5d805-4ffd-4e8e-8e63-6f129697563e.json,fff5d805-4ffd-4e8e-8e63-6f129697563e,18,"These highlights do not include all the information needed to use ZYKADIA safely and effectively. See full prescribing information for ZYKADIA.


ZYKADIA® (ceritinib) capsules, for oral use

ZYKADIA® (ceritinib) tablets, for oral use

Initial U.S. Approval: 2014",1535457,ceritinib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/train_xml/20240123_fff5d805-4ffd-4e8e-8e63-6f129697563e.json,fff5d805-4ffd-4e8e-8e63-6f129697563e,18,"These highlights do not include all the information needed to use ZYKADIA safely and effectively. See full prescribing information for ZYKADIA.


ZYKADIA® (ceritinib) capsules, for oral use

ZYKADIA® (ceritinib) tablets, for oral use

Initial U.S. Approval: 2014",1535457,ceritinib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230817_44492772-5aed-4627-bd85-e8e89f308bb3.json,44492772-5aed-4627-bd85-e8e89f308bb3,12,"These highlights do not include all the information needed to use MAYZENT safely and effectively. See full prescribing information for MAYZENT.


MAYZENT® (siponimod) tablets, for oral use

Initial U.S. Approval: 2019",2121085,siponimod,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231215_496b38ee-45b6-4bb2-a35e-9023c3b73719.json,496b38ee-45b6-4bb2-a35e-9023c3b73719,5,"These highlights do not include all the information needed to use TIOTROPIUM BROMIDE INHALATION POWDER safely and effectively. See full prescribing information for TIOTROPIUM BROMIDE INHALATION POWDER.
TIOTROPIUM BROMIDE inhalation powder, for oral inhalation useInitial U.S. Approval: 2004",69120,tiotropium,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,5cd725a1-2fa4-408a-a651-57a7b84b2118,18,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017",1875534,avelumab,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)",4502,flurbiprofen,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1156378,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240221_8d5ace90-983b-48c4-baf1-b44f6af146de.json,8d5ace90-983b-48c4-baf1-b44f6af146de,2,"Carbamazepine Oral Suspension, USP
 
Rx only
 
Prescribing Information",2002,carbamazepine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_4034fb6d-f55d-4df0-b500-d6a413591f6e.json,4034fb6d-f55d-4df0-b500-d6a413591f6e,39,"These highlights do not include all the information needed to use DOXAZOSIN TABLETS safely and effectively. See full prescribing information for DOXAZOSIN TABLETS.




DOXAZOSIN tablets, for oral use 




Initial U.S. Approval: 1990",49276,doxazosin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_10a3fbc9-00c6-ad83-e063-6294a90ae1ad.json,10a3fbc9-00c6-ad83-e063-6294a90ae1ad,1,"These highlights do not include all the information needed to use OMEPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for OMEPRAZOLE DELAYED-RELEASE CAPSULES.
 

OMEPRAZOLE delayed-release capsules, for oral use
 
Initial U.S. Approval: 1989",7646,omeprazole,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231221_8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb.json,8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb,19,Nisoldipine,7435,nisoldipine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_53103d2f-4453-49a8-9e36-888d919879f6.json,53103d2f-4453-49a8-9e36-888d919879f6,1,"Zaleplon Capsules, USP

CIV",74667,zaleplon,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20100125_c6c48eee-240b-4425-8691-35462523652e.json,c6c48eee-240b-4425-8691-35462523652e,1,"DARVON-N  - propoxyphene napsylate tablet, film coated",8785,propoxyphene,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_4314da8a-40e5-4aba-a32b-57b4166ade30.json,4314da8a-40e5-4aba-a32b-57b4166ade30,12,"These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.  AZITHROMYCIN tablets, for oral use Initial U.S. Approval: 1991",18631,azithromycin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_4314da8a-40e5-4aba-a32b-57b4166ade30.json,4314da8a-40e5-4aba-a32b-57b4166ade30,12,"These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.  AZITHROMYCIN tablets, for oral use Initial U.S. Approval: 1991",18631,azithromycin,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987",2551,ciprofloxacin,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1797513,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,76e1839b-7462-4344-b319-001a5f57d67a,12,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000",40790,pantoprazole,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,9678a98e-4aab-4d87-b5e1-37c3109e378e,16,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996",57258,tizanidine,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994",42355,fluvoxamine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,22174520-4b78-4841-96f7-530ba12d2cf1,8,"Paroxetine Tablets USP, film coated for oral use",32937,paroxetine,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,304a3059-4f7f-4ec4-839d-86492bb5e07b,6,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003",6719,memantine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)",52582,mesalamine,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,24926986-7552-4f1a-8366-f035bbd07104,7,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987",4493,fluoxetine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,755695,1,1
./data/2024_latest_labels/train_xml/20141007_144067b2-0532-476a-996e-e4a0a9d09b05.json,144067b2-0532-476a-996e-e4a0a9d09b05,1,"These highlights do not include all the information needed to use STRIBILD safely and effectively. See full prescribing information for STRIBILD.
 STRIBILD® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral useInitial U.S. Approval: 2012",300195,tenofovir disoproxil,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,ccd95dfc-9236-4707-a715-6a12c91519ff,6,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976",7258,naproxen,10062237,renal impairment,500000401,acute kidney injury,8,1,500000401,1115008,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240217_64b7df84-c990-49f7-bc04-0cccfd7d2019.json,64b7df84-c990-49f7-bc04-0cccfd7d2019,14,"These highlights do not include all the information needed to use TRAMADOL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAMADOL HYDROCHLORIDE TABLETS.
 



TRAMADOL HYDROCHLORIDE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1995",10689,tramadol,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,8345d55e-ad02-4726-a04b-1a46e3337a4b,13,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998",194000,capecitabine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,8345d55e-ad02-4726-a04b-1a46e3337a4b,13,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998",194000,capecitabine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_81d9e47e-ae81-4755-a5ee-546a038fadb4.json,81d9e47e-ae81-4755-a5ee-546a038fadb4,7,"These highlights do not include all the information needed to use MIRTAZAPINE TABLETS safely and effectively. See full prescribing information for MIRTAZAPINE TABLETS.
 

MIRTAZAPINE tablets, for oral use
 
Initial U.S. Approval: 1996",15996,mirtazapine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_d6364be4-056b-4ebe-83bc-3fc85e8f488c.json,d6364be4-056b-4ebe-83bc-3fc85e8f488c,7,"Lorazepam Tablets, USP CIV
 
Rx only",6470,lorazepam,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_3631ee95-692a-4426-8edf-62c27f7c32cb.json,3631ee95-692a-4426-8edf-62c27f7c32cb,100,"Ribavirin for Inhalation Solution, USP",9344,ribavirin,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_793062e5-5a0c-40f9-8d8b-ca0862cd8a37.json,793062e5-5a0c-40f9-8d8b-ca0862cd8a37,11,"These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS.
 



ARIPIPRAZOLE tablets, for oral use
 

Initial U.S. Approval: 2002",89013,aripiprazole,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_722ce9eb-8f7b-4651-a287-d53dd7ab3707.json,722ce9eb-8f7b-4651-a287-d53dd7ab3707,21,"Acarbose Tablets, USP",16681,acarbose,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_51a88e8e-da02-4b97-9e7e-442fbffd908d.json,51a88e8e-da02-4b97-9e7e-442fbffd908d,8,"These highlights do not include all the information needed to use AMIODARONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for AMIODARONE HYDROCHLORIDE TABLETS.
 

AMIODARONE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1985",703,amiodarone,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240124_2a90b899-7746-43dc-ac8a-e754428eb30c.json,2a90b899-7746-43dc-ac8a-e754428eb30c,13,"These highlights do not include all the information needed to use DESLORATADINE TABLETS safely and effectively. See full prescribing information for DESLORATADINE TABLETS.
DESLORATADINE tablets for oral use Initial U.S. Approval: 2001",275635,desloratadine,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006,134748,rasagiline,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231220_fd427d2d-b78b-412a-9c80-606bc88ad112.json,fd427d2d-b78b-412a-9c80-606bc88ad112,10,"These highlights do not include all the information needed to use ELETRIPTAN HYDROBROMIDE TABLETS safely and effectively. See full prescribing information for ELETRIPTAN HYDROBROMIDE TABLETS.


ELETRIPTAN hydrobromide tablets, for oral use 

Initial U.S. Approval: 2002",231049,eletriptan,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231220_fd427d2d-b78b-412a-9c80-606bc88ad112.json,fd427d2d-b78b-412a-9c80-606bc88ad112,10,"These highlights do not include all the information needed to use ELETRIPTAN HYDROBROMIDE TABLETS safely and effectively. See full prescribing information for ELETRIPTAN HYDROBROMIDE TABLETS.


ELETRIPTAN hydrobromide tablets, for oral use 

Initial U.S. Approval: 2002",231049,eletriptan,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1189697,1,1
./data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009",73689,febuxostat,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_de5bad69-a014-4e25-b1b9-214373ca57a5.json,de5bad69-a014-4e25-b1b9-214373ca57a5,1,"Triamcinolone Acetonide

 Cream USP, 0.1%",10759,triamcinolone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_7d655d6d-01da-488c-bd4e-c7fbe0ace38c.json,7d655d6d-01da-488c-bd4e-c7fbe0ace38c,5,"These highlights do not include all the information needed to use TESTOSTERONE GEL, 1% safely and effectively.  See full prescribing information for TESTOSTERONE GEL, 1%.

 TESTOSTERONE gel 1%, for topical use, CIII Initial U.S. Approval: 1953",10379,testosterone,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230105_e1114a58-9ab5-486e-85ed-360365b06396.json,e1114a58-9ab5-486e-85ed-360365b06396,1,"Methyldopa Tablets, USP",6876,methyldopa,10024690,liver function test abnormal,500000301,acute liver injury,15,1,500000301,1305447,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240220_f2f090c2-3ee1-7689-e053-2995a90abe38.json,f2f090c2-3ee1-7689-e053-2995a90abe38,3,"These highlights do not include all the information needed to use LEVOFLOXACIN TABLETS 
  safely and effectively. See full prescribing information for LEVOFLOXACIN TABLETS. 
 




LEVOFLOXACIN tablets, for oral use






Initial U.S. Approval: 1996",82122,levofloxacin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_74e5060c-8426-1b77-e053-2a91aa0a1f13.json,74e5060c-8426-1b77-e053-2a91aa0a1f13,8,SOLU-MEDROL® 40MG PER VIAL 1mL ACT-O-VIAL®,6902,methylprednisolone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,"Atenolol Tablets, USP Rx only",1202,atenolol,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_bf514e99-4958-44a0-a87a-02a950f87e60.json,bf514e99-4958-44a0-a87a-02a950f87e60,7,"Acetazolamide Extended-release Capsules, USP
Rx only",167,acetazolamide,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,929435,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240220_0422fe47-c372-494f-bac2-612f550b44a4.json,0422fe47-c372-494f-bac2-612f550b44a4,12,"Cefazolin for Injection, USP",2180,cefazolin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_69301126-c901-4d0d-9acb-91ba1a87cd21.json,69301126-c901-4d0d-9acb-91ba1a87cd21,26,"HIGHLIGHTS OF PRESCRIBING INFORMATION
 

These highlights do not include all the information needed to use valacyclovir hydrochloride safely and effectively. See full prescribing information for valacyclovir hydrochloride.
 

Valacyclovir Tablets, USP
 

Initial U.S. Approval:1995",73645,valacyclovir,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,51635427-fb13-45ee-813d-a40b0405d14f,7,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information",3355,diclofenac,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f.json,c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f,3,"Famciclovir Tablets
 
Rx only
 

These highlights do not include all the information needed to use FAMCICLOVIR TABLETS safely and effectively. See full prescribing information for FAMCICLOVIR TABLETS.
 

Initial U.S. Approval: 1994",68099,famciclovir,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_caad4ada-2cf9-4e12-99df-6ca4388cf0f6.json,caad4ada-2cf9-4e12-99df-6ca4388cf0f6,100,"These highlights do not include all the information needed to use DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES.


DEXLANSOPRAZOLE delayed-release capsules, for oral use 

Initial U.S. Approval: 1995 (lansoprazole)",816346,dexlansoprazole,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_caad4ada-2cf9-4e12-99df-6ca4388cf0f6.json,caad4ada-2cf9-4e12-99df-6ca4388cf0f6,100,"These highlights do not include all the information needed to use DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES.


DEXLANSOPRAZOLE delayed-release capsules, for oral use 

Initial U.S. Approval: 1995 (lansoprazole)",816346,dexlansoprazole,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230217_09716a24-d7da-42b2-af29-c03a1b6670bd.json,09716a24-d7da-42b2-af29-c03a1b6670bd,12,Mefloquine Hydrochloride Tablets USP,6694,mefloquine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240124_c3658bc8-1524-43db-930e-66f9ac01b808.json,c3658bc8-1524-43db-930e-66f9ac01b808,11,"These highlights do not include all the information needed to use TELMISARTAN TABLETS safely and effectively. See full prescribing information for TELMISARTAN TABLETS.  TELMISARTAN tablets, for oral useInitial U.S. Approval: 1998",73494,telmisartan,10062237,renal impairment,500000401,acute kidney injury,8,1,500000401,1317640,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240220_a3b50576-cd40-4f7e-9506-bd0a61988424.json,a3b50576-cd40-4f7e-9506-bd0a61988424,3,"These highlights do not include all the information needed to use FAMOTIDINE TABLETS safely and effectively. See full prescribing information for FAMOTIDINE TABLETS.
 
FAMOTIDINE tablets, for oral use
 
Initial U.S. Approval: 1986",4278,famotidine,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231230_cb960074-99c1-4a73-941f-f0644a7ec219.json,cb960074-99c1-4a73-941f-f0644a7ec219,40,"These highlights do not include all the information needed to use AGRYLIN safely and effectively. See full prescribing information for AGRYLIN.
AGRYLIN® (anagrelide) capsules, for oral useInitial U.S. Approval: 1997",596724,anagrelide,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_49aa3d6d-2270-4615-aafa-b440859ab870.json,49aa3d6d-2270-4615-aafa-b440859ab870,4,Naltrexone Hydrochloride Tablets USP 50 mg,7243,naltrexone,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_af9d68b3-c43e-44e5-bf7d-80dbc2edc53a.json,af9d68b3-c43e-44e5-bf7d-80dbc2edc53a,11,"These highlights do not include all the information needed to use HYDROXYUREA Capsules safely and effectively. See full prescribing information for HYDROXYUREA Capsules. HYDROXYUREA capsules, USP, for oral use
 

Initial U.S. Approval: 1967
 



---------------------RECENT MAJOR CHANGES--------------


Warnings and Precautions, Pulmonary Toxicity (5.9) 7/2019",5552,hydroxyurea,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20121026_32d632f6-e7cc-455e-bd9a-3dcfc99a794f.json,32d632f6-e7cc-455e-bd9a-3dcfc99a794f,1,"These highlights do not include all the information needed to use PRISTIQ safely and effectively. See full prescribing information for PRISTIQ.
PRISTIQ® (desvenlafaxine) Extended-Release Tablets, oralInitial U.S. Approval: 2008",734064,desvenlafaxine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_1c90aa68-cc12-41ef-aebc-2616ae45683a.json,1c90aa68-cc12-41ef-aebc-2616ae45683a,11,"These highlights do not include all the information needed to use 

candesartan cilexetil 

 safely and effectively.  See full prescribing information for 

candesartan cilexetil 

.

Candesartan cilexetil tablets, for oral use
Initial U.S. Approval: 1998",214354,candesartan,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1351557,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240209_53bdb79c-c4cf-4818-b1f0-225e67a14536.json,53bdb79c-c4cf-4818-b1f0-225e67a14536,24,"These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
 
CLOZAPINE tablets, for oral use
 
Initial U.S. Approval: 1989",2626,clozapine,10067125,liver injury,500000301,acute liver injury,6,1,500000301,800878,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240104_406883ea-7f97-4eff-8d43-0bab004654f1.json,406883ea-7f97-4eff-8d43-0bab004654f1,9,"These highlights do not include all the information needed to use INSULIN GLARGINE safely and effectively. See full prescribing information for INSULIN GLARGINE. 
INSULIN GLARGINE injection, for subcutaneous use Initial U.S. Approval: 2000 
This product is LANTUS® (insulin glargine).",274783,insulin glargine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231115_f9c6fd52-6e28-482c-8b76-bd111760a34c.json,f9c6fd52-6e28-482c-8b76-bd111760a34c,10,"These highlights do not include all the information needed to use NALFON safely and effectively. See full prescribing information for NALFON.
 



NALFON (fenoprofen calcium, USP) capsules, for oral use
 

Initial U.S. Approval: 1982",4331,fenoprofen,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_b1274d78-1096-4ae3-8299-a2e94eaa0ea5.json,b1274d78-1096-4ae3-8299-a2e94eaa0ea5,16,Itraconazole Capsules,28031,itraconazole,10000804,acute hepatic failure,500000301,acute liver injury,5,1,500000301,1703653,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240217_4238a064-1bfd-4ce3-b9d9-12c96eee8af0.json,4238a064-1bfd-4ce3-b9d9-12c96eee8af0,2,"These highlights do not include all the information needed to use OLMESARTAN MEDOXOMIL TABLETS safely and effectively. See full prescribing information for OLMESARTAN MEDOXOMIL TABLETS.  OLMESARTAN MEDOXOMIL tablets, for oral use   Initial U.S. Approval: 2002",321064,olmesartan,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,9803db35-2600-4f42-80c1-43216fd1ba3d,4,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004",82819,acamprosate,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,9803db35-2600-4f42-80c1-43216fd1ba3d,4,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004",82819,acamprosate,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,51635427-fb13-45ee-813d-a40b0405d14f,7,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information",3355,diclofenac,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240124_7276803b-5b97-d886-e053-2a91aa0a184e.json,7276803b-5b97-d886-e053-2a91aa0a184e,5,"Dofetilide Capsules
 

Rx Only
 















Rx only",49247,dofetilide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,56d64558-1fad-420e-8fcd-7103cd073127,1,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998",140587,celecoxib,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,500000301,1118084,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231101_f5a010cf-5954-4e6d-acfa-fb414efdf471.json,f5a010cf-5954-4e6d-acfa-fb414efdf471,1,"Mitomycin for Injection, USP Rx only",632,mitomycin,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240117_852f013f-6759-4438-83c1-8ff48133dc85.json,852f013f-6759-4438-83c1-8ff48133dc85,4,"HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALBENDAZOLE TABLETS safely and effectively. See full prescribing information for ALBENDAZOLE TABLETS.  ALBENDAZOLE tablets, for oral use  Initial U.S. Approval: 1996",430,albendazole,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_ae8d2354-7ddb-41b8-9d55-77c84782b18f.json,ae8d2354-7ddb-41b8-9d55-77c84782b18f,3,"These highlights do not include all the information needed to use TEMSIROLIMUS INJECTION safely and effectively.
 

See full prescribing information for TEMSIROLIMUS INJECTION.
 





TEMSIROLIMUS injection, for intravenous use
 

Initial U.S. Approval: 2007",657797,temsirolimus,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_a99335d0-1e87-4180-bde3-cbb12bf91a52.json,a99335d0-1e87-4180-bde3-cbb12bf91a52,1,"These highlights do not include all the information needed to use DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION.
DEXMEDETOMIDINE HYDROCHLORIDE in 0.9% SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 1999",48937,dexmedetomidine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_b31ff20a-c363-4be0-9bc0-3081c163b63c.json,b31ff20a-c363-4be0-9bc0-3081c163b63c,7,"These highlights do not include all the information needed to use ATOVAQUONE ORAL SUSPENSION safely and effectively. See full prescribing information for ATOVAQUONE ORAL SUSPENSION.


ATOVAQUONE oral suspension, for oral use


Initial U.S. Approval: 1992",60212,atovaquone,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230620_20e5acf0-90b7-45c8-be78-91eaf77c9ac0.json,20e5acf0-90b7-45c8-be78-91eaf77c9ac0,2,"These highlights do not include all the information needed to use FLUDARABINE phosphate injection safely and effectively. See full prescribing information for FLUDARABINE phosphate injection.
FLUDARABINE phosphate injection, for intravenous use onlyInitial U.S. Approval: 1991",24698,fludarabine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002",121243,voriconazole,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231004_63df5af3-b8ac-4e76-9830-2dbb340af922.json,63df5af3-b8ac-4e76-9830-2dbb340af922,27,"These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspensionInitial U.S. Approval: 2013",1433868,dolutegravir,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_90717878-64cb-4ffc-90bc-7b4e81e3d1cd.json,90717878-64cb-4ffc-90bc-7b4e81e3d1cd,12,"Nafcillin for Injection, USP Rx only",7233,nafcillin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988",5657,ifosfamide,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_0becbde8-6ec5-4830-a0d9-cfdb7b15eb84.json,0becbde8-6ec5-4830-a0d9-cfdb7b15eb84,11,"Minocycline Hydrochloride Capsules, USP
 

Rx only",6980,minocycline,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009",73689,febuxostat,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230420_5736aecc-cc1d-47dd-86c0-5fb2e9d70f61.json,5736aecc-cc1d-47dd-86c0-5fb2e9d70f61,5,CLADRIBINE INJECTION,44157,cladribine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_b272ef9c-4d83-4ee2-b9cc-477440822cca.json,b272ef9c-4d83-4ee2-b9cc-477440822cca,10,"CEFOXITIN FOR INJECTION, USP(For Intravenous Use)",2189,cefoxitin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230607_90f5c7ab-9f15-487d-ba69-ee4107434bcc.json,90f5c7ab-9f15-487d-ba69-ee4107434bcc,1,"Cytarabine Injection(For Intravenous, Intrathecal and Subcutaneous Use Only)",3041,cytarabine,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231224_0a273a2d-a1ff-412a-925e-696648730dae.json,0a273a2d-a1ff-412a-925e-696648730dae,5,"These highlights do not include all the information needed to use CLOFARABINE INJECTION safely and effectively. See full prescribing information for CLOFARABINE INJECTION.


CLOFARABINE injection, for intravenous use

Initial U.S. Approval: 2004",44151,clofarabine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231224_0a273a2d-a1ff-412a-925e-696648730dae.json,0a273a2d-a1ff-412a-925e-696648730dae,5,"These highlights do not include all the information needed to use CLOFARABINE INJECTION safely and effectively. See full prescribing information for CLOFARABINE INJECTION.


CLOFARABINE injection, for intravenous use

Initial U.S. Approval: 2004",44151,clofarabine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231223_8b4c8696-e23e-4c51-a4d2-babab5bd945a.json,8b4c8696-e23e-4c51-a4d2-babab5bd945a,3,"These highlights do not include all the information needed to use ULTIVA safely and effectively.  See full prescribing information for ULTIVA. 
ULTIVA® (remifentanil hydrochloride), for injection, for intravenous use, CII
Initial U.S. Approval: 1996",73032,remifentanil,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240120_9914e793-a49c-eb00-1ab7-f606c786fe25.json,9914e793-a49c-eb00-1ab7-f606c786fe25,7,"These highlights do not include all the information needed to use COSMEGEN safely and effectively. See full prescribing information for COSMEGEN. 

COSMEGEN  ® (dactinomycin for injection) for intravenous use 

Initial U.S. Approval: 1964",3100,dactinomycin,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b.json,3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b,13,"These highlights do not include all the information needed to use MICAFUNGIN FOR INJECTION safely and effectively. See full prescribing information for MICAFUNGIN FOR INJECTION.
 MICAFUNGIN for Injection, for intravenous infusion only Initial U.S. Approval: 2005",325887,micafungin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220223_c09c4cde-9f6c-4c4f-9d96-18beb5377564.json,c09c4cde-9f6c-4c4f-9d96-18beb5377564,1,"Methyltestosterone Capsules, USP, CIII (10 mg) Rx only",6904,methyltestosterone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_b848e6f3-63c0-4d2e-bda5-c9e961472092.json,b848e6f3-63c0-4d2e-bda5-c9e961472092,1,"These highlights do not include all the information needed to use LURASIDONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for LURASIDONE HYDROCHLORIDE TABLETS.LURASIDONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 2010",1040028,lurasidone,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_7b11f6ac-4c27-4748-9e65-22d4cf3adfb4.json,7b11f6ac-4c27-4748-9e65-22d4cf3adfb4,6,"These highlights do not include all the information needed to use SAXENDA® safely and effectively.  See full prescribing information for SAXENDA.SAXENDA (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010",475968,liraglutide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_7663c49d-1b1d-755d-e053-2991aa0a4ee3.json,7663c49d-1b1d-755d-e053-2991aa0a4ee3,9,"ADRENALIN® (EPINEPHRINE INJECTION, USP) 1mg/mL 1:1000 VIAL",3992,epinephrine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,0772eb61-ca42-39de-e063-6294a90a6632,1,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006",357977,sunitinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995",68149,mycophenolate mofetil,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002",121243,voriconazole,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230707_32167dd7-5d37-457b-9b00-cd735de6b060.json,32167dd7-5d37-457b-9b00-cd735de6b060,5,"These highlights do not include all the information needed to use TINIDAZOLE TABLETS safely and effectively. See full prescribing information for TINIDAZOLE TABLETS. TINIDAZOLE tablets, for oral use Initial U.S. Approval 2004",10612,tinidazole,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1702559,0,1
./data/2024_latest_labels/latest_labels_ingredients/20240210_7a7974c7-8b6c-41ae-9a48-a08a1439087a.json,7a7974c7-8b6c-41ae-9a48-a08a1439087a,100,"These highlights do not include all the information needed to use TRETINOIN CAPSULES safely and effectively. See full prescribing information for TRETINOIN CAPSULES
.



TRETINOIN 
capsules, for oral use 

Initial U.S. Approval: 1995",10753,tretinoin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,Mefenamic Acid Capsules USPRx Only,257844,mefenamate,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/gold_xml/20221119_5526617c-c7b9-4556-886d-729bbabbc566.json,5526617c-c7b9-4556-886d-729bbabbc566,21,"These highlights do not include all the information needed to use SAMSCA safely and effectively. See full prescribing information for SAMSCA.
 SAMSCA® (tolvaptan) tablets, for oral use Initial U.S. Approval: 2009",358257,tolvaptan,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220421_2102da5f-a1a0-4ac7-a1f6-38698cf7273a.json,2102da5f-a1a0-4ac7-a1f6-38698cf7273a,9,"These highlights do not include all the information needed to use IBSRELA® safely and effectively. See full prescribing information for IBSRELA.
IBSRELA (tenapanor) tablets, for oral useInitial U.S. Approval: 2019",2199674,tenapanor,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009",141704,everolimus,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231229_4a22e559-2dac-42d7-af8d-eb0ebbc2f76d.json,4a22e559-2dac-42d7-af8d-eb0ebbc2f76d,8,"Aminocaproic Acid Tablets, USP

(500 mg)

Rx only",99,6-aminocaproic acid,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722.json,ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722,38,"These highlights do not include all the information needed to use SOLIRIS safely and effectively.  See full prescribing information for SOLIRIS.
 SOLIRIS® (eculizumab) injection, for intravenous use Initial U.S. Approval: 2007",591781,eculizumab,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231224_6b4040a2-a5c5-4ff0-ab45-935d7e49cf78.json,6b4040a2-a5c5-4ff0-ab45-935d7e49cf78,7,"These highlights do not include all the information needed to use 
ALYMSYS
safely and effectively. See full prescribing information for
 ALYMSYS
. 
ALYMSYS
®
 (bevacizumab-maly) injection, for intravenous use 
Initial U.S. Approval: 2022 ALYMSYS (bevacizumab-maly) is biosimilar* to AVASTIN (bevacizumab)",253337,bevacizumab,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230420_5736aecc-cc1d-47dd-86c0-5fb2e9d70f61.json,5736aecc-cc1d-47dd-86c0-5fb2e9d70f61,5,CLADRIBINE INJECTION,44157,cladribine,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221103_da1c9f37-779e-4682-816f-93d0faa4cfc9.json,da1c9f37-779e-4682-816f-93d0faa4cfc9,16,"These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. 
OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014",1592737,nintedanib,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231122_faf3dd6a-9cd0-39c2-0d2e-232cb3f67565.json,faf3dd6a-9cd0-39c2-0d2e-232cb3f67565,26,"These highlights do not include all the information needed to use JARDIANCE safely and effectively.  See full prescribing information for JARDIANCE. 
JARDIANCE® (empagliflozin tablets), for oral useInitial U.S. Approval: 2014",1545653,empagliflozin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231216_6240792b-9224-2d10-e053-2a91aa0a2c3e.json,6240792b-9224-2d10-e053-2a91aa0a2c3e,8,"These highlights do not include all the information needed to use XENICAL safely and effectively. See full prescribing information for XENICAL.

 XENICAL (orlistat) Capsules for oral use Initial U.S. Approval: 1999",37925,orlistat,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,741530,0,1
./data/2024_latest_labels/latest_labels_ingredients/20230203_0b1332a1-0581-4707-9bf6-1eccfa39bef4.json,0b1332a1-0581-4707-9bf6-1eccfa39bef4,2,"These highlights do not include all the information needed to use LYTGOBI safely and effectively. See full prescribing information for LYTGOBI.
LYTGOBI® (futibatinib) tablets, for oral use
Initial U.S. Approval: 2022",2628190,futibatinib,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/gold_xml/20240110_4650d12c-b9c8-4525-b07f-a2d773eca155.json,4650d12c-b9c8-4525-b07f-a2d773eca155,26,"These highlights do not include all the information needed to use AUBAGIO® safely and effectively. See full prescribing information for AUBAGIO. 
AUBAGIO (teriflunomide) tablets, for oral use Initial U.S. Approval: 2012",1310520,teriflunomide,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013",224905,trastuzumab,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230215_57a597d2-03f0-472e-b148-016d7169169d.json,57a597d2-03f0-472e-b148-016d7169169d,12,"These highlights do not include all the information needed to use TRODELVY safely and effectively. See full prescribing information for TRODELVY 
 TRODELVY® (sacituzumab govitecan-hziy) for injection, for intravenous use Initial U.S. Approval: 2020",2360231,sacituzumab,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231014_e46db299-edd1-4457-89b2-c1e2e505f1b0.json,e46db299-edd1-4457-89b2-c1e2e505f1b0,9,"These highlights do not include all the information needed to use BYOOVIZ safely and effectively. See full prescribing information for BYOOVIZ. 
BYOOVIZ™ (ranibizumab-nuna) injection, for intravitreal use Initial U.S. Approval: 2021 
BYOOVIZ (ranibizumab-nuna) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of BYOOVIZ has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to LUCENTIS® (ranibizumab injection)",595060,ranibizumab,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230315_72d1a024-00b7-418a-b36e-b2cb48f2ab55.json,72d1a024-00b7-418a-b36e-b2cb48f2ab55,6,"These highlights do not include all the information needed to use LUTATHERA safely and effectively. See full prescribing information for LUTATHERA.
		

		LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use
		
		Initial U.S. Approval: 2018",1797118,dotatate,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,b118a40d-6b56-cee3-10f6-ded821a97018,275,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016",1747556,venetoclax,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230908_2b34d62d-e02a-4af3-bc0d-1571dd4ee76d.json,2b34d62d-e02a-4af3-bc0d-1571dd4ee76d,7,"These highlights do not include all the information needed to use LORBRENA safely and effectively. See full prescribing information for LORBRENA.
 LORBRENA® (lorlatinib) tablets, for oral use Initial U.S. Approval: 2018",2103164,lorlatinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230331_eb368bb6-80e3-4df9-8a85-91df0a2ada6a.json,eb368bb6-80e3-4df9-8a85-91df0a2ada6a,14,"These highlights do not include all the information needed to use ERIVEDGE safely and effectively. See full prescribing information for ERIVEDGE. 
ERIVEDGE® (vismodegib) capsules, for oral useInitial U.S. Approval: 2012",1242987,vismodegib,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/gold_xml/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013",1369713,pomalidomide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_9c44bd5b-4464-40a4-8933-8680950f00f2.json,9c44bd5b-4464-40a4-8933-8680950f00f2,29,"These highlights do not include all the information needed to use AMJEVITA™ safely and effectively. See full prescribing information for AMJEVITA. 
 AMJEVITA (adalimumab-atto) injection, for subcutaneous use    Initial U.S. Approval: 2016 
 AMJEVITA (adalimumab-atto) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of AMJEVITA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA® (adalimumab).",327361,adalimumab,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230429_b5ff59aa-9c0d-49a8-9053-1f179b482383.json,b5ff59aa-9c0d-49a8-9053-1f179b482383,9,"These highlights do not include all the information needed to use XOSPATA safely and effectively.  See full prescribing information for XOSPATA.
XOSPATA® (gilteritinib) tablets, for oral useInitial U.S. Approval: 2018",2105806,gilteritinib,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,6fa682c9-a312-4932-9831-f286908660ee,34,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016",1792776,atezolizumab,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,6fa682c9-a312-4932-9831-f286908660ee,34,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016",1792776,atezolizumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230527_11fa3fc9-6776-49a6-b1c1-653f627c3e58.json,11fa3fc9-6776-49a6-b1c1-653f627c3e58,11,"These highlights do not include all the information needed to use RYDAPT safely and effectively. See full prescribing information for RYDAPT.
RYDAPT® (midostaurin) capsules, for oral useInitial U.S. Approval: 2017",1919083,midostaurin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230530_16a160a4-3ec0-4ddf-99ce-05912dd3382d.json,16a160a4-3ec0-4ddf-99ce-05912dd3382d,5,"These highlights do not include all the information needed to use BLENREP safely and effectively. See full prescribing information for BLENREP.BLENREP (belantamab mafodotin-blmf) for injection, for intravenous useInitial U.S. Approval: 2020",2387834,belantamab mafodotin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/train_xml/20230627_3904f8dd-1aef-3490-e48f-bd55f32ed67f.json,3904f8dd-1aef-3490-e48f-bd55f32ed67f,34,"These highlights do not include all the information needed to use ADCETRIS safely and effectively. See full prescribing information for ADCETRIS. 
ADCETRIS® (brentuximab vedotin) for injection, for intravenous use Initial U.S. approval: 2011",1147320,brentuximab vedotin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,2265ef30-253e-11df-8a39-0800200c9a66,42,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011",1094833,ipilimumab,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_455892c3-d144-4ba8-9ab4-79cabff9876d.json,455892c3-d144-4ba8-9ab4-79cabff9876d,11,"These highlights do not include all the information needed to use TABRECTA safely and effectively. See full prescribing information for TABRECTA.
		
TABRECTA® (capmatinib) tablets, for oral use
		
		Initial U.S. Approval: 2020",2362165,capmatinib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,6093952a-5248-45cb-ad17-33716a411146,37,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007",662281,nilotinib,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231216_d66bdf0d-9d65-45de-ae5b-a58617c27492.json,d66bdf0d-9d65-45de-ae5b-a58617c27492,9,"These highlights do not include all the information needed to use UNITUXIN safely and effectively.  See Full Prescribing Information for UNITUXIN. 
UNITUXIN® (dinutuximab) injection, for intravenous use Initial U.S. Approval:  2015",1606274,dinutuximab,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/train_xml/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008",711942,eltrombopag,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_988513ab-b06f-4dd0-93f7-d2d4531dcce4.json,988513ab-b06f-4dd0-93f7-d2d4531dcce4,33,"These highlights do not include all the information needed to use FABRAZYME® safely and effectively. See full prescribing information for FABRAZYME®. 
 FABRAZYME® (agalsidase beta) for injection, for intravenous use  Initial U.S. Approval: 2003",338817,agalsidase beta,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013",224905,trastuzumab,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230908_bb9a3820-f31a-4dd9-bef4-97094c01a398.json,bb9a3820-f31a-4dd9-bef4-97094c01a398,7,"These highlights do not include all the information needed to use LEUKINE safely and effectively. See full prescribing information for LEUKINE.
		
LEUKINE® (sargramostim) for injection, for subcutaneous or intravenous use
		Initial U.S. Approval: 1991",69634,sargramostim,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230922_23527b8b-9b28-4e6d-9751-33b143975ac7.json,23527b8b-9b28-4e6d-9751-33b143975ac7,24,"These highlights do not include all the information needed to use FRAGMIN safely and effectively. See full prescribing information for FRAGMIN. 
FRAGMIN® (dalteparin sodium) injection, USP, for subcutaneous use Initial U.S. Approval: 1994",67109,dalteparin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231216_88d06d89-a3da-40b4-b273-8f4f7d56c4c9.json,88d06d89-a3da-40b4-b273-8f4f7d56c4c9,9,"These highlights do not include all the information needed to use NEXLETOL® safely and effectively.  See full prescribing information for NEXLETOL. 
NEXLETOL (bempedoic acid) tablets, for oral use Initial U.S. Approval:  2020",2282403,bempedoic acid,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,3850cce2-6137-42e5-a792-d318c4a4b3b5,14,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012",1363268,cabozantinib,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012",1363268,cabozantinib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,3850cce2-6137-42e5-a792-d318c4a4b3b5,14,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012",1363268,cabozantinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,84137882-e000-47da-bd5b-fa76ab3c76f9,20,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012",1242999,axitinib,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,84137882-e000-47da-bd5b-fa76ab3c76f9,20,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012",1242999,axitinib,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_4442f029-dd5e-4834-9b01-eb8c638ce4b1.json,4442f029-dd5e-4834-9b01-eb8c638ce4b1,100,"Nortriptyline Hydrochloride Capsules, USP",7531,nortriptyline,10019692,hepatic necrosis,500000301,acute liver injury,15,1,500000301,721724,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240217_0becbde8-6ec5-4830-a0d9-cfdb7b15eb84.json,0becbde8-6ec5-4830-a0d9-cfdb7b15eb84,11,"Minocycline Hydrochloride Capsules, USP
 

Rx only",6980,minocycline,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_8d5ace90-983b-48c4-baf1-b44f6af146de.json,8d5ace90-983b-48c4-baf1-b44f6af146de,2,"Carbamazepine Oral Suspension, USP
 
Rx only
 
Prescribing Information",2002,carbamazepine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220716_51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.json,51ff7db5-aaf9-4c3c-86e6-958ebf16b60f,10,"Nefazodone Hydrochloride Tablets, USP

Rx only

(Patient Information Included)",31565,nefazodone,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,714684,1,1
./data/2024_latest_labels/latest_labels_ingredients/20220716_51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.json,51ff7db5-aaf9-4c3c-86e6-958ebf16b60f,10,"Nefazodone Hydrochloride Tablets, USP

Rx only

(Patient Information Included)",31565,nefazodone,10019692,hepatic necrosis,500000301,acute liver injury,15,1,500000301,714684,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,"IBUPROFEN Tablets, USP",5640,ibuprofen,10024690,liver function test abnormal,500000301,acute liver injury,15,1,500000301,1177480,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_fbac3b4f-dc23-4359-ac3f-2b3fdde41af2.json,fbac3b4f-dc23-4359-ac3f-2b3fdde41af2,32,"These highlights do not include all the information needed to use ALLOPURINOL TABLETS safely and effectively. See full prescribing information for ALLOPURINOL TABLETS.


ALLOPURINOL tablets for oral use 

Initial U.S. Approval:1966",519,allopurinol,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_768aa02b-8231-5799-e053-2a91aa0a618d.json,768aa02b-8231-5799-e053-2a91aa0a618d,7,"ONDANSETRON INJECTION, USP 4mg/2mL (2mg/mL) VIAL",26225,ondansetron,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,51635427-fb13-45ee-813d-a40b0405d14f,7,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information",3355,diclofenac,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_64b7df84-c990-49f7-bc04-0cccfd7d2019.json,64b7df84-c990-49f7-bc04-0cccfd7d2019,14,"These highlights do not include all the information needed to use TRAMADOL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAMADOL HYDROCHLORIDE TABLETS.
 



TRAMADOL HYDROCHLORIDE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1995",10689,tramadol,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20100225_ef14122b-7fff-45fa-b13b-0ea9e48bd57d.json,ef14122b-7fff-45fa-b13b-0ea9e48bd57d,1,1  INDICATIONS AND USAGE,84108,rosiglitazone,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998",2556,citalopram,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,9678a98e-4aab-4d87-b5e1-37c3109e378e,16,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996",57258,tizanidine,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_ed3039d8-3d27-4b71-a4b0-812943c9457f.json,ed3039d8-3d27-4b71-a4b0-812943c9457f,10,"These highlights do not include all the information needed to use TRAZODONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAZODONE HYDROCHLORIDE TABLETS.





TRAZODONE HYDROCHLORIDE tablets, for oral use




Initial U.S. Approval: 1981",10737,trazodone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240120_d2af616e-673a-4fdd-ace8-db2d0f154604.json,d2af616e-673a-4fdd-ace8-db2d0f154604,15,"These highlights do not include all the information needed to use ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS. ALFUZOSIN HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 2003",17300,alfuzosin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,22174520-4b78-4841-96f7-530ba12d2cf1,8,"Paroxetine Tablets USP, film coated for oral use",32937,paroxetine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)",52582,mesalamine,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,24926986-7552-4f1a-8366-f035bbd07104,7,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987",4493,fluoxetine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_51cdb22b-035f-47d7-8048-38006e2589f2.json,51cdb22b-035f-47d7-8048-38006e2589f2,20,Rx only,7417,nifedipine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1318853,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240126_1fffe88d-50c8-45cf-ac7c-a62b665c89a8.json,1fffe88d-50c8-45cf-ac7c-a62b665c89a8,16,SULINDAC TABLETS USP,10237,sulindac,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1236607,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240222_bf93022c-a965-49c5-a852-c59e580d7d91.json,bf93022c-a965-49c5-a852-c59e580d7d91,14,"These highlights do not include all the information needed to use INDOMETHACIN CAPSULES safely and effectively. See full prescribing information for INDOMETHACIN CAPSULES.
 



INDOMETHACIN capsules, for oral use
 

Initial U.S. Approval: 1965",5781,indomethacin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1178663,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240104_5c40e41f-6401-4bda-975c-e1fac69867e9.json,5c40e41f-6401-4bda-975c-e1fac69867e9,12,"Isoniazid Tablets, USP",6038,isoniazid,10067125,liver injury,500000301,acute liver injury,6,1,500000301,1782521,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240214_0653b873-b74b-4ec6-b112-675760703d91.json,0653b873-b74b-4ec6-b112-675760703d91,3,"Nabumetone Tablets, USP

Rx only

8463021/1223F",31448,nabumetone,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993",8703,fenofibrate,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231030_3a1424d8-844c-4e24-9ebd-b2c2b61b61a3.json,3a1424d8-844c-4e24-9ebd-b2c2b61b61a3,6,"These highlights do not include all the information needed to use FOSAMPRENAVIR CALCIUM TABLETS safely and effectively.  See full prescribing information for FOSAMPRENAVIR CALCIUM TABLETS. FOSAMPRENAVIR CALCIUM tablets, for oral useInitial U.S. Approval: 2003",358262,fosamprenavir,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_b1bd0d02-eccb-4449-82b9-9b552835029e.json,b1bd0d02-eccb-4449-82b9-9b552835029e,10,"These highlights do not include all the information needed to use WARFARIN SODIUM TABLETS safely and effectively. See full prescribing information for WARFARIN SODIUM TABLETS.
 



WARFARIN SODIUM tablets, for oral use
 

Initial U.S. Approval: 1954",11289,warfarin,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,8345d55e-ad02-4726-a04b-1a46e3337a4b,13,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998",194000,capecitabine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20190118_17e597bc-d663-4d8e-a5d3-39816b628996.json,17e597bc-d663-4d8e-a5d3-39816b628996,8,"These highlights do not include all the information needed to use STAVUDINE FOR ORAL SOLUTION safely and effectively. See full prescribing information for STAVUDINE FOR ORAL SOLUTION.
STAVUDINE for oral solutionInitial U.S. Approval: 1994",59763,stavudine,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1781406,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_d6364be4-056b-4ebe-83bc-3fc85e8f488c.json,d6364be4-056b-4ebe-83bc-3fc85e8f488c,7,"Lorazepam Tablets, USP CIV
 
Rx only",6470,lorazepam,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_ba02a95d-d82e-4a13-90b4-a219abc0249a.json,ba02a95d-d82e-4a13-90b4-a219abc0249a,18,"Desipramine Hydrochloride Tablets, USP",3247,desipramine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,716968,1,1
./data/2024_latest_labels/latest_labels_ingredients/20210804_ed23b6bc-32c7-4c50-a53d-313ae78e5623.json,ed23b6bc-32c7-4c50-a53d-313ae78e5623,13,"CEFOTAXIME FOR INJECTION, USP",2186,cefotaxime,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,113558e6-8b45-cdbd-e063-6394a90ac036,2,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only",24605,etodolac,10019692,hepatic necrosis,500000301,acute liver injury,15,1,500000301,1195492,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240209_b3ecc533-dd55-4a2f-84c4-ecd454aae766.json,b3ecc533-dd55-4a2f-84c4-ecd454aae766,14,"These highlights do not include all the information needed to use BALSALAZIDE DISODIUM CAPSULES safely and effectively. See full prescribing information for BALSALAZIDE DISODIUM CAPSULES.
 

BALSALAZIDE DISODIUM capsules, for oral use
 
Initial U.S. Approval: 2000",18747,balsalazide,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_b3ecc533-dd55-4a2f-84c4-ecd454aae766.json,b3ecc533-dd55-4a2f-84c4-ecd454aae766,14,"These highlights do not include all the information needed to use BALSALAZIDE DISODIUM CAPSULES safely and effectively. See full prescribing information for BALSALAZIDE DISODIUM CAPSULES.
 

BALSALAZIDE DISODIUM capsules, for oral use
 
Initial U.S. Approval: 2000",18747,balsalazide,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_c2575a86-19e5-44df-8603-ff066bb9c9c5.json,c2575a86-19e5-44df-8603-ff066bb9c9c5,12,"",10800,trifluoperazine,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_d72e0e10-4557-41b0-b65d-d395468cad19.json,d72e0e10-4557-41b0-b65d-d395468cad19,11,"These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. 
APREPITANT capsules, for oral use Initial U.S. Approval: 2003",358255,aprepitant,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_14f3f9ba-7a4a-45d5-a25e-efe5cdff117d.json,14f3f9ba-7a4a-45d5-a25e-efe5cdff117d,8,"These highlights do not include all the information needed to use PREGABALIN CAPSULES safely and effectively. See full prescribing information for PREGABALIN CAPSULES.
 



PREGABALIN capsules, for oral use CV
 



Initial U.S. Approval: 2004",187832,pregabalin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_666f89b4-fd81-420a-a390-eb1cd4014f61.json,666f89b4-fd81-420a-a390-eb1cd4014f61,10,Rx only,3393,diflunisal,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1126128,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_2421dc8f-a60d-4249-b093-c9e8e1d4bb82.json,2421dc8f-a60d-4249-b093-c9e8e1d4bb82,10,"Glyburide Tablets, USP
 

1.25, 2.5, and 5 mg",4815,glyburide,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20181215_43ba3de1-ab2e-06f6-e054-00144ff8d46c.json,43ba3de1-ab2e-06f6-e054-00144ff8d46c,3,"PRESCRIBING INFORMATION
 



RIDAURA 
 ®




Auranofin
 



Capsules",1227,auranofin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231230_cb960074-99c1-4a73-941f-f0644a7ec219.json,cb960074-99c1-4a73-941f-f0644a7ec219,40,"These highlights do not include all the information needed to use AGRYLIN safely and effectively. See full prescribing information for AGRYLIN.
AGRYLIN® (anagrelide) capsules, for oral useInitial U.S. Approval: 1997",596724,anagrelide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,88441a9f-b4f9-455d-a355-46fb30699a7b,10,"Sulfasalazine Tablets, USP",9524,sulfasalazine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/gold_xml/20231205_5359b759-db7c-4672-9e8a-59c93869bd91.json,5359b759-db7c-4672-9e8a-59c93869bd91,5,"These highlights do not include all the information needed to use VIBATIV® (telavancin) safely and effectively. See full prescribing information for VIBATIV. 
VIBATIV® (telavancin) for injection, for intravenous use Initial U.S. Approval: 2009",473837,telavancin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231221_b0d6341b-d880-4f0b-8844-bc788c03004a.json,b0d6341b-d880-4f0b-8844-bc788c03004a,2,"Quinidine Sulfate Tablets, USP",9068,quinidine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_9c2e1055-2fa1-462c-90f3-6d77e89ea38a.json,9c2e1055-2fa1-462c-90f3-6d77e89ea38a,100,MEXILETINE HYDROCHLORIDE CAPSULES USP,6926,mexiletine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_d9db3882-a7b5-435b-9d5a-a5e4ef7c2537.json,d9db3882-a7b5-435b-9d5a-a5e4ef7c2537,2,"Fluphenazine Hydrochloride Tablets, USPRx only",4496,fluphenazine,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231115_f9c6fd52-6e28-482c-8b76-bd111760a34c.json,f9c6fd52-6e28-482c-8b76-bd111760a34c,10,"These highlights do not include all the information needed to use NALFON safely and effectively. See full prescribing information for NALFON.
 



NALFON (fenoprofen calcium, USP) capsules, for oral use
 

Initial U.S. Approval: 1982",4331,fenoprofen,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1153928,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240209_53bdb79c-c4cf-4818-b1f0-225e67a14536.json,53bdb79c-c4cf-4818-b1f0-225e67a14536,24,"These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
 
CLOZAPINE tablets, for oral use
 
Initial U.S. Approval: 1989",2626,clozapine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,800878,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240101_1aa40de5-c02d-49d6-8722-ed88c40c3ba6.json,1aa40de5-c02d-49d6-8722-ed88c40c3ba6,2,"Felbamate Tablets, USP

(400 mg and 600 mg)


Rx only",24812,felbamate,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,795661,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240104_b0075b72-c3cc-f844-e053-2a95a90a417f.json,b0075b72-c3cc-f844-e053-2a95a90a417f,5,"These highlights do not include all the information needed to use MEROPENEM FOR INJECTION safely and effectively. See full prescribing information for MEROPENEM FOR INJECTION
 







MEROPENEM for injection, for intravenous use
 







Initial U.S. Approval: 1996",29561,meropenem,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240201_f06d1bb3-83f1-4d84-8004-4c6681ad8a5a.json,f06d1bb3-83f1-4d84-8004-4c6681ad8a5a,4,"These highlights do not include all the information needed to use PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND) safely and effectively. See full prescribing information for PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND).
PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND), for intravenous use Initial U.S. Approval: 2005",56946,paclitaxel,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_5721b46a-4a9f-46c2-8804-a9bad4d5f80a.json,5721b46a-4a9f-46c2-8804-a9bad4d5f80a,5,FLUCYTOSINE Capsules USPRx only,4451,flucytosine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240213_a60c5173-6bc0-4c9d-9674-b3f4d68f79ba.json,a60c5173-6bc0-4c9d-9674-b3f4d68f79ba,4,"These highlights do not include all the information needed to use CISPLATIN INJECTION, USP safely and effectively. See full prescribing information for CISPLATIN INJECTION, USP.
 



CISPLATIN injection USP, for intravenous use
 



Initial U.S. Approval: 1978",2555,cisplatin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230228_eccf9fd9-53ac-4252-a106-5567b3a82a70.json,eccf9fd9-53ac-4252-a106-5567b3a82a70,3,"These highlights do not include all the information needed to use ZEMDRI™® safely and effectively. See full prescribing information for ZEMDRI.
 ZEMDRI (plazomicin) injection, for intravenous use Initial U.S. Approval: 2018",2049549,plazomicin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231228_e65d5108-22a2-4d87-a78d-15606f3cc9e2.json,e65d5108-22a2-4d87-a78d-15606f3cc9e2,3,"Nimodipine Capsules


For Oral Use


Rx only",7426,nimodipine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_413c645e-074d-4276-b39a-d83521077602.json,413c645e-074d-4276-b39a-d83521077602,14,"These highlights do not include all the information needed to use ABIRATERONE ACETATE TABLETS safely and effectively. See full prescribing information for ABIRATERONE ACETATE TABLETS.
  

ABIRATERONE ACETATE tablets,
 
for oral use 

Initial U.S. Approval: 2011",1100072,abiraterone,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231224_38955939-8d1e-4db2-9aed-3bab72ca5f8f.json,38955939-8d1e-4db2-9aed-3bab72ca5f8f,8,"​ 
BLEO 15K

Bleomycin sulfate.  

Bleomycin sulfate powder for injection contains bleomycin sulfate 15,000 IU per vial",1622,bleomycin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992",70223,aldesleukin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240201_b17679e8-88c8-4b8d-bfae-246fab6eead9.json,b17679e8-88c8-4b8d-bfae-246fab6eead9,13,"These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, for intravenous use
Initial U.S. Approval: 1996",72962,docetaxel,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240227_20293943-46ff-4345-1aa4-929b4e017a25.json,20293943-46ff-4345-1aa4-929b4e017a25,28,"These highlights do not include all the information needed to use SUFENTANIL CITRATE INJECTION, safely and effectively. See full prescribing information for SUFENTANIL CITRATE INJECTION.
Sufentanil Citrate Injection, for intravenous and epidural use, CIIInitial U.S. Approval: 1984",56795,sufentanil,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,b605b541-4bfd-db3e-9710-11c27f6dee6c,2,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003",358258,bortezomib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009",73689,febuxostat,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_c76f4b3b-9f93-349f-e053-2995a90a2d57.json,c76f4b3b-9f93-349f-e053-2995a90a2d57,2,SOTRADECOL® 1% (SODIUM TETRADECYL SULFATE INJECTION) 20mg/2mL (10mg/mL),9913,sodium tetradecyl sulfate,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231014_1a2c0a9a-c637-4485-ad4b-0b6d0b05fa20.json,1a2c0a9a-c637-4485-ad4b-0b6d0b05fa20,3,"Dipyridamole 5 mg/mL Injection, USP 10 mL Single Dose Vial",3521,dipyridamole,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1331270,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240208_27f15fac-7d98-4114-a2ec-92494a91da98.json,27f15fac-7d98-4114-a2ec-92494a91da98,8,"These highlights do not include all the information needed to use RYBELSUS®
 safely and effectively.  See full prescribing information for RYBELSUS.
RYBELSUS (semaglutide) tablets, for oral use
Initial U.S. Approval: 2017",1991302,semaglutide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005",614373,deferasirox,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994",42355,fluvoxamine,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_1ecb2311-eee3-4230-a019-a3496308cff1.json,1ecb2311-eee3-4230-a019-a3496308cff1,9,"Dihydroertotamine Mesylate Nasal Spray, 4 mg/mL",3418,dihydroergotamine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240118_b471eb51-488e-5312-e053-2a95a90a8116.json,b471eb51-488e-5312-e053-2a95a90a8116,5,"These highlights do not include all the information needed to use FULVESTRANT INJECTION safely and effectively. See full prescribing information for FULVESTRANT INJECTION.
 
FULVESTRANT injection, for intramuscular use
 
Initial U.S. Approval: 2002",282357,fulvestrant,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_d267f492-43f6-45ba-8421-82ae2771788b.json,d267f492-43f6-45ba-8421-82ae2771788b,6,"These highlights do not include all the information needed to use MONTELUKAST SODIUM TABLETS and MONTELUKAST SODIUM CHEWABLE TABLETS safely and effectively. See full prescribing information for MONTELUKAST SODIUM TABLETS and MONTELUKAST SODIUM CHEWABLE TABLETS .


MONTELUKAST SODIUM tablets, for oral use
  
MONTELUKAST SODIUM chewable tablets, for oral use 
 

Initial U.S. Approval: 1998",88249,montelukast,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/gold_xml/20230715_5a9ef4ea-c76a-4d34-a604-27c5b505f5a4.json,5a9ef4ea-c76a-4d34-a604-27c5b505f5a4,27,"These highlights do not include all the information needed to use VICTOZA safely and effectively. See full prescribing information for VICTOZA.VICTOZA® (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010",475968,liraglutide,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_7b11f6ac-4c27-4748-9e65-22d4cf3adfb4.json,7b11f6ac-4c27-4748-9e65-22d4cf3adfb4,6,"These highlights do not include all the information needed to use SAXENDA® safely and effectively.  See full prescribing information for SAXENDA.SAXENDA (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010",475968,liraglutide,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_7663c49d-1b1d-755d-e053-2991aa0a4ee3.json,7663c49d-1b1d-755d-e053-2991aa0a4ee3,9,"ADRENALIN® (EPINEPHRINE INJECTION, USP) 1mg/mL 1:1000 VIAL",3992,epinephrine,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231128_3bad23a6-09a6-4194-9182-093ed61bc71c.json,3bad23a6-09a6-4194-9182-093ed61bc71c,39,"These highlights do not include all the information needed to use CANCIDAS safely and effectively. See full prescribing information for CANCIDAS.
CANCIDAS® (caspofungin acetate) for injection, for intravenous useInitial U.S. Approval: 2001",140108,caspofungin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1718054,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231222_674e0e6d-46ed-4868-9196-04019d667716.json,674e0e6d-46ed-4868-9196-04019d667716,24,"",8011,pentostatin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002",121243,voriconazole,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230707_32167dd7-5d37-457b-9b00-cd735de6b060.json,32167dd7-5d37-457b-9b00-cd735de6b060,5,"These highlights do not include all the information needed to use TINIDAZOLE TABLETS safely and effectively. See full prescribing information for TINIDAZOLE TABLETS. TINIDAZOLE tablets, for oral use Initial U.S. Approval 2004",10612,tinidazole,10000804,acute hepatic failure,500000301,acute liver injury,5,1,500000301,1702559,0,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_fbac3b4f-dc23-4359-ac3f-2b3fdde41af2.json,fbac3b4f-dc23-4359-ac3f-2b3fdde41af2,32,"These highlights do not include all the information needed to use ALLOPURINOL TABLETS safely and effectively. See full prescribing information for ALLOPURINOL TABLETS.


ALLOPURINOL tablets for oral use 

Initial U.S. Approval:1966",519,allopurinol,10062237,renal impairment,500000401,acute kidney injury,8,1,500000401,1167322,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240210_7a7974c7-8b6c-41ae-9a48-a08a1439087a.json,7a7974c7-8b6c-41ae-9a48-a08a1439087a,100,"These highlights do not include all the information needed to use TRETINOIN CAPSULES safely and effectively. See full prescribing information for TRETINOIN CAPSULES
.



TRETINOIN 
capsules, for oral use 

Initial U.S. Approval: 1995",10753,tretinoin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_61492681-4be8-448b-b4c6-ef2261503d1a.json,61492681-4be8-448b-b4c6-ef2261503d1a,12,"These highlights do not include all the information needed to use METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS.
 

METFORMIN HYDROCHLORIDE extended-release tablets, for oral use
 

Initial U.S. Approval: 1995",6809,metformin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220308_efbdafa9-d18c-4e85-b4a2-1e620fc74e50.json,efbdafa9-d18c-4e85-b4a2-1e620fc74e50,11,"These highlights do not include all the information needed to use ZYDELIG safely and effectively. See full prescribing information for ZYDELIG. 
 ZYDELIG® (idelalisib) tablets, for oral use Initial U.S. Approval: 2014",1544460,idelalisib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_8d663642-f52e-49c0-a023-2da083fdfc0b.json,8d663642-f52e-49c0-a023-2da083fdfc0b,6,"These highlights do not include all the information needed to use SYLVANT 
 ®safely and effectively. See full prescribing information for SYLVANT.
 

SYLVANT (siltuximab) for injection, for intravenous use
 
Initial U.S. Approval: 2014",1535218,siltuximab,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231129_d1e41dcf-e82a-47c2-a0ad-6c6eef621834.json,d1e41dcf-e82a-47c2-a0ad-6c6eef621834,16,"These highlights do not include all the information needed to use NERLYNX safely and effectively. See full prescribing information for NERLYNX.
 



NERLYNX 
 ®(neratinib) tablets, for oral use
 

Initial U.S. Approval: 2017",1940643,neratinib,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220618_42c49deb-713b-427a-9670-08af08adcffb.json,42c49deb-713b-427a-9670-08af08adcffb,22,"These highlights do not include all the information needed to use ALECENSA safely and effectively. See full prescribing information for ALECENSA. 
ALECENSA® (alectinib) capsules, for oral useInitial U.S. Approval: 2015",1727455,alectinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,c98fb504-76d0-4c25-9c0b-412885828a7a,7,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005",342369,lenalidomide,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,c98fb504-76d0-4c25-9c0b-412885828a7a,7,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005",342369,lenalidomide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220826_de77155c-ecf2-4f15-9758-21d271449d83.json,de77155c-ecf2-4f15-9758-21d271449d83,2,"These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. 
FOTIVDA® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021",2534233,tivozanib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231128_dd966338-c820-4270-b704-09ef75fa3ceb.json,dd966338-c820-4270-b704-09ef75fa3ceb,19,"These highlights do not include all the information needed to use DIFICID safely and effectively. See full prescribing information for DIFICID. 
DIFICID® (fidaxomicin) tablets, for oral use DIFICID® (fidaxomicin) for oral suspension Initial U.S. Approval: 2011",1111103,fidaxomicin,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/train_xml/20221118_a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330.json,a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330,4,"These highlights do not include all the information needed to use Cleviprex safely and effectively. See full prescribing information for Cleviprex.
 



Cleviprex (clevidipine) injectable emulsion, for intravenous use
 

Initial U.S. Approval: 2008",233603,clevidipine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_49aa3d6d-2270-4615-aafa-b440859ab870.json,49aa3d6d-2270-4615-aafa-b440859ab870,4,Naltrexone Hydrochloride Tablets USP 50 mg,7243,naltrexone,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/train_xml/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012",1302966,carfilzomib,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221103_da1c9f37-779e-4682-816f-93d0faa4cfc9.json,da1c9f37-779e-4682-816f-93d0faa4cfc9,16,"These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. 
OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014",1592737,nintedanib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221103_da1c9f37-779e-4682-816f-93d0faa4cfc9.json,da1c9f37-779e-4682-816f-93d0faa4cfc9,16,"These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. 
OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014",1592737,nintedanib,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221122_6935e846-d5a1-49e5-89a2-f8ebe4d5590d.json,6935e846-d5a1-49e5-89a2-f8ebe4d5590d,22,"These highlights do not include all the information needed to use FUZEON safely and effectively. See full prescribing information for FUZEON. 
 FUZEON® (enfuvirtide) for Injection  Initial U.S. Approval: 2003",139896,enfuvirtide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231202_824f19c9-0546-4a8a-8d8f-c4055c04f7c7.json,824f19c9-0546-4a8a-8d8f-c4055c04f7c7,33,"These highlights do not include all the information needed to use STIVARGA safely and effectively.  See full prescribing information for STIVARGA.STIVARGA® (regorafenib) tablets, for oral useInitial U.S. Approval: 2012",1312397,regorafenib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221217_2c3db989-d7ad-41ed-9ebf-698dcf6c24ec.json,2c3db989-d7ad-41ed-9ebf-698dcf6c24ec,7,"These highlights do not include all the information needed to use DEFITELIO safely and effectively.  See full prescribing information for DEFITELIO.
DEFITELIO (defibrotide sodium) injection, for intravenous useInitial U.S. Approval: 2016",1311089,defibrotide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_2a7300d3-95e3-427e-bf37-55fa654cc90a.json,2a7300d3-95e3-427e-bf37-55fa654cc90a,9,"These highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS.


OLANZAPINE
 tablets, for oral use 


Initial U.S. Approval: 1996",61381,olanzapine,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221230_f1906fc9-cb3c-4e13-8a4a-da76100c1bf3.json,f1906fc9-cb3c-4e13-8a4a-da76100c1bf3,10,"These highlights do not include all the information needed to use PRETOMANID TABLETS safely and effectively.  See full prescribing information for PRETOMANID TABLETS. 
PRETOMANID tablets, for oral use
Initial U.S. Approval: 2019LIMITED POPULATION",2198359,pretomanid,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_4f9bd52a-99a7-4606-92b4-456a917aabef.json,4f9bd52a-99a7-4606-92b4-456a917aabef,13,"These highlights do not include all the information needed to use BRILINTA safely and effectively. See full prescribing information for BRILINTA.
BRILINTA® (ticagrelor) tablets, for oral useInitial U.S. Approval: 2011",1116632,ticagrelor,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,"FORANE (isoflurane, USP) liquid for inhalation",6026,isoflurane,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_c5116390-e0fe-4969-94cb-e9de5165fbab.json,c5116390-e0fe-4969-94cb-e9de5165fbab,23,"These highlights do not include all the information needed to use ONGLYZA safely and effectively. See full prescribing information for ONGLYZA.
ONGLYZA® (saxagliptin) tablets, for oral useInitial U.S. Approval: 2009",857974,saxagliptin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230301_d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6.json,d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6,21,"Synarel®


(nafarelin acetate)

nasal solution",28656,nafarelin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/gold_xml/20230331_eb368bb6-80e3-4df9-8a85-91df0a2ada6a.json,eb368bb6-80e3-4df9-8a85-91df0a2ada6a,14,"These highlights do not include all the information needed to use ERIVEDGE safely and effectively. See full prescribing information for ERIVEDGE. 
ERIVEDGE® (vismodegib) capsules, for oral useInitial U.S. Approval: 2012",1242987,vismodegib,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230407_bbd8ab99-552e-4b81-aca4-6b0c7af8b9ae.json,bbd8ab99-552e-4b81-aca4-6b0c7af8b9ae,16,"These highlights do not include all the information needed to use THYMOGLOBULIN® safely and effectively.  See full prescribing information for THYMOGLOBULIN. 
THYMOGLOBULIN (anti-thymocyte globulin [rabbit]) for injection, for intravenous use Initial U.S. Approval: 1998",1011,"lymphocyte immune globulin, anti-thymocyte globulin",10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/gold_xml/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013",1369713,pomalidomide,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_9c44bd5b-4464-40a4-8933-8680950f00f2.json,9c44bd5b-4464-40a4-8933-8680950f00f2,29,"These highlights do not include all the information needed to use AMJEVITA™ safely and effectively. See full prescribing information for AMJEVITA. 
 AMJEVITA (adalimumab-atto) injection, for subcutaneous use    Initial U.S. Approval: 2016 
 AMJEVITA (adalimumab-atto) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of AMJEVITA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA® (adalimumab).",327361,adalimumab,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_7a7974c7-8b6c-41ae-9a48-a08a1439087a.json,7a7974c7-8b6c-41ae-9a48-a08a1439087a,100,"These highlights do not include all the information needed to use TRETINOIN CAPSULES safely and effectively. See full prescribing information for TRETINOIN CAPSULES
.



TRETINOIN 
capsules, for oral use 

Initial U.S. Approval: 1995",10753,tretinoin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230429_b5ff59aa-9c0d-49a8-9053-1f179b482383.json,b5ff59aa-9c0d-49a8-9053-1f179b482383,9,"These highlights do not include all the information needed to use XOSPATA safely and effectively.  See full prescribing information for XOSPATA.
XOSPATA® (gilteritinib) tablets, for oral useInitial U.S. Approval: 2018",2105806,gilteritinib,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/gold_xml/20230510_ad965f38-dd22-4607-a673-2fb92f3b527a.json,ad965f38-dd22-4607-a673-2fb92f3b527a,8,"These highlights do not include all the information needed to use ARCALYST safely and effectively. See full prescribing information for ARCALYST. 
ARCALYST® (rilonacept) for injection, for subcutaneous use Initial U.S. Approval: 2008",763450,rilonacept,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231218_8edd78a9-d762-4578-a610-28d6595f4bf3.json,8edd78a9-d762-4578-a610-28d6595f4bf3,1,Melphalan Hydrochloride for Injection(For Intravenous Infusion),6718,melphalan,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_5451bcaa-0aca-4581-bcea-2f9c2a33b260.json,5451bcaa-0aca-4581-bcea-2f9c2a33b260,20,"These highlights do not include all the information needed to use OXYCODONE HYDROCHLORIDE ORAL SOLUTION safely and effectively. See full prescribing information for OXYCODONE HYDROCHLORIDE ORAL SOLUTION.
OXYCODONE HYDROCHLORIDE oral solution, CIIInitial U.S. Approval: 1950",7804,oxycodone,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,6093952a-5248-45cb-ad17-33716a411146,37,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007",662281,nilotinib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_58d80bc6-bdfb-4908-93e7-aace447c8d1a.json,58d80bc6-bdfb-4908-93e7-aace447c8d1a,1,"These highlights do not include all the information needed to use MYCAPSSA® safely and effectively. See full prescribing information for MYCAPSSA.
 MYCAPSSA (octreotide) delayed-release capsules, for oral use Initial U.S. Approval: 1988",7617,octreotide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20230720_de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa.json,de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,24,"These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA.
 JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010",996051,cabazitaxel,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230804_80eb1080-fe20-4af0-b2a5-a67999923fa8.json,80eb1080-fe20-4af0-b2a5-a67999923fa8,10,"These highlights do not include all the information needed to use ELZONRIS®safely and effectively.  See full prescribing information for ELZONRIS.
			
ELZONRIS (tagraxofusp-erzs) injection, for intravenous use
			Initial U.S. Approval: 2018",2109055,tagraxofusp,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230901_0fe9ff20-d402-41f3-bc1e-7002ea7007db.json,0fe9ff20-d402-41f3-bc1e-7002ea7007db,14,"These highlights do not include all the information needed to use ALUNBRIG safely and effectively. See full prescribing information for ALUNBRIG.
 ALUNBRIG® (brigatinib) tablets, for oral use Initial U.S. Approval: 2017",1921217,brigatinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013",1424911,dabrafenib,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230921_a865e0ef-8685-4f69-8838-648c4f3bab47.json,a865e0ef-8685-4f69-8838-648c4f3bab47,6,"These highlights do not include all the information needed to use GAMIFANT safely and effectively. See full prescribing information for GAMIFANT.
GAMIFANT® (emapalumab-lzsg) injection, for intravenous use Initial U.S. Approval: 2018",2104604,emapalumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,5cd725a1-2fa4-408a-a651-57a7b84b2118,18,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017",1875534,avelumab,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231019_235dfc38-0f0b-4037-b501-7a9f4294740c.json,235dfc38-0f0b-4037-b501-7a9f4294740c,16,"These highlights do not include all the information needed to use BRAFTOVI safely and effectively. See full prescribing information for BRAFTOVI.
BRAFTOVI® (encorafenib) capsules, for oral useInitial U.S. Approval: 2018",2049106,encorafenib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240203_e23dcfd0-071a-4458-a595-3562fabccbd4.json,e23dcfd0-071a-4458-a595-3562fabccbd4,3,Dantrolene Sodium capsules,3105,dantrolene,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,4911f343-68e6-71b0-e054-00144ff8d46c,5,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000",41493,meloxicam,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,4911f343-68e6-71b0-e054-00144ff8d46c,5,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000",41493,meloxicam,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1150345,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240223_4442f029-dd5e-4834-9b01-eb8c638ce4b1.json,4442f029-dd5e-4834-9b01-eb8c638ce4b1,100,"Nortriptyline Hydrochloride Capsules, USP",7531,nortriptyline,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,721724,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231215_8ded0773-3aec-4e89-9836-d22a5a84abf0.json,8ded0773-3aec-4e89-9836-d22a5a84abf0,17,Quinapril Tablets USP,35208,quinapril,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_f5f56c59-04d5-4c5d-9441-5a93d3bdec82.json,f5f56c59-04d5-4c5d-9441-5a93d3bdec82,6,"Felodipine Extended-Release Tablets, USP
 Rx only",4316,felodipine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,7652adc6-1aad-4422-b85c-0c6b11c23b73,7,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993",25480,gabapentin,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011",25480,gabapentin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,56d64558-1fad-420e-8fcd-7103cd073127,1,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998",140587,celecoxib,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1118084,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240221_106d9730-5938-8f27-e063-6294a90adc68.json,106d9730-5938-8f27-e063-6294a90adc68,2,"Cyclobenzaprine hydrochloride Tablets, USP",21949,cyclobenzaprine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,9678a98e-4aab-4d87-b5e1-37c3109e378e,16,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996",57258,tizanidine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,575da603-b038-421f-9894-6796d9ac33cc,11,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991",36437,sertraline,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)",52582,mesalamine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231111_57f8aac6-3bd3-4ae1-aab2-759c8bc23292.json,57f8aac6-3bd3-4ae1-aab2-759c8bc23292,4,Trandolapril Tablets USP Rx only,38454,trandolapril,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,500000301,1342439,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_0e98593a-8424-48c8-acc0-671f4b566aee.json,0e98593a-8424-48c8-acc0-671f4b566aee,9,"These highlights do not include all the information needed to use CARVEDILOL TABLETS safely and effectively. See full prescribing information for CARVEDILOL TABLETS.
 

CARVEDILOL tablets, for oral use
 
Initial U.S. Approval: 1995",20352,carvedilol,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_48ffeac8-38e8-4007-903a-dbffce25d679.json,48ffeac8-38e8-4007-903a-dbffce25d679,2,"These highlights do not include all the information needed to use ETRAVIRINE TABLETS safely and effectively.See full prescribing information for ETRAVIRINE TABLETS.
ETRAVIRINE tablets, for oral useInitial U.S. Approval: 2008",475969,etravirine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_48ffeac8-38e8-4007-903a-dbffce25d679.json,48ffeac8-38e8-4007-903a-dbffce25d679,2,"These highlights do not include all the information needed to use ETRAVIRINE TABLETS safely and effectively.See full prescribing information for ETRAVIRINE TABLETS.
ETRAVIRINE tablets, for oral useInitial U.S. Approval: 2008",475969,etravirine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/train_xml/20230816_6a9cbc29-9f15-4b24-8d86-206b82887f3d.json,6a9cbc29-9f15-4b24-8d86-206b82887f3d,24,"These highlights do not include all the information needed to use INTELENCE safely and effectively. See full prescribing information for INTELENCE.
 





INTELENCE 
 ®(etravirine) tablets, for oral use
 

Initial U.S. Approval: 2008",475969,etravirine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20120618_83aeddf8-6fed-487c-858b-2240f0a0e8af.json,83aeddf8-6fed-487c-858b-2240f0a0e8af,1,"CRIXIVAN®
(INDINAVIR SULFATE)CAPSULES",114289,indinavir,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20120618_83aeddf8-6fed-487c-858b-2240f0a0e8af.json,83aeddf8-6fed-487c-858b-2240f0a0e8af,1,"CRIXIVAN®
(INDINAVIR SULFATE)CAPSULES",114289,indinavir,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_55ae23ff-60f5-4de6-bd1b-472243b8636b.json,55ae23ff-60f5-4de6-bd1b-472243b8636b,8,"These highlights do not include all the information needed to use PIOGLITAZONE TABLETS safely and effectively. See full prescribing information for PIOGLITAZONE TABLETS
 







PIOGLITAZONE tablets, for oral use
 



Initial U.S. Approval: 1999",33738,pioglitazone,10024690,liver function test abnormal,500000301,acute liver injury,15,1,500000301,1525215,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240127_083a3282-254f-4042-b0eb-70f76a279f10.json,083a3282-254f-4042-b0eb-70f76a279f10,100,"These highlights do not include all the information needed to use VARDENAFIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for VARDENAFIL HYDROCHLORIDE TABLETS.
 



VARDENAFIL HYDROCHLORIDE tablets, for oral use
 

Initial U.S. Approval: 2003",306674,vardenafil,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240127_083a3282-254f-4042-b0eb-70f76a279f10.json,083a3282-254f-4042-b0eb-70f76a279f10,100,"These highlights do not include all the information needed to use VARDENAFIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for VARDENAFIL HYDROCHLORIDE TABLETS.
 



VARDENAFIL HYDROCHLORIDE tablets, for oral use
 

Initial U.S. Approval: 2003",306674,vardenafil,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_16a4a314-f97e-4e91-95e9-576a3773d284.json,16a4a314-f97e-4e91-95e9-576a3773d284,35,"These highlights do not include all the information needed to use 
SAVELLA
 
safely and effectively. See full prescribing information for 
SAVELLA
.  

   

SAVELLA
®
 (
milnacipran HCl
) 
t
ablets

Initial U.S. Approval: 2009",588250,milnacipran,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_03151cb5-d32b-4484-8f2a-8c5d24c7f6f1.json,03151cb5-d32b-4484-8f2a-8c5d24c7f6f1,10,"These highlights do not include all the information needed to use GLIPIZIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for GLIPIZIDE EXTENDED-RELEASE TABLETS.
 



GLIPIZIDE extended-release tablets, for oral use
 

Initial U.S. Approval: 1994",4821,glipizide,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_b6b1d427-e19a-4fc1-b518-f58bacc46736.json,b6b1d427-e19a-4fc1-b518-f58bacc46736,8,"Guanfacine Tablets, USP 


Rx only",40114,guanfacine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,11344047-7ed4-61e7-e063-6394a90a332d,1,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995",17128,lansoprazole,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_7df922bc-5750-4259-906f-64f960c38d5f.json,7df922bc-5750-4259-906f-64f960c38d5f,9,"These highlights do not include all the information needed to use ESZOPICLONE TABLETS safely and effectively. See full prescribing information for ESZOPICLONE TABLETS.
 



ESZOPICLONE tablets, for oral use, CIV
 

Initial U.S. Approval: 2004",461016,eszopiclone,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006,134748,rasagiline,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994",28439,lamotrigine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,500000301,705103,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240110_d953457e-0aff-6c38-e053-2995a90a7d32.json,d953457e-0aff-6c38-e053-2995a90a7d32,3,"Eplerenone Tablet
 
Rx Only
 

These highlights do not include all the information needed to use EPLERENONE TABLETS safely and effectively. See full prescribing information for EPLERENONE TABLETS.
 

Initial U.S. Approval: 2002",298869,eplerenone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231128_fc38f1bb-f175-4a81-8ed9-c8701efdea35.json,fc38f1bb-f175-4a81-8ed9-c8701efdea35,102,"FOSINOPRILSODIUM TABLETS, USP10mg, 20mg and 40mgRx Only",50166,fosinopril,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_f5e8d1da-8911-42db-9f90-cba04b28d011.json,f5e8d1da-8911-42db-9f90-cba04b28d011,102,"These highlights do not include all the information needed to use FLUVASTATIN CAPSULES safely and effectively.  See full prescribing information for FLUVASTATIN CAPSULES. 
FLUVASTATIN capsules, for oral useInitial U.S. Approval: 1993",41127,fluvastatin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995",68149,mycophenolate mofetil,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_11fad602-16c2-4c1f-bdf1-867d95f063ca.json,11fad602-16c2-4c1f-bdf1-867d95f063ca,10,"These highlights do not include all the information needed to use ROSUVASTATIN TABLETS safely and effectively. See full prescribing information for ROSUVASTATIN TABLETS.
 

ROSUVASTATIN tablets, for oral use
 
Initial U.S. Approval: 2003",301542,rosuvastatin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_14f3f9ba-7a4a-45d5-a25e-efe5cdff117d.json,14f3f9ba-7a4a-45d5-a25e-efe5cdff117d,8,"These highlights do not include all the information needed to use PREGABALIN CAPSULES safely and effectively. See full prescribing information for PREGABALIN CAPSULES.
 



PREGABALIN capsules, for oral use CV
 



Initial U.S. Approval: 2004",187832,pregabalin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information",3008,cyclosporine,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,19010482,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240214_f34c08e6-fe74-4de3-9e36-a82c3c1c183b.json,f34c08e6-fe74-4de3-9e36-a82c3c1c183b,9,"These highlights do not include all the information needed to use MOXIFLOXACIN TABLETS safely and effectively. See full prescribing information for MOXIFLOXACIN TABLETS.
 MOXIFLOXACIN tablets, for oral use Initial U.S. Approval: 1999",139462,moxifloxacin,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_4314da8a-40e5-4aba-a32b-57b4166ade30.json,4314da8a-40e5-4aba-a32b-57b4166ade30,12,"These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.  AZITHROMYCIN tablets, for oral use Initial U.S. Approval: 1991",18631,azithromycin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_029a90b6-0722-49be-8400-3ec29526aafd.json,029a90b6-0722-49be-8400-3ec29526aafd,6,"These highlights do not include all the information needed to use IRBESARTAN TABLETS safely and effectively. See full prescribing information for IRBESARTAN TABLETS.
 



IRBESARTAN tablets, for oral use
 

Initial U.S. Approval: 1997",83818,irbesartan,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f.json,c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f,3,"Famciclovir Tablets
 
Rx only
 

These highlights do not include all the information needed to use FAMCICLOVIR TABLETS safely and effectively. See full prescribing information for FAMCICLOVIR TABLETS.
 

Initial U.S. Approval: 1994",68099,famciclovir,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,5108ca9c-b307-4cb2-8ea1-6553764f375a,13,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002",321988,escitalopram,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_f3b50bbb-df03-4ed7-9d8d-180edc2abd54.json,f3b50bbb-df03-4ed7-9d8d-180edc2abd54,9,"Betaxolol Tablets, USP",1520,betaxolol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230223_4764f37b-c9e6-4ede-bcc2-8a03b7c521df.json,4764f37b-c9e6-4ede-bcc2-8a03b7c521df,46,"These highlights do not include all the information needed to use SPRYCEL® safely and effectively. See full prescribing information for SPRYCEL.

SPRYCEL (dasatinib) tablets, for oral useInitial U.S. Approval: 2006",475342,dasatinib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231205_5359b759-db7c-4672-9e8a-59c93869bd91.json,5359b759-db7c-4672-9e8a-59c93869bd91,5,"These highlights do not include all the information needed to use VIBATIV® (telavancin) safely and effectively. See full prescribing information for VIBATIV. 
VIBATIV® (telavancin) for injection, for intravenous use Initial U.S. Approval: 2009",473837,telavancin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_0becbde8-6ec5-4830-a0d9-cfdb7b15eb84.json,0becbde8-6ec5-4830-a0d9-cfdb7b15eb84,11,"Minocycline Hydrochloride Capsules, USP
 

Rx only",6980,minocycline,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230115_35addab5-09db-4f8a-9c69-6fbce33ecc37.json,35addab5-09db-4f8a-9c69-6fbce33ecc37,5,"These highlights do not include all the information needed to use GANCICLOVIR FOR INJECTION safely and effectively. See full prescribing information for GANCICLOVIR FOR INJECTION.GANCICLOVIR FOR INJECTION, for intravenous useInitial U.S. Approval: 1989Rx only",4678,ganciclovir,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231117_8512d0c6-db4e-4673-b3b4-28975c18413f.json,8512d0c6-db4e-4673-b3b4-28975c18413f,12,"",32385,olsalazine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_bf3425e0-428d-4bdb-ac9a-3b9d483df83a.json,bf3425e0-428d-4bdb-ac9a-3b9d483df83a,9,"Isradipine Capsules, USP

Rx only",33910,isradipine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_53bdb79c-c4cf-4818-b1f0-225e67a14536.json,53bdb79c-c4cf-4818-b1f0-225e67a14536,24,"These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
 
CLOZAPINE tablets, for oral use
 
Initial U.S. Approval: 1989",2626,clozapine,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,800878,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240102_7036c6df-6527-4701-b484-6b962914b52a.json,7036c6df-6527-4701-b484-6b962914b52a,7,Tiagabine Hydrochloride Tablets,31914,tiagabine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_b0075b72-c3cc-f844-e053-2a95a90a417f.json,b0075b72-c3cc-f844-e053-2a95a90a417f,5,"These highlights do not include all the information needed to use MEROPENEM FOR INJECTION safely and effectively. See full prescribing information for MEROPENEM FOR INJECTION
 







MEROPENEM for injection, for intravenous use
 







Initial U.S. Approval: 1996",29561,meropenem,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_b0075b72-c3cc-f844-e053-2a95a90a417f.json,b0075b72-c3cc-f844-e053-2a95a90a417f,5,"These highlights do not include all the information needed to use MEROPENEM FOR INJECTION safely and effectively. See full prescribing information for MEROPENEM FOR INJECTION
 







MEROPENEM for injection, for intravenous use
 







Initial U.S. Approval: 1996",29561,meropenem,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240201_f06d1bb3-83f1-4d84-8004-4c6681ad8a5a.json,f06d1bb3-83f1-4d84-8004-4c6681ad8a5a,4,"These highlights do not include all the information needed to use PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND) safely and effectively. See full prescribing information for PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND).
PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND), for intravenous use Initial U.S. Approval: 2005",56946,paclitaxel,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231208_fea50328-b3d5-4300-8c67-82cda0a975b7.json,fea50328-b3d5-4300-8c67-82cda0a975b7,6,"Triamterene Capsule, USP Potassium-Sparing Diuretic",10763,triamterene,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240117_852f013f-6759-4438-83c1-8ff48133dc85.json,852f013f-6759-4438-83c1-8ff48133dc85,4,"HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALBENDAZOLE TABLETS safely and effectively. See full prescribing information for ALBENDAZOLE TABLETS.  ALBENDAZOLE tablets, for oral use  Initial U.S. Approval: 1996",430,albendazole,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240202_86c0b4ae-5e38-4efe-88af-50ac560e294f.json,86c0b4ae-5e38-4efe-88af-50ac560e294f,8,"These highlights do not include all the information needed to use IBANDRONATE SODIUM TABLETS safely and effectively. See full prescribing information for IBANDRONATE SODIUM TABLETS.
 IBANDRONATE SODIUM tablets, for oral use Initial U.S. Approval: 2003",115264,ibandronate,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988",5657,ifosfamide,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_b856bfaf-ec6b-4171-81c4-b9b07f780084.json,b856bfaf-ec6b-4171-81c4-b9b07f780084,2,"These highlights do not include all the information needed to use VALGANCICLOVIR HYDROCHLORIDE FOR ORAL SOLUTION safely and effectively. See full prescribing information for VALGANCICLOVIR HYDROCHLORIDE FOR ORAL SOLUTION. VALGANCICLOVIR HYDROCHLORIDE, for oral solution Initial U.S. Approval: 2001",275891,valganciclovir,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_3495a71a-cc04-4776-851f-f185956f32af.json,3495a71a-cc04-4776-851f-f185956f32af,22,"These highlights do not include all the information needed to use VIDAZA safely and effectively. See full prescribing information for VIDAZA.
VIDAZA (azacitidine for injection), for subcutaneous or intravenous useInitial U.S. Approval: 2004",1251,azacitidine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_246e0ed0-f8ca-483b-a1ce-91052f3f35f0.json,246e0ed0-f8ca-483b-a1ce-91052f3f35f0,9,"Enalapril Maleate Tablets, USP",3827,enalapril,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002",121243,voriconazole,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,a1787fad-3612-43e1-98fa-ce62361e0b3c,13,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001",282388,imatinib,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1304107,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240221_6fc9c8e2-6f34-aa43-e053-2a91aa0ac377.json,6fc9c8e2-6f34-aa43-e053-2a91aa0ac377,10,"QUETIAPINE TABLETS. These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
 

Quetiapine tablets, for oral use
 

Initial U.S. Approval: 1997",51272,quetiapine,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992",70223,aldesleukin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210106_dd367eec-359a-4065-b5c3-7c0107c823fe.json,dd367eec-359a-4065-b5c3-7c0107c823fe,7,"Tolcapone Tablets

100 mg",72937,tolcapone,10019837,hepatocellular injury,500000301,acute liver injury,3,1,500000301,715727,1,1
./data/2024_latest_labels/gold_xml/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,7e9ab975-db2f-423c-a089-bc5a73313609,11,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011",1114195,rivaroxaban,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information",3008,cyclosporine,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,19010482,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240105_dc8d68d1-0c5c-4004-b71d-22b83daf4270.json,dc8d68d1-0c5c-4004-b71d-22b83daf4270,6,"These highlights do not include all the information needed to use BEXAROTENE CAPSULES safely and effectively.  See full prescribing information for BEXAROTENE CAPSULES.BEXAROTENE capsules, for oral useInitial U.S. Approval: 1999",233272,bexarotene,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220712_5ccf0e9a-8935-4c8c-b883-b4967281eb4a.json,5ccf0e9a-8935-4c8c-b883-b4967281eb4a,7,"NILANDRON®
 (nilutamide) Tablets",31805,nilutamide,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,cc7014b1-c775-411d-b374-8113248b4077,4,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017",1942950,inotuzumab ozogamicin,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959""",3002,cyclophosphamide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_8ea61d0d-4403-4d9f-a946-85a459cc0aa0.json,8ea61d0d-4403-4d9f-a946-85a459cc0aa0,5,"These highlights do not include all the information needed to use FONDAPARINUX SODIUM INJECTION safely and effectively. See full prescribing information for FONDAPARINUX SODIUM INJECTION.
 FONDAPARINUX SODIUM injection, for subcutaneous use Initial U.S. Approval: 2001",321208,fondaparinux,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221019_f2abe3ed-ed3d-4215-a489-b18341ce85bc.json,f2abe3ed-ed3d-4215-a489-b18341ce85bc,2,"These highlights do not include all the information needed to use ZONTIVITY safely and effectively. See full prescribing information for ZONTIVITY.
 



ZONTIVITY 
 ® (vorapaxar) Tablets 2.08 mg*, for oral use
 

*Equivalent to 2.5 mg vorapaxar sulfate
 

Initial U.S. Approval: 2014",1537034,vorapaxar,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_03819118-86f6-4329-adaf-4599e7b71f46.json,03819118-86f6-4329-adaf-4599e7b71f46,29,"These highlights do not include all the information needed to use
 
BUPRENORPHINE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE
 
SUBLINGUAL TABLETS.

       

BUPRENORPHINE 
s
ublingual 
t
ablets, CIII

Initial U.S. Approval: 1981",1819,buprenorphine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_8849c8f9-ee41-4ccd-8a62-67b04e80a276.json,8849c8f9-ee41-4ccd-8a62-67b04e80a276,1,"These highlights do not include all the information needed to use ARSENIC TRIOXIDE INJECTION safely and effectively. See full prescribing information for ARSENIC TRIOXIDE INJECTION. ARSENIC TRIOXIDE injection, for intravenous use Initial U.S. Approval: 2000",18330,arsenic trioxide,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_8849c8f9-ee41-4ccd-8a62-67b04e80a276.json,8849c8f9-ee41-4ccd-8a62-67b04e80a276,1,"These highlights do not include all the information needed to use ARSENIC TRIOXIDE INJECTION safely and effectively. See full prescribing information for ARSENIC TRIOXIDE INJECTION. ARSENIC TRIOXIDE injection, for intravenous use Initial U.S. Approval: 2000",18330,arsenic trioxide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_8849c8f9-ee41-4ccd-8a62-67b04e80a276.json,8849c8f9-ee41-4ccd-8a62-67b04e80a276,1,"These highlights do not include all the information needed to use ARSENIC TRIOXIDE INJECTION safely and effectively. See full prescribing information for ARSENIC TRIOXIDE INJECTION. ARSENIC TRIOXIDE injection, for intravenous use Initial U.S. Approval: 2000",18330,arsenic trioxide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210905_32fd2bb2-1cfa-4250-feb8-d7956c794e05.json,32fd2bb2-1cfa-4250-feb8-d7956c794e05,16,"These highlights do not include all the information needed to use MYLOTARG safely and effectively. See full prescribing information for MYLOTARG.
 MYLOTARG™ (gemtuzumab ozogamicin) for injection, for intravenous use Initial U.S. Approval: 2000",1294580,gemtuzumab ozogamicin,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_cfeab9e3-58b9-4890-9185-11b62904e2af.json,cfeab9e3-58b9-4890-9185-11b62904e2af,13,Metronidazole Tablets USP,6922,metronidazole,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_19880f51-badb-4846-a02a-592a210690ab.json,19880f51-badb-4846-a02a-592a210690ab,10,"These highlights do not include all the information needed to use SIROLIMUS ORAL SOLUTION safely and effectively. See full prescribing information for SIROLIMUS ORAL SOLUTION.


SIROLIMUS oral solutionInitial U.S. Approval: 1999",35302,sirolimus,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,"IBUPROFEN Tablets, USP",5640,ibuprofen,10062237,renal impairment,500000401,acute kidney injury,8,1,500000401,1177480,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231205_17a8d11b-73b0-4833-a0b4-cf1ef85edefb.json,17a8d11b-73b0-4833-a0b4-cf1ef85edefb,29,"These highlights do not include all the information needed to use ARISTADA® safely and effectively. See full prescribing information for ARISTADA®.
ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular useInitial U.S. Approval: 2015",1673265,aripiprazole lauroxil,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,Mefenamic Acid Capsules USPRx Only,257844,mefenamate,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1197736,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240217_33f3b99b-fa82-42e0-26bf-f49891ae3d22.json,33f3b99b-fa82-42e0-26bf-f49891ae3d22,38,"These highlights do not include all the information needed to use INVANZ safely and effectively. See full prescribing information for INVANZ. 
INVANZ® (ertapenem for injection), for intravenous or intramuscular use Initial U.S. Approval: 2001",325642,ertapenem,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231121_b98ee838-ed23-42a9-93b5-72579e490fba.json,b98ee838-ed23-42a9-93b5-72579e490fba,19,"These highlights do not include all the information needed to use CYSTARAN 
 ®safely and effectively. See full prescribing information for CYSTARAN.
 







CYSTARAN (cysteamine ophthalmic solution) 0.44%, for topical ophthalmic use
 



Initial U.S. Approval: 1994",3022,cysteamine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220623_08982e49-d2eb-4b25-b01a-1be52fd669ef.json,08982e49-d2eb-4b25-b01a-1be52fd669ef,16,"These highlights do not include all the information needed to use APTIVUS safely and effectively.  See full prescribing information for APTIVUS. 
APTIVUS® (tipranavir) capsules, for oral use APTIVUS® (tipranavir) oral solution Initial U.S. Approval: 2005",190548,tipranavir,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_e4dbaa72-7b3e-4aef-983b-90efb2b343cd.json,e4dbaa72-7b3e-4aef-983b-90efb2b343cd,6,"These highlights do not include all the information needed to use PRAVASTATIN SODIUM TABLETS safely and effectively. See full prescribing information for PRAVASTATIN SODIUM TABLETS.
 

PRAVASTATIN SODIUM tablets, for oral use
 
Initial U.S. Approval: 1991",42463,pravastatin,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240204_1abc06c7-6a45-4a0b-b2da-c228aaa137ed.json,1abc06c7-6a45-4a0b-b2da-c228aaa137ed,3,"These highlights do not include all the information needed to use PIRFENIDONE TABLETS safely and effectively. See full prescribing information for PIRFENIDONE TABLETS.
 

PIRFENIDONE tablets, for oral use
 
Initial U.S. Approval: 2014",1592254,pirfenidone,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240117_55859d2d-0456-4fa9-b41f-f535accc97db.json,55859d2d-0456-4fa9-b41f-f535accc97db,11,"These highlights do not include all the information needed to use MONOFERRIC safely and effectively. See Full Prescribing Information for MONOFERRIC.
 



MONOFERRIC (ferric derisomaltose) injection, for intravenous use
 

Initial U.S. Approval: 2020",2274394,ferric derisomaltose,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/train_xml/20231128_dd966338-c820-4270-b704-09ef75fa3ceb.json,dd966338-c820-4270-b704-09ef75fa3ceb,19,"These highlights do not include all the information needed to use DIFICID safely and effectively. See full prescribing information for DIFICID. 
DIFICID® (fidaxomicin) tablets, for oral use DIFICID® (fidaxomicin) for oral suspension Initial U.S. Approval: 2011",1111103,fidaxomicin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012",1302966,carfilzomib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221108_bca1e4c6-4b2b-4876-8ab3-654629c4ff1b.json,bca1e4c6-4b2b-4876-8ab3-654629c4ff1b,10,"These highlights do not include all the information needed to use MOTEGRITY safely and effectively. See full prescribing information for MOTEGRITY. 
 MOTEGRITY (prucalopride) tablets, for oral use Initial U.S. Approval: 2018",2107310,prucalopride,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231215_9f489295-1156-52c7-5fd0-5c4c52f9b813.json,9f489295-1156-52c7-5fd0-5c4c52f9b813,8,"These highlights do not include all the information needed to use LUPKYNIS™ safely and effectively. See full prescribing information for LUPKYNIS.








LUPKYNIS (voclosporin) capsules, for oral use




Initial U.S. Approval: 2021",2475166,voclosporin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231230_038f2461-834b-4488-9ebd-863c83eef5a7.json,038f2461-834b-4488-9ebd-863c83eef5a7,10,"These highlights do not include all the information needed to use NINLARO safely and effectively. See full prescribing information for NINLARO.
 NINLARO® (ixazomib) capsules, for oral use Initial U.S. Approval: 2015",1723735,ixazomib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231202_824f19c9-0546-4a8a-8d8f-c4055c04f7c7.json,824f19c9-0546-4a8a-8d8f-c4055c04f7c7,33,"These highlights do not include all the information needed to use STIVARGA safely and effectively.  See full prescribing information for STIVARGA.STIVARGA® (regorafenib) tablets, for oral useInitial U.S. Approval: 2012",1312397,regorafenib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/gold_xml/20231201_a398400e-bd31-41a9-9696-4f7c06569ede.json,a398400e-bd31-41a9-9696-4f7c06569ede,14,"These highlights do not include all the information needed to use XOFIGO safely and effectively.  See full prescribing information for XOFIGO.
XOFIGO (radium Ra 223 dichloride) injection, for intravenous useInitial U.S. Approval: 2013",1546450,radium,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231216_6240792b-9224-2d10-e053-2a91aa0a2c3e.json,6240792b-9224-2d10-e053-2a91aa0a2c3e,8,"These highlights do not include all the information needed to use XENICAL safely and effectively. See full prescribing information for XENICAL.

 XENICAL (orlistat) Capsules for oral use Initial U.S. Approval: 1999",37925,orlistat,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,741530,1,1
./data/2024_latest_labels/train_xml/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008",709271,certolizumab pegol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231229_6402435f-9f6a-4f02-91a2-6267d783fa78.json,6402435f-9f6a-4f02-91a2-6267d783fa78,3,"These highlights do not include all the information needed to use GEFITINIB TABLETS safely and effectively. See full prescribing information for GEFITINIB TABLETS.GEFITINIB tablets, for oral useInitial U.S. Approval: 2015",328134,gefitinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,b118a40d-6b56-cee3-10f6-ded821a97018,275,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016",1747556,venetoclax,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230331_4a0c7c8b-b95f-455d-9600-b7351e4397fe.json,4a0c7c8b-b95f-455d-9600-b7351e4397fe,2,"These highlights do not include all the information needed to use REZLIDHIA safely and effectively. See full prescribing information for REZLIDHIA.
REZLIDHIA™ (olutasidenib) capsules, for oral useInitial U.S. Approval: 2022",2623641,olutasidenib,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_9c44bd5b-4464-40a4-8933-8680950f00f2.json,9c44bd5b-4464-40a4-8933-8680950f00f2,29,"These highlights do not include all the information needed to use AMJEVITA™ safely and effectively. See full prescribing information for AMJEVITA. 
 AMJEVITA (adalimumab-atto) injection, for subcutaneous use    Initial U.S. Approval: 2016 
 AMJEVITA (adalimumab-atto) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of AMJEVITA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA® (adalimumab).",327361,adalimumab,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_9c44bd5b-4464-40a4-8933-8680950f00f2.json,9c44bd5b-4464-40a4-8933-8680950f00f2,29,"These highlights do not include all the information needed to use AMJEVITA™ safely and effectively. See full prescribing information for AMJEVITA. 
 AMJEVITA (adalimumab-atto) injection, for subcutaneous use    Initial U.S. Approval: 2016 
 AMJEVITA (adalimumab-atto) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of AMJEVITA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA® (adalimumab).",327361,adalimumab,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230428_e53960ab-42a1-40d1-9c7d-eb013fe7f18f.json,e53960ab-42a1-40d1-9c7d-eb013fe7f18f,14,"These highlights do not include all the information needed to use POTELIGEO safely and effectively. See full prescribing information for POTELIGEO.
POTELIGEO® (mogamulizumab-kpkc) injection, for intravenous useInitial U.S. Approval: 2018",2054068,mogamulizumab,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_a9b01bc6-95ac-46f9-befa-d845a74d53c1.json,a9b01bc6-95ac-46f9-befa-d845a74d53c1,16,"Emcyt®


 estramustine phosphate sodium

capsules",4089,estramustine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230509_c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0.json,c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0,8,"These highlights do not include all the information needed to use LIVTENCITY safely and effectively. See full prescribing information for LIVTENCITY.
 LIVTENCITY™  (maribavir) tablets, for oral use Initial U.S. Approval: 2021",2586068,maribavir,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230516_2e8ef36b-71fa-4492-a16f-577d5f7d111d.json,2e8ef36b-71fa-4492-a16f-577d5f7d111d,7,"These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ.
 BELEODAQ® (belinostat) for injection, for intravenous use Initial U.S. Approval: 2014",1543543,belinostat,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,6fa682c9-a312-4932-9831-f286908660ee,34,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016",1792776,atezolizumab,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230526_d7836711-b677-412d-bf2d-0f7c8444103a.json,d7836711-b677-412d-bf2d-0f7c8444103a,3,"These highlights do not include all the information needed to use EPKINLY safely and effectively. See full prescribing information for EPKINLY.
 EPKINLY™ (epcoritamab-bysp) injection, for subcutaneous use Initial U.S. Approval: 2023",2637392,epcoritamab,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230613_90073508-6dca-4d27-aa5a-ed837737c35b.json,90073508-6dca-4d27-aa5a-ed837737c35b,1,"These highlights do not include all the information needed to use REZZAYO safely and effectively. See full prescribing information for REZZAYO.
 REZZAYO™ (rezafungin for injection), for intravenous useInitial U.S. Approval: 2023",2639155,rezafungin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230617_3423ac0f-9585-4abf-a8ba-a5123a8277ee.json,3423ac0f-9585-4abf-a8ba-a5123a8277ee,8,"These highlights do not include all the information needed to use AZEDRA safely and effectively.  See full prescribing information for AZEDRA. 		
AZEDRA® (iobenguane I 131) injection, for intravenous use 		Initial U.S. Approval: 2018",14448,3-iodobenzylguanidine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231223_8baba4ea-2855-42fa-9bd9-5a7548d4cec3.json,8baba4ea-2855-42fa-9bd9-5a7548d4cec3,24,"These highlights do not include all the information needed to use IMFINZI safely and effectively.  See full prescribing information for IMFINZI.
IMFINZI® (durvalumab) injection, for intravenous useInitial U.S. Approval: 2017",1919503,durvalumab,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231223_8baba4ea-2855-42fa-9bd9-5a7548d4cec3.json,8baba4ea-2855-42fa-9bd9-5a7548d4cec3,24,"These highlights do not include all the information needed to use IMFINZI safely and effectively.  See full prescribing information for IMFINZI.
IMFINZI® (durvalumab) injection, for intravenous useInitial U.S. Approval: 2017",1919503,durvalumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_455892c3-d144-4ba8-9ab4-79cabff9876d.json,455892c3-d144-4ba8-9ab4-79cabff9876d,11,"These highlights do not include all the information needed to use TABRECTA safely and effectively. See full prescribing information for TABRECTA.
		
TABRECTA® (capmatinib) tablets, for oral use
		
		Initial U.S. Approval: 2020",2362165,capmatinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230720_de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa.json,de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,24,"These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA.
 JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010",996051,cabazitaxel,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231230_b5631d3e-4604-4363-8f20-11dfc5a4a8ed.json,b5631d3e-4604-4363-8f20-11dfc5a4a8ed,13,"These highlights do not include all the information needed to use PADCEV safely and effectively. See full prescribing information for PADCEV.
PADCEV® (enfortumab vedotin-ejfv) for injection, for intravenous useInitial U.S. Approval: 2019",2268307,enfortumab,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012",1363268,cabozantinib,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,5cd725a1-2fa4-408a-a651-57a7b84b2118,18,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017",1875534,avelumab,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,84137882-e000-47da-bd5b-fa76ab3c76f9,20,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012",1242999,axitinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231019_6c3408ac-d401-4925-8a03-26591afbc240.json,6c3408ac-d401-4925-8a03-26591afbc240,10,"These highlights do not include all the information needed to use MEKTOVI safely and effectively. See full prescribing information for MEKTOVI.
MEKTOVI® (binimetinib) tablets, for oral useInitial U.S. Approval: 2018",2049122,binimetinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230707_a6f42739-5bfc-4b76-8795-e93fa58f3d29.json,a6f42739-5bfc-4b76-8795-e93fa58f3d29,12,"Oxandrolone Tablet, USP",7779,oxandrolone,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)",4502,flurbiprofen,10018830,haematemesis,500001001,gi bleed,11,1,500001001,1156378,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240222_584abe73-8290-4484-ff8e-5890831c095e.json,584abe73-8290-4484-ff8e-5890831c095e,21,"These highlights do not include all the information needed to use IMITREX safely and effectively. See full prescribing information for IMITREX.IMITREX (sumatriptan) tablets, for oral useInitial U.S. Approval: 1992",37418,sumatriptan,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,7652adc6-1aad-4422-b85c-0c6b11c23b73,7,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993",25480,gabapentin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,7ee820e4-a479-4b7d-8730-101ac1f8015c,102,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982",8356,piroxicam,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,500000301,1146810,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231220_11d5a86e-7861-43f1-ae04-84daa0de7888.json,11d5a86e-7861-43f1-ae04-84daa0de7888,13,"These highlights do not include all the information needed to use EXEMESTANE TABLETS safely and effectively. See full prescribing information for EXEMESTANE TABLETS. 


EXEMESTANE tablets, for oral use 

Initial U.S. Approval: 1999",258494,exemestane,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,"Venlafaxine Tablets, USP
 
Rx only",39786,venlafaxine,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240120_c522c860-84ce-4c61-ab72-077de73195df.json,c522c860-84ce-4c61-ab72-077de73195df,1,"Tetracycline Hydrochloride Tablets, USP For Oral Use",10395,tetracycline,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230921_e72c2bc6-9462-4a2e-8e1d-b97592376cbd.json,e72c2bc6-9462-4a2e-8e1d-b97592376cbd,32,"These highlights do not include all the information needed to use VIRACEPT safely and effectively. See full prescribing information for VIRACEPT.
 VIRACEPT® (nelfinavir mesylate) Tablets, for oral use  VIRACEPT®  (nelfinavir mesylate) Oral Powder, for oral use Initial U.S. Approval: 1997",134527,nelfinavir,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999",21107,cilostazol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_64b7df84-c990-49f7-bc04-0cccfd7d2019.json,64b7df84-c990-49f7-bc04-0cccfd7d2019,14,"These highlights do not include all the information needed to use TRAMADOL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAMADOL HYDROCHLORIDE TABLETS.
 



TRAMADOL HYDROCHLORIDE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1995",10689,tramadol,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_116f4f0d-66c5-49dd-e063-6394a90ab2b5.json,116f4f0d-66c5-49dd-e063-6394a90ab2b5,1,"Acyclovir Tablets, USP",281,acyclovir,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1703687,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231204_8bdb47c5-9d19-4d59-94c8-62c117525e7f.json,8bdb47c5-9d19-4d59-94c8-62c117525e7f,1,Zafirlukast Tablets Rx only,114970,zafirlukast,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1111706,1,1
./data/2024_latest_labels/train_xml/20230816_6a9cbc29-9f15-4b24-8d86-206b82887f3d.json,6a9cbc29-9f15-4b24-8d86-206b82887f3d,24,"These highlights do not include all the information needed to use INTELENCE safely and effectively. See full prescribing information for INTELENCE.
 





INTELENCE 
 ®(etravirine) tablets, for oral use
 

Initial U.S. Approval: 2008",475969,etravirine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231210_7e659505-c902-4906-9461-1cc83e2236d2.json,7e659505-c902-4906-9461-1cc83e2236d2,25,"These highlights do not include all the information needed to use ISENTRESS safely and effectively. See full prescribing information for ISENTRESS. 
ISENTRESS® (raltegravir) film-coated tablets, for oral useISENTRESS® HD (raltegravir) film-coated tablets, for oral useISENTRESS® (raltegravir) chewable tablets, for oral useISENTRESS® (raltegravir) for oral suspensionInitial U.S. Approval: 2007",719872,raltegravir,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20100824_983ce15f-cd37-4f3a-9e51-205860e80976.json,983ce15f-cd37-4f3a-9e51-205860e80976,3,DESCRIPTION,36709,sodium phosphate,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_eb354221-c476-41cb-ad87-52423f81d698.json,eb354221-c476-41cb-ad87-52423f81d698,3,"Cefdinir Capsules, USP
 
Rx only",25037,cefdinir,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_b023a9f2-1a99-4b40-a953-edac7e3a79bf.json,b023a9f2-1a99-4b40-a953-edac7e3a79bf,15,"These highlights do not include all the information needed to use anastrozole tablets safely and effectively. See full prescribing information for anastrozole tablets.
 

ANASTROZOLE tablet for oral use
 

Initial U.S. Approval: 1995",84857,anastrozole,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997",746741,pramipexole,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,11344047-7ed4-61e7-e063-6394a90a332d,1,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995",17128,lansoprazole,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997",72302,ropinirole,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997",72302,ropinirole,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_1b5646a9-4724-44b8-8cd0-9c14f5e87f86.json,1b5646a9-4724-44b8-8cd0-9c14f5e87f86,12,"These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
 



LAMOTRIGINE Tablets, for oral use
 



Initial U.S. Approval: 1994",28439,lamotrigine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009",73689,febuxostat,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_d953457e-0aff-6c38-e053-2995a90a7d32.json,d953457e-0aff-6c38-e053-2995a90a7d32,3,"Eplerenone Tablet
 
Rx Only
 

These highlights do not include all the information needed to use EPLERENONE TABLETS safely and effectively. See full prescribing information for EPLERENONE TABLETS.
 

Initial U.S. Approval: 2002",298869,eplerenone,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_4ffd02a3-86b8-4af7-b539-aa32e38c6b12.json,4ffd02a3-86b8-4af7-b539-aa32e38c6b12,14,"These highlights do not include all the information needed to use COLESEVELAM HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for COLESEVELAM HYDROCHLORIDE TABLETS.
 COLESEVELAM HYDROCHLORIDE tablets, for oral use
 Initial U.S. Approval: 2000",141626,colesevelam,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231128_fc38f1bb-f175-4a81-8ed9-c8701efdea35.json,fc38f1bb-f175-4a81-8ed9-c8701efdea35,102,"FOSINOPRILSODIUM TABLETS, USP10mg, 20mg and 40mgRx Only",50166,fosinopril,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243.json,a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243,9,"These highlights do not include all the information needed to use GALANTAMINE TABLETS safely and effectively. See full prescribing information for GALANTAMINE TABLETS.
 GALANTAMINE tablets, for oral use Initial U.S. Approval: 2001",4637,galantamine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995",68149,mycophenolate mofetil,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_f2f090c2-3ee1-7689-e053-2995a90abe38.json,f2f090c2-3ee1-7689-e053-2995a90abe38,3,"These highlights do not include all the information needed to use LEVOFLOXACIN TABLETS 
  safely and effectively. See full prescribing information for LEVOFLOXACIN TABLETS. 
 




LEVOFLOXACIN tablets, for oral use






Initial U.S. Approval: 1996",82122,levofloxacin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_f2f090c2-3ee1-7689-e053-2995a90abe38.json,f2f090c2-3ee1-7689-e053-2995a90abe38,3,"These highlights do not include all the information needed to use LEVOFLOXACIN TABLETS 
  safely and effectively. See full prescribing information for LEVOFLOXACIN TABLETS. 
 




LEVOFLOXACIN tablets, for oral use






Initial U.S. Approval: 1996",82122,levofloxacin,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,500000301,1742253,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_b8d657ac-dbda-4455-8bb5-3896951c3b67.json,b8d657ac-dbda-4455-8bb5-3896951c3b67,4,"These highlights do not include all the information needed to use ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS safely and effectively. See full prescribing information for ZOLMITRIPTAN ORALLY DISINTEGRATING TABLETS.
 ZOLMITRIPTAN orally disintegrating tablets Initial U.S. Approval: 1997",135775,zolmitriptan,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1116031,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240227_b1ac4c92-e1fd-4015-b172-0932790ae019.json,b1ac4c92-e1fd-4015-b172-0932790ae019,2,"Prednisone Tablets, USP   Rx only",8640,prednisone,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240117_8ca926e0-4c3c-473f-9cd0-ff38032d6963.json,8ca926e0-4c3c-473f-9cd0-ff38032d6963,2,"These highlights do not include all the information needed to use OSELTAMIVIR PHOSPHATE CAPSULES safely and effectively. See full prescribing information for OSELTAMIVIR PHOSPHATE CAPSULES. 
OSELTAMIVIR phosphate capsules, for oral useInitial U.S. Approval: 1999",260101,oseltamivir,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240117_7c295b64-ec39-42ec-9f02-da5b42e775e1.json,7c295b64-ec39-42ec-9f02-da5b42e775e1,8,"These highlights do not include all the information needed to use BICALUTAMIDE TABLETS safely and effectively. See full prescribing information for BICALUTAMIDE TABLETS.
 



BICALUTAMIDE TABLETS, for oral use
 



Initial U.S. Approval: 1995",83008,bicalutamide,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20120511_ba1cca98-f350-4655-88e3-6ef990779fb9.json,ba1cca98-f350-4655-88e3-6ef990779fb9,1,"KETEK®
(telithromycin) Tablets",274786,telithromycin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_1c90aa68-cc12-41ef-aebc-2616ae45683a.json,1c90aa68-cc12-41ef-aebc-2616ae45683a,11,"These highlights do not include all the information needed to use 

candesartan cilexetil 

 safely and effectively.  See full prescribing information for 

candesartan cilexetil 

.

Candesartan cilexetil tablets, for oral use
Initial U.S. Approval: 1998",214354,candesartan,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,88441a9f-b4f9-455d-a355-46fb30699a7b,10,"Sulfasalazine Tablets, USP",9524,sulfasalazine,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230115_35addab5-09db-4f8a-9c69-6fbce33ecc37.json,35addab5-09db-4f8a-9c69-6fbce33ecc37,5,"These highlights do not include all the information needed to use GANCICLOVIR FOR INJECTION safely and effectively. See full prescribing information for GANCICLOVIR FOR INJECTION.GANCICLOVIR FOR INJECTION, for intravenous useInitial U.S. Approval: 1989Rx only",4678,ganciclovir,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,9803db35-2600-4f42-80c1-43216fd1ba3d,4,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004",82819,acamprosate,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_4dd14728-02b4-4e75-b9c6-227be7816d5b.json,4dd14728-02b4-4e75-b9c6-227be7816d5b,9,"These highlights do not include all the information needed to use ABACAVIR TABLETS safely and effectively. See full prescribing information for ABACAVIR TABLETS.
 



ABACAVIR tablets, for oral use
 

Initial U.S. Approval: 1998",190521,abacavir,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240202_5c380ab0-4386-48b6-80ab-ca594b23bc74.json,5c380ab0-4386-48b6-80ab-ca594b23bc74,11,"Nembutal® Sodium Solution  CII(pentobarbital sodium injection, USP)",8004,pentobarbital,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240202_86c0b4ae-5e38-4efe-88af-50ac560e294f.json,86c0b4ae-5e38-4efe-88af-50ac560e294f,8,"These highlights do not include all the information needed to use IBANDRONATE SODIUM TABLETS safely and effectively. See full prescribing information for IBANDRONATE SODIUM TABLETS.
 IBANDRONATE SODIUM tablets, for oral use Initial U.S. Approval: 2003",115264,ibandronate,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_adfc2b23-00a5-4f05-a08b-83087e1e4843.json,adfc2b23-00a5-4f05-a08b-83087e1e4843,1,"These highlights do not include all the information needed to use ENOXAPARIN SODIUM INJECTION safely and effectively. See full prescribing information for ENOXAPARIN SODIUM INJECTION.ENOXAPARIN SODIUM injection, for subcutaneous and intravenous useInitial U.S. Approval: 1993",67108,enoxaparin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_059a3306-6207-497f-a947-33198f18761f.json,059a3306-6207-497f-a947-33198f18761f,9,"These highlights do not include all the information needed to use LEVOLEUCOVORIN INJECTION safely and effectively. See full prescribing information for LEVOLEUCOVORIN INJECTION.LEVOLEUCOVORIN injection, for intravenous useInitial U.S. Approval: 1952 (d,l-leucovorin)",877015,levoleucovorin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992",70223,aldesleukin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_b605b541-4bfd-db3e-9710-11c27f6dee6c.json,b605b541-4bfd-db3e-9710-11c27f6dee6c,2,"These highlights do not include all the information needed to use BORTEZOMIB FOR INJECTION safely and effectively. See full prescribing information for BORTEZOMIB FOR INJECTION.
 BORTEZOMIB for injection, for subcutaneous or intravenous useInitial U.S. Approval: 2003",358258,bortezomib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,7e9ab975-db2f-423c-a089-bc5a73313609,11,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011",1114195,rivaroxaban,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231208_7e9ab975-db2f-423c-a089-bc5a73313609.json,7e9ab975-db2f-423c-a089-bc5a73313609,11,"These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO.
 



XARELTO 
 ® (rivaroxaban) tablets, for oral use
 

XARELTO 
 ® (rivaroxaban) for oral suspension
 

Initial U.S. Approval: 2011",1114195,rivaroxaban,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_c0781dae-3ef6-4cab-b084-01d2e45f3764.json,c0781dae-3ef6-4cab-b084-01d2e45f3764,1,"These highlights do not include all the information needed to use EPTIFIBATIDE INJECTION safely and effectively. See full prescribing information for EPTIFIBATIDE INJECTION.
EPTIFIBATIDE injection, for intravenous useInitial U.S. Approval: 1998",75635,eptifibatide,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_34de1806-d921-4d2f-8c7f-03625b717a70.json,34de1806-d921-4d2f-8c7f-03625b717a70,25,"These highlights do not include all the information needed to use METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS.


METHYLPHENIDATE HCl extended-release tablets, for oral administration CII 

Initial U.S. Approval: 2000",6901,methylphenidate,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,cc7014b1-c775-411d-b374-8113248b4077,4,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017",1942950,inotuzumab ozogamicin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005",614373,deferasirox,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005",614373,deferasirox,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b.json,3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b,13,"These highlights do not include all the information needed to use MICAFUNGIN FOR INJECTION safely and effectively. See full prescribing information for MICAFUNGIN FOR INJECTION.
 MICAFUNGIN for Injection, for intravenous infusion only Initial U.S. Approval: 2005",325887,micafungin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_29ba0172-7ca3-4122-af1b-f0da522318cb.json,29ba0172-7ca3-4122-af1b-f0da522318cb,6,"These highlights do not include all the information needed to use HYDROXYCHLOROQUINE SULFATE TABLETS safely and effectively. See full prescribing information for HYDROXYCHLOROQUINE SULFATE TABLETS.
HYDROXYCHLOROQUINE SULFATE Tablets, for oral use
Initial U.S. Approval: 1955",5521,hydroxychloroquine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_03819118-86f6-4329-adaf-4599e7b71f46.json,03819118-86f6-4329-adaf-4599e7b71f46,29,"These highlights do not include all the information needed to use
 
BUPRENORPHINE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE
 
SUBLINGUAL TABLETS.

       

BUPRENORPHINE 
s
ublingual 
t
ablets, CIII

Initial U.S. Approval: 1981",1819,buprenorphine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,22174520-4b78-4841-96f7-530ba12d2cf1,8,"Paroxetine Tablets USP, film coated for oral use",32937,paroxetine,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,0772eb61-ca42-39de-e063-6294a90a6632,1,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006",357977,sunitinib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231128_3bad23a6-09a6-4194-9182-093ed61bc71c.json,3bad23a6-09a6-4194-9182-093ed61bc71c,39,"These highlights do not include all the information needed to use CANCIDAS safely and effectively. See full prescribing information for CANCIDAS.
CANCIDAS® (caspofungin acetate) for injection, for intravenous useInitial U.S. Approval: 2001",140108,caspofungin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220218_47547f93-489c-4298-aeea-d6a37ca6cb1d.json,47547f93-489c-4298-aeea-d6a37ca6cb1d,5,"These highlights do not include all the information needed to use COPIKTRA safely and effectively. See full prescribing information for COPIKTRA.
  



COPIKTRA (duvelisib), capsules for oral use
  

Initial U.S. Approval: 2018",2058509,duvelisib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_33f3b99b-fa82-42e0-26bf-f49891ae3d22.json,33f3b99b-fa82-42e0-26bf-f49891ae3d22,38,"These highlights do not include all the information needed to use INVANZ safely and effectively. See full prescribing information for INVANZ. 
INVANZ® (ertapenem for injection), for intravenous or intramuscular use Initial U.S. Approval: 2001",325642,ertapenem,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009",141704,everolimus,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009",141704,everolimus,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240112_ae77f00f-d43b-4b75-afd5-a2a9cb7138da.json,ae77f00f-d43b-4b75-afd5-a2a9cb7138da,9,"These highlights do not include all the information needed to use PEMETREXED FOR INJECTION safely and effectively. See full prescribing information for PEMETREXED FOR INJECTION.
PEMETREXED FOR INJECTION, for Intravenous Use Initial U.S. Approval: 2004",68446,pemetrexed,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220618_42c49deb-713b-427a-9670-08af08adcffb.json,42c49deb-713b-427a-9670-08af08adcffb,22,"These highlights do not include all the information needed to use ALECENSA safely and effectively. See full prescribing information for ALECENSA. 
ALECENSA® (alectinib) capsules, for oral useInitial U.S. Approval: 2015",1727455,alectinib,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_ec1bb0d1-f38a-4080-831a-68791d1d1fdb.json,ec1bb0d1-f38a-4080-831a-68791d1d1fdb,7,"These highlights do not include all the information needed to use ZORYVE cream safely and effectively. See full prescribing information for ZORYVE cream.
 ZORYVE® (roflumilast) cream, for topical use Initial U.S. Approval: 2011",1091836,roflumilast,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,7fa848ba-a59c-4144-9f52-64d090f4d828,10,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020",2370147,selpercatinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_49aa3d6d-2270-4615-aafa-b440859ab870.json,49aa3d6d-2270-4615-aafa-b440859ab870,4,Naltrexone Hydrochloride Tablets USP 50 mg,7243,naltrexone,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012",1302966,carfilzomib,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231005_499ab990-2b21-474f-aaba-d86388965f40.json,499ab990-2b21-474f-aaba-d86388965f40,9,"These highlights do not include all the information needed to use ARIKAYCE safely and effectively. See full prescribing information for ARIKAYCE. 
ARIKAYCE® (amikacin liposome inhalation suspension), for oral inhalation use Initial U.S. Approval: 2018 LIMITED POPULATION",641,amikacin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231216_d9fd11d0-4269-12fb-95cf-b3c11d75e479.json,d9fd11d0-4269-12fb-95cf-b3c11d75e479,6,"These highlights do not include all the information needed to use TOLVAPTAN TABLETS safely and effectively. See full prescribing information for TOLVAPTAN TABLETS.

TOLVAPTAN tablets, for oral use

Initial U.S. Approval: 2009",358257,tolvaptan,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/gold_xml/20231129_c6080942-dee6-423e-b688-1272c2ae90d4.json,c6080942-dee6-423e-b688-1272c2ae90d4,40,"These highlights do not include all the information needed to use CYRAMZA safely and effectively. See full prescribing information for CYRAMZA.
CYRAMZA (ramucirumab) injection, for intravenous useInitial U.S. Approval: 2014",1535922,ramucirumab,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/train_xml/20231213_01f90c94-71cb-4a1f-81ff-8004b850529b.json,01f90c94-71cb-4a1f-81ff-8004b850529b,15,"These highlights do not include all the information needed to use FARXIGA safely and effectively.  See full prescribing information for FARXIGA.
FARXIGA® (dapagliflozin) tablets, for oral useInitial U.S. Approval: 2014",1488564,dapagliflozin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230517_58a3c995-5ad6-465d-8437-5970c9088213.json,58a3c995-5ad6-465d-8437-5970c9088213,1,"LEUKERAN®
(chlorambucil) Tablets",2346,chlorambucil,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230106_74a611bc-9977-46bb-b626-0370b3031628.json,74a611bc-9977-46bb-b626-0370b3031628,8,"These highlights do not include all the information needed to use FEXINIDAZOLE TABLETS safely and effectively. See full prescribing information for FEXINIDAZOLE TABLETS.
 



FEXINIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2021",2564146,fexinidazole,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240112_8f7f73b8-586a-4df0-935f-fecd4696c16c.json,8f7f73b8-586a-4df0-935f-fecd4696c16c,17,"These highlights do not include all the information needed to use CRESEMBA® safely and effectively. See full prescribing information for CRESEMBA®.
CRESEMBA® (isavuconazonium sulfate) capsules, for oral useCRESEMBA® (isavuconazonium sulfate) for injection, for intravenous useInitial U.S. Approval: 2015",1608322,isavuconazonium,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240112_8f7f73b8-586a-4df0-935f-fecd4696c16c.json,8f7f73b8-586a-4df0-935f-fecd4696c16c,17,"These highlights do not include all the information needed to use CRESEMBA® safely and effectively. See full prescribing information for CRESEMBA®.
CRESEMBA® (isavuconazonium sulfate) capsules, for oral useCRESEMBA® (isavuconazonium sulfate) for injection, for intravenous useInitial U.S. Approval: 2015",1608322,isavuconazonium,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230125_80686b7e-f6f4-4154-b5c0-c846425e2d91.json,80686b7e-f6f4-4154-b5c0-c846425e2d91,12,"These highlights do not include all the information needed to use EMPLICITI safely and effectively. See full prescribing information for EMPLICITI.
EMPLICITI
®
 (elotuzumab) for injection, for intravenous useInitial U.S. Approval: 2015",1726104,elotuzumab,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230125_c16ac648-d5d2-9f7d-8637-e2328572754e.json,c16ac648-d5d2-9f7d-8637-e2328572754e,15,"These highlights do not include all the information needed to use NULOJIX safely and effectively. See full prescribing information for NULOJIX.
NULOJIX (belatacept) for injection, for intravenous useInitial U.S. Approval: 2011",1112973,belatacept,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/train_xml/20230125_c16ac648-d5d2-9f7d-8637-e2328572754e.json,c16ac648-d5d2-9f7d-8637-e2328572754e,15,"These highlights do not include all the information needed to use NULOJIX safely and effectively. See full prescribing information for NULOJIX.
NULOJIX (belatacept) for injection, for intravenous useInitial U.S. Approval: 2011",1112973,belatacept,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/gold_xml/20230219_e4f2a84f-5117-4738-b769-aba8debbddb0.json,e4f2a84f-5117-4738-b769-aba8debbddb0,11,"These highlights do not include all the information needed to use ONGLYZA safely and effectively. See full prescribing information for ONGLYZA.
ONGLYZA® (saxagliptin) tablets, for oral useInitial U.S. Approval: 2009",857974,saxagliptin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/gold_xml/20230219_e4f2a84f-5117-4738-b769-aba8debbddb0.json,e4f2a84f-5117-4738-b769-aba8debbddb0,11,"These highlights do not include all the information needed to use ONGLYZA safely and effectively. See full prescribing information for ONGLYZA.
ONGLYZA® (saxagliptin) tablets, for oral useInitial U.S. Approval: 2009",857974,saxagliptin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230223_4764f37b-c9e6-4ede-bcc2-8a03b7c521df.json,4764f37b-c9e6-4ede-bcc2-8a03b7c521df,46,"These highlights do not include all the information needed to use SPRYCEL® safely and effectively. See full prescribing information for SPRYCEL.

SPRYCEL (dasatinib) tablets, for oral useInitial U.S. Approval: 2006",475342,dasatinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013",1369713,pomalidomide,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/gold_xml/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013",1369713,pomalidomide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230411_2b25ef01-5c9e-11e1-b86c-0800200c9a66.json,2b25ef01-5c9e-11e1-b86c-0800200c9a66,24,"These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.
 POMALYST® (pomalidomide) capsules, for oral use Initial U.S. Approval:  2013",1369713,pomalidomide,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_be4bc0de-0fdc-4d46-8d25-be43c79e6a06.json,be4bc0de-0fdc-4d46-8d25-be43c79e6a06,22,"These highlights do not include all the information needed to use VERZENIO safely and effectively. See full prescribing information for VERZENIO.
VERZENIO® (abemaciclib) tablets, for oral useInitial U.S. Approval: 2017",1946825,abemaciclib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_60f0aa03-ad25-4d48-80ce-7fcfa76f325f.json,60f0aa03-ad25-4d48-80ce-7fcfa76f325f,10,"These highlights do not include all the information needed to use TEZSPIRE safely and effectively.  See full prescribing information for TEZSPIRE.
TEZSPIRE® (tezepelumab-ekko) injection, for subcutaneous useInitial U.S. Approval: 2021",2587789,tezepelumab,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230615_1e484a50-55db-4b85-8c57-6cd1b0353abd.json,1e484a50-55db-4b85-8c57-6cd1b0353abd,32,"These highlights do not include all the information needed to use OPSUMIT safely and effectively. See full prescribing information for OPSUMIT.
 



OPSUMIT 
 ® (macitentan) tablets, for oral use
 

Initial U.S. Approval: 2013",1442132,macitentan,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230615_9e1f2222-1d89-4e63-989c-ccebe2ab1eb4.json,9e1f2222-1d89-4e63-989c-ccebe2ab1eb4,11,"These highlights do not include all the information needed to use PEMAZYRE safely and effectively. See full prescribing information for PEMAZYRE.


PEMAZYRE® (pemigatinib) tablets, for oral use

Initial U.S. Approval: 
2020",2359268,pemigatinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_0b8bf078-34c2-4f45-9012-38a8ac082b01.json,0b8bf078-34c2-4f45-9012-38a8ac082b01,6,"These highlights do not include all the information needed to use KRAZATI safely and effectively. See full prescribing information for KRAZATI. 
 KRAZATI® (adagrasib) tablets, for oral use  Initial U.S. Approval: 2022",2625882,adagrasib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231223_8baba4ea-2855-42fa-9bd9-5a7548d4cec3.json,8baba4ea-2855-42fa-9bd9-5a7548d4cec3,24,"These highlights do not include all the information needed to use IMFINZI safely and effectively.  See full prescribing information for IMFINZI.
IMFINZI® (durvalumab) injection, for intravenous useInitial U.S. Approval: 2017",1919503,durvalumab,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,2265ef30-253e-11df-8a39-0800200c9a66,42,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011",1094833,ipilimumab,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008",711942,eltrombopag,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231209_e3484bc6-ed7f-43ef-9d49-c131a8dff2dd.json,e3484bc6-ed7f-43ef-9d49-c131a8dff2dd,8,"Sterile Water for Irrigation, USP",11295,water,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230908_c0978fa8-53ff-4ca2-82a7-567fd3e958ca.json,c0978fa8-53ff-4ca2-82a7-567fd3e958ca,16,"These highlights do not include all the information needed to use VEKLURY safely and effectively. See full prescribing information for VEKLURY.
 VEKLURY® (remdesivir) for injection, for intravenous use  VEKLURY® (remdesivir) injection, for intravenous use Initial U.S. Approval: 2020",2284718,remdesivir,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240201_0836c6ac-ee37-5640-2fed-a3185a0b16eb.json,0836c6ac-ee37-5640-2fed-a3185a0b16eb,32,"These highlights do not include all the information needed to use ORENCIA safely and effectively. See full prescribing information for ORENCIA.
ORENCIA (abatacept) for injection, for intravenous useORENCIA (abatacept) injection, for subcutaneous useInitial U.S. Approval: 2005",614391,abatacept,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/train_xml/20231122_2a51b0de-47d6-455e-a94c-d2c737b04ff7.json,2a51b0de-47d6-455e-a94c-d2c737b04ff7,43,"These highlights do not include all the information needed to use XALKORI® safely and effectively. See full prescribing information for XALKORI. 
XALKORI® (crizotinib) capsules, for oral useXALKORI® (crizotinib) oral pelletsInitial U.S. Approval: 2011",1148495,crizotinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_c23d89e9-b00b-4520-e053-2995a90a95af.json,c23d89e9-b00b-4520-e053-2995a90a95af,9,"These highlights do not include all the information needed to use EMPAVELI safely and effectively. See full prescribing information for EMPAVELI. 
EMPAVELI® (pegcetacoplan) injection, for subcutaneous use Initial U.S. Approval: 2021",2557372,pegcetacoplan,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992",70223,aldesleukin,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231018_1534c9ae-4948-4cf4-9f66-222a99db6d0e.json,1534c9ae-4948-4cf4-9f66-222a99db6d0e,26,"These highlights do not include all the information needed to use SIRTURO safely and effectively. See full prescribing information for SIRTURO.
 

SIRTURO 
 ®(bedaquiline) tablets, for oral use
 
Initial U.S. Approval: 2012",1364504,bedaquiline,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_0bc4b876-ddee-4f03-b44f-544348739a26.json,0bc4b876-ddee-4f03-b44f-544348739a26,13,"Clotrimazole Troche
(lozenges) USP",2623,clotrimazole,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)",4502,flurbiprofen,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1156378,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,"Atenolol Tablets, USP Rx only",1202,atenolol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220716_51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.json,51ff7db5-aaf9-4c3c-86e6-958ebf16b60f,10,"Nefazodone Hydrochloride Tablets, USP

Rx only

(Patient Information Included)",31565,nefazodone,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231220_9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23.json,9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23,21,Pamidronate Disodium Injection,11473,pamidronate,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240117_7c295b64-ec39-42ec-9f02-da5b42e775e1.json,7c295b64-ec39-42ec-9f02-da5b42e775e1,8,"These highlights do not include all the information needed to use BICALUTAMIDE TABLETS safely and effectively. See full prescribing information for BICALUTAMIDE TABLETS.
 



BICALUTAMIDE TABLETS, for oral use
 



Initial U.S. Approval: 1995",83008,bicalutamide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_0be26591-e0dd-429d-a4c7-b2e39aab13dd.json,0be26591-e0dd-429d-a4c7-b2e39aab13dd,9,"These highlights do not include all the information needed to use TERBINAFINE TABLETS safely and effectively. See full prescribing information for TERBINAFINE TABLETS
 

TERBINAFINE tablets, for oral use
 
Initial U.S. Approval: 1992",37801,terbinafine,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,500000301,1741309,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240202_a3d68763-95e0-4ad6-89c2-c4b1c0b43948.json,a3d68763-95e0-4ad6-89c2-c4b1c0b43948,1,"Torsemide Tablets, USP
 


These highlights do not include all the information needed to use TORSEMIDE TABLETS safely and effectively. See full prescribing information for TORSEMIDE TABLETS
 

TORSEMIDE tablets, for oral use
 
Initial U.S. Approval: 1993",38413,torsemide,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,56d64558-1fad-420e-8fcd-7103cd073127,1,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998",140587,celecoxib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,51635427-fb13-45ee-813d-a40b0405d14f,7,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information",3355,diclofenac,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_584abe73-8290-4484-ff8e-5890831c095e.json,584abe73-8290-4484-ff8e-5890831c095e,21,"These highlights do not include all the information needed to use IMITREX safely and effectively. See full prescribing information for IMITREX.IMITREX (sumatriptan) tablets, for oral useInitial U.S. Approval: 1992",37418,sumatriptan,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_4314da8a-40e5-4aba-a32b-57b4166ade30.json,4314da8a-40e5-4aba-a32b-57b4166ade30,12,"These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.  AZITHROMYCIN tablets, for oral use Initial U.S. Approval: 1991",18631,azithromycin,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,7ee820e4-a479-4b7d-8730-101ac1f8015c,102,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982",8356,piroxicam,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1146810,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,7ee820e4-a479-4b7d-8730-101ac1f8015c,102,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982",8356,piroxicam,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1146810,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240220_115a4125-07df-9f9b-e063-6394a90a3e49.json,115a4125-07df-9f9b-e063-6394a90a3e49,1,"PROCHLORPERAZINE MALEATE TABLETS, USP
 

Rx Only",8704,prochlorperazine,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_cee5b232-0464-4697-93ef-77e044c83776.json,cee5b232-0464-4697-93ef-77e044c83776,8,"These highlights do not include all the information needed to use CLOPIDOGREL TABLETS safely and effectively. See full prescribing information for CLOPIDOGREL TABLETS.
 



CLOPIDOGREL tablets, for oral use
 



Initial U.S. Approval: 1997",32968,clopidogrel,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_cee5b232-0464-4697-93ef-77e044c83776.json,cee5b232-0464-4697-93ef-77e044c83776,8,"These highlights do not include all the information needed to use CLOPIDOGREL TABLETS safely and effectively. See full prescribing information for CLOPIDOGREL TABLETS.
 



CLOPIDOGREL tablets, for oral use
 



Initial U.S. Approval: 1997",32968,clopidogrel,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,76e1839b-7462-4344-b319-001a5f57d67a,12,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000",40790,pantoprazole,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994",42355,fluvoxamine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240202_c0d1c22b-566b-4776-bdbf-00f96dad0cae.json,c0d1c22b-566b-4776-bdbf-00f96dad0cae,9,"These highlights do not include all the information needed to use ZARXIO safely and effectively. See full prescribing information for ZARXIO.
ZARXIO® (filgrastim-sndz) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2015ZARXIO (filgrastim-sndz) is biosimilar* to NEUPOGEN (filgrastim).",68442,filgrastim,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,304a3059-4f7f-4ec4-839d-86492bb5e07b,6,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003",6719,memantine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,304a3059-4f7f-4ec4-839d-86492bb5e07b,6,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003",6719,memantine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_a23063c0-099a-4256-b95f-3a857bbf704b.json,a23063c0-099a-4256-b95f-3a857bbf704b,18,"These highlights do not include all the information needed to use ALPRAZOLAM TABLETS safely and effectively. See full prescribing information for ALPRAZOLAM TABLETS.


ALPRAZOLAM tablets, for oral use, CIV 


Initial U.S. Approval: 1981",596,alprazolam,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_c5d0b74b-e5bc-4e81-91e8-4bfc587bf54c.json,c5d0b74b-e5bc-4e81-91e8-4bfc587bf54c,6,"Misoprostol
 

Tablets",42331,misoprostol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240111_7f0bc342-0a0a-1d28-e053-2991aa0a28b9.json,7f0bc342-0a0a-1d28-e053-2991aa0a28b9,4,"TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 
Rx only
 

These highlights do not include all the information needed to use TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for TENOFOVIR DISOPROXIL FUMARATE TABLETS.
 

TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 

Initial U.S. Approval: 2001",300195,tenofovir disoproxil,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_64b7df84-c990-49f7-bc04-0cccfd7d2019.json,64b7df84-c990-49f7-bc04-0cccfd7d2019,14,"These highlights do not include all the information needed to use TRAMADOL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAMADOL HYDROCHLORIDE TABLETS.
 



TRAMADOL HYDROCHLORIDE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1995",10689,tramadol,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_5d31d815-50fa-4e78-8ebd-affc2514ce78.json,5d31d815-50fa-4e78-8ebd-affc2514ce78,10,"These highlights do not include all the information needed to use METOCLOPRAMIDE TABLETS safely and effectively. See full prescribing information for METOCLOPRAMIDE TABLETS.
 



METOCLOPRAMIDE tablets, for oral use
 

Initial U.S. Approval: 1979",6915,metoclopramide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231202_08e07fae-3191-b6a3-c894-d3a8cc53923f.json,08e07fae-3191-b6a3-c894-d3a8cc53923f,5,"These highlights do not include all the information needed to use ADEFOVIR DIPIVOXIL TABLETS safely and effectively. See full prescribing information for ADEFOVIR DIPIVOXIL TABLETS. 
ADEFOVIR DIPIVOXIL tablets, for oral use Initial U.S. Approval: 2002",16521,adefovir,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_3631ee95-692a-4426-8edf-62c27f7c32cb.json,3631ee95-692a-4426-8edf-62c27f7c32cb,100,"Ribavirin for Inhalation Solution, USP",9344,ribavirin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20120508_829e744d-7bd4-43dc-9b58-ffb016cb8e67.json,829e744d-7bd4-43dc-9b58-ffb016cb8e67,1,These highlights do not include all the information needed to use didanosine delayed-release capsules safely and effectively. See full prescribing information for didanosine delayed-release capsules. Initial U.S. Approval: 1991,3364,didanosine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_eb354221-c476-41cb-ad87-52423f81d698.json,eb354221-c476-41cb-ad87-52423f81d698,3,"Cefdinir Capsules, USP
 
Rx only",25037,cefdinir,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_793062e5-5a0c-40f9-8d8b-ca0862cd8a37.json,793062e5-5a0c-40f9-8d8b-ca0862cd8a37,11,"These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS.
 



ARIPIPRAZOLE tablets, for oral use
 

Initial U.S. Approval: 2002",89013,aripiprazole,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_8b365514-c859-ff93-e053-2a95a90ac698.json,8b365514-c859-ff93-e053-2a95a90ac698,4,"LEFLUNOMIDE TABLETS
   

Rx Only
   

These highlights do not include all the information needed to use
   

See full prescribing information for
   

Initial U.S. Approval",27169,leflunomide,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_51a88e8e-da02-4b97-9e7e-442fbffd908d.json,51a88e8e-da02-4b97-9e7e-442fbffd908d,8,"These highlights do not include all the information needed to use AMIODARONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for AMIODARONE HYDROCHLORIDE TABLETS.
 

AMIODARONE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1985",703,amiodarone,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,113558e6-8b45-cdbd-e063-6394a90ac036,2,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only",24605,etodolac,10062237,renal impairment,500000401,acute kidney injury,8,1,500000401,1195492,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006,134748,rasagiline,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231108_4be9cc3f-0016-4426-a700-574b45ce245b.json,4be9cc3f-0016-4426-a700-574b45ce245b,10,"Rifabutin Capsules USP, 150 mg
Rx only",55672,rifabutin,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_3fe92511-0b4a-43f4-9c89-c8599469c1e2.json,3fe92511-0b4a-43f4-9c89-c8599469c1e2,10,"VITAMIN D (Ergocalciferol Capsules, USP)
 

1.25mg (50,000 USP Units)
 



Each capsule contains Vitamin D (Ergocalciferol) 1.25 mg equivalent to 50,000 USP Units.",4018,ergocalciferol,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_baac91ad-f8ee-4694-89f8-5c47a8eda39a.json,baac91ad-f8ee-4694-89f8-5c47a8eda39a,10,"Moexipril Hydrochloride Tablets USP

7.5 mg and 15 mg",30131,moexipril,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1310756,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995",68149,mycophenolate mofetil,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_4c9eb5d2-8d2c-4ce7-b45e-c92d3ce9532a.json,4c9eb5d2-8d2c-4ce7-b45e-c92d3ce9532a,11,"Isosorbide Mononitrate Tablets, USP




Rx only",6057,isosorbide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_d4737be8-7c17-4548-b380-808c5b4ad7ac.json,d4737be8-7c17-4548-b380-808c5b4ad7ac,8,"These highlights do not include all the information needed to use OXCARBAZEPINE TABLETS safely and effectively. See full prescribing information for OXCARBAZEPINE TABLETS.
 



OXCARBAZEPINE tablets, for oral use
 

Initial U.S. Approval: 2000",32624,oxcarbazepine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20181215_43ba3de1-ab2e-06f6-e054-00144ff8d46c.json,43ba3de1-ab2e-06f6-e054-00144ff8d46c,3,"PRESCRIBING INFORMATION
 



RIDAURA 
 ®




Auranofin
 



Capsules",1227,auranofin,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231104_7fa41601-7fb5-4155-8e50-2ae903f0d2d6.json,7fa41601-7fb5-4155-8e50-2ae903f0d2d6,31,"These highlights do not include all the information needed to use MULTAQ safely and effectively. See full prescribing information for MULTAQ.
 MULTAQ® (dronedarone) tablets, for oral use Initial U.S. Approval: 2009",233698,dronedarone,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811.json,a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811,1,"These highlights do not include all the information needed to use LISDEXAMFETAMINE DIMESYLATE CHEWABLE TABLETS safely and effectively. See full prescribing information for LISDEXAMFETAMINE DIMESYLATE CHEWABLE TABLETS. LISDEXAMFETAMINE DIMESYLATE chewable tablets, for oral use, CII Initial U.S. Approval: 2007",700810,lisdexamfetamine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,c35e019d-ec34-4e61-9400-a7ae7913e025,3,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004",337525,erlotinib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_9bd4fcd3-3020-41f2-b112-023b5db4487d.json,9bd4fcd3-3020-41f2-b112-023b5db4487d,3,"Bumetanide Tablets, USP

(0.5 mg, 1 mg and 2 mg)

Rx Only",1808,bumetanide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_9001c081-f455-4fb0-aef0-175d41810c12.json,9001c081-f455-4fb0-aef0-175d41810c12,8,"Mercaptopurine Tablets 50 mg
 

HIGHLIGHTS OF PRESCRIBING INFORMATION
 
These highlights do not include all the information needed to use Mercaptopurine Tablets safely and effectively. See full prescribing information for Mercaptopurine Tablets.
 
Mercaptopurine tablets, for oral use
 
Initial U.S. Approval: 1953",103,mercaptopurine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230414_6fa380c4-c885-4743-85bf-88819ae68645.json,6fa380c4-c885-4743-85bf-88819ae68645,8,"These highlights do not include all the information needed to use ALMOTRIPTAN TABLETS safely and effectively. See full prescribing information for ALMOTRIPTAN TABLETS.   ALMOTRIPTAN tablets, for oral use Initial U.S. Approval: 2001",279645,almotriptan,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1103552,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240203_453a5759-2f0d-421d-be78-81ab97c8ce77.json,453a5759-2f0d-421d-be78-81ab97c8ce77,1,"These highlights do not include all the information needed to use DESVENLAFAXINE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DESVENLAFAXINE EXTENDED-RELEASE TABLETS.DESVENLAFAXINE extended-release tablets, for oral useInitial U.S. Approval: 2008",734064,desvenlafaxine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231026_44966a7e-d777-40fb-956f-d0f31f737848.json,44966a7e-d777-40fb-956f-d0f31f737848,17,"Cidofovir Injection, USP Rx onlyFOR INTRAVENOUS INFUSION ONLY.NOT FOR INTRAOCULAR INJECTION.",83171,cidofovir,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231205_5359b759-db7c-4672-9e8a-59c93869bd91.json,5359b759-db7c-4672-9e8a-59c93869bd91,5,"These highlights do not include all the information needed to use VIBATIV® (telavancin) safely and effectively. See full prescribing information for VIBATIV. 
VIBATIV® (telavancin) for injection, for intravenous use Initial U.S. Approval: 2009",473837,telavancin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230912_4031017d-d768-46de-8081-476bcb883f5e.json,4031017d-d768-46de-8081-476bcb883f5e,5,"These highlights do not include all the information needed to use GEMCITABINE INJECTION safely and effectively. See full prescribing information for GEMCITABINE INJECTION.
 



GEMCITABINE injection, for intravenous use
 

Initial U.S. Approval: 1996",12574,gemcitabine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230912_4031017d-d768-46de-8081-476bcb883f5e.json,4031017d-d768-46de-8081-476bcb883f5e,5,"These highlights do not include all the information needed to use GEMCITABINE INJECTION safely and effectively. See full prescribing information for GEMCITABINE INJECTION.
 



GEMCITABINE injection, for intravenous use
 

Initial U.S. Approval: 1996",12574,gemcitabine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231221_645af8f4-0843-4afb-9ddc-f587f38adb68.json,645af8f4-0843-4afb-9ddc-f587f38adb68,8,"DEMECLOCYCLINE HYDROCHLORIDE TABLETS, USPRx only",3154,demeclocycline,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_2d45dd3c-71c3-4cc1-92ac-6dcecb195dd2.json,2d45dd3c-71c3-4cc1-92ac-6dcecb195dd2,7,"Loxapine Capsules, USP",6475,loxapine,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240101_1aa40de5-c02d-49d6-8722-ed88c40c3ba6.json,1aa40de5-c02d-49d6-8722-ed88c40c3ba6,2,"Felbamate Tablets, USP

(400 mg and 600 mg)


Rx only",24812,felbamate,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987",2551,ciprofloxacin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1797513,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240216_49873158-5c0a-41da-86a2-369ef6b0cbc8.json,49873158-5c0a-41da-86a2-369ef6b0cbc8,2,"These highlights do not include all the information needed to use RANOLAZINE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for RANOLAZINE EXTENDED-RELEASE TABLETS.
 RANOLAZINE extended-release tablets, for oral use Initial U.S. Approval: 2006",35829,ranolazine,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_b1274d78-1096-4ae3-8299-a2e94eaa0ea5.json,b1274d78-1096-4ae3-8299-a2e94eaa0ea5,16,Itraconazole Capsules,28031,itraconazole,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1703653,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240124_7276803b-5b97-d886-e053-2a91aa0a184e.json,7276803b-5b97-d886-e053-2a91aa0a184e,5,"Dofetilide Capsules
 

Rx Only
 















Rx only",49247,dofetilide,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231101_f5a010cf-5954-4e6d-acfa-fb414efdf471.json,f5a010cf-5954-4e6d-acfa-fb414efdf471,1,"Mitomycin for Injection, USP Rx only",632,mitomycin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240117_852f013f-6759-4438-83c1-8ff48133dc85.json,852f013f-6759-4438-83c1-8ff48133dc85,4,"HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALBENDAZOLE TABLETS safely and effectively. See full prescribing information for ALBENDAZOLE TABLETS.  ALBENDAZOLE tablets, for oral use  Initial U.S. Approval: 1996",430,albendazole,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231226_39b58213-b9e2-4847-9010-99e187c1b778.json,39b58213-b9e2-4847-9010-99e187c1b778,19,"These highlights do not include all the information needed to use FOSPHENYTOIN SODIUM INJECTION safely and effectively. See full prescribing information for FOSPHENYTOIN SODIUM  INJECTION.




FOSPHENYTOIN SODIUM injection, for intravenous or intramuscular use

Initial U.S. Approval: 1996",72236,fosphenytoin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231202_f9ab6b1c-98d0-4373-0e9b-b10cb4a67543.json,f9ab6b1c-98d0-4373-0e9b-b10cb4a67543,22,"These highlights do not include all the information needed to use DEFEROXAMINE MESYLATE safely and effectively. See full prescribing information for DEFEROXAMINE MESYLATE.

DEFEROXAMINE MESYLATE for injection, for intramuscular, intravenous, or subcutaneous use
Initial U.S. Approval: 1968",3131,deferoxamine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,7ee820e4-a479-4b7d-8730-101ac1f8015c,102,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982",8356,piroxicam,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1146810,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240131_a4978a54-1799-43d6-85dd-05fa9de0a5d7.json,a4978a54-1799-43d6-85dd-05fa9de0a5d7,8,"These highlights do not include all the information needed to use AMBRISENTAN TABLETS safely and effectively. See full prescribing information for AMBRISENTAN TABLETS.  AMBRISENTAN tablets, for oral use  Initial U.S. Approval: 2007",358274,ambrisentan,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef.json,7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef,5,"These highlights do not include all the information needed to use DAPTOMYCIN IN SODIUM CHLORIDE INJECTION safely and effectively.  See full prescribing information for DAPTOMYCIN IN SODIUM CHLORIDE INJECTION.
DAPTOMYCIN IN SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 2003",22299,daptomycin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_d35193e4-0b0e-4a0a-acd8-aa90cc075a2b.json,d35193e4-0b0e-4a0a-acd8-aa90cc075a2b,16,"These highlights do not include all the information needed to use METHOTREXATE TABLETS safely and effectively. See full prescribing information for METHOTREXATE TABLETS.
 

METHOTREXATE tablets, for oral use
 
Initial U.S. Approval: 1953",6851,methotrexate,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230420_5736aecc-cc1d-47dd-86c0-5fb2e9d70f61.json,5736aecc-cc1d-47dd-86c0-5fb2e9d70f61,5,CLADRIBINE INJECTION,44157,cladribine,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240117_4681f23e-6b5e-433b-b245-3d0b4e64ebb2.json,4681f23e-6b5e-433b-b245-3d0b4e64ebb2,4,FLOXURIDINE FOR INJECTION USP,4488,floxuridine,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_94d8cfb1-ff2a-4956-8954-17635ac505d9.json,94d8cfb1-ff2a-4956-8954-17635ac505d9,8,"These highlights do not include all the information needed to use SEVELAMER CARBONATE TABLETS safely and effectively. See full prescribing information for SEVELAMER CARBONATE TABLETS.


SEVELAMER CARBONATE tablets, for oral use 

Initial U.S. Approval: 2000",214824,sevelamer,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_ee6f6f94-1ca7-481e-9909-b19ae64e80c2.json,ee6f6f94-1ca7-481e-9909-b19ae64e80c2,5,"These highlights do not include all the information needed to use PALONOSETRON HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for PALONOSETRON HYDROCHLORIDE INJECTION.
 



PALONOSETRON HYDROCHLORIDE injection, for intravenous use
 

Initial U.S. Approval: 2003",70561,palonosetron,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_34de1806-d921-4d2f-8c7f-03625b717a70.json,34de1806-d921-4d2f-8c7f-03625b717a70,25,"These highlights do not include all the information needed to use METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS.


METHYLPHENIDATE HCl extended-release tablets, for oral administration CII 

Initial U.S. Approval: 2000",6901,methylphenidate,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959""",3002,cyclophosphamide,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_746f3ab9-9e6e-4ce8-9384-0c7a57de8007.json,746f3ab9-9e6e-4ce8-9384-0c7a57de8007,9,"Haloperidol Tablets, USP",5093,haloperidol,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_c89e8f4d-96c0-44c6-906a-b803141920b1.json,c89e8f4d-96c0-44c6-906a-b803141920b1,27,"These highlights do not include all the information needed to use CEFUROXIME AXETIL TABLETS safely and effectively. See full prescribing information for CEFUROXIME AXETIL TABLETS.  CEFUROXIME AXETIL tablets, for oral use  Initial U.S. Approval: 1987",2194,cefuroxime,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210202_eccd8340-ead3-4363-8902-0c19d33aa2ac.json,eccd8340-ead3-4363-8902-0c19d33aa2ac,13,"BREVITAL®


 (methohexital sodium) for injection, USP",6847,methohexital,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_7602fb73-3ce3-5978-e053-2991aa0abea3.json,7602fb73-3ce3-5978-e053-2991aa0abea3,8,"PHENYLEPHRINE HCI INJECTION, USP 10mg/mL 1mL VIAL",8163,phenylephrine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210729_1b97bd3a-1040-4511-b0e6-4758e8083ae5.json,1b97bd3a-1040-4511-b0e6-4758e8083ae5,3,"These highlights do not include all the information needed to use FARYDAK safely and effectively. See full prescribing information for FARYDAK.


FARYDAK® (panobinostat) capsules, for oral use

Initial U.S. Approval: 2015",1603350,panobinostat,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210923_3784c35c-e87f-410c-900b-8fd6313c6010.json,3784c35c-e87f-410c-900b-8fd6313c6010,13,"These highlights do not include all the information needed to use TYBOST safely and effectively. See full prescribing information for TYBOST. 
TYBOST® (cobicistat) tablets, for oral use Initial U.S. Approval: 2012",1306284,cobicistat,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231215_201b0eb8-4a1e-4e22-ab4b-addb642710d6.json,201b0eb8-4a1e-4e22-ab4b-addb642710d6,6,Anzemet,68091,dolasetron,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230707_32167dd7-5d37-457b-9b00-cd735de6b060.json,32167dd7-5d37-457b-9b00-cd735de6b060,5,"These highlights do not include all the information needed to use TINIDAZOLE TABLETS safely and effectively. See full prescribing information for TINIDAZOLE TABLETS. TINIDAZOLE tablets, for oral use Initial U.S. Approval 2004",10612,tinidazole,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1702559,0,1
./data/2024_latest_labels/latest_labels_ingredients/20240124_0d6111be-aabe-88e2-e063-6394a90a3963.json,0d6111be-aabe-88e2-e063-6394a90a3963,2,"These highlights do not include all the information needed to use MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS.


MYCOPHENOLIC ACID delayed-release tablets, for oral use

Initial U.S. Approval: 2004",7145,mycophenolic acid,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_19880f51-badb-4846-a02a-592a210690ab.json,19880f51-badb-4846-a02a-592a210690ab,10,"These highlights do not include all the information needed to use SIROLIMUS ORAL SOLUTION safely and effectively. See full prescribing information for SIROLIMUS ORAL SOLUTION.


SIROLIMUS oral solutionInitial U.S. Approval: 1999",35302,sirolimus,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,"IBUPROFEN Tablets, USP",5640,ibuprofen,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1177480,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240210_7a7974c7-8b6c-41ae-9a48-a08a1439087a.json,7a7974c7-8b6c-41ae-9a48-a08a1439087a,100,"These highlights do not include all the information needed to use TRETINOIN CAPSULES safely and effectively. See full prescribing information for TRETINOIN CAPSULES
.



TRETINOIN 
capsules, for oral use 

Initial U.S. Approval: 1995",10753,tretinoin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_61a0be9d-ee58-43e0-b5cb-141011835081.json,61a0be9d-ee58-43e0-b5cb-141011835081,23,"These highlights do not include all the information needed to use JUXTAPID safely and effectively. See full prescribing information for JUXTAPID. 
JUXTAPID® (lomitapide) capsules, for oral use Initial U.S. Approval: 2012",1364479,lomitapide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20231214_77a67dc6-35d3-48ff-9d18-292d4d442f70.json,77a67dc6-35d3-48ff-9d18-292d4d442f70,15,"These highlights do not include all the information needed to use ENTEREG safely and effectively. See full prescribing information for ENTEREG.
 ENTEREG® (alvimopan) capsules, for oral use Initial U.S. Approval: 2008",480639,alvimopan,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,c98fb504-76d0-4c25-9c0b-412885828a7a,7,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005",342369,lenalidomide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,c98fb504-76d0-4c25-9c0b-412885828a7a,7,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005",342369,lenalidomide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20230811_a3768c7e-aa4c-44d3-bc53-43bb7346c0b0.json,a3768c7e-aa4c-44d3-bc53-43bb7346c0b0,21,"These highlights do not include all the information needed to use NESINA safely and effectively. See full prescribing information for NESINA. 
NESINA (alogliptin) tablets, for oral use Initial U.S. Approval: 2013",1368001,alogliptin,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/train_xml/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012",1302966,carfilzomib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/gold_xml/20221103_03880372-2c68-45c6-a53a-f420c49541d6.json,03880372-2c68-45c6-a53a-f420c49541d6,21,"These highlights do not include all the information needed to use EDURANT safely and effectively. See full prescribing information for EDURANT. 
EDURANT® (rilpivirine) tablets for oral useInitial U.S. Approval: 2011",1102270,rilpivirine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/gold_xml/20221119_5526617c-c7b9-4556-886d-729bbabbc566.json,5526617c-c7b9-4556-886d-729bbabbc566,21,"These highlights do not include all the information needed to use SAMSCA safely and effectively. See full prescribing information for SAMSCA.
 SAMSCA® (tolvaptan) tablets, for oral use Initial U.S. Approval: 2009",358257,tolvaptan,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230607_5e4cf15b-bf7b-4b83-863e-e9ef27741a51.json,5e4cf15b-bf7b-4b83-863e-e9ef27741a51,25,"These highlights do not include all the information needed to use FOLOTYN® safely and effectively. See full prescribing information for FOLOTYN. FOLOTYN (pralatrexate injection), for intravenous use   Initial U.S. Approval: 2009",662019,pralatrexate,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231215_9f489295-1156-52c7-5fd0-5c4c52f9b813.json,9f489295-1156-52c7-5fd0-5c4c52f9b813,8,"These highlights do not include all the information needed to use LUPKYNIS™ safely and effectively. See full prescribing information for LUPKYNIS.








LUPKYNIS (voclosporin) capsules, for oral use




Initial U.S. Approval: 2021",2475166,voclosporin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231216_3fc03452-cbfb-48a2-a747-45b03399741c.json,3fc03452-cbfb-48a2-a747-45b03399741c,8,"These highlights do not include all the information needed to use INVOKANA safely and effectively. See full prescribing information for INVOKANA.
 

INVOKANA 
 ®(canagliflozin) tablets, for oral use
 
Initial U.S. Approval: 2013",1373458,canagliflozin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231213_58353438-3236-4596-9324-62fed9615cb7.json,58353438-3236-4596-9324-62fed9615cb7,12,"These highlights do not include all the information needed to use TRULICITY safely and effectively. See full prescribing information for TRULICITY.
TRULICITY (dulaglutide) injection, for subcutaneous useInitial U.S. Approval: 2014",1551291,dulaglutide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_8d5ace90-983b-48c4-baf1-b44f6af146de.json,8d5ace90-983b-48c4-baf1-b44f6af146de,2,"Carbamazepine Oral Suspension, USP
 
Rx only
 
Prescribing Information",2002,carbamazepine,10067125,liver injury,500000301,acute liver injury,6,1,500000301,740275,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240123_a4d0efe9-5e54-467e-9eb4-56fa7d53b60b.json,a4d0efe9-5e54-467e-9eb4-56fa7d53b60b,34,"These highlights do not include all the information needed to use DARZALEX safely and effectively. See full prescribing information for DARZALEX.
 



DARZALEX 
 ®(daratumumab) injection, for intravenous use
 

Initial U.S. Approval: 2015",1721947,daratumumab,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_a4d0efe9-5e54-467e-9eb4-56fa7d53b60b.json,a4d0efe9-5e54-467e-9eb4-56fa7d53b60b,34,"These highlights do not include all the information needed to use DARZALEX safely and effectively. See full prescribing information for DARZALEX.
 



DARZALEX 
 ®(daratumumab) injection, for intravenous use
 

Initial U.S. Approval: 2015",1721947,daratumumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230204_f27eb1b9-b7fc-424e-988f-84dd7bb195a3.json,f27eb1b9-b7fc-424e-988f-84dd7bb195a3,6,"These highlights do not include all the information needed to use TUKYSA safely and effectively. See full prescribing information for TUKYSA.
TUKYSA® (tucatinib) tablets, for oral use Initial U.S. Approval: 2020",2361285,tucatinib,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230215_57a597d2-03f0-472e-b148-016d7169169d.json,57a597d2-03f0-472e-b148-016d7169169d,12,"These highlights do not include all the information needed to use TRODELVY safely and effectively. See full prescribing information for TRODELVY 
 TRODELVY® (sacituzumab govitecan-hziy) for injection, for intravenous use Initial U.S. Approval: 2020",2360231,sacituzumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_793062e5-5a0c-40f9-8d8b-ca0862cd8a37.json,793062e5-5a0c-40f9-8d8b-ca0862cd8a37,11,"These highlights do not include all the information needed to use ARIPIPRAZOLE TABLETS safely and effectively. See full prescribing information for ARIPIPRAZOLE TABLETS.
 



ARIPIPRAZOLE tablets, for oral use
 

Initial U.S. Approval: 2002",89013,aripiprazole,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230315_72d1a024-00b7-418a-b36e-b2cb48f2ab55.json,72d1a024-00b7-418a-b36e-b2cb48f2ab55,6,"These highlights do not include all the information needed to use LUTATHERA safely and effectively. See full prescribing information for LUTATHERA.
		

		LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use
		
		Initial U.S. Approval: 2018",1797118,dotatate,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1.json,b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1,5,"These highlights do not include all the information needed to use PRIALT safely and effectively.  See full prescribing information for PRIALT.PRIALT (ziconotide) solution, intrathecal infusion Initial U.S. Approval: 2004",68503,ziconotide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230331_4a0c7c8b-b95f-455d-9600-b7351e4397fe.json,4a0c7c8b-b95f-455d-9600-b7351e4397fe,2,"These highlights do not include all the information needed to use REZLIDHIA safely and effectively. See full prescribing information for REZLIDHIA.
REZLIDHIA™ (olutasidenib) capsules, for oral useInitial U.S. Approval: 2022",2623641,olutasidenib,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230411_827bc01c-d379-4266-a18c-c7f904b76af3.json,827bc01c-d379-4266-a18c-c7f904b76af3,10,"These highlights do not include all the information needed to use KEVZARA® safely and effectively. See full prescribing information for KEVZARA. 
KEVZARA (sarilumab) injection, for subcutaneous use Initial U.S. Approval: 2017",1923319,sarilumab,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231117_102e4ef4-7f84-4e34-8df1-479c24d1575d.json,102e4ef4-7f84-4e34-8df1-479c24d1575d,5,"These highlights do not include all the information needed to use REZUROCK safely and effectively. See full prescribing information for REZUROCK.


REZUROCK® (belumosudil) tablets, for oral use
Initial U.S. Approval: 2021",2564025,belumosudil,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_20a16ab2-f338-4abb-9dcd-254bd949a2bc.json,20a16ab2-f338-4abb-9dcd-254bd949a2bc,8,"These highlights do not include all the information needed to use POLIVY safely and effectively. See full prescribing information for POLIVY.
 POLIVY® (polatuzumab vedotin-piiq) for injection, for intravenous use Initial U.S. Approval: 2019",2174090,polatuzumab vedotin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230629_2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c.json,2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c,3,"These highlights do not include all the information needed to use ANDEXXA safely and effectively.  See Full Prescribing Information for ANDEXXA.
 ANDEXXA® (coagulation factor Xa (recombinant), inactivated-zhzo) Lyophilized powder for solution for intravenous injection Initial U.S. Approval:  2018",2045114,andexanet alfa,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230627_3904f8dd-1aef-3490-e48f-bd55f32ed67f.json,3904f8dd-1aef-3490-e48f-bd55f32ed67f,34,"These highlights do not include all the information needed to use ADCETRIS safely and effectively. See full prescribing information for ADCETRIS. 
ADCETRIS® (brentuximab vedotin) for injection, for intravenous use Initial U.S. approval: 2011",1147320,brentuximab vedotin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_38b482a8-960b-4591-9857-5031ecb830aa.json,38b482a8-960b-4591-9857-5031ecb830aa,35,"These highlights do not include all the information needed to use BLINCYTO® safely and effectively. See full prescribing information for BLINCYTO.  
BLINCYTO® (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014",1597258,blinatumomab,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_81a33cfa-262f-4432-a05d-7dd260928437.json,81a33cfa-262f-4432-a05d-7dd260928437,7,"These highlights do not include all the information needed to use ABRILADA safely and effectively. See full prescribing information for ABRILADA.
ABRILADA™ (adalimumab-afzb) injection, for subcutaneous useInitial U.S. Approval: 2019
ABRILADA (adalimumab-afzb) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ABRILADA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA (adalimumab).",797541,isopropyl alcohol,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230714_64c156a4-9bad-4d45-a294-0733c141f47b.json,64c156a4-9bad-4d45-a294-0733c141f47b,9,"These highlights do not include all the information needed to use ENSPRYNG safely and effectively. See full prescribing information for ENSPRYNG. 
ENSPRYNG® (satralizumab-mwge) injection, for subcutaneous use Initial U.S. Approval: 2020",2391541,satralizumab,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240124_b20b4e18-7a4b-4500-a08f-06c6dab0ee5b.json,b20b4e18-7a4b-4500-a08f-06c6dab0ee5b,10,"These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY.


PIQRAY® (alpelisib) tablets, for oral use

Initial U.S. Approval: 2019",2169285,alpelisib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_fff5d805-4ffd-4e8e-8e63-6f129697563e.json,fff5d805-4ffd-4e8e-8e63-6f129697563e,18,"These highlights do not include all the information needed to use ZYKADIA safely and effectively. See full prescribing information for ZYKADIA.


ZYKADIA® (ceritinib) capsules, for oral use

ZYKADIA® (ceritinib) tablets, for oral use

Initial U.S. Approval: 2014",1535457,ceritinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_fff5d805-4ffd-4e8e-8e63-6f129697563e.json,fff5d805-4ffd-4e8e-8e63-6f129697563e,18,"These highlights do not include all the information needed to use ZYKADIA safely and effectively. See full prescribing information for ZYKADIA.


ZYKADIA® (ceritinib) capsules, for oral use

ZYKADIA® (ceritinib) tablets, for oral use

Initial U.S. Approval: 2014",1535457,ceritinib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230817_44492772-5aed-4627-bd85-e8e89f308bb3.json,44492772-5aed-4627-bd85-e8e89f308bb3,12,"These highlights do not include all the information needed to use MAYZENT safely and effectively. See full prescribing information for MAYZENT.


MAYZENT® (siponimod) tablets, for oral use

Initial U.S. Approval: 2019",2121085,siponimod,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230817_5be69660-738c-4db7-b0d4-517aa873dc41.json,5be69660-738c-4db7-b0d4-517aa873dc41,9,"These highlights do not include all the information needed to use PONVORY safely and effectively. See full prescribing information for PONVORY.
 

PONVORY 
 ®(ponesimod) tablets, for oral use
 
Initial U.S. Approval: 2021",2532300,ponesimod,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231116_487cd7e7-434c-4925-99fa-aa80b1cc776b.json,487cd7e7-434c-4925-99fa-aa80b1cc776b,3,"These highlights do not include all the information needed to use ZEPBOUND safely and effectively. See full prescribing information for ZEPBOUND.ZEPBOUND™ (tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022",2601723,tirzepatide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,3850cce2-6137-42e5-a792-d318c4a4b3b5,14,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012",1363268,cabozantinib,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012",1363268,cabozantinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,5cd725a1-2fa4-408a-a651-57a7b84b2118,18,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017",1875534,avelumab,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,5cd725a1-2fa4-408a-a651-57a7b84b2118,18,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017",1875534,avelumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231019_235dfc38-0f0b-4037-b501-7a9f4294740c.json,235dfc38-0f0b-4037-b501-7a9f4294740c,16,"These highlights do not include all the information needed to use BRAFTOVI safely and effectively. See full prescribing information for BRAFTOVI.
BRAFTOVI® (encorafenib) capsules, for oral useInitial U.S. Approval: 2018",2049106,encorafenib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231019_6c3408ac-d401-4925-8a03-26591afbc240.json,6c3408ac-d401-4925-8a03-26591afbc240,10,"These highlights do not include all the information needed to use MEKTOVI safely and effectively. See full prescribing information for MEKTOVI.
MEKTOVI® (binimetinib) tablets, for oral useInitial U.S. Approval: 2018",2049122,binimetinib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231019_6c3408ac-d401-4925-8a03-26591afbc240.json,6c3408ac-d401-4925-8a03-26591afbc240,10,"These highlights do not include all the information needed to use MEKTOVI safely and effectively. See full prescribing information for MEKTOVI.
MEKTOVI® (binimetinib) tablets, for oral useInitial U.S. Approval: 2018",2049122,binimetinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20231020_0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.json,0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25,30,"These highlights do not include all the information needed to use KALYDECO safely and effectively. See full prescribing information for KALYDECO.
KALYDECO® (ivacaftor) tablets, for oral useKALYDECO® (ivacaftor) oral granulesInitial U.S. Approval: 2012",1243041,ivacaftor,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240203_e23dcfd0-071a-4458-a595-3562fabccbd4.json,e23dcfd0-071a-4458-a595-3562fabccbd4,3,Dantrolene Sodium capsules,3105,dantrolene,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240106_fe0ddd44-ef02-4827-b164-7fcbb45bcc1b.json,fe0ddd44-ef02-4827-b164-7fcbb45bcc1b,4,"These highlights do not include all the information needed to use BUSULFAN INJECTION safely and effectively. See full prescribing information for BUSULFAN INJECTION.
 



BUSULFAN Injection, for intravenous use
 

Initial U.S. Approval: 1999",1828,busulfan,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_5c8cebcd-699f-4c4c-900b-94e0fe519345.json,5c8cebcd-699f-4c4c-900b-94e0fe519345,100,"These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.
PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989",8754,propafenone,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_74d94dbf-0567-6c15-e053-2991aa0ac6e4.json,74d94dbf-0567-6c15-e053-2991aa0ac6e4,5,"VERAPAMIL HYDROCHLORIDE INJECTION, USP 10mg (2.5 mg/mL) 4mL ANSYR SYR",11170,verapamil,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_2b705cb6-cb75-4c2a-907a-4bd45d18bc2c.json,2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,18,"These highlights do not include all the information needed to use METOPROLOL TARTRATE TABLETS safely and effectively. See full prescribing information for METOPROLOL TARTRATE TABLETS.
 METOPROLOL TARTRATE tablets, for oral use Initial U.S. Approval: 1992",6918,metoprolol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,56d64558-1fad-420e-8fcd-7103cd073127,1,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998",140587,celecoxib,10024690,liver function test abnormal,500000301,acute liver injury,15,1,500000301,1118084,1,1
./data/2024_latest_labels/latest_labels_ingredients/20100125_c6c48eee-240b-4425-8691-35462523652e.json,c6c48eee-240b-4425-8691-35462523652e,1,"DARVON-N  - propoxyphene napsylate tablet, film coated",8785,propoxyphene,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,51635427-fb13-45ee-813d-a40b0405d14f,7,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information",3355,diclofenac,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,51635427-fb13-45ee-813d-a40b0405d14f,7,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information",3355,diclofenac,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992",32613,oxaprozin,10018830,haematemesis,500001001,gi bleed,11,1,500001001,1118045,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240220_106b33e3-b199-e555-e063-6294a90a5af5.json,106b33e3-b199-e555-e063-6294a90a5af5,1,"Diltiazem Hydrochloride Tablets, USP


Tablets",3443,diltiazem,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/train_xml/20231208_df918ec2-0907-443f-a52a-b72866959644.json,df918ec2-0907-443f-a52a-b72866959644,22,"These highlights do not include all the information needed to use GRANIX safely and effectively.  See full prescribing information for GRANIX.GRANIX® (tbo-filgrastim) injection, for subcutaneous use Initial U.S. Approval: 2012",68442,filgrastim,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_4dd14728-02b4-4e75-b9c6-227be7816d5b.json,4dd14728-02b4-4e75-b9c6-227be7816d5b,9,"These highlights do not include all the information needed to use ABACAVIR TABLETS safely and effectively. See full prescribing information for ABACAVIR TABLETS.
 



ABACAVIR tablets, for oral use
 

Initial U.S. Approval: 1998",190521,abacavir,10024690,liver function test abnormal,500000301,acute liver injury,15,1,500000301,1736971,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240124_c732b415-e1f9-478f-896d-1dc8b6362da4.json,c732b415-e1f9-478f-896d-1dc8b6362da4,9,ETHAMBUTOL HYDROCHLORIDE TABLETS USP,4110,ethambutol,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_d6364be4-056b-4ebe-83bc-3fc85e8f488c.json,d6364be4-056b-4ebe-83bc-3fc85e8f488c,7,"Lorazepam Tablets, USP CIV
 
Rx only",6470,lorazepam,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_246e0ed0-f8ca-483b-a1ce-91052f3f35f0.json,246e0ed0-f8ca-483b-a1ce-91052f3f35f0,9,"Enalapril Maleate Tablets, USP",3827,enalapril,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_ed977166-7ac0-4a8c-a10c-4b19a69403c0.json,ed977166-7ac0-4a8c-a10c-4b19a69403c0,1,"These highlights do not include all the information needed to use DARUNAVIR TABLETS safely and effectively. See Full Prescribing Information for DARUNAVIR TABLETS.
DARUNAVIR tablets, for oral useInitial U.S. Approval: 2006",460132,darunavir,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1756831,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240210_0d976866-81b3-5db8-e063-6294a90a39f9.json,0d976866-81b3-5db8-e063-6294a90a39f9,3,"",8727,progesterone,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_8b365514-c859-ff93-e053-2a95a90ac698.json,8b365514-c859-ff93-e053-2a95a90ac698,4,"LEFLUNOMIDE TABLETS
   

Rx Only
   

These highlights do not include all the information needed to use
   

See full prescribing information for
   

Initial U.S. Approval",27169,leflunomide,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,113558e6-8b45-cdbd-e063-6394a90ac036,2,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only",24605,etodolac,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,500000301,1195492,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,"IBUPROFEN Tablets, USP",5640,ibuprofen,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_9929c166-8ba3-4159-a5f9-4618d5d227b0.json,9929c166-8ba3-4159-a5f9-4618d5d227b0,102,Flecainide Acetate Tablets USPRx only,4441,flecainide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,KIPROFEN™ Capsules,6142,ketoprofen,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1185922,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240203_0a2acdc0-aab6-462e-a377-67a0f3d55ec6.json,0a2acdc0-aab6-462e-a377-67a0f3d55ec6,4,"Nadolol Tablets, USP",7226,nadolol,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/train_xml/20191219_24ac0ee2-cd7b-4dda-a1bb-271e32331758.json,24ac0ee2-cd7b-4dda-a1bb-271e32331758,3,"These HIGHLIGHTS do not include all the information needed to use ULORIC safely and effectively. See full prescribing information for ULORIC. 
 ULORIC (febuxostat) tablet for oral use  Initial U.S. Approval: 2009",73689,febuxostat,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_b7b679a9-6823-4ef8-8d31-3ab5058ffcfc.json,b7b679a9-6823-4ef8-8d31-3ab5058ffcfc,11,"These highlights do not include all the information needed to use ELIGARD
®
 safely and effectively. See full prescribing information for ELIGARD.
ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002",42375,leuprolide,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_41c095b6-acd9-4627-a813-bbca7ecafee5.json,41c095b6-acd9-4627-a813-bbca7ecafee5,10,"These highlights do not include all the information needed to use DONEPEZIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for DONEPEZIL HYDROCHLORIDE TABLETS.
 

DONEPEZIL HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1996",135447,donepezil,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_fedbffa7-087d-4448-85c9-0350a3947080.json,fedbffa7-087d-4448-85c9-0350a3947080,10,"HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use LINEZOLID INJECTION safely and effectively. See full prescribing information for LINEZOLID INJECTION.




LINEZOLID injection, for intravenous use

Initial U.S. Approval: 2000",190376,linezolid,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231128_fc38f1bb-f175-4a81-8ed9-c8701efdea35.json,fc38f1bb-f175-4a81-8ed9-c8701efdea35,102,"FOSINOPRILSODIUM TABLETS, USP10mg, 20mg and 40mgRx Only",50166,fosinopril,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243.json,a0dc1a93-b7b8-4179-8ea7-ceecbe1ef243,9,"These highlights do not include all the information needed to use GALANTAMINE TABLETS safely and effectively. See full prescribing information for GALANTAMINE TABLETS.
 GALANTAMINE tablets, for oral use Initial U.S. Approval: 2001",4637,galantamine,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240227_a586be28-96af-4fed-a13f-9b94fd4c7405.json,a586be28-96af-4fed-a13f-9b94fd4c7405,24,"PROVERA®

 (medroxyprogesterone acetate tablets, USP)",6691,medroxyprogesterone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_f7e9a4b3-a2ee-4f0a-becd-6ef90867332b.json,f7e9a4b3-a2ee-4f0a-becd-6ef90867332b,37,"These highlights do not include all the information needed to use MORPHINE SULFATE EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for MORPHINE SULFATE EXTENDED-RELEASE CAPSULES.


MORPHINE SULFATE extended-release capsules, for oral use, CIIInitial U.S. Approval: 1941",7052,morphine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_99e9d85a-ec8e-48d2-acd0-5dda3b741838.json,99e9d85a-ec8e-48d2-acd0-5dda3b741838,6,"Ceftriaxone for Injection, USP


Rx Only",2193,ceftriaxone,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_f2f090c2-3ee1-7689-e053-2995a90abe38.json,f2f090c2-3ee1-7689-e053-2995a90abe38,3,"These highlights do not include all the information needed to use LEVOFLOXACIN TABLETS 
  safely and effectively. See full prescribing information for LEVOFLOXACIN TABLETS. 
 




LEVOFLOXACIN tablets, for oral use






Initial U.S. Approval: 1996",82122,levofloxacin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1742253,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240210_666f89b4-fd81-420a-a390-eb1cd4014f61.json,666f89b4-fd81-420a-a390-eb1cd4014f61,10,Rx only,3393,diflunisal,10062237,renal impairment,500000401,acute kidney injury,8,1,500000401,1126128,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,"Atenolol Tablets, USP Rx only",1202,atenolol,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_18bbd246-5709-4477-b10a-f811f3801962.json,18bbd246-5709-4477-b10a-f811f3801962,6,"Imipramine Hydrochloride Tablets, USP
 
Rx Only",5691,imipramine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,778268,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240111_0fdaee3c-2144-4ca7-9868-54d251f468c0.json,0fdaee3c-2144-4ca7-9868-54d251f468c0,3,"Milrinone Lactate Injection, USP",52769,milrinone,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240227_b1ac4c92-e1fd-4015-b172-0932790ae019.json,b1ac4c92-e1fd-4015-b172-0932790ae019,2,"Prednisone Tablets, USP   Rx only",8640,prednisone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240117_8ca926e0-4c3c-473f-9cd0-ff38032d6963.json,8ca926e0-4c3c-473f-9cd0-ff38032d6963,2,"These highlights do not include all the information needed to use OSELTAMIVIR PHOSPHATE CAPSULES safely and effectively. See full prescribing information for OSELTAMIVIR PHOSPHATE CAPSULES. 
OSELTAMIVIR phosphate capsules, for oral useInitial U.S. Approval: 1999",260101,oseltamivir,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f.json,c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f,3,"Famciclovir Tablets
 
Rx only
 

These highlights do not include all the information needed to use FAMCICLOVIR TABLETS safely and effectively. See full prescribing information for FAMCICLOVIR TABLETS.
 

Initial U.S. Approval: 1994",68099,famciclovir,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240201_202d5142-6180-4d48-9a9f-1bd6992fc49b.json,202d5142-6180-4d48-9a9f-1bd6992fc49b,2,"These highlights do not include all the information needed to use NEBIVOLOL TABLETS safely and effectively. See full prescribing information for NEBIVOLOL TABLETS.
 
NEBIVOLOL tablets, for oral use
 
Initial U.S. Approval: 2007",31555,nebivolol,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,c35e019d-ec34-4e61-9400-a7ae7913e025,3,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004",337525,erlotinib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231111_57f8aac6-3bd3-4ae1-aab2-759c8bc23292.json,57f8aac6-3bd3-4ae1-aab2-759c8bc23292,4,Trandolapril Tablets USP Rx only,38454,trandolapril,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231014_2d18cfc4-e0de-4814-a712-c1b7c504bff5.json,2d18cfc4-e0de-4814-a712-c1b7c504bff5,31,"These highlights do not include all the information needed to use BYDUREON BCISE safely and effectively. See full prescribing information for BYDUREON BCISE.
BYDUREON BCISE® (exenatide) extended-release injectable suspension, for subcutaneous useInitial U.S. Approval: 2005",60548,exenatide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20120328_03cdbf5b-b572-448f-80e9-b3e812959901.json,03cdbf5b-b572-448f-80e9-b3e812959901,2,DESCRIPTION,33747,estropipate,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1525278,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,5108ca9c-b307-4cb2-8ea1-6553764f375a,13,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002",321988,escitalopram,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,715939,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_55ae23ff-60f5-4de6-bd1b-472243b8636b.json,55ae23ff-60f5-4de6-bd1b-472243b8636b,8,"These highlights do not include all the information needed to use PIOGLITAZONE TABLETS safely and effectively. See full prescribing information for PIOGLITAZONE TABLETS
 







PIOGLITAZONE tablets, for oral use
 



Initial U.S. Approval: 1999",33738,pioglitazone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/train_xml/20121026_32d632f6-e7cc-455e-bd9a-3dcfc99a794f.json,32d632f6-e7cc-455e-bd9a-3dcfc99a794f,1,"These highlights do not include all the information needed to use PRISTIQ safely and effectively. See full prescribing information for PRISTIQ.
PRISTIQ® (desvenlafaxine) Extended-Release Tablets, oralInitial U.S. Approval: 2008",734064,desvenlafaxine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_1c90aa68-cc12-41ef-aebc-2616ae45683a.json,1c90aa68-cc12-41ef-aebc-2616ae45683a,11,"These highlights do not include all the information needed to use 

candesartan cilexetil 

 safely and effectively.  See full prescribing information for 

candesartan cilexetil 

.

Candesartan cilexetil tablets, for oral use
Initial U.S. Approval: 1998",214354,candesartan,10062237,renal impairment,500000401,acute kidney injury,8,1,500000401,1351557,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231117_8512d0c6-db4e-4673-b3b4-28975c18413f.json,8512d0c6-db4e-4673-b3b4-28975c18413f,12,"",32385,olsalazine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231117_8512d0c6-db4e-4673-b3b4-28975c18413f.json,8512d0c6-db4e-4673-b3b4-28975c18413f,12,"",32385,olsalazine,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_53bdb79c-c4cf-4818-b1f0-225e67a14536.json,53bdb79c-c4cf-4818-b1f0-225e67a14536,24,"These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
 
CLOZAPINE tablets, for oral use
 
Initial U.S. Approval: 1989",2626,clozapine,10019692,hepatic necrosis,500000301,acute liver injury,15,1,500000301,800878,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240209_53bdb79c-c4cf-4818-b1f0-225e67a14536.json,53bdb79c-c4cf-4818-b1f0-225e67a14536,24,"These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
 
CLOZAPINE tablets, for oral use
 
Initial U.S. Approval: 1989",2626,clozapine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_1276283e-21b0-4932-864f-547c62bd49e5.json,1276283e-21b0-4932-864f-547c62bd49e5,5,"Ursodiol Capsules, USP
 

Rx Only
 

Prescribing Information",62427,ursodeoxycholate,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_5a1cbf7e-0352-aa3b-080c-222a6423ecd8.json,5a1cbf7e-0352-aa3b-080c-222a6423ecd8,11,"Entecavir Tablets, USP
 
Rx Only
 

These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS.
 

Initial U.S. Approval: 2005",306266,entecavir,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1711246,0,1
./data/2024_latest_labels/latest_labels_ingredients/20240102_7036c6df-6527-4701-b484-6b962914b52a.json,7036c6df-6527-4701-b484-6b962914b52a,7,Tiagabine Hydrochloride Tablets,31914,tiagabine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_f299b2d2-86ed-4fb8-822e-65455a0bb75a.json,f299b2d2-86ed-4fb8-822e-65455a0bb75a,6,"These highlights do not include all the information needed to use OXALIPLATIN INJECTION safely and effectively. See full prescribing information for OXALIPLATIN INJECTION.OXALIPLATIN injection, for intravenous useInitial U.S. Approval: 2002",32592,oxaliplatin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_e95b1ab8-0fd9-4399-897a-5ae73b36af45.json,e95b1ab8-0fd9-4399-897a-5ae73b36af45,2,CARBIDOPA tablets,2019,carbidopa,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_e95b1ab8-0fd9-4399-897a-5ae73b36af45.json,e95b1ab8-0fd9-4399-897a-5ae73b36af45,2,CARBIDOPA tablets,2019,carbidopa,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_02e2aa54-1ed8-445a-a082-ac2c64b339fe.json,02e2aa54-1ed8-445a-a082-ac2c64b339fe,16,"These highlights do not include all the information needed to use SOLIFENACIN SUCCINATE TABLETS safely and effectively. See full prescribing information for SOLIFENACIN SUCCINATE TABLETS.


SOLIFENACIN SUCCINATE tablets for oral use 

Initial U.S. Approval: 2004",322167,solifenacin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231226_39b58213-b9e2-4847-9010-99e187c1b778.json,39b58213-b9e2-4847-9010-99e187c1b778,19,"These highlights do not include all the information needed to use FOSPHENYTOIN SODIUM INJECTION safely and effectively. See full prescribing information for FOSPHENYTOIN SODIUM  INJECTION.




FOSPHENYTOIN SODIUM injection, for intravenous or intramuscular use

Initial U.S. Approval: 1996",72236,fosphenytoin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231202_f9ab6b1c-98d0-4373-0e9b-b10cb4a67543.json,f9ab6b1c-98d0-4373-0e9b-b10cb4a67543,22,"These highlights do not include all the information needed to use DEFEROXAMINE MESYLATE safely and effectively. See full prescribing information for DEFEROXAMINE MESYLATE.

DEFEROXAMINE MESYLATE for injection, for intramuscular, intravenous, or subcutaneous use
Initial U.S. Approval: 1968",3131,deferoxamine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_8b365514-c859-ff93-e053-2a95a90ac698.json,8b365514-c859-ff93-e053-2a95a90ac698,4,"LEFLUNOMIDE TABLETS
   

Rx Only
   

These highlights do not include all the information needed to use
   

See full prescribing information for
   

Initial U.S. Approval",27169,leflunomide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,c35e019d-ec34-4e61-9400-a7ae7913e025,3,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004",337525,erlotinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231221_a32cb2e3-d4e5-4bbf-9d88-20b2b249e779.json,a32cb2e3-d4e5-4bbf-9d88-20b2b249e779,23,"These highlights do not include all the information needed to use RITONAVIR TABLETS safely and effectively. See full prescribing information for RITONAVIR TABLETS.
 


RITONAVIR tablets, for oral use
 

Initial U.S. Approval: 1996",85762,ritonavir,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231221_a32cb2e3-d4e5-4bbf-9d88-20b2b249e779.json,a32cb2e3-d4e5-4bbf-9d88-20b2b249e779,23,"These highlights do not include all the information needed to use RITONAVIR TABLETS safely and effectively. See full prescribing information for RITONAVIR TABLETS.
 


RITONAVIR tablets, for oral use
 

Initial U.S. Approval: 1996",85762,ritonavir,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20231004_63df5af3-b8ac-4e76-9830-2dbb340af922.json,63df5af3-b8ac-4e76-9830-2dbb340af922,27,"These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspensionInitial U.S. Approval: 2013",1433868,dolutegravir,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,a1787fad-3612-43e1-98fa-ce62361e0b3c,13,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001",282388,imatinib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20211016_4e338e89-3cf2-48eb-b6e2-a06c608c6513.json,4e338e89-3cf2-48eb-b6e2-a06c608c6513,36,"These highlights do not include all the information needed to use ZYTIGA safely and effectively. See full prescribing information for ZYTIGA. 
ZYTIGA® (abiraterone acetate) tablets, for oral use Initial U.S. Approval: 2011",1100072,abiraterone,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/train_xml/20211016_4e338e89-3cf2-48eb-b6e2-a06c608c6513.json,4e338e89-3cf2-48eb-b6e2-a06c608c6513,36,"These highlights do not include all the information needed to use ZYTIGA safely and effectively. See full prescribing information for ZYTIGA. 
ZYTIGA® (abiraterone acetate) tablets, for oral use Initial U.S. Approval: 2011",1100072,abiraterone,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_d35193e4-0b0e-4a0a-acd8-aa90cc075a2b.json,d35193e4-0b0e-4a0a-acd8-aa90cc075a2b,16,"These highlights do not include all the information needed to use METHOTREXATE TABLETS safely and effectively. See full prescribing information for METHOTREXATE TABLETS.
 

METHOTREXATE tablets, for oral use
 
Initial U.S. Approval: 1953",6851,methotrexate,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1305058,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,"FORANE (isoflurane, USP) liquid for inhalation",6026,isoflurane,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_0c717ae4-ec27-47db-ac1b-e504dbb379be.json,0c717ae4-ec27-47db-ac1b-e504dbb379be,11,"These highlights do not include all the information needed to use DEXMETHYLPHENIDATE hydrochloride tablets safely and effectively. See full prescribing information for DEXMETHYLPHENIDATE hydrochloride tablets.
  



DEXMETHYLPHENIDATE HYDROCHLORIDE TABLETS, for oral use, CII
  

Initial U.S. Approval: 2001",352372,dexmethylphenidate,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959""",3002,cyclophosphamide,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_e07862df-f324-4575-a1ef-f7e1cbab4c7a.json,e07862df-f324-4575-a1ef-f7e1cbab4c7a,11,"These highlights do not include all the information needed to use Granisetron Hydrochloride Injection, USP safely and effectively. See full prescribing information for Granisetron Hydrochloride Injection, USP.  

GRANISETRON hydrochloride injection, USP for intravenous use

Initial U.S. Approval: 1993",26237,granisetron,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b.json,3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b,13,"These highlights do not include all the information needed to use MICAFUNGIN FOR INJECTION safely and effectively. See full prescribing information for MICAFUNGIN FOR INJECTION.
 MICAFUNGIN for Injection, for intravenous infusion only Initial U.S. Approval: 2005",325887,micafungin,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231205_8c9607a2-5b57-4a59-b159-cf196deebdd9.json,8c9607a2-5b57-4a59-b159-cf196deebdd9,5,"These highlights do not include all the information needed to use VYLEESI® safely and effectively. See full prescribing information for VYLEESI
VYLEESI (bremelanotide injection), for subcutaneous useInitial U.S. Approval: 2019",2176312,bremelanotide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/gold_xml/20221019_f2abe3ed-ed3d-4215-a489-b18341ce85bc.json,f2abe3ed-ed3d-4215-a489-b18341ce85bc,2,"These highlights do not include all the information needed to use ZONTIVITY safely and effectively. See full prescribing information for ZONTIVITY.
 



ZONTIVITY 
 ® (vorapaxar) Tablets 2.08 mg*, for oral use
 

*Equivalent to 2.5 mg vorapaxar sulfate
 

Initial U.S. Approval: 2014",1537034,vorapaxar,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/gold_xml/20230715_5a9ef4ea-c76a-4d34-a604-27c5b505f5a4.json,5a9ef4ea-c76a-4d34-a604-27c5b505f5a4,27,"These highlights do not include all the information needed to use VICTOZA safely and effectively. See full prescribing information for VICTOZA.VICTOZA® (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010",475968,liraglutide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,22174520-4b78-4841-96f7-530ba12d2cf1,8,"Paroxetine Tablets USP, film coated for oral use",32937,paroxetine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/train_xml/20231215_665d7e74-036c-5f68-5b67-ab84b9b49151.json,665d7e74-036c-5f68-5b67-ab84b9b49151,53,"These highlights do not include all the information needed to use TECFIDERA safely and effectively. See full prescribing information for TECFIDERA.TECFIDERA® (dimethyl fumarate) delayed-release capsules, for oral useInitial U.S. Approval: 2013",1373478,dimethyl fumarate,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231128_3bad23a6-09a6-4194-9182-093ed61bc71c.json,3bad23a6-09a6-4194-9182-093ed61bc71c,39,"These highlights do not include all the information needed to use CANCIDAS safely and effectively. See full prescribing information for CANCIDAS.
CANCIDAS® (caspofungin acetate) for injection, for intravenous useInitial U.S. Approval: 2001",140108,caspofungin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20231130_02c91fba-9c47-43ef-ac78-e82369798834.json,02c91fba-9c47-43ef-ac78-e82369798834,16,These highlights do not include all the information needed to use NATAZIA safely and effectively.  See full prescribing information for NATAZIA.NATAZIA (estradiol valerate and estradiol valerate/dienogest) tablets for oral useInitial U.S. Approval: 2010,4083,estradiol,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20211124_75c0c785-38e0-4049-a6fb-b77581f5b35c.json,75c0c785-38e0-4049-a6fb-b77581f5b35c,6,"These highlights do not include all the information needed to use FETROJA® safely and effectively. See full prescribing information for FETROJA. 
 FETROJA (cefiderocol) for injection, for intravenous use  Initial U.S. Approval: 2019",2265702,cefiderocol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_220a9b3c-c583-49e3-8bf0-d0c97dc9b829.json,220a9b3c-c583-49e3-8bf0-d0c97dc9b829,102,"Lovastatin Tablet USP
 


Revision M",6472,lovastatin,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220218_47547f93-489c-4298-aeea-d6a37ca6cb1d.json,47547f93-489c-4298-aeea-d6a37ca6cb1d,5,"These highlights do not include all the information needed to use COPIKTRA safely and effectively. See full prescribing information for COPIKTRA.
  



COPIKTRA (duvelisib), capsules for oral use
  

Initial U.S. Approval: 2018",2058509,duvelisib,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_3cbb485b-6df1-49ce-8747-592b395b1988.json,3cbb485b-6df1-49ce-8747-592b395b1988,10,"These highlights do not include all the information needed to use SOMAVERT safely and effectively. See full prescribing information for SOMAVERT.
SOMAVERT (pegvisomant) for injection, for subcutaneous use Initial U.S. Approval: 2003",278739,pegvisomant,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231205_17a8d11b-73b0-4833-a0b4-cf1ef85edefb.json,17a8d11b-73b0-4833-a0b4-cf1ef85edefb,29,"These highlights do not include all the information needed to use ARISTADA® safely and effectively. See full prescribing information for ARISTADA®.
ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular useInitial U.S. Approval: 2015",1673265,aripiprazole lauroxil,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,Mefenamic Acid Capsules USPRx Only,257844,mefenamate,10018830,haematemesis,500001001,gi bleed,11,1,500001001,1197736,1,1
./data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,2150f73a-179b-4afc-b8ce-67c85cc72f04,60,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009",141704,everolimus,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_766b73e2-49bb-47f9-bbb1-44cfa1a3197e.json,766b73e2-49bb-47f9-bbb1-44cfa1a3197e,4,"These highlights do not include all the information needed to use BENDAMUSTINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for BENDAMUSTINE HYDROCHLORIDE INJECTION. 
	BENDAMUSTINE HYDROCHLORIDE injection,	 for intravenous use. 	Initial U.S. Approval: 2008",134547,bendamustine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230803_0919b927-c57c-40ae-88a8-39e9efe4f677.json,0919b927-c57c-40ae-88a8-39e9efe4f677,5,"",5542,17-alpha-hydroxyprogesterone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722.json,ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722,38,"These highlights do not include all the information needed to use SOLIRIS safely and effectively.  See full prescribing information for SOLIRIS.
 SOLIRIS® (eculizumab) injection, for intravenous use Initial U.S. Approval: 2007",591781,eculizumab,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_973ed458-f46b-4f61-a329-816c4db79a2c.json,973ed458-f46b-4f61-a329-816c4db79a2c,5,"These highlights do not include all the information needed to use ETHYOL safely and effectively. See full prescribing information for ETHYOL.
ETHYOL® (amifostine) for injection, for intravenous useInitial U.S. Approval: 1995",4126,amifostine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,d5929f91-6496-4c0e-97e8-0bd524e15763,3,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/train_xml/20231128_dd966338-c820-4270-b704-09ef75fa3ceb.json,dd966338-c820-4270-b704-09ef75fa3ceb,19,"These highlights do not include all the information needed to use DIFICID safely and effectively. See full prescribing information for DIFICID. 
DIFICID® (fidaxomicin) tablets, for oral use DIFICID® (fidaxomicin) for oral suspension Initial U.S. Approval: 2011",1111103,fidaxomicin,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231129_83a504ef-cf92-467d-9ecf-d251194a3484.json,83a504ef-cf92-467d-9ecf-d251194a3484,20,"These highlights do not include all the information needed to use SYNRIBO safely and effectively.  See full prescribing information for SYNRIBO. 
SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous useInitial U.S. Approval: 2012",27100,omacetaxine mepesuccinate,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6.json,a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6,10,"These highlights do not include all the information needed to use IDHIFA safely and effectively. See full prescribing information for IDHIFA. 
IDHIFA® (enasidenib) tablets, for oral use Initial U.S. Approval: 2017",1940332,enasidenib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012",1302966,carfilzomib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/gold_xml/20221103_da1c9f37-779e-4682-816f-93d0faa4cfc9.json,da1c9f37-779e-4682-816f-93d0faa4cfc9,16,"These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. 
OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014",1592737,nintedanib,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009",141704,everolimus,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,2150f73a-179b-4afc-b8ce-67c85cc72f04,60,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009",141704,everolimus,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/gold_xml/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010",612865,tocilizumab,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230202_241f0b1e-8b95-470d-876f-bf1804daaf18.json,241f0b1e-8b95-470d-876f-bf1804daaf18,11,"These highlights do not include all the information needed to use IXEMPRA 
 ® safely and effectively. See full prescribing information for IXEMPRA 
 ®.
 



IXEMPRA 
 ® 
Kit (ixabepilone) for Injection, for intravenous infusion only
 



Initial U.S. Approval: 2007",337523,ixabepilone,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230202_241f0b1e-8b95-470d-876f-bf1804daaf18.json,241f0b1e-8b95-470d-876f-bf1804daaf18,11,"These highlights do not include all the information needed to use IXEMPRA 
 ® safely and effectively. See full prescribing information for IXEMPRA 
 ®.
 



IXEMPRA 
 ® 
Kit (ixabepilone) for Injection, for intravenous infusion only
 



Initial U.S. Approval: 2007",337523,ixabepilone,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230204_f27eb1b9-b7fc-424e-988f-84dd7bb195a3.json,f27eb1b9-b7fc-424e-988f-84dd7bb195a3,6,"These highlights do not include all the information needed to use TUKYSA safely and effectively. See full prescribing information for TUKYSA.
TUKYSA® (tucatinib) tablets, for oral use Initial U.S. Approval: 2020",2361285,tucatinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231111_8983d6a0-f63f-4f8e-bba4-38223f39e29b.json,8983d6a0-f63f-4f8e-bba4-38223f39e29b,11,"These highlights do not include all the information needed to use BENZNIDAZOLE TABLETS safely and effectively. See full prescribing information for BENZNIDAZOLE TABLETS.
 



BENZNIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2017",18994,benznidazole,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_c5116390-e0fe-4969-94cb-e9de5165fbab.json,c5116390-e0fe-4969-94cb-e9de5165fbab,23,"These highlights do not include all the information needed to use ONGLYZA safely and effectively. See full prescribing information for ONGLYZA.
ONGLYZA® (saxagliptin) tablets, for oral useInitial U.S. Approval: 2009",857974,saxagliptin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231203_b1b84d62-a369-a4b7-5c41-dd1f553a18f3.json,b1b84d62-a369-a4b7-5c41-dd1f553a18f3,15,"These highlights do not include all the information needed to use TRELSTAR safely and effectively. See full prescribing information for TRELSTAR.
TRELSTAR®  (triptorelin pamoate for injectable suspension), for intramuscular use  Initial U.S. Approval: 2000",38782,triptorelin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230315_72d1a024-00b7-418a-b36e-b2cb48f2ab55.json,72d1a024-00b7-418a-b36e-b2cb48f2ab55,6,"These highlights do not include all the information needed to use LUTATHERA safely and effectively. See full prescribing information for LUTATHERA.
		

		LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use
		
		Initial U.S. Approval: 2018",1797118,dotatate,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230318_b118a40d-6b56-cee3-10f6-ded821a97018.json,b118a40d-6b56-cee3-10f6-ded821a97018,275,"These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA.


VENCLEXTA

®

 (venetoclax tablets), for oral use 

Initial U.S. Approval: 2016",1747556,venetoclax,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230517_35b2db65-4c6c-4173-ab56-b2bca69193bd.json,35b2db65-4c6c-4173-ab56-b2bca69193bd,6,"These highlights do not include all the information needed to use HEMGENIX safely and effectively. See full prescribing information for HEMGENIX.
 HEMGENIX (etranacogene dezaparvovec-drlb) suspension, for intravenous infusion Initial U.S. Approval: 2022",2626727,etranacogene dezaparvovec,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230615_1e484a50-55db-4b85-8c57-6cd1b0353abd.json,1e484a50-55db-4b85-8c57-6cd1b0353abd,32,"These highlights do not include all the information needed to use OPSUMIT safely and effectively. See full prescribing information for OPSUMIT.
 



OPSUMIT 
 ® (macitentan) tablets, for oral use
 

Initial U.S. Approval: 2013",1442132,macitentan,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231218_8edd78a9-d762-4578-a610-28d6595f4bf3.json,8edd78a9-d762-4578-a610-28d6595f4bf3,1,Melphalan Hydrochloride for Injection(For Intravenous Infusion),6718,melphalan,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230622_3516e753-f064-4d30-9bd5-e3f2e143f75d.json,3516e753-f064-4d30-9bd5-e3f2e143f75d,2,"These highlights do not include all the information needed to use COLUMVI™ safely and effectively. See full prescribing information for COLUMVI. 
 COLUMVI (glofitamab-gxbm) injection, for intravenous use  Initial U.S. Approval: 2023",2639782,glofitamab,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230629_2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c.json,2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c,3,"These highlights do not include all the information needed to use ANDEXXA safely and effectively.  See Full Prescribing Information for ANDEXXA.
 ANDEXXA® (coagulation factor Xa (recombinant), inactivated-zhzo) Lyophilized powder for solution for intravenous injection Initial U.S. Approval:  2018",2045114,andexanet alfa,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_bf514e99-4958-44a0-a87a-02a950f87e60.json,bf514e99-4958-44a0-a87a-02a950f87e60,7,"Acetazolamide Extended-release Capsules, USP
Rx only",167,acetazolamide,10019692,hepatic necrosis,500000301,acute liver injury,15,1,500000301,929435,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231208_e0022c28-8cda-4f1e-bcf1-1f440d37ec4a.json,e0022c28-8cda-4f1e-bcf1-1f440d37ec4a,6,"These highlights do not include all the information needed to use RETHYMIC safely and effectively. See full prescribing information for RETHYMIC.


RETHYMIC (Allogeneic processed thymus tissue–agdc)
For surgical implantation
Initial U.S. Approval: 2021",2626460,allogeneic processed thymus tissue,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231208_e0022c28-8cda-4f1e-bcf1-1f440d37ec4a.json,e0022c28-8cda-4f1e-bcf1-1f440d37ec4a,6,"These highlights do not include all the information needed to use RETHYMIC safely and effectively. See full prescribing information for RETHYMIC.


RETHYMIC (Allogeneic processed thymus tissue–agdc)
For surgical implantation
Initial U.S. Approval: 2021",2626460,allogeneic processed thymus tissue,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/train_xml/20240123_fff5d805-4ffd-4e8e-8e63-6f129697563e.json,fff5d805-4ffd-4e8e-8e63-6f129697563e,18,"These highlights do not include all the information needed to use ZYKADIA safely and effectively. See full prescribing information for ZYKADIA.


ZYKADIA® (ceritinib) capsules, for oral use

ZYKADIA® (ceritinib) tablets, for oral use

Initial U.S. Approval: 2014",1535457,ceritinib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_988513ab-b06f-4dd0-93f7-d2d4531dcce4.json,988513ab-b06f-4dd0-93f7-d2d4531dcce4,33,"These highlights do not include all the information needed to use FABRAZYME® safely and effectively. See full prescribing information for FABRAZYME®. 
 FABRAZYME® (agalsidase beta) for injection, for intravenous use  Initial U.S. Approval: 2003",338817,agalsidase beta,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230816_5c4841b4-fbc0-4163-8ee1-cb28629cbfbf.json,5c4841b4-fbc0-4163-8ee1-cb28629cbfbf,13,"These highlights do not include all the information needed to use PHOTOFRIN 
 ® safely and effectively. See full prescribing information for PHOTOFRIN.
 



PHOTOFRIN (porfimer sodium) for injection, for intravenous useInitial U.S. Approval: 1995",23066,dihematoporphyrin ether,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230817_44492772-5aed-4627-bd85-e8e89f308bb3.json,44492772-5aed-4627-bd85-e8e89f308bb3,12,"These highlights do not include all the information needed to use MAYZENT safely and effectively. See full prescribing information for MAYZENT.


MAYZENT® (siponimod) tablets, for oral use

Initial U.S. Approval: 2019",2121085,siponimod,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,b6465b44-a6dd-f99c-d009-6851cf05169c,11,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab).",224905,trastuzumab,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231003_3850cce2-6137-42e5-a792-d318c4a4b3b5.json,3850cce2-6137-42e5-a792-d318c4a4b3b5,14,"These highlights do not include all the information needed to use CABOMETYX safely and effectively.  See full prescribing information for CABOMETYX.CABOMETYX® (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012",1363268,cabozantinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,5cd725a1-2fa4-408a-a651-57a7b84b2118,18,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017",1875534,avelumab,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,84137882-e000-47da-bd5b-fa76ab3c76f9,20,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012",1242999,axitinib,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231019_235dfc38-0f0b-4037-b501-7a9f4294740c.json,235dfc38-0f0b-4037-b501-7a9f4294740c,16,"These highlights do not include all the information needed to use BRAFTOVI safely and effectively. See full prescribing information for BRAFTOVI.
BRAFTOVI® (encorafenib) capsules, for oral useInitial U.S. Approval: 2018",2049106,encorafenib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)",4502,flurbiprofen,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_8d5ace90-983b-48c4-baf1-b44f6af146de.json,8d5ace90-983b-48c4-baf1-b44f6af146de,2,"Carbamazepine Oral Suspension, USP
 
Rx only
 
Prescribing Information",2002,carbamazepine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,500000301,740275,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240106_fe0ddd44-ef02-4827-b164-7fcbb45bcc1b.json,fe0ddd44-ef02-4827-b164-7fcbb45bcc1b,4,"These highlights do not include all the information needed to use BUSULFAN INJECTION safely and effectively. See full prescribing information for BUSULFAN INJECTION.
 



BUSULFAN Injection, for intravenous use
 

Initial U.S. Approval: 1999",1828,busulfan,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1333357,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_9d88f915-13dd-5463-e053-2a95a90a09bf.json,9d88f915-13dd-5463-e053-2a95a90a09bf,3,ENALAPRILAT INJECTION 1.25mg/mL 1mL VIAL,3829,enalaprilat,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1342001,1,1
./data/2024_latest_labels/latest_labels_ingredients/20220716_51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.json,51ff7db5-aaf9-4c3c-86e6-958ebf16b60f,10,"Nefazodone Hydrochloride Tablets, USP

Rx only

(Patient Information Included)",31565,nefazodone,10024690,liver function test abnormal,500000301,acute liver injury,15,1,500000301,714684,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_7652adc6-1aad-4422-b85c-0c6b11c23b73.json,7652adc6-1aad-4422-b85c-0c6b11c23b73,7,"These highlights do not include all the information needed to use GABAPENTIN CAPSULES safely and effectively. See full prescribing information for GABAPENTIN CAPSULES.
 

GABAPENTIN capsules, for oral use
 

Initial U.S. Approval: 1993",25480,gabapentin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_7d655d6d-01da-488c-bd4e-c7fbe0ace38c.json,7d655d6d-01da-488c-bd4e-c7fbe0ace38c,5,"These highlights do not include all the information needed to use TESTOSTERONE GEL, 1% safely and effectively.  See full prescribing information for TESTOSTERONE GEL, 1%.

 TESTOSTERONE gel 1%, for topical use, CIII Initial U.S. Approval: 1953",10379,testosterone,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_768aa02b-8231-5799-e053-2a91aa0a618d.json,768aa02b-8231-5799-e053-2a91aa0a618d,7,"ONDANSETRON INJECTION, USP 4mg/2mL (2mg/mL) VIAL",26225,ondansetron,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20100125_c6c48eee-240b-4425-8691-35462523652e.json,c6c48eee-240b-4425-8691-35462523652e,1,"DARVON-N  - propoxyphene napsylate tablet, film coated",8785,propoxyphene,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20100125_c6c48eee-240b-4425-8691-35462523652e.json,c6c48eee-240b-4425-8691-35462523652e,1,"DARVON-N  - propoxyphene napsylate tablet, film coated",8785,propoxyphene,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20100115_2dd58c88-142f-41ad-bc31-0a4fff074970.json,2dd58c88-142f-41ad-bc31-0a4fff074970,1,"CEDAX® 
(ceftibuten capsules) and (ceftibuten for oral suspension)",20492,ceftibuten,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221228_39e62997-8781-449a-e054-00144ff88e88.json,39e62997-8781-449a-e054-00144ff88e88,7,"Nizatidine Oral Solution 

15 mg/mL 

 
Rx only",42319,nizatidine,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987",2551,ciprofloxacin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,500000301,1797513,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240221_9678a98e-4aab-4d87-b5e1-37c3109e378e.json,9678a98e-4aab-4d87-b5e1-37c3109e378e,16,"These highlights do not include all the information needed to use TIZANIDINE Tablets, USP safely and effectively. See full prescribing information for TIZANIDINE Tablets, USP.TIZANIDINE (tizanidine hydrochloride) Tablets USP, for oral useInitial U.S. Approval:1996",57258,tizanidine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,"Venlafaxine Tablets, USP
 
Rx only",39786,venlafaxine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230221_87768fbf-7c63-47da-8925-0316f343d6ef.json,87768fbf-7c63-47da-8925-0316f343d6ef,16,"These highlights do not include all the information needed to use PERINDOPRIL ERBUMINE TABLETS safely and effectively. See full prescribing information for PERINDOPRIL ERBUMINE TABLETS.
 PERINDOPRIL erbumine tablets, for oral use Initial U.S. Approval: 1993",54552,perindopril,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_e4dbaa72-7b3e-4aef-983b-90efb2b343cd.json,e4dbaa72-7b3e-4aef-983b-90efb2b343cd,6,"These highlights do not include all the information needed to use PRAVASTATIN SODIUM TABLETS safely and effectively. See full prescribing information for PRAVASTATIN SODIUM TABLETS.
 

PRAVASTATIN SODIUM tablets, for oral use
 
Initial U.S. Approval: 1991",42463,pravastatin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_304a3059-4f7f-4ec4-839d-86492bb5e07b.json,304a3059-4f7f-4ec4-839d-86492bb5e07b,6,"These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE TABLETS.
 
MEMANTINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2003",6719,memantine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230921_e72c2bc6-9462-4a2e-8e1d-b97592376cbd.json,e72c2bc6-9462-4a2e-8e1d-b97592376cbd,32,"These highlights do not include all the information needed to use VIRACEPT safely and effectively. See full prescribing information for VIRACEPT.
 VIRACEPT® (nelfinavir mesylate) Tablets, for oral use  VIRACEPT®  (nelfinavir mesylate) Oral Powder, for oral use Initial U.S. Approval: 1997",134527,nelfinavir,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240111_7f0bc342-0a0a-1d28-e053-2991aa0a28b9.json,7f0bc342-0a0a-1d28-e053-2991aa0a28b9,4,"TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 
Rx only
 

These highlights do not include all the information needed to use TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for TENOFOVIR DISOPROXIL FUMARATE TABLETS.
 

TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 

Initial U.S. Approval: 2001",300195,tenofovir disoproxil,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231221_f567d5c7-ea5d-49a7-a035-b47208135f73.json,f567d5c7-ea5d-49a7-a035-b47208135f73,9,"These highlights do not include all the information needed to use 
QUININE SULFATE CAPSULES safely and effectively. See full prescribing information for
 QUININE SULFATE CAPSULES.


QUININE sulfate capsules, for oral use

Initial U.S. Approval: 2005",9071,quinine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231129_5fccc31d-32c9-49e7-91a9-664cc726872b.json,5fccc31d-32c9-49e7-91a9-664cc726872b,102,"These highlights do not include all the information needed to use TRIAZOLAM TABLETS safely and effectively. See full prescribing information for TRIAZOLAM TABLETS. 

TRIAZOLAM tablets, for oral use, CIV

Initial U.S. Approval: 1982",10767,triazolam,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/train_xml/20230816_6a9cbc29-9f15-4b24-8d86-206b82887f3d.json,6a9cbc29-9f15-4b24-8d86-206b82887f3d,24,"These highlights do not include all the information needed to use INTELENCE safely and effectively. See full prescribing information for INTELENCE.
 





INTELENCE 
 ®(etravirine) tablets, for oral use
 

Initial U.S. Approval: 2008",475969,etravirine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20120618_83aeddf8-6fed-487c-858b-2240f0a0e8af.json,83aeddf8-6fed-487c-858b-2240f0a0e8af,1,"CRIXIVAN®
(INDINAVIR SULFATE)CAPSULES",114289,indinavir,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_1de49a4d-dc7e-48ff-b18c-e1414282fe71.json,1de49a4d-dc7e-48ff-b18c-e1414282fe71,102,"These highlights do not include all the information needed to use IMIQUIMOD Cream safely and effectively. See full prescribing information for IMIQUIMOD Cream.
IMIQUIMOD cream, for topical useInitial U.S. Approval: 1997",59943,imiquimod,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,11344047-7ed4-61e7-e063-6394a90a332d,1,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995",17128,lansoprazole,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,113558e6-8b45-cdbd-e063-6394a90ac036,2,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only",24605,etodolac,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1195492,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,113558e6-8b45-cdbd-e063-6394a90ac036,2,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only",24605,etodolac,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1195492,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240119_3e4842ec-773b-4aeb-b37d-1c4e3cf53424.json,3e4842ec-773b-4aeb-b37d-1c4e3cf53424,102,"Dicloxacillin Sodium Capsules USP


Rx only",3356,dicloxacillin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009",73689,febuxostat,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999",21107,cilostazol,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_53486382-eee0-4cbe-bc4a-a57484e0d5a7.json,53486382-eee0-4cbe-bc4a-a57484e0d5a7,104,"These highlights do not include all the information needed to use CILOSTAZOL TABLETS safely and effectively. See full prescribing information for CILOSTAZOL TABLETS.CILOSTAZOL tablets, for oral useInitial U.S. Approval: 1999",21107,cilostazol,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_34de1806-d921-4d2f-8c7f-03625b717a70.json,34de1806-d921-4d2f-8c7f-03625b717a70,25,"These highlights do not include all the information needed to use METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS.


METHYLPHENIDATE HCl extended-release tablets, for oral administration CII 

Initial U.S. Approval: 2000",6901,methylphenidate,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_918d0e2a-3af3-46e8-ad06-528263e03ba0.json,918d0e2a-3af3-46e8-ad06-528263e03ba0,11,"These highlights do not include all the information needed to use fentanyl buccal tablet safely and effectively.  See full prescribing information for fentanyl buccal tablet. 
 Fentanyl Buccal Tablet, CII    Initial U.S. Approval: 1968",4337,fentanyl,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20231216_cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae.json,cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae,12,"These highlights do not include all the information needed to use PRADAXA Capsules safely and effectively.  See full prescribing information for PRADAXA Capsules. 
 PRADAXA® (dabigatran etexilate) capsules, for oral use Initial U.S. Approval: 2010",1037042,dabigatran etexilate,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230713_740a0f37-aa95-4558-b415-be516b8c40a3.json,740a0f37-aa95-4558-b415-be516b8c40a3,2,"Tolmetin Sodium Capsules, USP 400 mg
 Rx only",10636,tolmetin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_90717878-64cb-4ffc-90bc-7b4e81e3d1cd.json,90717878-64cb-4ffc-90bc-7b4e81e3d1cd,12,"Nafcillin for Injection, USP Rx only",7233,nafcillin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987",2551,ciprofloxacin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_51a88e8e-da02-4b97-9e7e-442fbffd908d.json,51a88e8e-da02-4b97-9e7e-442fbffd908d,8,"These highlights do not include all the information needed to use AMIODARONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for AMIODARONE HYDROCHLORIDE TABLETS.
 

AMIODARONE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1985",703,amiodarone,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231227_d3832a1a-a140-49c1-a7df-134fa81341e3.json,d3832a1a-a140-49c1-a7df-134fa81341e3,8,"Disulfiram Tablets, USP
 
IN ALCOHOLISM
 

Rx only",3554,disulfiram,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,735850,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231230_cb960074-99c1-4a73-941f-f0644a7ec219.json,cb960074-99c1-4a73-941f-f0644a7ec219,40,"These highlights do not include all the information needed to use AGRYLIN safely and effectively. See full prescribing information for AGRYLIN.
AGRYLIN® (anagrelide) capsules, for oral useInitial U.S. Approval: 1997",596724,anagrelide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240203_453a5759-2f0d-421d-be78-81ab97c8ce77.json,453a5759-2f0d-421d-be78-81ab97c8ce77,1,"These highlights do not include all the information needed to use DESVENLAFAXINE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DESVENLAFAXINE EXTENDED-RELEASE TABLETS.DESVENLAFAXINE extended-release tablets, for oral useInitial U.S. Approval: 2008",734064,desvenlafaxine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20130606_d5050d0e-81d1-4707-a38a-e80de2aebf09.json,d5050d0e-81d1-4707-a38a-e80de2aebf09,2,Cefditoren Pivoxil Tablets 200 mg and 400 mg,83682,cefditoren,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_f5e8d1da-8911-42db-9f90-cba04b28d011.json,f5e8d1da-8911-42db-9f90-cba04b28d011,102,"These highlights do not include all the information needed to use FLUVASTATIN CAPSULES safely and effectively.  See full prescribing information for FLUVASTATIN CAPSULES. 
FLUVASTATIN capsules, for oral useInitial U.S. Approval: 1993",41127,fluvastatin,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231228_755476e5-62a2-4f01-92a3-307e192ad42c.json,755476e5-62a2-4f01-92a3-307e192ad42c,5,"These highlights do not include all the information needed to use PARICALCITOL CAPSULES safely and effectively.
 
See full prescribing information for PARICALCITOL CAPSULES.
 

PARICALCITOL capsules, for oral use
 
Initial U.S. Approval: 1998",73710,paricalcitol,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_1d3a45f3-3854-4d0c-9241-770aa24063fd.json,1d3a45f3-3854-4d0c-9241-770aa24063fd,5,"These highlights do not include all the information needed to use DULOXETINE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DULOXETINE DELAYED-RELEASE CAPSULES.
 
DULOXETINE delayed-release capsules for oral use.
 
Initial U.S. Approval: 2004",72625,duloxetine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231103_c654ef2e-1067-4026-8931-6a0dc2a17ad1.json,c654ef2e-1067-4026-8931-6a0dc2a17ad1,4,"These highlights do not include all the information needed to use CEFEPIME FOR INJECTION safely and effectively. See full prescribing information for CEFEPIME FOR INJECTION. CEFEPIME for injection, for intravenous or intramuscular useInitial U.S. Approval: 1996",20481,cefepime,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_1276283e-21b0-4932-864f-547c62bd49e5.json,1276283e-21b0-4932-864f-547c62bd49e5,5,"Ursodiol Capsules, USP
 

Rx Only
 

Prescribing Information",62427,ursodeoxycholate,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_5a1cbf7e-0352-aa3b-080c-222a6423ecd8.json,5a1cbf7e-0352-aa3b-080c-222a6423ecd8,11,"Entecavir Tablets, USP
 
Rx Only
 

These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS.
 

Initial U.S. Approval: 2005",306266,entecavir,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_8192d79d-da2b-2532-e053-2991aa0ae8ad.json,8192d79d-da2b-2532-e053-2991aa0ae8ad,6,"PROCAINAMIDE HCI INJECTION, USP 1gram/10mL TOTAL (100mg/mL) 10mL VIAL",8700,procainamide,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_a07195bc-7442-32b4-e053-2995a90a0151.json,a07195bc-7442-32b4-e053-2995a90a0151,2,"HEPARIN SODIUM INJECTION, USP 10,000 USP UNITS/mL 1mL VIAL",5224,heparin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221224_eeb0fcfd-e4e8-4fb1-9635-901dc9446235.json,eeb0fcfd-e4e8-4fb1-9635-901dc9446235,8,"These highlights do not include all the information needed to use ILOPERIDONE TABLETS safely and effectively. See full prescribing information for ILOPERIDONE TABLETS.
ILOPERIDONE tablets, for oral use
Initial U.S. Approval: 2009",73178,iloperidone,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,56d64558-1fad-420e-8fcd-7103cd073127,1,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998",140587,celecoxib,10019692,hepatic necrosis,500000301,acute liver injury,15,1,500000301,1118084,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240104_8e99d6fe-42ab-44c1-8b51-e4ac7406dbe4.json,8e99d6fe-42ab-44c1-8b51-e4ac7406dbe4,2,"Oxacillin for Injection, USP
 

For Intramuscular or Intravenous Injection",7773,oxacillin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231226_39b58213-b9e2-4847-9010-99e187c1b778.json,39b58213-b9e2-4847-9010-99e187c1b778,19,"These highlights do not include all the information needed to use FOSPHENYTOIN SODIUM INJECTION safely and effectively. See full prescribing information for FOSPHENYTOIN SODIUM  INJECTION.




FOSPHENYTOIN SODIUM injection, for intravenous or intramuscular use

Initial U.S. Approval: 1996",72236,fosphenytoin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988",5657,ifosfamide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231229_4a22e559-2dac-42d7-af8d-eb0ebbc2f76d.json,4a22e559-2dac-42d7-af8d-eb0ebbc2f76d,8,"Aminocaproic Acid Tablets, USP

(500 mg)

Rx only",99,6-aminocaproic acid,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240203_de03bd69-2dca-459c-93b4-541fd3e9571c.json,de03bd69-2dca-459c-93b4-541fd3e9571c,36,"These highlights do not include all the information needed to use ONFI safely and effectively. See full prescribing information for ONFI.


ONFI® (clobazam) tablets, for oral use, CIV

ONFI® (clobazam) oral suspension, CIV

Initial U.S. Approval: 2011",21241,clobazam,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_3495a71a-cc04-4776-851f-f185956f32af.json,3495a71a-cc04-4776-851f-f185956f32af,22,"These highlights do not include all the information needed to use VIDAZA safely and effectively. See full prescribing information for VIDAZA.
VIDAZA (azacitidine for injection), for subcutaneous or intravenous useInitial U.S. Approval: 2004",1251,azacitidine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_c8b58efa-1820-48a4-b70d-62918fc4abfc.json,c8b58efa-1820-48a4-b70d-62918fc4abfc,6,"These highlights do not include all the information needed to use ONIVYDE® safely and effectively. See full prescribing information for ONIVYDE®
 ONIVYDE® (irinotecan liposome injection), for intravenous use Initial U.S. Approval: 1996",51499,irinotecan,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210804_ed23b6bc-32c7-4c50-a53d-313ae78e5623.json,ed23b6bc-32c7-4c50-a53d-313ae78e5623,13,"CEFOTAXIME FOR INJECTION, USP",2186,cefotaxime,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,cc7014b1-c775-411d-b374-8113248b4077,4,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017",1942950,inotuzumab ozogamicin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/gold_xml/20240203_a88ac1b4-e2c9-45c0-b321-4785902172e3.json,a88ac1b4-e2c9-45c0-b321-4785902172e3,41,"These highlights do not include all the information needed to use 
SABRIL
 
safely and effectively. See full prescribing information for 
SABRIL
.


SABRIL

®

 
(
vigabatrin
)
  
t
ablet
s
, for oral use

SABRIL

®

 
(
vigabatrin
) 
for 
o
ral 
s
olution       
Initial U.S. Approval:
 
2009",14851,vigabatrin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231205_a64a50ba-e3da-4227-9bce-87101d60409e.json,a64a50ba-e3da-4227-9bce-87101d60409e,2,"These highlights do not include all the information needed to use SAPROPTERIN DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SAPROPTERIN DIHYDROCHLORIDE TABLETS.
 
SAPROPTERIN DIHYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 2007",753340,sapropterin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b.json,3bc8668e-8ec3-4c54-b46b-5ca0dac87c1b,13,"These highlights do not include all the information needed to use MICAFUNGIN FOR INJECTION safely and effectively. See full prescribing information for MICAFUNGIN FOR INJECTION.
 MICAFUNGIN for Injection, for intravenous infusion only Initial U.S. Approval: 2005",325887,micafungin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_f1be363d-6fc5-4b08-9b96-976933db19e1.json,f1be363d-6fc5-4b08-9b96-976933db19e1,9,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
 



ELIQUIS 
 ® (apixaban) tablets, for oral use
 

Initial U.S. Approval: 2012",1364430,apixaban,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_f1be363d-6fc5-4b08-9b96-976933db19e1.json,f1be363d-6fc5-4b08-9b96-976933db19e1,9,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
 



ELIQUIS 
 ® (apixaban) tablets, for oral use
 

Initial U.S. Approval: 2012",1364430,apixaban,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/gold_xml/20230722_afad3051-9df2-4c54-9684-e8262a133af8.json,afad3051-9df2-4c54-9684-e8262a133af8,35,"These highlights do not include all the information needed to use LATUDA safely and effectively.  See full prescribing information for LATUDA.
LATUDA (lurasidone hydrochloride) tablets, for oral use Initial U.S. Approval: 2010",1040028,lurasidone,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240118_b471eb51-488e-5312-e053-2a95a90a8116.json,b471eb51-488e-5312-e053-2a95a90a8116,5,"These highlights do not include all the information needed to use FULVESTRANT INJECTION safely and effectively. See full prescribing information for FULVESTRANT INJECTION.
 
FULVESTRANT injection, for intramuscular use
 
Initial U.S. Approval: 2002",282357,fulvestrant,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_b856ac70-71cd-477b-95b1-0a6132c260e8.json,b856ac70-71cd-477b-95b1-0a6132c260e8,6,"These highlights do not include all the information needed to use DIMETHYL FUMARATE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DIMETHYL FUMARATE DELAYED-RELEASE CAPSULES.
 

DIMETHYL FUMARATE delayed-release capsules, for oral use
 

Initial U.S. Approval: 2013",1373478,dimethyl fumarate,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210812_df4cd207-c3b8-4008-5290-02f296c2b4a6.json,df4cd207-c3b8-4008-5290-02f296c2b4a6,21,"These highlights do not include all the information needed to use CORLOPAM® safely and effectively.  See full prescribing information for CORLOPAM®. 
CORLOPAM® (fenoldopam mesylate) injection, for intravenous use Initial U.S. Approval: 1997",24853,fenoldopam,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231128_3bad23a6-09a6-4194-9182-093ed61bc71c.json,3bad23a6-09a6-4194-9182-093ed61bc71c,39,"These highlights do not include all the information needed to use CANCIDAS safely and effectively. See full prescribing information for CANCIDAS.
CANCIDAS® (caspofungin acetate) for injection, for intravenous useInitial U.S. Approval: 2001",140108,caspofungin,10019692,hepatic necrosis,500000301,acute liver injury,15,1,500000301,1718054,1,1
./data/2024_latest_labels/gold_xml/20230603_03b39d40-90fe-11df-9de6-0002a5d5c51b.json,03b39d40-90fe-11df-9de6-0002a5d5c51b,21,"These highlights do not include all the information needed to use ISTODAX safely and effectively.  See full prescribing information for ISTODAX.
ISTODAX® (romidepsin) for injection, for intravenous useInitial U.S. Approval:  2009",877510,romidepsin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013",224905,trastuzumab,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_cfeab9e3-58b9-4890-9185-11b62904e2af.json,cfeab9e3-58b9-4890-9185-11b62904e2af,13,Metronidazole Tablets USP,6922,metronidazole,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240124_0d6111be-aabe-88e2-e063-6394a90a3963.json,0d6111be-aabe-88e2-e063-6394a90a3963,2,"These highlights do not include all the information needed to use MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS.


MYCOPHENOLIC ACID delayed-release tablets, for oral use

Initial U.S. Approval: 2004",7145,mycophenolic acid,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231115_fb77637a-88d9-4aea-958f-e270030ce30d.json,fb77637a-88d9-4aea-958f-e270030ce30d,18,"These highlights do not include all the information needed to use BAXDELA® safely and effectively. See full prescribing information for BAXDELA. 
BAXDELA (delafloxacin) tablets, for oral use BAXDELA (delafloxacin) for injection, for intravenous use Initial U.S. Approval: 2017",1927663,delafloxacin,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/gold_xml/20220430_e4c45bb5-15f4-437e-ab98-a649b3676d14.json,e4c45bb5-15f4-437e-ab98-a649b3676d14,22,"These highlights do not include all the information needed to use JUXTAPID safely and effectively. See full prescribing information for JUXTAPID. 
JUXTAPID® (lomitapide) capsules, for oral use Initial U.S. Approval: 2012",1364479,lomitapide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240213_c98fb504-76d0-4c25-9c0b-412885828a7a.json,c98fb504-76d0-4c25-9c0b-412885828a7a,7,"These highlights do not include all the information needed to use LENALIDOMIDE CAPSULES safely and effectively. See full prescribing information for LENALIDOMIDE CAPSULES.
LENALIDOMIDE capsules, for oral use
Initial U.S. Approval:2005",342369,lenalidomide,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231207_50d0dd0c-7682-43d0-aa1b-ca26e9181aee.json,50d0dd0c-7682-43d0-aa1b-ca26e9181aee,3,"These highlights do not include all the information needed to use lapatinib tablets safely and effectively. See full prescribing information for lapatinib tablets. LAPATINIB tablets, for oral use Initial U.S. Approval: 2007",480167,lapatinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240203_374013c9-18c9-4419-b9fb-9bc5c765688e.json,374013c9-18c9-4419-b9fb-9bc5c765688e,1,"Budesonide Inhalation Suspension
 

These highlights do not include all the information needed to use BUDESONIDE INHALATION SUSPENSION safely and effectively. See full prescribing information for BUDESONIDE INHALATION SUSPENSION.
 

BUDESONIDE Inhalation Suspension, for inhalation suspension
 
Initial U.S. Approval: 2000",19831,budesonide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220723_fd638e5e-8032-e7ca-0179-95e96ab5d387.json,fd638e5e-8032-e7ca-0179-95e96ab5d387,18,"These highlights do not include all the information needed to use GILOTRIF safely and effectively.  See full prescribing information for GILOTRIF. 
GILOTRIF® (afatinib tablets), for oral use Initial U.S. Approval: 2013",1430438,afatinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/train_xml/20240220_4b4674d8-4d1e-4728-8465-d42ada33fa5c.json,4b4674d8-4d1e-4728-8465-d42ada33fa5c,23,"These highlights do not include all the information needed to use 
DALVANCE

®

 
safely and effectively.  
See full prescribing information for 
DALVANCE
.  

   

DALVANCE
 (
dalbavancin
)
 
for 
injection
,
 
for 
intravenous 
use 

Initial U.S. Approval: 
2014",1539239,dalbavancin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_4b4674d8-4d1e-4728-8465-d42ada33fa5c.json,4b4674d8-4d1e-4728-8465-d42ada33fa5c,23,"These highlights do not include all the information needed to use 
DALVANCE

®

 
safely and effectively.  
See full prescribing information for 
DALVANCE
.  

   

DALVANCE
 (
dalbavancin
)
 
for 
injection
,
 
for 
intravenous 
use 

Initial U.S. Approval: 
2014",1539239,dalbavancin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994",42355,fluvoxamine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/train_xml/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012",1302966,carfilzomib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231129_c6080942-dee6-423e-b688-1272c2ae90d4.json,c6080942-dee6-423e-b688-1272c2ae90d4,40,"These highlights do not include all the information needed to use CYRAMZA safely and effectively. See full prescribing information for CYRAMZA.
CYRAMZA (ramucirumab) injection, for intravenous useInitial U.S. Approval: 2014",1535922,ramucirumab,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_7499fc35-fae8-44ad-bbab-9a1a589bf3ee.json,7499fc35-fae8-44ad-bbab-9a1a589bf3ee,20,"These highlights do not include all the information needed to use ETOPOPHOS safely and effectively. See full prescribing information for ETOPOPHOS.
ETOPOPHOS® (etoposide phosphate) for injection, for intravenous useInitial U.S. Approval: 1983",4179,etoposide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_979205ee-b0b8-4483-ae61-f283f750bb7f.json,979205ee-b0b8-4483-ae61-f283f750bb7f,100,"These highlights do not include all the information needed to use DAPAGLIFLOZIN TABLETS  safely and effectively.  See full prescribing information for DAPAGLIFLOZIN TABLETS.
DAPAGLIFLOZIN tablets, for oral useInitial U.S. Approval: 2014",1488564,dapagliflozin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008",709271,certolizumab pegol,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_cee4cdd0-58c5-4704-9fb6-d4bffb1764a8.json,cee4cdd0-58c5-4704-9fb6-d4bffb1764a8,2,"Midazolam Injection, USP

 CIV

 (For Intravenous or Intramuscular Use Only)

 Rx only

 NOT FOR USE IN NEONATES

 CONTAINS BENZYL ALCOHOL",6960,midazolam,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230301_36d50a08-60bd-40eb-807c-778d69bf2d2e.json,36d50a08-60bd-40eb-807c-778d69bf2d2e,1,"These highlights do not include all the information needed to use 
LAMZEDE

®

 
safely and effectively. 
See full prescribing information for 
LAMZEDE
.

  

LAMZEDE
 (
velmanase alfa
-
tycv
) 
for 
injection
, 
for intravenous use

Initial U.S. Approval: 
2023",2630725,velmanase alfa,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231222_4338428e-43d4-4e02-ac9d-bd98e738a7da.json,4338428e-43d4-4e02-ac9d-bd98e738a7da,5,"These highlights do not include all the information needed to use APRETUDE safely and effectively. See full prescribing information for APRETUDE.
APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular useInitial U.S. Approval: 2021",2475077,cabotegravir,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_fb973a8d-7fea-4a7a-963f-2a8e67a46e55.json,fb973a8d-7fea-4a7a-963f-2a8e67a46e55,6,"These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.
		

		PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use
		
		Initial U.S. Approval: 2022",2597054,vipivotide tetraxetan,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_20a16ab2-f338-4abb-9dcd-254bd949a2bc.json,20a16ab2-f338-4abb-9dcd-254bd949a2bc,8,"These highlights do not include all the information needed to use POLIVY safely and effectively. See full prescribing information for POLIVY.
 POLIVY® (polatuzumab vedotin-piiq) for injection, for intravenous use Initial U.S. Approval: 2019",2174090,polatuzumab vedotin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240109_b7f675e2-159c-490c-b6f4-3f16d9492b7d.json,b7f675e2-159c-490c-b6f4-3f16d9492b7d,3,"These highlights do not include all the information needed to use ZEJULA safely and effectively.  See full prescribing information for ZEJULA.
ZEJULA (niraparib) tablets, for oral useInitial U.S. Approval: 2017",1918231,niraparib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230613_c387579e-cee0-4334-bd1e-73f93ac1bde6.json,c387579e-cee0-4334-bd1e-73f93ac1bde6,18,"These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.
COTELLIC®  (cobimetinib) tablets, for oral useInitial U.S. Approval: 2015",1722365,cobimetinib,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_0b8bf078-34c2-4f45-9012-38a8ac082b01.json,0b8bf078-34c2-4f45-9012-38a8ac082b01,6,"These highlights do not include all the information needed to use KRAZATI safely and effectively. See full prescribing information for KRAZATI. 
 KRAZATI® (adagrasib) tablets, for oral use  Initial U.S. Approval: 2022",2625882,adagrasib,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_0b8bf078-34c2-4f45-9012-38a8ac082b01.json,0b8bf078-34c2-4f45-9012-38a8ac082b01,6,"These highlights do not include all the information needed to use KRAZATI safely and effectively. See full prescribing information for KRAZATI. 
 KRAZATI® (adagrasib) tablets, for oral use  Initial U.S. Approval: 2022",2625882,adagrasib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230629_e0fa4bca-f245-4d92-ae29-b0c630a315c2.json,e0fa4bca-f245-4d92-ae29-b0c630a315c2,157,"These highlights do not include all the information needed to use 
VECTIBIX
 safely and effectively.  See full prescribing information for 
VECTIBIX
.

   

VECTIBIX

®

 
(panitumumab)
 
I
njection 
for 
intravenous 
use

Initial U.S. Approval: 
200
6",263034,panitumumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,2265ef30-253e-11df-8a39-0800200c9a66,42,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011",1094833,ipilimumab,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_81a33cfa-262f-4432-a05d-7dd260928437.json,81a33cfa-262f-4432-a05d-7dd260928437,7,"These highlights do not include all the information needed to use ABRILADA safely and effectively. See full prescribing information for ABRILADA.
ABRILADA™ (adalimumab-afzb) injection, for subcutaneous useInitial U.S. Approval: 2019
ABRILADA (adalimumab-afzb) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ABRILADA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA (adalimumab).",797541,isopropyl alcohol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230825_df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda.json,df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda,19,"These highlights do not include all the information needed to use GAZYVA safely and effectively. See full prescribing information for GAZYVA. 
GAZYVA® (obinutuzumab) injection, for intravenous use Initial U.S. Approval: 2013",974779,obinutuzumab,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20230910_fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea.json,fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea,26,"These highlights do not include all the information needed to use TAFINLAR safely and effectively. See full prescribing information for TAFINLAR.
TAFINLAR® (dabrafenib) capsules, for oral useTAFINLAR® (dabrafenib) tablets for oral suspensionInitial U.S. Approval: 2013",1424911,dabrafenib,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,0002ad27-779d-42ab-83b5-bc65453412a1,22,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013",1425099,trametinib,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230914_f015fe60-3128-4a43-8c31-19fc6b5def3f.json,f015fe60-3128-4a43-8c31-19fc6b5def3f,13,"These highlights do not include all the information needed to use FIRDAPSE® safely and effectively. See full prescribing information for FIRDAPSE®.
 FIRDAPSE® (amifampridine) tablets, for oral use Initial U.S. Approval: 2018",2106338,amifampridine,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230921_a865e0ef-8685-4f69-8838-648c4f3bab47.json,a865e0ef-8685-4f69-8838-648c4f3bab47,6,"These highlights do not include all the information needed to use GAMIFANT safely and effectively. See full prescribing information for GAMIFANT.
GAMIFANT® (emapalumab-lzsg) injection, for intravenous use Initial U.S. Approval: 2018",2104604,emapalumab,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/train_xml/20231018_1534c9ae-4948-4cf4-9f66-222a99db6d0e.json,1534c9ae-4948-4cf4-9f66-222a99db6d0e,26,"These highlights do not include all the information needed to use SIRTURO safely and effectively. See full prescribing information for SIRTURO.
 

SIRTURO 
 ®(bedaquiline) tablets, for oral use
 
Initial U.S. Approval: 2012",1364504,bedaquiline,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,f47d4365-40a8-445b-99cd-49edad6a8ffc,15,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only",35827,ketorolac,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1136980,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240223_4911f343-68e6-71b0-e054-00144ff8d46c.json,4911f343-68e6-71b0-e054-00144ff8d46c,5,"These highlights do not include all the information needed to use MELOXICAM TABLETS safely and effectively. See full prescribing information for MELOXICAM TABLETS.
 

Initial U.S. Approval: 2000",41493,meloxicam,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_5c8cebcd-699f-4c4c-900b-94e0fe519345.json,5c8cebcd-699f-4c4c-900b-94e0fe519345,100,"These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.
PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989",8754,propafenone,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_ab8616a5-ea72-4df7-b095-54ea19ef6fba.json,ab8616a5-ea72-4df7-b095-54ea19ef6fba,10,"These highlights do not include all the information needed to use DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES.
 



DIVALPROEX SODIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989",40254,valproate,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_10a3fbc9-00c6-ad83-e063-6294a90ae1ad.json,10a3fbc9-00c6-ad83-e063-6294a90ae1ad,1,"These highlights do not include all the information needed to use OMEPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for OMEPRAZOLE DELAYED-RELEASE CAPSULES.
 

OMEPRAZOLE delayed-release capsules, for oral use
 
Initial U.S. Approval: 1989",7646,omeprazole,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/train_xml/20230830_4c486fc7-c8c4-4c6c-b30c-366dabaeaadd.json,4c486fc7-c8c4-4c6c-b30c-366dabaeaadd,14,"These highlights do not include all the information needed to use HORIZANT safely and effectively. See full prescribing information for HORIZANT. 
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets for oral use Initial U.S. Approval: 2011",25480,gabapentin,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_25c2b417-eeea-4ba6-8eb9-a7d8a08c6093.json,25c2b417-eeea-4ba6-8eb9-a7d8a08c6093,2,"These highlights do not include all the information needed to use POTASSIUM CHLORIDE ORAL SOLUTION safely and effectively. See full prescribing information for POTASSIUM CHLORIDE ORAL SOLUTION.
 

POTASSIUM CHLORIDE oral solution
 
Initial U.S. Approval: 1948",8591,potassium chloride,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,19049105,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240220_6f4998ac-0714-4f5d-8944-9e6902b9f0a6.json,6f4998ac-0714-4f5d-8944-9e6902b9f0a6,12,"These highlights do not include all the information needed to use LEVOTHYROXINE SODIUM TABLETS safely and effectively. See full prescribing information for LEVOTHYROXINE SODIUM TABLETS.
 

LEVOTHYROXINE SODIUM tablets, for oral use
 

Initial U.S. Approval: 2002",10582,levothyroxine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_fabf55db-8b50-491f-b76d-a0fe5fb6c9b0.json,fabf55db-8b50-491f-b76d-a0fe5fb6c9b0,17,"These highlights do not include all the information needed to use CIPROFLOXACIN TABLETS safely and effectively. See full prescribing information for CIPROFLOXACIN TABLETS.
 

CIPROFLOXACIN tablet, for oral use
 
Initial U.S. Approval: 1987",2551,ciprofloxacin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992",32613,oxaprozin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1118045,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_42f49299-7ae5-4d30-86eb-66b739c0e95d.json,42f49299-7ae5-4d30-86eb-66b739c0e95d,5,"These highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS
 



LISINOPRIL tablets, for oral use
 



Initial U.S. Approval: 1988",29046,lisinopril,10069339,acute kidney injury,500000401,acute kidney injury,6,1,500000401,1308216,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240214_f34c08e6-fe74-4de3-9e36-a82c3c1c183b.json,f34c08e6-fe74-4de3-9e36-a82c3c1c183b,9,"These highlights do not include all the information needed to use MOXIFLOXACIN TABLETS safely and effectively. See full prescribing information for MOXIFLOXACIN TABLETS.
 MOXIFLOXACIN tablets, for oral use Initial U.S. Approval: 1999",139462,moxifloxacin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,76e1839b-7462-4344-b319-001a5f57d67a,12,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000",40790,pantoprazole,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,76e1839b-7462-4344-b319-001a5f57d67a,12,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000",40790,pantoprazole,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994",42355,fluvoxamine,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,"Venlafaxine Tablets, USP
 
Rx only",39786,venlafaxine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_e4dbaa72-7b3e-4aef-983b-90efb2b343cd.json,e4dbaa72-7b3e-4aef-983b-90efb2b343cd,6,"These highlights do not include all the information needed to use PRAVASTATIN SODIUM TABLETS safely and effectively. See full prescribing information for PRAVASTATIN SODIUM TABLETS.
 

PRAVASTATIN SODIUM tablets, for oral use
 
Initial U.S. Approval: 1991",42463,pravastatin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_22174520-4b78-4841-96f7-530ba12d2cf1.json,22174520-4b78-4841-96f7-530ba12d2cf1,8,"Paroxetine Tablets USP, film coated for oral use",32937,paroxetine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_3a404db2-7a7d-476f-81cf-979a67d37f66.json,3a404db2-7a7d-476f-81cf-979a67d37f66,7,"These highlights do not include all the information needed to use ALYQ™ safely and effectively.  See full prescribing information for ALYQ™. 


ALYQ™ (tadalafil) tablets for oral administration

Initial U.S. Approval: 2003",358263,tadalafil,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,24926986-7552-4f1a-8366-f035bbd07104,7,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987",4493,fluoxetine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_c0946de1-2a2d-47ff-8071-50c1d3ad7982.json,c0946de1-2a2d-47ff-8071-50c1d3ad7982,8,"These highlights do not include all the information needed to use EXTENDED PHENYTOIN SODIUM CAPSULES safely and effectively. See full prescribing information for EXTENDED PHENYTOIN SODIUM CAPSULES.
 

EXTENDED PHENYTOIN SODIUM capsules, for oral use
 
Initial U.S. Approval: 1953",8183,phenytoin,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_0653b873-b74b-4ec6-b112-675760703d91.json,0653b873-b74b-4ec6-b112-675760703d91,3,"Nabumetone Tablets, USP

Rx only

8463021/1223F",31448,nabumetone,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_0653b873-b74b-4ec6-b112-675760703d91.json,0653b873-b74b-4ec6-b112-675760703d91,3,"Nabumetone Tablets, USP

Rx only

8463021/1223F",31448,nabumetone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1113648,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240216_49873158-5c0a-41da-86a2-369ef6b0cbc8.json,49873158-5c0a-41da-86a2-369ef6b0cbc8,2,"These highlights do not include all the information needed to use RANOLAZINE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for RANOLAZINE EXTENDED-RELEASE TABLETS.
 RANOLAZINE extended-release tablets, for oral use Initial U.S. Approval: 2006",35829,ranolazine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_ff3b5265-f533-4332-a861-d8c9c1664ffd.json,ff3b5265-f533-4332-a861-d8c9c1664ffd,15,"These highlights do not include all the information needed to use LAMIVUDINE TABLETS safely and effectively. See full prescribing information for LAMIVUDINE TABLETS.LAMIVUDINE tablets, for oral useInitial U.S. Approval: 1995",68244,lamivudine,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1704183,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231221_f567d5c7-ea5d-49a7-a035-b47208135f73.json,f567d5c7-ea5d-49a7-a035-b47208135f73,9,"These highlights do not include all the information needed to use 
QUININE SULFATE CAPSULES safely and effectively. See full prescribing information for
 QUININE SULFATE CAPSULES.


QUININE sulfate capsules, for oral use

Initial U.S. Approval: 2005",9071,quinine,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,52781229-ee82-43f9-a113-4419a611978d,1,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000",183379,rivastigmine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240119_6d1c87df-b319-4c63-9f19-6584d7c4ff8e.json,6d1c87df-b319-4c63-9f19-6584d7c4ff8e,8,Rifampin Capsules USP,9384,rifampin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_03151cb5-d32b-4484-8f2a-8c5d24c7f6f1.json,03151cb5-d32b-4484-8f2a-8c5d24c7f6f1,10,"These highlights do not include all the information needed to use GLIPIZIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for GLIPIZIDE EXTENDED-RELEASE TABLETS.
 



GLIPIZIDE extended-release tablets, for oral use
 

Initial U.S. Approval: 1994",4821,glipizide,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_246e0ed0-f8ca-483b-a1ce-91052f3f35f0.json,246e0ed0-f8ca-483b-a1ce-91052f3f35f0,9,"Enalapril Maleate Tablets, USP",3827,enalapril,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_48ffeac8-38e8-4007-903a-dbffce25d679.json,48ffeac8-38e8-4007-903a-dbffce25d679,2,"These highlights do not include all the information needed to use ETRAVIRINE TABLETS safely and effectively.See full prescribing information for ETRAVIRINE TABLETS.
ETRAVIRINE tablets, for oral useInitial U.S. Approval: 2008",475969,etravirine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231214_c82eb602-12e1-692b-d660-f8d5b5736b54.json,c82eb602-12e1-692b-d660-f8d5b5736b54,11,"These highlights do not include all the information needed to use CALCITONIN SALMON NASAL SPRAY safely and effectively. See full prescribing information for CALCITONIN SALMON NASAL SPRAY. 

CALCITONIN SALMON nasal sprayInitial U.S. Approval: 1975",36118,salmon calcitonin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_0be243c6-de02-45dd-8210-cab1bbc8dfa7.json,0be243c6-de02-45dd-8210-cab1bbc8dfa7,28,"These highlights do not include all the information needed to use CLARITHROMYCIN TABLETS safely and effectively. See full prescribing information for CLARITHROMYCIN TABLETS.
 

CLARITHROMYCIN tablets, for oral use
 
Initial U.S. Approval: 1991",21212,clarithromycin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997",746741,pramipexole,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,11344047-7ed4-61e7-e063-6394a90a332d,1,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995",17128,lansoprazole,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,113558e6-8b45-cdbd-e063-6394a90ac036,2,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only",24605,etodolac,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1195492,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240220_113558e6-8b45-cdbd-e063-6394a90ac036.json,113558e6-8b45-cdbd-e063-6394a90ac036,2,"Etodolac Tablets, USP
  
(400 mg and 500 mg) 
 

Rx only",24605,etodolac,10018830,haematemesis,500001001,gi bleed,11,1,500001001,1195492,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240220_9e5c0ef3-3179-4d7b-bc76-901473c73ce8.json,9e5c0ef3-3179-4d7b-bc76-901473c73ce8,20,"These highlights do not include all the information needed to use VARENICLINE TABLETS safely and effectively. See full prescribing information for VARENICLINE TABLETS.



VARENICLINE tablets, for oral use 

Initial U.S. Approval: 2006",591622,varenicline,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_a42a35e6-3e08-4b4f-ae56-47d4aec2322a.json,a42a35e6-3e08-4b4f-ae56-47d4aec2322a,7,"These highlights do not include all the information needed to use RISEDRONATE SODIUM TABLETS safely and effectively. See Full Prescribing Information for RISEDRONATE SODIUM TABLETS.
 RISEDRONATE SODIUM tablets, for oral use Initial U.S. Approval: 1998",73056,risedronate,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_09c6c750-ae05-459f-83e8-4a9e4fd85212.json,09c6c750-ae05-459f-83e8-4a9e4fd85212,28,"These highlights do not include all the information needed to use ATORVASTATIN CALCIUM TABLETS safely and effectively. See full prescribing information for ATORVASTATIN CALCIUM TABLETS.
 

ATORVASTATIN CALCIUM tablets, for oral use
 

Initial U.S. Approval: 1996",83367,atorvastatin,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_9929c166-8ba3-4159-a5f9-4618d5d227b0.json,9929c166-8ba3-4159-a5f9-4618d5d227b0,102,Flecainide Acetate Tablets USPRx only,4441,flecainide,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_369e89a4-9898-4a9f-a316-17d0fce8a08b.json,369e89a4-9898-4a9f-a316-17d0fce8a08b,100,Methazolamide Tablets USP Rx only,6826,methazolamide,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_5c8cebcd-699f-4c4c-900b-94e0fe519345.json,5c8cebcd-699f-4c4c-900b-94e0fe519345,100,"These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.
PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989",8754,propafenone,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_5c8cebcd-699f-4c4c-900b-94e0fe519345.json,5c8cebcd-699f-4c4c-900b-94e0fe519345,100,"These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.
PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989",8754,propafenone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231130_2b70cf0c-45be-428f-b396-5001ed4e30fc.json,2b70cf0c-45be-428f-b396-5001ed4e30fc,6,"Amiloride HCl Tablets, USP",644,amiloride,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230910_eed5e856-dd7b-4eaa-9dad-508f2bef9328.json,eed5e856-dd7b-4eaa-9dad-508f2bef9328,1,"Amoxapine Tablets, USP
 
Rx only",722,amoxapine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,713109,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_11fad602-16c2-4c1f-bdf1-867d95f063ca.json,11fad602-16c2-4c1f-bdf1-867d95f063ca,10,"These highlights do not include all the information needed to use ROSUVASTATIN TABLETS safely and effectively. See full prescribing information for ROSUVASTATIN TABLETS.
 

ROSUVASTATIN tablets, for oral use
 
Initial U.S. Approval: 2003",301542,rosuvastatin,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_0f15cb50-5917-c928-e063-6294a90ab284.json,0f15cb50-5917-c928-e063-6294a90ab284,2,"Cevimeline Hydrochloride Capsules
 
Rx only",44281,cevimeline,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_222f77ff-d3f7-40f9-989c-e5902f44ef1e.json,222f77ff-d3f7-40f9-989c-e5902f44ef1e,10,"These highlights do not include all the information needed to use RIZATRIPTAN BENZOATE TABLETS safely and effectively. See full prescribing information for RIZATRIPTAN BENZOATE TABLETS.
 RIZATRIPTAN BENZOATE tablets, for oral use Initial U.S. Approval: 1998",88014,rizatriptan,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1154077,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240217_69301126-c901-4d0d-9acb-91ba1a87cd21.json,69301126-c901-4d0d-9acb-91ba1a87cd21,26,"HIGHLIGHTS OF PRESCRIBING INFORMATION
 

These highlights do not include all the information needed to use valacyclovir hydrochloride safely and effectively. See full prescribing information for valacyclovir hydrochloride.
 

Valacyclovir Tablets, USP
 

Initial U.S. Approval:1995",73645,valacyclovir,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240201_202d5142-6180-4d48-9a9f-1bd6992fc49b.json,202d5142-6180-4d48-9a9f-1bd6992fc49b,2,"These highlights do not include all the information needed to use NEBIVOLOL TABLETS safely and effectively. See full prescribing information for NEBIVOLOL TABLETS.
 
NEBIVOLOL tablets, for oral use
 
Initial U.S. Approval: 2007",31555,nebivolol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_0be243c6-de02-45dd-8210-cab1bbc8dfa7.json,0be243c6-de02-45dd-8210-cab1bbc8dfa7,28,"These highlights do not include all the information needed to use CLARITHROMYCIN TABLETS safely and effectively. See full prescribing information for CLARITHROMYCIN TABLETS.
 

CLARITHROMYCIN tablets, for oral use
 
Initial U.S. Approval: 1991",21212,clarithromycin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,5108ca9c-b307-4cb2-8ea1-6553764f375a,13,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002",321988,escitalopram,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231230_cb960074-99c1-4a73-941f-f0644a7ec219.json,cb960074-99c1-4a73-941f-f0644a7ec219,40,"These highlights do not include all the information needed to use AGRYLIN safely and effectively. See full prescribing information for AGRYLIN.
AGRYLIN® (anagrelide) capsules, for oral useInitial U.S. Approval: 1997",596724,anagrelide,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_49aa3d6d-2270-4615-aafa-b440859ab870.json,49aa3d6d-2270-4615-aafa-b440859ab870,4,Naltrexone Hydrochloride Tablets USP 50 mg,7243,naltrexone,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231215_fc2a08dd-4fb6-4ac4-9082-f99552fae25c.json,fc2a08dd-4fb6-4ac4-9082-f99552fae25c,11,Parlodel Capsules and Tablets,1760,bromocriptine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20120511_ba1cca98-f350-4655-88e3-6ef990779fb9.json,ba1cca98-f350-4655-88e3-6ef990779fb9,1,"KETEK®
(telithromycin) Tablets",274786,telithromycin,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_4b8a3fce-5400-4d81-8b72-90c4b59b80a8.json,4b8a3fce-5400-4d81-8b72-90c4b59b80a8,7,"Phenobarbital Tablets, USP


CIV
  

Rx only",8134,phenobarbital,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231026_44966a7e-d777-40fb-956f-d0f31f737848.json,44966a7e-d777-40fb-956f-d0f31f737848,17,"Cidofovir Injection, USP Rx onlyFOR INTRAVENOUS INFUSION ONLY.NOT FOR INTRAOCULAR INJECTION.",83171,cidofovir,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_f5e8d1da-8911-42db-9f90-cba04b28d011.json,f5e8d1da-8911-42db-9f90-cba04b28d011,102,"These highlights do not include all the information needed to use FLUVASTATIN CAPSULES safely and effectively.  See full prescribing information for FLUVASTATIN CAPSULES. 
FLUVASTATIN capsules, for oral useInitial U.S. Approval: 1993",41127,fluvastatin,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240126_55ad6325-16f6-4f0c-a1dc-734847052d0b.json,55ad6325-16f6-4f0c-a1dc-734847052d0b,2,"Danazol Capsules, USP
 

Rx only",3102,danazol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240116_7f10bf63-06c8-477d-a13e-fb88e287617a.json,7f10bf63-06c8-477d-a13e-fb88e287617a,103,"These highlights do not include all the information needed to use REPAGLINIDE TABLETS safely and effectively.  See full prescribing information for REPAGLINIDE TABLETS.REPAGLINIDE tablets, for oral useInitial U.S. Approval: 1997",73044,repaglinide,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231228_67e3ba3c-77e1-43b5-a93c-5bf5e3855780.json,67e3ba3c-77e1-43b5-a93c-5bf5e3855780,2,"GRISEOFULVIN ORAL SUSPENSION, USP


Microsize


125 mg/5 mL




Rx only",5021,griseofulvin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1763779,0,1
./data/2024_latest_labels/latest_labels_ingredients/20240222_bf93022c-a965-49c5-a852-c59e580d7d91.json,bf93022c-a965-49c5-a852-c59e580d7d91,14,"These highlights do not include all the information needed to use INDOMETHACIN CAPSULES safely and effectively. See full prescribing information for INDOMETHACIN CAPSULES.
 



INDOMETHACIN capsules, for oral use
 

Initial U.S. Approval: 1965",5781,indomethacin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1178663,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231107_9803db35-2600-4f42-80c1-43216fd1ba3d.json,9803db35-2600-4f42-80c1-43216fd1ba3d,4,"These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS.
ACAMPROSATE CALCIUM delayed-release tablets, for oral useInitial U.S. Approval: 2004",82819,acamprosate,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240104_b0075b72-c3cc-f844-e053-2a95a90a417f.json,b0075b72-c3cc-f844-e053-2a95a90a417f,5,"These highlights do not include all the information needed to use MEROPENEM FOR INJECTION safely and effectively. See full prescribing information for MEROPENEM FOR INJECTION
 







MEROPENEM for injection, for intravenous use
 







Initial U.S. Approval: 1996",29561,meropenem,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/train_xml/20210916_33f60b40-3fca-11de-8f56-0002a5d5c51b.json,33f60b40-3fca-11de-8f56-0002a5d5c51b,24,"These highlights do not include all the information needed to use FANAPT safely and effectively. See full prescribing information for FANAPT.


FANAPT® (iloperidone) tablets, for oral use

Initial U.S. Approval: 2009",73178,iloperidone,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_4dd14728-02b4-4e75-b9c6-227be7816d5b.json,4dd14728-02b4-4e75-b9c6-227be7816d5b,9,"These highlights do not include all the information needed to use ABACAVIR TABLETS safely and effectively. See full prescribing information for ABACAVIR TABLETS.
 



ABACAVIR tablets, for oral use
 

Initial U.S. Approval: 1998",190521,abacavir,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1736971,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240213_a60c5173-6bc0-4c9d-9674-b3f4d68f79ba.json,a60c5173-6bc0-4c9d-9674-b3f4d68f79ba,4,"These highlights do not include all the information needed to use CISPLATIN INJECTION, USP safely and effectively. See full prescribing information for CISPLATIN INJECTION, USP.
 



CISPLATIN injection USP, for intravenous use
 



Initial U.S. Approval: 1978",2555,cisplatin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,575da603-b038-421f-9894-6796d9ac33cc,11,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991",36437,sertraline,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_ae8d2354-7ddb-41b8-9d55-77c84782b18f.json,ae8d2354-7ddb-41b8-9d55-77c84782b18f,3,"These highlights do not include all the information needed to use TEMSIROLIMUS INJECTION safely and effectively.
 

See full prescribing information for TEMSIROLIMUS INJECTION.
 





TEMSIROLIMUS injection, for intravenous use
 

Initial U.S. Approval: 2007",657797,temsirolimus,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220115_56b6ba36-9b49-4422-a2a4-7bfa0d941a5d.json,56b6ba36-9b49-4422-a2a4-7bfa0d941a5d,2,EULEXINTM (flutamide) CAPSULES USP,4508,flutamide,10019692,hepatic necrosis,500000301,acute liver injury,15,1,500000301,1356461,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231221_a32cb2e3-d4e5-4bbf-9d88-20b2b249e779.json,a32cb2e3-d4e5-4bbf-9d88-20b2b249e779,23,"These highlights do not include all the information needed to use RITONAVIR TABLETS safely and effectively. See full prescribing information for RITONAVIR TABLETS.
 


RITONAVIR tablets, for oral use
 

Initial U.S. Approval: 1996",85762,ritonavir,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20200926_bd22c66b-8a1c-44c8-b5b6-3ab0ce5c800e.json,bd22c66b-8a1c-44c8-b5b6-3ab0ce5c800e,8,"Cefotetan for Injection, USP",2187,cefotetan,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,a1787fad-3612-43e1-98fa-ce62361e0b3c,13,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001",282388,imatinib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_bf514e99-4958-44a0-a87a-02a950f87e60.json,bf514e99-4958-44a0-a87a-02a950f87e60,7,"Acetazolamide Extended-release Capsules, USP
Rx only",167,acetazolamide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_6fc9c8e2-6f34-aa43-e053-2a91aa0ac377.json,6fc9c8e2-6f34-aa43-e053-2a91aa0ac377,10,"QUETIAPINE TABLETS. These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
 

Quetiapine tablets, for oral use
 

Initial U.S. Approval: 1997",51272,quetiapine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992",70223,aldesleukin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992",70223,aldesleukin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef.json,7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef,5,"These highlights do not include all the information needed to use DAPTOMYCIN IN SODIUM CHLORIDE INJECTION safely and effectively.  See full prescribing information for DAPTOMYCIN IN SODIUM CHLORIDE INJECTION.
DAPTOMYCIN IN SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 2003",22299,daptomycin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_d35193e4-0b0e-4a0a-acd8-aa90cc075a2b.json,d35193e4-0b0e-4a0a-acd8-aa90cc075a2b,16,"These highlights do not include all the information needed to use METHOTREXATE TABLETS safely and effectively. See full prescribing information for METHOTREXATE TABLETS.
 

METHOTREXATE tablets, for oral use
 
Initial U.S. Approval: 1953",6851,methotrexate,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)",4502,flurbiprofen,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240124_0d6111be-aabd-88e2-e063-6394a90a3963.json,0d6111be-aabd-88e2-e063-6394a90a3963,2,"These highlights do not include all the information needed to use MEGESTROL ACETATE ORAL SUSPENSION safely and effectively. See full prescribing information for MEGESTROL ACETATE ORAL SUSPENSION.
 

MEGESTROL ACETATE oral suspension
 
Initial U.S. Approval: 1993",6703,megestrol,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_b272ef9c-4d83-4ee2-b9cc-477440822cca.json,b272ef9c-4d83-4ee2-b9cc-477440822cca,10,"CEFOXITIN FOR INJECTION, USP(For Intravenous Use)",2189,cefoxitin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/gold_xml/20231205_8e47618e-af46-4d82-94e8-1507c042252d.json,8e47618e-af46-4d82-94e8-1507c042252d,16,"These highlights do not include all the information needed to use AKYNZEO® safely and effectively. See full prescribing information for AKYNZEO®. 
AKYNZEO® (netupitant and palonosetron) capsules, for oral use Initial U.S. Approval: 2014AKYNZEO® (fosnetupitant and palonosetron) for injection, for intravenous useInitial U.S. Approval: 2018",70561,palonosetron,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_a99335d0-1e87-4180-bde3-cbb12bf91a52.json,a99335d0-1e87-4180-bde3-cbb12bf91a52,1,"These highlights do not include all the information needed to use DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION.
DEXMEDETOMIDINE HYDROCHLORIDE in 0.9% SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 1999",48937,dexmedetomidine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959""",3002,cyclophosphamide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_746f3ab9-9e6e-4ce8-9384-0c7a57de8007.json,746f3ab9-9e6e-4ce8-9384-0c7a57de8007,9,"Haloperidol Tablets, USP",5093,haloperidol,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231103_8e4b636e-ee9c-4111-779d-28c8369d283b.json,8e4b636e-ee9c-4111-779d-28c8369d283b,22,"These highlights do not include all the information needed to use FLOLAN safely and effectively. See full prescribing information for FLOLAN.
FLOLAN (epoprostenol sodium) for injection, for intravenous useInitial U.S. Approval: 1995",8814,epoprostenol,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/train_xml/20211231_ca70b23e-6f02-43a8-9c88-9550c0d230cf.json,ca70b23e-6f02-43a8-9c88-9550c0d230cf,100,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012",1364430,apixaban,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210508_a20eb852-4c25-49f0-98bc-aed493336e75.json,a20eb852-4c25-49f0-98bc-aed493336e75,12,"These highlights do not include all the information needed to use PRALUENT safely and effectively.  See full prescribing information for PRALUENT. 
PRALUENT® (alirocumab) injection, for subcutaneous use Initial U.S. Approval:  2015",1659152,alirocumab,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231118_4c61e68e-f2d1-4998-aae7-62997971dab7.json,4c61e68e-f2d1-4998-aae7-62997971dab7,4,"FOSCAVIR 
 ® 


(foscarnet sodium) INJECTION",33562,foscarnet,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240213_a60c5173-6bc0-4c9d-9674-b3f4d68f79ba.json,a60c5173-6bc0-4c9d-9674-b3f4d68f79ba,4,"These highlights do not include all the information needed to use CISPLATIN INJECTION, USP safely and effectively. See full prescribing information for CISPLATIN INJECTION, USP.
 



CISPLATIN injection USP, for intravenous use
 



Initial U.S. Approval: 1978",2555,cisplatin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,0772eb61-ca42-39de-e063-6294a90a6632,1,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006",357977,sunitinib,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231128_3bad23a6-09a6-4194-9182-093ed61bc71c.json,3bad23a6-09a6-4194-9182-093ed61bc71c,39,"These highlights do not include all the information needed to use CANCIDAS safely and effectively. See full prescribing information for CANCIDAS.
CANCIDAS® (caspofungin acetate) for injection, for intravenous useInitial U.S. Approval: 2001",140108,caspofungin,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1718054,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231128_3bad23a6-09a6-4194-9182-093ed61bc71c.json,3bad23a6-09a6-4194-9182-093ed61bc71c,39,"These highlights do not include all the information needed to use CANCIDAS safely and effectively. See full prescribing information for CANCIDAS.
CANCIDAS® (caspofungin acetate) for injection, for intravenous useInitial U.S. Approval: 2001",140108,caspofungin,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,500000301,1718054,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240217_a4b188d4-f467-470c-ad7b-25ffbdd8862a.json,a4b188d4-f467-470c-ad7b-25ffbdd8862a,8,"These highlights do not include all the information needed to use XERAVA safely and effectively. See full prescribing information for XERAVA.



XERAVA® (eravacycline) for injection, for intravenous use

Initial U.S. Approval: 2018",2055906,eravacycline,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20211121_17f85d17-ab71-4f5b-9fe3-0b8c822f69ff.json,17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,19,"These highlights do not include all the information needed to use PERJETA safely and effectively.  See full prescribing information for PERJETA. 
PERJETA® (pertuzumab) injection, for intravenous use Initial U.S. Approval:  2012",1298944,pertuzumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230627_a0478684-e477-4b52-97a9-04a76e794c87.json,a0478684-e477-4b52-97a9-04a76e794c87,5,"These highlights do not include all the information needed to use ROMIDEPSIN INJECTION safely and effectively. See full prescribing information for ROMIDEPSIN INJECTION.




ROMIDEPSIN injection, for intravenous use

Initial U.S. Approval: 2009",877510,romidepsin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013",224905,trastuzumab,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,Mefenamic Acid Capsules USPRx Only,257844,mefenamate,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1197736,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_fbac3b4f-dc23-4359-ac3f-2b3fdde41af2.json,fbac3b4f-dc23-4359-ac3f-2b3fdde41af2,32,"These highlights do not include all the information needed to use ALLOPURINOL TABLETS safely and effectively. See full prescribing information for ALLOPURINOL TABLETS.


ALLOPURINOL tablets for oral use 

Initial U.S. Approval:1966",519,allopurinol,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1167322,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240220_766b73e2-49bb-47f9-bbb1-44cfa1a3197e.json,766b73e2-49bb-47f9-bbb1-44cfa1a3197e,4,"These highlights do not include all the information needed to use BENDAMUSTINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for BENDAMUSTINE HYDROCHLORIDE INJECTION. 
	BENDAMUSTINE HYDROCHLORIDE injection,	 for intravenous use. 	Initial U.S. Approval: 2008",134547,bendamustine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/gold_xml/20141028_0ab861c2-d5ca-4f92-854c-6477971a1b38.json,0ab861c2-d5ca-4f92-854c-6477971a1b38,1,"These highlights do not include all the information needed to use ESBRIET safely and effectively.  See full prescribing information for ESBRIET.
ESBRIET® (pirfenidone) capsules, for oral useInitial U.S. Approval: 2014",1592254,pirfenidone,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,d5929f91-6496-4c0e-97e8-0bd524e15763,3,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231129_cd86ee78-2781-468b-930c-3c4677bcc092.json,cd86ee78-2781-468b-930c-3c4677bcc092,25,"These highlights do not include all the information needed to use ZOLINZA safely and effectively. See full prescribing information for ZOLINZA. 
ZOLINZA® (vorinostat capsules, for oral use) Initial U.S. Approval: 2006",194337,vorinostat,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220826_de77155c-ecf2-4f15-9758-21d271449d83.json,de77155c-ecf2-4f15-9758-21d271449d83,2,"These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. 
FOTIVDA® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021",2534233,tivozanib,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240202_860c799c-5199-4f0c-b21b-9910273474d9.json,860c799c-5199-4f0c-b21b-9910273474d9,6,Pentamidine isethionate for injection,7994,pentamidine,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,7fa848ba-a59c-4144-9f52-64d090f4d828,10,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020",2370147,selpercatinib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_7fa848ba-a59c-4144-9f52-64d090f4d828.json,7fa848ba-a59c-4144-9f52-64d090f4d828,10,"These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO.RETEVMO® (selpercatinib) capsules, for oral useInitial U.S. Approval: 2020",2370147,selpercatinib,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012",1302966,carfilzomib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221103_da1c9f37-779e-4682-816f-93d0faa4cfc9.json,da1c9f37-779e-4682-816f-93d0faa4cfc9,16,"These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. 
OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014",1592737,nintedanib,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221115_16d804b6-4957-43ee-b18c-3b36ec37c5ac.json,16d804b6-4957-43ee-b18c-3b36ec37c5ac,15,"These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. 
ICLUSIG® (ponatinib) tablets, for oral use Initial U.S. Approval: 2012",1364347,ponatinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231216_d9fd11d0-4269-12fb-95cf-b3c11d75e479.json,d9fd11d0-4269-12fb-95cf-b3c11d75e479,6,"These highlights do not include all the information needed to use TOLVAPTAN TABLETS safely and effectively. See full prescribing information for TOLVAPTAN TABLETS.

TOLVAPTAN tablets, for oral use

Initial U.S. Approval: 2009",358257,tolvaptan,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/train_xml/20221118_3ecde48b-75a2-4beb-9999-369f3f61bb8a.json,3ecde48b-75a2-4beb-9999-369f3f61bb8a,37,"These highlights do not include all the information needed to use
 
T
EFLARO 
safely and effectively. See full prescribing information for 
TE
FLARO
.

    

TE
FLARO

®

 (ceftaroline fosamil) 
for 
injection
,
 for intravenous use

Initial U.S. Approval: 
2010",1040004,ceftaroline fosamil,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231215_9f489295-1156-52c7-5fd0-5c4c52f9b813.json,9f489295-1156-52c7-5fd0-5c4c52f9b813,8,"These highlights do not include all the information needed to use LUPKYNIS™ safely and effectively. See full prescribing information for LUPKYNIS.








LUPKYNIS (voclosporin) capsules, for oral use




Initial U.S. Approval: 2021",2475166,voclosporin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009",141704,everolimus,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/gold_xml/20231202_824f19c9-0546-4a8a-8d8f-c4055c04f7c7.json,824f19c9-0546-4a8a-8d8f-c4055c04f7c7,33,"These highlights do not include all the information needed to use STIVARGA safely and effectively.  See full prescribing information for STIVARGA.STIVARGA® (regorafenib) tablets, for oral useInitial U.S. Approval: 2012",1312397,regorafenib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/gold_xml/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010",612865,tocilizumab,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,"FORANE (isoflurane, USP) liquid for inhalation",6026,isoflurane,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_7d655d6d-01da-488c-bd4e-c7fbe0ace38c.json,7d655d6d-01da-488c-bd4e-c7fbe0ace38c,5,"These highlights do not include all the information needed to use TESTOSTERONE GEL, 1% safely and effectively.  See full prescribing information for TESTOSTERONE GEL, 1%.

 TESTOSTERONE gel 1%, for topical use, CIII Initial U.S. Approval: 1953",10379,testosterone,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240124_d2daba09-f1c2-4764-a567-1291be4892b9.json,d2daba09-f1c2-4764-a567-1291be4892b9,100,"These highlights do not include all the information needed to use
POSACONAZOLE DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for

POSACONAZOLE

DELAYED-RELEASE TABLETS
.



POSACONAZOLE

delayed-release tablets, for oral use

Initial U.S. Approval: 2006",282446,posaconazole,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230329_64000394-1ef6-4e76-8ba8-11f25ba1b167.json,64000394-1ef6-4e76-8ba8-11f25ba1b167,6,"These highlights do not include all the information needed to use LIVMARLI safely and effectively. See full prescribing information for LIVMARLI. 
 LIVMARLI® (maralixibat) oral solution  Initial U.S. Approval:  2021",2571074,maralixibat,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_f34c08e6-fe74-4de3-9e36-a82c3c1c183b.json,f34c08e6-fe74-4de3-9e36-a82c3c1c183b,9,"These highlights do not include all the information needed to use MOXIFLOXACIN TABLETS safely and effectively. See full prescribing information for MOXIFLOXACIN TABLETS.
 MOXIFLOXACIN tablets, for oral use Initial U.S. Approval: 1999",139462,moxifloxacin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231117_102e4ef4-7f84-4e34-8df1-479c24d1575d.json,102e4ef4-7f84-4e34-8df1-479c24d1575d,5,"These highlights do not include all the information needed to use REZUROCK safely and effectively. See full prescribing information for REZUROCK.


REZUROCK® (belumosudil) tablets, for oral use
Initial U.S. Approval: 2021",2564025,belumosudil,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240109_b7f675e2-159c-490c-b6f4-3f16d9492b7d.json,b7f675e2-159c-490c-b6f4-3f16d9492b7d,3,"These highlights do not include all the information needed to use ZEJULA safely and effectively.  See full prescribing information for ZEJULA.
ZEJULA (niraparib) tablets, for oral useInitial U.S. Approval: 2017",1918231,niraparib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230608_517b4a19-45b3-4286-9f6a-ced4e10447de.json,517b4a19-45b3-4286-9f6a-ced4e10447de,28,"These highlights do not include all the information needed to use Injectafer safely and effectively. See full prescribing information for Injectafer.


INJECTAFER® (ferric carboxymaltose injection), f
or intravenous use

Initial U.S. Approval: 2013",1433693,ferric carboxymaltose,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/gold_xml/20230615_1e484a50-55db-4b85-8c57-6cd1b0353abd.json,1e484a50-55db-4b85-8c57-6cd1b0353abd,32,"These highlights do not include all the information needed to use OPSUMIT safely and effectively. See full prescribing information for OPSUMIT.
 



OPSUMIT 
 ® (macitentan) tablets, for oral use
 

Initial U.S. Approval: 2013",1442132,macitentan,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_6690679c-be2f-4588-a2e4-89fff74dd6be.json,6690679c-be2f-4588-a2e4-89fff74dd6be,9,"These highlights do not include all the information needed to use IMJUDO safely and effectively. See full prescribing information for IMJUDO.IMJUDO® (tremelimumab-actl) injection, for intravenous useInitial U.S. Approval: 2022",2619313,tremelimumab,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230629_0fd36cb9-c4f6-4167-93c9-8530865db3f9.json,0fd36cb9-c4f6-4167-93c9-8530865db3f9,155,"These highlights do not include all the information needed to use 
ARANESP 
safely and effectively.  
See full prescribing information for 
ARANESP
.

   

ARANESP

®

 (darbepoetin alfa
)
 
i
njection, for intravenous or subcutaneous use

Initial U.S. Approval: 2001",283838,darbepoetin alfa,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1304643,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,6093952a-5248-45cb-ad17-33716a411146,37,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007",662281,nilotinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_72e6b33c-0351-4070-9172-eeaa186c01d2.json,72e6b33c-0351-4070-9172-eeaa186c01d2,14,"These highlights do not include all the information needed to use VEMLIDY safely and effectively. See full prescribing information for VEMLIDY. 
 VEMLIDY® (tenofovir alafenamide) tablets, for oral use  Initial U.S. Approval: 2015",1721603,tenofovir alafenamide,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008",711942,eltrombopag,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013",224905,trastuzumab,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230907_d82aa06e-5a33-4844-99b7-4701313455a4.json,d82aa06e-5a33-4844-99b7-4701313455a4,4,"These highlights do not include all the information needed to use JESDUVROQ safely and effectively. See full prescribing information for JESDUVROQ.JESDUVROQ (daprodustat) tablets, for oral useInitial U.S. Approval: 2023",2628210,daprodustat,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_00fb869a-40e7-4c85-8380-c5e0cdee8018.json,00fb869a-40e7-4c85-8380-c5e0cdee8018,4,"HiGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use MARCAINE™ and MARCAINE™ WITH EPINEPHRINE safely and effectively. See full prescribing information for MARCAINE™ and MARCAINE™ WITH EPINEPHRINE.
  MARCAINE™ (bupivacaine hydrochloride) injection, for infiltration, perineural, caudal, epidural, or retrobulbar useMARCAINE™ WITH EPINEPHRINE (bupivacaine hydrochloride and epinephrine) injection, for infiltration, perineural, caudal, or epidural useInitial U.S. Approval: 1972",1815,bupivacaine,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,5108ca9c-b307-4cb2-8ea1-6553764f375a,13,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002",321988,escitalopram,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230910_fa7d93e3-b69b-4e02-8146-89760cd8e9d6.json,fa7d93e3-b69b-4e02-8146-89760cd8e9d6,6,"These highlights do not include all the information needed to use 
STENDRA
 safely and effectively.  See full prescribing information for 
STENDRA
.



STENDRA

®

 (avanafil) 
tablets, for oral use

Initial U.S. Approval:  
2012",1291301,avanafil,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_4b5f7c65-aa2d-452a-b3db-bc85c06ff12f.json,4b5f7c65-aa2d-452a-b3db-bc85c06ff12f,20,"These highlights do not include all the information needed to use 
VRAYLAR
 safely and effectively.  
See full prescribing information for 
VRAYLAR
.  

   

VRAYLAR

®

 (
cariprazine
)
 
c
apsules
,
 
for 
o
ral 
u
se

Initial U.S. Approval: 
2015",1667655,cariprazine,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/train_xml/20240301_0dfd0279-ff17-4ea9-89be-9803c71bab44.json,0dfd0279-ff17-4ea9-89be-9803c71bab44,53,"These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA.

 

IMBRUVICA

®

 (ibrutinib) capsules, for oral use

IMBRUVICA

®

 (ibrutinib) tablets, for oral use

IMBRUVICA

®

 (ibrutinib) oral suspension

Initial U.S. Approval: 2013",1442981,ibrutinib,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,5cd725a1-2fa4-408a-a651-57a7b84b2118,18,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017",1875534,avelumab,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/train_xml/20231018_1534c9ae-4948-4cf4-9f66-222a99db6d0e.json,1534c9ae-4948-4cf4-9f66-222a99db6d0e,26,"These highlights do not include all the information needed to use SIRTURO safely and effectively. See full prescribing information for SIRTURO.
 

SIRTURO 
 ®(bedaquiline) tablets, for oral use
 
Initial U.S. Approval: 2012",1364504,bedaquiline,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_74d94dbf-0567-6c15-e053-2991aa0ac6e4.json,74d94dbf-0567-6c15-e053-2991aa0ac6e4,5,"VERAPAMIL HYDROCHLORIDE INJECTION, USP 10mg (2.5 mg/mL) 4mL ANSYR SYR",11170,verapamil,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231221_8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb.json,8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb,19,Nisoldipine,7435,nisoldipine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_7c6c02a1-1774-4332-babd-dff86f9638a0.json,7c6c02a1-1774-4332-babd-dff86f9638a0,102,"Chlorzoxazone Tablets, USP 500 mg",2410,chlorzoxazone,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,7ee820e4-a479-4b7d-8730-101ac1f8015c,102,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982",8356,piroxicam,10018830,haematemesis,500001001,gi bleed,11,1,500001001,1146810,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992",32613,oxaprozin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,500000401,1118045,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240222_cee5b232-0464-4697-93ef-77e044c83776.json,cee5b232-0464-4697-93ef-77e044c83776,8,"These highlights do not include all the information needed to use CLOPIDOGREL TABLETS safely and effectively. See full prescribing information for CLOPIDOGREL TABLETS.
 



CLOPIDOGREL tablets, for oral use
 



Initial U.S. Approval: 1997",32968,clopidogrel,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240120_c522c860-84ce-4c61-ab72-077de73195df.json,c522c860-84ce-4c61-ab72-077de73195df,1,"Tetracycline Hydrochloride Tablets, USP For Oral Use",10395,tetracycline,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,ccd95dfc-9236-4707-a715-6a12c91519ff,6,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976",7258,naproxen,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1115008,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,ccd95dfc-9236-4707-a715-6a12c91519ff,6,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976",7258,naproxen,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,500000301,1115008,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)",52582,mesalamine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,52781229-ee82-43f9-a113-4419a611978d,1,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000",183379,rivastigmine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240111_52781229-ee82-43f9-a113-4419a611978d.json,52781229-ee82-43f9-a113-4419a611978d,1,"These highlights do not include all the information needed to use RIVASTIGMINE TARTRATE CAPSULES safely and effectively. See full prescribing information for RIVASTIGMINE TARTRATE CAPSULES.
 
RIVASTIGMINE TARTRATE capsules, for oral use
 
Initial U.S. Approval: 2000",183379,rivastigmine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20190118_17e597bc-d663-4d8e-a5d3-39816b628996.json,17e597bc-d663-4d8e-a5d3-39816b628996,8,"These highlights do not include all the information needed to use STAVUDINE FOR ORAL SOLUTION safely and effectively. See full prescribing information for STAVUDINE FOR ORAL SOLUTION.
STAVUDINE for oral solutionInitial U.S. Approval: 1994",59763,stavudine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1781406,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240104_03a58215-dba7-4f63-8b98-d74d054a574a.json,03a58215-dba7-4f63-8b98-d74d054a574a,6,"These highlights do not include all the information needed to use FROVATRIPTAN SUCCINATE TABLETS safely and effectively. See full prescribing information for FROVATRIPTAN SUCCINATE TABLETS.
FROVATRIPTAN SUCCINATE tablets, for oral useInitial U.S. Approval:  2001",228783,frovatriptan,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1189458,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240112_23b1f2f5-2d84-4a1e-997f-6489204878b2.json,23b1f2f5-2d84-4a1e-997f-6489204878b2,102,"Captopril Tablets, USP

for oral use

Rx only",1998,captopril,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240112_23b1f2f5-2d84-4a1e-997f-6489204878b2.json,23b1f2f5-2d84-4a1e-997f-6489204878b2,102,"Captopril Tablets, USP

for oral use

Rx only",1998,captopril,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1340128,1,1
./data/2024_latest_labels/latest_labels_ingredients/20100824_983ce15f-cd37-4f3a-9e51-205860e80976.json,983ce15f-cd37-4f3a-9e51-205860e80976,3,DESCRIPTION,36709,sodium phosphate,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,f47d4365-40a8-445b-99cd-49edad6a8ffc,15,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only",35827,ketorolac,10018830,haematemesis,500001001,gi bleed,11,1,500001001,1136980,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,f47d4365-40a8-445b-99cd-49edad6a8ffc,15,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only",35827,ketorolac,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1136980,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997",746741,pramipexole,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997",72302,ropinirole,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240119_3e4842ec-773b-4aeb-b37d-1c4e3cf53424.json,3e4842ec-773b-4aeb-b37d-1c4e3cf53424,102,"Dicloxacillin Sodium Capsules USP


Rx only",3356,dicloxacillin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,KIPROFEN™ Capsules,6142,ketoprofen,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1185922,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_41c095b6-acd9-4627-a813-bbca7ecafee5.json,41c095b6-acd9-4627-a813-bbca7ecafee5,10,"These highlights do not include all the information needed to use DONEPEZIL HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for DONEPEZIL HYDROCHLORIDE TABLETS.
 

DONEPEZIL HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1996",135447,donepezil,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_0f672b76-f673-4cba-99d2-818a9e2e6d7f.json,0f672b76-f673-4cba-99d2-818a9e2e6d7f,7,"These highlights do not include all the information needed to use LOSARTAN POTASSIUM TABLETS safely and effectively. see full prescribing information for LOSARTAN POTASSIUM TABLETS.
 



LOSARTAN POTASSIUM tablets, for oral use
 

Initial U.S. Approval: 1995",52175,losartan,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231128_fc38f1bb-f175-4a81-8ed9-c8701efdea35.json,fc38f1bb-f175-4a81-8ed9-c8701efdea35,102,"FOSINOPRILSODIUM TABLETS, USP10mg, 20mg and 40mgRx Only",50166,fosinopril,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_dd47a015-ff90-d7a7-8dcb-4e6e31a68071.json,dd47a015-ff90-d7a7-8dcb-4e6e31a68071,1,"These highlights do not include all the information needed to use DABIGATRAN 
ETEXILATE CAPSULES
 safely and effectively. See full prescribing information for 
DABIGATRAN
 ETEXILATE CAPSULES.


DABIGATRAN E
TEXILATE capsules, for oral use 

Initial U.S. Approval: 2010",1037042,dabigatran etexilate,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_bc737938-ae36-460b-a2a8-609f3fe59156.json,bc737938-ae36-460b-a2a8-609f3fe59156,2,"These highlights do not include all the information needed to use VANCOMYCIN HYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for VANCOMYCIN HYDROCHLORIDE CAPSULES.  VANCOMYCIN HYDROCHLORIDE capsules, for oral use Initial U.S. Approval: 1986 To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin hydrochloride capsules and other antibacterial drugs, vancomycin hydrochloride capsules should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.",11124,vancomycin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995",68149,mycophenolate mofetil,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_f2f090c2-3ee1-7689-e053-2995a90abe38.json,f2f090c2-3ee1-7689-e053-2995a90abe38,3,"These highlights do not include all the information needed to use LEVOFLOXACIN TABLETS 
  safely and effectively. See full prescribing information for LEVOFLOXACIN TABLETS. 
 




LEVOFLOXACIN tablets, for oral use






Initial U.S. Approval: 1996",82122,levofloxacin,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1742253,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240127_03af7d09-314a-fe85-e063-6294a90afa25.json,03af7d09-314a-fe85-e063-6294a90afa25,1,"These highlights do not include all the information needed to use VALSARTAN TABLETS safely and effectively. See full prescribing information for VALSARTAN TABLETS.
 

VALSARTAN tablets, for ORAL use
 
Initial U.S. Approval: 1996",69749,valsartan,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information",3008,cyclosporine,10019837,hepatocellular injury,500000301,acute liver injury,3,1,500000301,19010482,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information",3008,cyclosporine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,19010482,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240214_f34c08e6-fe74-4de3-9e36-a82c3c1c183b.json,f34c08e6-fe74-4de3-9e36-a82c3c1c183b,9,"These highlights do not include all the information needed to use MOXIFLOXACIN TABLETS safely and effectively. See full prescribing information for MOXIFLOXACIN TABLETS.
 MOXIFLOXACIN tablets, for oral use Initial U.S. Approval: 1999",139462,moxifloxacin,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_2d599ccf-8e63-4ff1-aa52-4809744ea97a.json,2d599ccf-8e63-4ff1-aa52-4809744ea97a,9,"These highlights do not include all the information needed to use TEMOZOLOMIDE CAPSULES safely and effectively. See full prescribing information for TEMOZOLOMIDE CAPSULES.
 



TEMOZOLOMIDE capsules, for oral use
 



Initial U.S. Approval: 1999",37776,temozolomide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231110_88698921-cd8f-4d41-96e6-ff671913c5c3.json,88698921-cd8f-4d41-96e6-ff671913c5c3,7,"These highlights do not include all the information needed to use NATEGLINIDE TABELTS safely and effectively. See full prescribing information for NATEGLINIDE TABELTS.
NATEGLINIDE tablets, for oral useInitial U.S. Approval: 2000",274332,nateglinide,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_029a90b6-0722-49be-8400-3ec29526aafd.json,029a90b6-0722-49be-8400-3ec29526aafd,6,"These highlights do not include all the information needed to use IRBESARTAN TABLETS safely and effectively. See full prescribing information for IRBESARTAN TABLETS.
 



IRBESARTAN tablets, for oral use
 

Initial U.S. Approval: 1997",83818,irbesartan,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_caad4ada-2cf9-4e12-99df-6ca4388cf0f6.json,caad4ada-2cf9-4e12-99df-6ca4388cf0f6,100,"These highlights do not include all the information needed to use DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES.


DEXLANSOPRAZOLE delayed-release capsules, for oral use 

Initial U.S. Approval: 1995 (lansoprazole)",816346,dexlansoprazole,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_5108ca9c-b307-4cb2-8ea1-6553764f375a.json,5108ca9c-b307-4cb2-8ea1-6553764f375a,13,"These highlights do not include all the information needed to use ESCITALOPRAM TABLETS safely and effectively. See full prescribing information for ESCITALOPRAM TABLETS.
 



ESCITALOPRAM tablets, for oral use
 








Initial U.S. Approval: 2002",321988,escitalopram,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20120511_ba1cca98-f350-4655-88e3-6ef990779fb9.json,ba1cca98-f350-4655-88e3-6ef990779fb9,1,"KETEK®
(telithromycin) Tablets",274786,telithromycin,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_58d80bc6-bdfb-4908-93e7-aace447c8d1a.json,58d80bc6-bdfb-4908-93e7-aace447c8d1a,1,"These highlights do not include all the information needed to use MYCAPSSA® safely and effectively. See full prescribing information for MYCAPSSA.
 MYCAPSSA (octreotide) delayed-release capsules, for oral use Initial U.S. Approval: 1988",7617,octreotide,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20130606_d5050d0e-81d1-4707-a38a-e80de2aebf09.json,d5050d0e-81d1-4707-a38a-e80de2aebf09,2,Cefditoren Pivoxil Tablets 200 mg and 400 mg,83682,cefditoren,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231026_44966a7e-d777-40fb-956f-d0f31f737848.json,44966a7e-d777-40fb-956f-d0f31f737848,17,"Cidofovir Injection, USP Rx onlyFOR INTRAVENOUS INFUSION ONLY.NOT FOR INTRAOCULAR INJECTION.",83171,cidofovir,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_c394914b-2334-418e-bf86-9f9100323717.json,c394914b-2334-418e-bf86-9f9100323717,6,KETOCONAZOLE CREAM 2%,6135,ketoconazole,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_c0946de1-2a2d-47ff-8071-50c1d3ad7982.json,c0946de1-2a2d-47ff-8071-50c1d3ad7982,8,"These highlights do not include all the information needed to use EXTENDED PHENYTOIN SODIUM CAPSULES safely and effectively. See full prescribing information for EXTENDED PHENYTOIN SODIUM CAPSULES.
 

EXTENDED PHENYTOIN SODIUM capsules, for oral use
 
Initial U.S. Approval: 1953",8183,phenytoin,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240101_1aa40de5-c02d-49d6-8722-ed88c40c3ba6.json,1aa40de5-c02d-49d6-8722-ed88c40c3ba6,2,"Felbamate Tablets, USP

(400 mg and 600 mg)


Rx only",24812,felbamate,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_99e9d85a-ec8e-48d2-acd0-5dda3b741838.json,99e9d85a-ec8e-48d2-acd0-5dda3b741838,6,"Ceftriaxone for Injection, USP


Rx Only",2193,ceftriaxone,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_b1274d78-1096-4ae3-8299-a2e94eaa0ea5.json,b1274d78-1096-4ae3-8299-a2e94eaa0ea5,16,Itraconazole Capsules,28031,itraconazole,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,500000301,1703653,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,ccd95dfc-9236-4707-a715-6a12c91519ff,6,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976",7258,naproxen,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1115008,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240117_79eec27d-ac63-4996-8b1a-c2cd52ad2b2c.json,79eec27d-ac63-4996-8b1a-c2cd52ad2b2c,5,"These highlights do not include all the information needed to use ARGATROBAN INJECTION safely and effectively. See full prescribing information for ARGATROBAN INJECTION.


ARGATROBAN INJECTION, for intravenous infusion only 

Initial U.S. Approval: 2000",15202,argatroban,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240117_79eec27d-ac63-4996-8b1a-c2cd52ad2b2c.json,79eec27d-ac63-4996-8b1a-c2cd52ad2b2c,5,"These highlights do not include all the information needed to use ARGATROBAN INJECTION safely and effectively. See full prescribing information for ARGATROBAN INJECTION.


ARGATROBAN INJECTION, for intravenous infusion only 

Initial U.S. Approval: 2000",15202,argatroban,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231208_fea50328-b3d5-4300-8c67-82cda0a975b7.json,fea50328-b3d5-4300-8c67-82cda0a975b7,6,"Triamterene Capsule, USP Potassium-Sparing Diuretic",10763,triamterene,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_b31ff20a-c363-4be0-9bc0-3081c163b63c.json,b31ff20a-c363-4be0-9bc0-3081c163b63c,7,"These highlights do not include all the information needed to use ATOVAQUONE ORAL SUSPENSION safely and effectively. See full prescribing information for ATOVAQUONE ORAL SUSPENSION.


ATOVAQUONE oral suspension, for oral use


Initial U.S. Approval: 1992",60212,atovaquone,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002",121243,voriconazole,10024690,liver function test abnormal,500000301,acute liver injury,15,1,500000301,1714277,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002",121243,voriconazole,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231004_63df5af3-b8ac-4e76-9830-2dbb340af922.json,63df5af3-b8ac-4e76-9830-2dbb340af922,27,"These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspensionInitial U.S. Approval: 2013",1433868,dolutegravir,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,a1787fad-3612-43e1-98fa-ce62361e0b3c,13,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001",282388,imatinib,10000804,acute hepatic failure,500000301,acute liver injury,5,1,500000301,1304107,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,a1787fad-3612-43e1-98fa-ce62361e0b3c,13,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001",282388,imatinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_413c645e-074d-4276-b39a-d83521077602.json,413c645e-074d-4276-b39a-d83521077602,14,"These highlights do not include all the information needed to use ABIRATERONE ACETATE TABLETS safely and effectively. See full prescribing information for ABIRATERONE ACETATE TABLETS.
  

ABIRATERONE ACETATE tablets,
 
for oral use 

Initial U.S. Approval: 2011",1100072,abiraterone,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_6ee2265b-1da5-4215-848b-12aa5eb25eff.json,6ee2265b-1da5-4215-848b-12aa5eb25eff,10,Rx only,5470,hydralazine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_ad750031-08ec-4d92-af2d-97a80c454e14.json,ad750031-08ec-4d92-af2d-97a80c454e14,1,"These highlights do not include all the information needed to use TIOPRONIN DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for TIOPRONIN DELAYED-RELEASE TABLETS.
TIOPRONIN delayed-release tablets, for oral use Initial U.S. Approval: 1988",6765,tiopronin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_a4978a54-1799-43d6-85dd-05fa9de0a5d7.json,a4978a54-1799-43d6-85dd-05fa9de0a5d7,8,"These highlights do not include all the information needed to use AMBRISENTAN TABLETS safely and effectively. See full prescribing information for AMBRISENTAN TABLETS.  AMBRISENTAN tablets, for oral use  Initial U.S. Approval: 2007",358274,ambrisentan,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_d35193e4-0b0e-4a0a-acd8-aa90cc075a2b.json,d35193e4-0b0e-4a0a-acd8-aa90cc075a2b,16,"These highlights do not include all the information needed to use METHOTREXATE TABLETS safely and effectively. See full prescribing information for METHOTREXATE TABLETS.
 

METHOTREXATE tablets, for oral use
 
Initial U.S. Approval: 1953",6851,methotrexate,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1305058,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240117_8c5d6067-16a1-43ab-9e52-a33c600a5c44.json,8c5d6067-16a1-43ab-9e52-a33c600a5c44,2,"These highlights do not include all the information needed to use DECITABINE FOR INJECTION safely and effectively. See full prescribing information for DECITABINE FOR INJECTION.
DECITABINE for injection, for intravenous useInitial U.S. Approval: 2006",15657,decitabine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_068e6edd-a5fe-40d8-8dcf-ac82b78dced4.json,068e6edd-a5fe-40d8-8dcf-ac82b78dced4,9,"These highlights do not include all the information needed to use CEFIXIME FOR ORAL SUSPENSION safely and effectively. See full prescribing information for CEFIXIME FOR ORAL SUSPENSION.
 CEFIXIME for oral suspension Initial U.S. Approval: 1986",25033,cefixime,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_068e6edd-a5fe-40d8-8dcf-ac82b78dced4.json,068e6edd-a5fe-40d8-8dcf-ac82b78dced4,9,"These highlights do not include all the information needed to use CEFIXIME FOR ORAL SUSPENSION safely and effectively. See full prescribing information for CEFIXIME FOR ORAL SUSPENSION.
 CEFIXIME for oral suspension Initial U.S. Approval: 1986",25033,cefixime,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20200101_f073b58e-56d6-4c8d-a2ce-b37719402d77.json,f073b58e-56d6-4c8d-a2ce-b37719402d77,3,Vinblastine Sulfate Injection,11198,vinblastine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_dc8d68d1-0c5c-4004-b71d-22b83daf4270.json,dc8d68d1-0c5c-4004-b71d-22b83daf4270,6,"These highlights do not include all the information needed to use BEXAROTENE CAPSULES safely and effectively.  See full prescribing information for BEXAROTENE CAPSULES.BEXAROTENE capsules, for oral useInitial U.S. Approval: 1999",233272,bexarotene,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_dc8d68d1-0c5c-4004-b71d-22b83daf4270.json,dc8d68d1-0c5c-4004-b71d-22b83daf4270,6,"These highlights do not include all the information needed to use BEXAROTENE CAPSULES safely and effectively.  See full prescribing information for BEXAROTENE CAPSULES.BEXAROTENE capsules, for oral useInitial U.S. Approval: 1999",233272,bexarotene,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/gold_xml/20240110_4650d12c-b9c8-4525-b07f-a2d773eca155.json,4650d12c-b9c8-4525-b07f-a2d773eca155,26,"These highlights do not include all the information needed to use AUBAGIO® safely and effectively. See full prescribing information for AUBAGIO. 
AUBAGIO (teriflunomide) tablets, for oral use Initial U.S. Approval: 2012",1310520,teriflunomide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/gold_xml/20240110_4650d12c-b9c8-4525-b07f-a2d773eca155.json,4650d12c-b9c8-4525-b07f-a2d773eca155,26,"These highlights do not include all the information needed to use AUBAGIO® safely and effectively. See full prescribing information for AUBAGIO. 
AUBAGIO (teriflunomide) tablets, for oral use Initial U.S. Approval: 2012",1310520,teriflunomide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240203_a88ac1b4-e2c9-45c0-b321-4785902172e3.json,a88ac1b4-e2c9-45c0-b321-4785902172e3,41,"These highlights do not include all the information needed to use 
SABRIL
 
safely and effectively. See full prescribing information for 
SABRIL
.


SABRIL

®

 
(
vigabatrin
)
  
t
ablet
s
, for oral use

SABRIL

®

 
(
vigabatrin
) 
for 
o
ral 
s
olution       
Initial U.S. Approval:
 
2009",14851,vigabatrin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959""",3002,cyclophosphamide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_90717878-64cb-4ffc-90bc-7b4e81e3d1cd.json,90717878-64cb-4ffc-90bc-7b4e81e3d1cd,12,"Nafcillin for Injection, USP Rx only",7233,nafcillin,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240120_9914e793-a49c-eb00-1ab7-f606c786fe25.json,9914e793-a49c-eb00-1ab7-f606c786fe25,7,"These highlights do not include all the information needed to use COSMEGEN safely and effectively. See full prescribing information for COSMEGEN. 

COSMEGEN  ® (dactinomycin for injection) for intravenous use 

Initial U.S. Approval: 1964",3100,dactinomycin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_f1be363d-6fc5-4b08-9b96-976933db19e1.json,f1be363d-6fc5-4b08-9b96-976933db19e1,9,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
 



ELIQUIS 
 ® (apixaban) tablets, for oral use
 

Initial U.S. Approval: 2012",1364430,apixaban,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230616_326ef804-8d3a-425e-8513-8c9811856aa0.json,326ef804-8d3a-425e-8513-8c9811856aa0,100,"TRIMIPRAMINE MALEATE CAPSULES, 25 MG, 50 MG and 100 MG Rx Only",10834,trimipramine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_7663c49d-1b1d-755d-e053-2991aa0a4ee3.json,7663c49d-1b1d-755d-e053-2991aa0a4ee3,9,"ADRENALIN® (EPINEPHRINE INJECTION, USP) 1mg/mL 1:1000 VIAL",3992,epinephrine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_6c5c47ab-28ee-11e1-bfc2-0800200c9a66.json,6c5c47ab-28ee-11e1-bfc2-0800200c9a66,19,"These highlights do not include all the information needed to use MINIVELLE safely and effectively. See full prescribing information for MINIVELLE.
         

MINIVELLE® (estradiol transdermal system) 
Initial U.S. Approval: 1975",4083,estradiol,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013",224905,trastuzumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_80a31286-a741-4440-b200-290c08925d06.json,80a31286-a741-4440-b200-290c08925d06,9,"These highlights do not include all the information needed to use ATROPINE SULFATE INJECTION safely and effectively. See full prescribing information for ATROPINE SULFATE INJECTION.
ATROPINE SULFATE injection, for intravenous use
Initial U.S. Approval: 1960",1223,atropine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231219_93b7e6c2-e6a7-4f6b-9ecd-62d6bb0a6dda.json,93b7e6c2-e6a7-4f6b-9ecd-62d6bb0a6dda,3,"These highlights do not include all the information needed to use NARATRIPTAN TABLETS safely and effectively. See full prescribing information for NARATRIPTAN TABLETS.


NARATRIPTAN tablets, for oral use


Initial U.S. Approval: 1998",141366,naratriptan,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1118117,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231213_c488fb7c-0a5b-487c-b452-996809d1cb99.json,c488fb7c-0a5b-487c-b452-996809d1cb99,65,"These highlights do not include all the information needed to use RELISTOR safely and effectively. See full prescribing information for RELISTOR.
 

RELISTOR 
 ®(methylnaltrexone bromide) tablets, for oral use
 
RELISTOR 
 ®(methylnaltrexone bromide) injection, for subcutaneous use
 
Initial U.S. Approval: 2008",29899,methylnaltrexone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_fc25635d-7449-4853-8a6e-b5b4b53fbd03.json,fc25635d-7449-4853-8a6e-b5b4b53fbd03,101,Fosfomycin Tromethamine Granules for Oral Solution Rx only,4550,fosfomycin,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,Mefenamic Acid Capsules USPRx Only,257844,mefenamate,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/train_xml/20220308_efbdafa9-d18c-4e85-b4a2-1e620fc74e50.json,efbdafa9-d18c-4e85-b4a2-1e620fc74e50,11,"These highlights do not include all the information needed to use ZYDELIG safely and effectively. See full prescribing information for ZYDELIG. 
 ZYDELIG® (idelalisib) tablets, for oral use Initial U.S. Approval: 2014",1544460,idelalisib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240126_55ad6325-16f6-4f0c-a1dc-734847052d0b.json,55ad6325-16f6-4f0c-a1dc-734847052d0b,2,"Danazol Capsules, USP
 

Rx only",3102,danazol,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_b7b679a9-6823-4ef8-8d31-3ab5058ffcfc.json,b7b679a9-6823-4ef8-8d31-3ab5058ffcfc,11,"These highlights do not include all the information needed to use ELIGARD
®
 safely and effectively. See full prescribing information for ELIGARD.
ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use Initial U.S. Approval: 2002",42375,leuprolide,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231129_d1e41dcf-e82a-47c2-a0ad-6c6eef621834.json,d1e41dcf-e82a-47c2-a0ad-6c6eef621834,16,"These highlights do not include all the information needed to use NERLYNX safely and effectively. See full prescribing information for NERLYNX.
 



NERLYNX 
 ®(neratinib) tablets, for oral use
 

Initial U.S. Approval: 2017",1940643,neratinib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220729_d3bebc1c-f032-402a-bbc9-aff024276ed1.json,d3bebc1c-f032-402a-bbc9-aff024276ed1,24,"These highlights do not include all the information needed to use VENTAVIS safely and effectively. See full prescribing information for VENTAVIS. 
 VENTAVIS® (iloprost) inhalation solution, for oral inhalation use  Initial U.S. Approval:  2004",40138,iloprost,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_973ed458-f46b-4f61-a329-816c4db79a2c.json,973ed458-f46b-4f61-a329-816c4db79a2c,5,"These highlights do not include all the information needed to use ETHYOL safely and effectively. See full prescribing information for ETHYOL.
ETHYOL® (amifostine) for injection, for intravenous useInitial U.S. Approval: 1995",4126,amifostine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220916_c669f77c-fa48-478b-a14b-80b20a0139c2.json,c669f77c-fa48-478b-a14b-80b20a0139c2,12,"These highlights do not include all the information needed to use ACTIVASE safely and effectively. See full prescribing information for ACTIVASE. 
Activase (alteplase) for injection, for intravenous use Initial U.S. Approval: 1987",8410,alteplase,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/gold_xml/20221103_da1c9f37-779e-4682-816f-93d0faa4cfc9.json,da1c9f37-779e-4682-816f-93d0faa4cfc9,16,"These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. 
OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014",1592737,nintedanib,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_979205ee-b0b8-4483-ae61-f283f750bb7f.json,979205ee-b0b8-4483-ae61-f283f750bb7f,100,"These highlights do not include all the information needed to use DAPAGLIFLOZIN TABLETS  safely and effectively.  See full prescribing information for DAPAGLIFLOZIN TABLETS.
DAPAGLIFLOZIN tablets, for oral useInitial U.S. Approval: 2014",1488564,dapagliflozin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_a6d46c03-bb1d-417b-b8e5-3bffe352fe29.json,a6d46c03-bb1d-417b-b8e5-3bffe352fe29,14,"These highlights do not include all the information needed to use RUBRACA safely and effectively. See full prescribing information for RUBRACA.
 
RUBRACA 
 ®(rucaparib) tablets, for oral use
 
Initial U.S. Approval: 2016",1862579,rucaparib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240126_8513207e-b55f-417b-9473-af785146a543.json,8513207e-b55f-417b-9473-af785146a543,10,"These highlights do not include all the information needed to use TEGSEDI® safely and effectively.  See full prescribing information for TEGSEDI.
			
TEGSEDI (inotersen) injection, for subcutaneous use
			Initial U.S. Approval: 2018",2099289,inotersen,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240112_8f7f73b8-586a-4df0-935f-fecd4696c16c.json,8f7f73b8-586a-4df0-935f-fecd4696c16c,17,"These highlights do not include all the information needed to use CRESEMBA® safely and effectively. See full prescribing information for CRESEMBA®.
CRESEMBA® (isavuconazonium sulfate) capsules, for oral useCRESEMBA® (isavuconazonium sulfate) for injection, for intravenous useInitial U.S. Approval: 2015",1608322,isavuconazonium,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230125_80686b7e-f6f4-4154-b5c0-c846425e2d91.json,80686b7e-f6f4-4154-b5c0-c846425e2d91,12,"These highlights do not include all the information needed to use EMPLICITI safely and effectively. See full prescribing information for EMPLICITI.
EMPLICITI
®
 (elotuzumab) for injection, for intravenous useInitial U.S. Approval: 2015",1726104,elotuzumab,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,b6465b44-a6dd-f99c-d009-6851cf05169c,11,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab).",224905,trastuzumab,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/gold_xml/20230219_e4f2a84f-5117-4738-b769-aba8debbddb0.json,e4f2a84f-5117-4738-b769-aba8debbddb0,11,"These highlights do not include all the information needed to use ONGLYZA safely and effectively. See full prescribing information for ONGLYZA.
ONGLYZA® (saxagliptin) tablets, for oral useInitial U.S. Approval: 2009",857974,saxagliptin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240112_2d74414f-6b83-4ea2-9a95-3cecabbce774.json,2d74414f-6b83-4ea2-9a95-3cecabbce774,11,"These highlights do not include all the information needed to use VUMERITY® safely and effectively. See full prescribing information for VUMERITY.
VUMERITY® (diroximel fumarate) delayed-release capsules, for oral useInitial U.S. Approval: 2013",2261783,diroximel fumarate,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240124_d2daba09-f1c2-4764-a567-1291be4892b9.json,d2daba09-f1c2-4764-a567-1291be4892b9,100,"These highlights do not include all the information needed to use
POSACONAZOLE DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for

POSACONAZOLE

DELAYED-RELEASE TABLETS
.



POSACONAZOLE

delayed-release tablets, for oral use

Initial U.S. Approval: 2006",282446,posaconazole,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,500000301,1704139,1,1
./data/2024_latest_labels/latest_labels_ingredients/20230315_72d1a024-00b7-418a-b36e-b2cb48f2ab55.json,72d1a024-00b7-418a-b36e-b2cb48f2ab55,6,"These highlights do not include all the information needed to use LUTATHERA safely and effectively. See full prescribing information for LUTATHERA.
		

		LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use
		
		Initial U.S. Approval: 2018",1797118,dotatate,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230315_72d1a024-00b7-418a-b36e-b2cb48f2ab55.json,72d1a024-00b7-418a-b36e-b2cb48f2ab55,6,"These highlights do not include all the information needed to use LUTATHERA safely and effectively. See full prescribing information for LUTATHERA.
		

		LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use
		
		Initial U.S. Approval: 2018",1797118,dotatate,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,2eda833b-1357-4ed4-a093-194524fcb061,25,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998",10432,thalidomide,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/train_xml/20231122_f86cb4a7-c358-4136-ae57-b32bda9bba00.json,f86cb4a7-c358-4136-ae57-b32bda9bba00,34,"These highlights do not include all the information needed to use SIMPONI safely and effectively. See full prescribing information for SIMPONI.
 



SIMPONI (golimumab) injection, for subcutaneous use
 

Initial U.S. Approval: 2009",819300,golimumab,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_a9b01bc6-95ac-46f9-befa-d845a74d53c1.json,a9b01bc6-95ac-46f9-befa-d845a74d53c1,16,"Emcyt®


 estramustine phosphate sodium

capsules",4089,estramustine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_f1a1100e-8318-1596-e053-2995a90a533e.json,f1a1100e-8318-1596-e053-2995a90a533e,4,"These highlights do not include all the information needed to use SKYCLARYS safely and effectively. See full prescribing information for SKYCLARYS.
SKYCLARYS® (omaveloxolone) capsules, for oral useInitial U.S. Approval:  2023",2631931,omaveloxolone,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_d138ab10-1ed9-44be-8d81-49dda1e434ac.json,d138ab10-1ed9-44be-8d81-49dda1e434ac,2,"These highlights do not include all the information needed to use ERAXIS safely and effectively. See full prescribing information for ERAXIS. 
ERAXIS® (anidulafungin) for injection, for intravenous use Initial U.S. Approval: 2006",341018,anidulafungin,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,6fa682c9-a312-4932-9831-f286908660ee,34,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016",1792776,atezolizumab,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,6fa682c9-a312-4932-9831-f286908660ee,34,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016",1792776,atezolizumab,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,6fa682c9-a312-4932-9831-f286908660ee,34,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016",1792776,atezolizumab,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240209_19880f51-badb-4846-a02a-592a210690ab.json,19880f51-badb-4846-a02a-592a210690ab,10,"These highlights do not include all the information needed to use SIROLIMUS ORAL SOLUTION safely and effectively. See full prescribing information for SIROLIMUS ORAL SOLUTION.


SIROLIMUS oral solutionInitial U.S. Approval: 1999",35302,sirolimus,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230527_11fa3fc9-6776-49a6-b1c1-653f627c3e58.json,11fa3fc9-6776-49a6-b1c1-653f627c3e58,11,"These highlights do not include all the information needed to use RYDAPT safely and effectively. See full prescribing information for RYDAPT.
RYDAPT® (midostaurin) capsules, for oral useInitial U.S. Approval: 2017",1919083,midostaurin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230613_c387579e-cee0-4334-bd1e-73f93ac1bde6.json,c387579e-cee0-4334-bd1e-73f93ac1bde6,18,"These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.
COTELLIC®  (cobimetinib) tablets, for oral useInitial U.S. Approval: 2015",1722365,cobimetinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/gold_xml/20230615_1e484a50-55db-4b85-8c57-6cd1b0353abd.json,1e484a50-55db-4b85-8c57-6cd1b0353abd,32,"These highlights do not include all the information needed to use OPSUMIT safely and effectively. See full prescribing information for OPSUMIT.
 



OPSUMIT 
 ® (macitentan) tablets, for oral use
 

Initial U.S. Approval: 2013",1442132,macitentan,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231121_2966aec7-2ef0-923c-d8ff-fe1a957bf095.json,2966aec7-2ef0-923c-d8ff-fe1a957bf095,84,"These highlights do not include all the information needed to use RINVOQ safely and effectively. See full prescribing information for RINVOQ.

 

RINVOQ

®

 (upadacitinib) extended-release tablets, for oral use

Initial U.S. Approval: 2019",2196092,upadacitinib,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,2265ef30-253e-11df-8a39-0800200c9a66,42,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011",1094833,ipilimumab,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,2265ef30-253e-11df-8a39-0800200c9a66,42,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011",1094833,ipilimumab,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,2265ef30-253e-11df-8a39-0800200c9a66,42,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011",1094833,ipilimumab,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,2265ef30-253e-11df-8a39-0800200c9a66,42,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011",1094833,ipilimumab,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,2265ef30-253e-11df-8a39-0800200c9a66,42,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011",1094833,ipilimumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231208_e0022c28-8cda-4f1e-bcf1-1f440d37ec4a.json,e0022c28-8cda-4f1e-bcf1-1f440d37ec4a,6,"These highlights do not include all the information needed to use RETHYMIC safely and effectively. See full prescribing information for RETHYMIC.


RETHYMIC (Allogeneic processed thymus tissue–agdc)
For surgical implantation
Initial U.S. Approval: 2021",2626460,allogeneic processed thymus tissue,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230720_de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa.json,de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,24,"These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA.
 JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010",996051,cabazitaxel,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230720_de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa.json,de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,24,"These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA.
 JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010",996051,cabazitaxel,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/train_xml/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008",711942,eltrombopag,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20240123_fff5d805-4ffd-4e8e-8e63-6f129697563e.json,fff5d805-4ffd-4e8e-8e63-6f129697563e,18,"These highlights do not include all the information needed to use ZYKADIA safely and effectively. See full prescribing information for ZYKADIA.


ZYKADIA® (ceritinib) capsules, for oral use

ZYKADIA® (ceritinib) tablets, for oral use

Initial U.S. Approval: 2014",1535457,ceritinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230818_59984249-e3ff-4f97-8d7a-c1a905d604a8.json,59984249-e3ff-4f97-8d7a-c1a905d604a8,14,"These highlights do not include all the information needed to use GAVRETO safely and effectively.  See full prescribing information for GAVRETO.
 GAVRETO® (pralsetinib) capsules, for oral use Initial U.S. Approval: 2020",2394936,pralsetinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/gold_xml/20230825_df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda.json,df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda,19,"These highlights do not include all the information needed to use GAZYVA safely and effectively. See full prescribing information for GAZYVA. 
GAZYVA® (obinutuzumab) injection, for intravenous use Initial U.S. Approval: 2013",974779,obinutuzumab,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/gold_xml/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,0002ad27-779d-42ab-83b5-bc65453412a1,22,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013",1425099,trametinib,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230927_3cdf28fc-4194-4ad6-aa03-c9eaa68da83e.json,3cdf28fc-4194-4ad6-aa03-c9eaa68da83e,5,"These highlights do not include all the information needed to use BRENZAVVY™ safely and effectively. See full prescribing information for BRENZAVVY. BRENZAVVY (bexagliflozin) tablets, for oral use Initial U.S. Approval: 2023",2627044,bexagliflozin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,84137882-e000-47da-bd5b-fa76ab3c76f9,20,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012",1242999,axitinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,f47d4365-40a8-445b-99cd-49edad6a8ffc,15,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only",35827,ketorolac,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1136980,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240201_aa80b9f4-8a5d-3e14-e053-2a95a90a8aab.json,aa80b9f4-8a5d-3e14-e053-2a95a90a8aab,4,"Theophylline (Anhydrous) Extended-Release Tablets
 

400 mg and 600 mg",10438,theophylline,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240128_c27f2d57-4b9d-4b78-8d85-3bac84f733b1.json,c27f2d57-4b9d-4b78-8d85-3bac84f733b1,5,"Flurbiprofen Sodium Ophthalmic Solution, USP 0.03% 

(Sterile)",4502,flurbiprofen,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,"Atenolol Tablets, USP Rx only",1202,atenolol,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_0e98593a-8424-48c8-acc0-671f4b566aee.json,0e98593a-8424-48c8-acc0-671f4b566aee,9,"These highlights do not include all the information needed to use CARVEDILOL TABLETS safely and effectively. See full prescribing information for CARVEDILOL TABLETS.
 

CARVEDILOL tablets, for oral use
 
Initial U.S. Approval: 1995",20352,carvedilol,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_ab8616a5-ea72-4df7-b095-54ea19ef6fba.json,ab8616a5-ea72-4df7-b095-54ea19ef6fba,10,"These highlights do not include all the information needed to use DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES.
 



DIVALPROEX SODIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989",40254,valproate,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,745466,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240223_e55f3dc2-c754-4550-a2c0-c304471a8791.json,e55f3dc2-c754-4550-a2c0-c304471a8791,2,"Nitrofurantoin Capsules, USP (monohydrate/macrocrystals)

Rx Only",7454,nitrofurantoin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231215_8ded0773-3aec-4e89-9836-d22a5a84abf0.json,8ded0773-3aec-4e89-9836-d22a5a84abf0,17,Quinapril Tablets USP,35208,quinapril,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998",2556,citalopram,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_fdbcc274-c343-4461-9db9-6ff1be15d727.json,fdbcc274-c343-4461-9db9-6ff1be15d727,10,"These highlights do not include all the information needed to use 
  BUPROPIONHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for 
  BUPROPIONHYDROCHLORIDE TABLETS. 
 


BUPROPION HYDROCHLORIDE tablets, for oral use
  
Initial U.S. Approval: 1985",42347,bupropion,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_fdbcc274-c343-4461-9db9-6ff1be15d727.json,fdbcc274-c343-4461-9db9-6ff1be15d727,10,"These highlights do not include all the information needed to use 
  BUPROPIONHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for 
  BUPROPIONHYDROCHLORIDE TABLETS. 
 


BUPROPION HYDROCHLORIDE tablets, for oral use
  
Initial U.S. Approval: 1985",42347,bupropion,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230221_87768fbf-7c63-47da-8925-0316f343d6ef.json,87768fbf-7c63-47da-8925-0316f343d6ef,16,"These highlights do not include all the information needed to use PERINDOPRIL ERBUMINE TABLETS safely and effectively. See full prescribing information for PERINDOPRIL ERBUMINE TABLETS.
 PERINDOPRIL erbumine tablets, for oral use Initial U.S. Approval: 1993",54552,perindopril,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_575da603-b038-421f-9894-6796d9ac33cc.json,575da603-b038-421f-9894-6796d9ac33cc,11,"These highlights do not include all the information needed to use SERTRALINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for SERTRALINE HYDROCHLORIDE TABLETS.
 

SERTRALINE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1991",36437,sertraline,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)",52582,mesalamine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_c5d0b74b-e5bc-4e81-91e8-4bfc587bf54c.json,c5d0b74b-e5bc-4e81-91e8-4bfc587bf54c,6,"Misoprostol
 

Tablets",42331,misoprostol,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,24926986-7552-4f1a-8366-f035bbd07104,7,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987",4493,fluoxetine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_51cdb22b-035f-47d7-8048-38006e2589f2.json,51cdb22b-035f-47d7-8048-38006e2589f2,20,Rx only,7417,nifedipine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240111_7f0bc342-0a0a-1d28-e053-2991aa0a28b9.json,7f0bc342-0a0a-1d28-e053-2991aa0a28b9,4,"TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 
Rx only
 

These highlights do not include all the information needed to use TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for TENOFOVIR DISOPROXIL FUMARATE TABLETS.
 

TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use
 

Initial U.S. Approval: 2001",300195,tenofovir disoproxil,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,8345d55e-ad02-4726-a04b-1a46e3337a4b,13,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998",194000,capecitabine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_1d3a45f3-3854-4d0c-9241-770aa24063fd.json,1d3a45f3-3854-4d0c-9241-770aa24063fd,5,"These highlights do not include all the information needed to use DULOXETINE DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DULOXETINE DELAYED-RELEASE CAPSULES.
 
DULOXETINE delayed-release capsules for oral use.
 
Initial U.S. Approval: 2004",72625,duloxetine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993",8703,fenofibrate,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_f7e9a4b3-a2ee-4f0a-becd-6ef90867332b.json,f7e9a4b3-a2ee-4f0a-becd-6ef90867332b,37,"These highlights do not include all the information needed to use MORPHINE SULFATE EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for MORPHINE SULFATE EXTENDED-RELEASE CAPSULES.


MORPHINE SULFATE extended-release capsules, for oral use, CIIInitial U.S. Approval: 1941",7052,morphine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_eb354221-c476-41cb-ad87-52423f81d698.json,eb354221-c476-41cb-ad87-52423f81d698,3,"Cefdinir Capsules, USP
 
Rx only",25037,cefdinir,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997",746741,pramipexole,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_11344047-7ed4-61e7-e063-6394a90a332d.json,11344047-7ed4-61e7-e063-6394a90a332d,1,"These highlights do not include all the information needed to use 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULESsafely and effectively. See full prescribing information for 
 LANSOPRAZOLE DELAYED-RELEASE CAPSULES.
 

LANSOPRAZOLE delayed-release capsules, for oral use
  
Initial U.S. Approval: 1995",17128,lansoprazole,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,"IBUPROFEN Tablets, USP",5640,ibuprofen,10018830,haematemesis,500001001,gi bleed,11,1,500001001,1177480,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231111_962b20df-88ff-4ab7-a900-135adb6c1d74.json,962b20df-88ff-4ab7-a900-135adb6c1d74,5,Indapamide Tablets USP Rx only,5764,indapamide,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_37241e87-4af4-4dc3-a1aa-ea6f20d8dc40.json,37241e87-4af4-4dc3-a1aa-ea6f20d8dc40,45,"These highlights do not include all the information needed to use CELLCEPT® safely and effectively. See full prescribing information for CELLCEPT® 
CELLCEPT® (mycophenolate mofetil) capsules, for oral use CELLCEPT® (mycophenolate mofetil) tablets, for oral use CELLCEPT®  Oral Suspension (mycophenolate mofetil), for oral suspension CELLCEPT®  Intravenous (mycophenolate mofetil) for injection, for intravenous use Initial U.S. Approval: 1995",68149,mycophenolate mofetil,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240127_03af7d09-314a-fe85-e063-6294a90afa25.json,03af7d09-314a-fe85-e063-6294a90afa25,1,"These highlights do not include all the information needed to use VALSARTAN TABLETS safely and effectively. See full prescribing information for VALSARTAN TABLETS.
 

VALSARTAN tablets, for ORAL use
 
Initial U.S. Approval: 1996",69749,valsartan,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_d4737be8-7c17-4548-b380-808c5b4ad7ac.json,d4737be8-7c17-4548-b380-808c5b4ad7ac,8,"These highlights do not include all the information needed to use OXCARBAZEPINE TABLETS safely and effectively. See full prescribing information for OXCARBAZEPINE TABLETS.
 



OXCARBAZEPINE tablets, for oral use
 

Initial U.S. Approval: 2000",32624,oxcarbazepine,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,c35e019d-ec34-4e61-9400-a7ae7913e025,3,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004",337525,erlotinib,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240124_c3658bc8-1524-43db-930e-66f9ac01b808.json,c3658bc8-1524-43db-930e-66f9ac01b808,11,"These highlights do not include all the information needed to use TELMISARTAN TABLETS safely and effectively. See full prescribing information for TELMISARTAN TABLETS.  TELMISARTAN tablets, for oral useInitial U.S. Approval: 1998",73494,telmisartan,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231014_2d18cfc4-e0de-4814-a712-c1b7c504bff5.json,2d18cfc4-e0de-4814-a712-c1b7c504bff5,31,"These highlights do not include all the information needed to use BYDUREON BCISE safely and effectively. See full prescribing information for BYDUREON BCISE.
BYDUREON BCISE® (exenatide) extended-release injectable suspension, for subcutaneous useInitial U.S. Approval: 2005",60548,exenatide,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20130606_d5050d0e-81d1-4707-a38a-e80de2aebf09.json,d5050d0e-81d1-4707-a38a-e80de2aebf09,2,Cefditoren Pivoxil Tablets 200 mg and 400 mg,83682,cefditoren,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_c89e8f4d-96c0-44c6-906a-b803141920b1.json,c89e8f4d-96c0-44c6-906a-b803141920b1,27,"These highlights do not include all the information needed to use CEFUROXIME AXETIL TABLETS safely and effectively. See full prescribing information for CEFUROXIME AXETIL TABLETS.  CEFUROXIME AXETIL tablets, for oral use  Initial U.S. Approval: 1987",2194,cefuroxime,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,88441a9f-b4f9-455d-a355-46fb30699a7b,10,"Sulfasalazine Tablets, USP",9524,sulfasalazine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231205_5359b759-db7c-4672-9e8a-59c93869bd91.json,5359b759-db7c-4672-9e8a-59c93869bd91,5,"These highlights do not include all the information needed to use VIBATIV® (telavancin) safely and effectively. See full prescribing information for VIBATIV. 
VIBATIV® (telavancin) for injection, for intravenous use Initial U.S. Approval: 2009",473837,telavancin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_ab8616a5-ea72-4df7-b095-54ea19ef6fba.json,ab8616a5-ea72-4df7-b095-54ea19ef6fba,10,"These highlights do not include all the information needed to use DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES safely and effectively. See full prescribing information for DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES.
 



DIVALPROEX SODIUM delayed-release capsules, for oral use
 

Initial U.S. Approval: 1989",40254,valproate,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,745466,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231228_755476e5-62a2-4f01-92a3-307e192ad42c.json,755476e5-62a2-4f01-92a3-307e192ad42c,5,"These highlights do not include all the information needed to use PARICALCITOL CAPSULES safely and effectively.
 
See full prescribing information for PARICALCITOL CAPSULES.
 

PARICALCITOL capsules, for oral use
 
Initial U.S. Approval: 1998",73710,paricalcitol,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240116_7f10bf63-06c8-477d-a13e-fb88e287617a.json,7f10bf63-06c8-477d-a13e-fb88e287617a,103,"These highlights do not include all the information needed to use REPAGLINIDE TABLETS safely and effectively.  See full prescribing information for REPAGLINIDE TABLETS.REPAGLINIDE tablets, for oral useInitial U.S. Approval: 1997",73044,repaglinide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)",52582,mesalamine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20160806_77d619f8-05a3-408a-a6f8-1511694b6a24.json,77d619f8-05a3-408a-a6f8-1511694b6a24,3,TICLOPIDINE HYDROCHLORIDE TABLETS USP 0154 Rx only,10594,ticlopidine,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240101_1aa40de5-c02d-49d6-8722-ed88c40c3ba6.json,1aa40de5-c02d-49d6-8722-ed88c40c3ba6,2,"Felbamate Tablets, USP

(400 mg and 600 mg)


Rx only",24812,felbamate,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240102_7036c6df-6527-4701-b484-6b962914b52a.json,7036c6df-6527-4701-b484-6b962914b52a,7,Tiagabine Hydrochloride Tablets,31914,tiagabine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240108_1c275825-0275-4c73-b650-e4c1519f13b8.json,1c275825-0275-4c73-b650-e4c1519f13b8,2,"CARBOplatin Injection
 

Rx Only",40048,carboplatin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_8192d79d-da2b-2532-e053-2991aa0ae8ad.json,8192d79d-da2b-2532-e053-2991aa0ae8ad,6,"PROCAINAMIDE HCI INJECTION, USP 1gram/10mL TOTAL (100mg/mL) 10mL VIAL",8700,procainamide,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_5721b46a-4a9f-46c2-8804-a9bad4d5f80a.json,5721b46a-4a9f-46c2-8804-a9bad4d5f80a,5,FLUCYTOSINE Capsules USPRx only,4451,flucytosine,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231101_f5a010cf-5954-4e6d-acfa-fb414efdf471.json,f5a010cf-5954-4e6d-acfa-fb414efdf471,1,"Mitomycin for Injection, USP Rx only",632,mitomycin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_7d655d6d-01da-488c-bd4e-c7fbe0ace38c.json,7d655d6d-01da-488c-bd4e-c7fbe0ace38c,5,"These highlights do not include all the information needed to use TESTOSTERONE GEL, 1% safely and effectively.  See full prescribing information for TESTOSTERONE GEL, 1%.

 TESTOSTERONE gel 1%, for topical use, CIII Initial U.S. Approval: 1953",10379,testosterone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231116_b7241707-7538-4d1a-91e7-3a25a91e0b9a.json,b7241707-7538-4d1a-91e7-3a25a91e0b9a,14,"These highlights do not include all the information needed to use IFEX (ifosfamide) safely and effectively.  See full prescribing information for IFEX.
IFEX (ifosfamide) for injection, intravenous useInitial U.S. Approval: 1988",5657,ifosfamide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_1738a682-5903-b675-3a7a-61d299a6f248.json,1738a682-5903-b675-3a7a-61d299a6f248,19,"These highlights do not include all the information needed to use ZOLEDRONIC ACID INJECTION safely and effectively. See full prescribing information for ZOLEDRONIC ACID INJECTION. ZOLEDRONIC ACID injection, for intravenous use 
Initial U.S. Approval: 2001",77655,zoledronic acid,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_b856bfaf-ec6b-4171-81c4-b9b07f780084.json,b856bfaf-ec6b-4171-81c4-b9b07f780084,2,"These highlights do not include all the information needed to use VALGANCICLOVIR HYDROCHLORIDE FOR ORAL SOLUTION safely and effectively. See full prescribing information for VALGANCICLOVIR HYDROCHLORIDE FOR ORAL SOLUTION. VALGANCICLOVIR HYDROCHLORIDE, for oral solution Initial U.S. Approval: 2001",275891,valganciclovir,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002",121243,voriconazole,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,a1787fad-3612-43e1-98fa-ce62361e0b3c,13,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001",282388,imatinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1304107,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240131_a4978a54-1799-43d6-85dd-05fa9de0a5d7.json,a4978a54-1799-43d6-85dd-05fa9de0a5d7,8,"These highlights do not include all the information needed to use AMBRISENTAN TABLETS safely and effectively. See full prescribing information for AMBRISENTAN TABLETS.  AMBRISENTAN tablets, for oral use  Initial U.S. Approval: 2007",358274,ambrisentan,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef.json,7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef,5,"These highlights do not include all the information needed to use DAPTOMYCIN IN SODIUM CHLORIDE INJECTION safely and effectively.  See full prescribing information for DAPTOMYCIN IN SODIUM CHLORIDE INJECTION.
DAPTOMYCIN IN SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 2003",22299,daptomycin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240117_8c5d6067-16a1-43ab-9e52-a33c600a5c44.json,8c5d6067-16a1-43ab-9e52-a33c600a5c44,2,"These highlights do not include all the information needed to use DECITABINE FOR INJECTION safely and effectively. See full prescribing information for DECITABINE FOR INJECTION.
DECITABINE for injection, for intravenous useInitial U.S. Approval: 2006",15657,decitabine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_246d42e5-5418-42ba-aff9-ae399b166c69.json,246d42e5-5418-42ba-aff9-ae399b166c69,4,"These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS.
 







TERIFLUNOMIDE tablets, for oral use
 



Initial U.S. Approval: 2012",1310520,teriflunomide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231221_c6c7c39e-e510-4f4a-bf7a-926f0e075d3a.json,c6c7c39e-e510-4f4a-bf7a-926f0e075d3a,10,"Protriptyline Hydrochloride Tablets, USPRx Only",8886,protriptyline,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20200922_cc7014b1-c775-411d-b374-8113248b4077.json,cc7014b1-c775-411d-b374-8113248b4077,4,"These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA.
BESPONSA (inotuzumab ozogamicin) for injection, for intravenous useInitial U.S. Approval: 2017",1942950,inotuzumab ozogamicin,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20200923_472bd78e-be17-4b9d-90f4-9482c3aec9ff.json,472bd78e-be17-4b9d-90f4-9482c3aec9ff,12,"These highlights do not include all the information needed to use YONDELIS® safely and effectively. See full prescribing information for YONDELIS.
YONDELIS (trabectedin) for injection, for intravenous useInitial U.S. Approval: 2015",1716278,trabectedin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac.json,bfb4db4a-88e6-4c36-afeb-cb0ea00ae2ac,4,"These highlights do not include all the information needed to use DEFERASIROX TABLETS FOR ORAL SUSPENSION safely and effectively. See full prescribing information for DEFERASIROX TABLETS FOR ORAL SUSPENSION. 
DEFERASIROX tablets, for oral suspensionInitial U.S. Approval: 2005",614373,deferasirox,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240120_9914e793-a49c-eb00-1ab7-f606c786fe25.json,9914e793-a49c-eb00-1ab7-f606c786fe25,7,"These highlights do not include all the information needed to use COSMEGEN safely and effectively. See full prescribing information for COSMEGEN. 

COSMEGEN  ® (dactinomycin for injection) for intravenous use 

Initial U.S. Approval: 1964",3100,dactinomycin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240120_9914e793-a49c-eb00-1ab7-f606c786fe25.json,9914e793-a49c-eb00-1ab7-f606c786fe25,7,"These highlights do not include all the information needed to use COSMEGEN safely and effectively. See full prescribing information for COSMEGEN. 

COSMEGEN  ® (dactinomycin for injection) for intravenous use 

Initial U.S. Approval: 1964",3100,dactinomycin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_34de1806-d921-4d2f-8c7f-03625b717a70.json,34de1806-d921-4d2f-8c7f-03625b717a70,25,"These highlights do not include all the information needed to use METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for METHYLPHENIDATE HCl EXTENDED-RELEASE TABLETS.


METHYLPHENIDATE HCl extended-release tablets, for oral administration CII 

Initial U.S. Approval: 2000",6901,methylphenidate,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231205_3d0c9554-eaeb-4694-8089-00133fcadce3.json,3d0c9554-eaeb-4694-8089-00133fcadce3,16,"These highlights do not include all the information needed to use APTIOM safely and effectively.  See full prescribing information for APTIOM.  
APTIOM® (eslicarbazepine acetate) tablets, for oral useInitial U.S. Approval: 2013",1482502,eslicarbazepine,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_454f092e-dcd0-47bd-a521-b07400403dad.json,454f092e-dcd0-47bd-a521-b07400403dad,5,"These highlights do not include all the information needed to use BRONCHITOL safely and effectively. See full prescribing information for BRONCHITOL.BRONCHITOL® (mannitol) inhalation powder, for oral inhalation useInitial U.S. Approval: 1964",6628,mannitol,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240118_b471eb51-488e-5312-e053-2a95a90a8116.json,b471eb51-488e-5312-e053-2a95a90a8116,5,"These highlights do not include all the information needed to use FULVESTRANT INJECTION safely and effectively. See full prescribing information for FULVESTRANT INJECTION.
 
FULVESTRANT injection, for intramuscular use
 
Initial U.S. Approval: 2002",282357,fulvestrant,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/train_xml/20231216_cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae.json,cb4e6ba6-f216-4ed2-85d2-9f86f3b441ae,12,"These highlights do not include all the information needed to use PRADAXA Capsules safely and effectively.  See full prescribing information for PRADAXA Capsules. 
 PRADAXA® (dabigatran etexilate) capsules, for oral use Initial U.S. Approval: 2010",1037042,dabigatran etexilate,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231206_06a0322b-eb28-44e2-9925-88bebd8fa91b.json,06a0322b-eb28-44e2-9925-88bebd8fa91b,9,"These highlights do not include all the information needed to use carmustine for injection, USP safely and effectively. See full prescribing information for carmustine for injection, USP.
Carmustine for injection, USP, for intravenous use Initial U.S. Approval: 1977",2105,carmustine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_1502544d-1b3a-46bd-84f5-af92cab72ce8.json,1502544d-1b3a-46bd-84f5-af92cab72ce8,9,"These highlights do not include all the information needed to use PRIFTIN® safely and effectively. See full prescribing information for PRIFTIN.
 PRIFTIN (rifapentine) tablets, for oral use Initial U.S. Approval: 1998",35617,rifapentine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_dbf738c4-3fac-4422-a9d8-51d9c83a8789.json,dbf738c4-3fac-4422-a9d8-51d9c83a8789,3,"These highlights do not include all the information needed to use RENFLEXIS® safely and effectively. See full prescribing information for RENFLEXIS. 
RENFLEXIS (infliximab-abda) for injection, for intravenous use Initial U.S. Approval: 2017 RENFLEXIS (infliximab-abda) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of RENFLEXIS has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to REMICADE (infliximab).",191831,infliximab,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,500000301,937368,1,1
./data/2024_latest_labels/latest_labels_ingredients/20211124_75c0c785-38e0-4049-a6fb-b77581f5b35c.json,75c0c785-38e0-4049-a6fb-b77581f5b35c,6,"These highlights do not include all the information needed to use FETROJA® safely and effectively. See full prescribing information for FETROJA. 
 FETROJA (cefiderocol) for injection, for intravenous use  Initial U.S. Approval: 2019",2265702,cefiderocol,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_cfeab9e3-58b9-4890-9185-11b62904e2af.json,cfeab9e3-58b9-4890-9185-11b62904e2af,13,Metronidazole Tablets USP,6922,metronidazole,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_fbac3b4f-dc23-4359-ac3f-2b3fdde41af2.json,fbac3b4f-dc23-4359-ac3f-2b3fdde41af2,32,"These highlights do not include all the information needed to use ALLOPURINOL TABLETS safely and effectively. See full prescribing information for ALLOPURINOL TABLETS.


ALLOPURINOL tablets for oral use 

Initial U.S. Approval:1966",519,allopurinol,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1167322,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,Mefenamic Acid Capsules USPRx Only,257844,mefenamate,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230609_36377351-d208-4363-8826-0acfea3f0cc1.json,36377351-d208-4363-8826-0acfea3f0cc1,5,"These highlights do not include all the information needed to use sodium ferric gluconate complex in sucrose injection safely and effectively. See full prescribing information for sodium ferric gluconate complex in sucrose injection.
Sodium ferric gluconate complex in sucrose injection, for intravenous use 
Initial U.S. Approval: 1999",261435,sodium ferric gluconate complex,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240219_06f442d6-071e-4081-b7f7-40f3b803ab3f.json,06f442d6-071e-4081-b7f7-40f3b803ab3f,4,"These highlights do not include all the information needed to use SORAFENIB TABLETS safely and effectively.
 
See full prescribing information for SORAFENIB TABLETS.
 
Sorafenib tablets, for oral use
 
Initial U.S. Approval: 2005",495881,sorafenib,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220623_08982e49-d2eb-4b25-b01a-1be52fd669ef.json,08982e49-d2eb-4b25-b01a-1be52fd669ef,16,"These highlights do not include all the information needed to use APTIVUS safely and effectively.  See full prescribing information for APTIVUS. 
APTIVUS® (tipranavir) capsules, for oral use APTIVUS® (tipranavir) oral solution Initial U.S. Approval: 2005",190548,tipranavir,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,500000301,1736999,1,1
./data/2024_latest_labels/latest_labels_ingredients/20220623_471baba2-7154-4488-9891-0db2f46791e7.json,471baba2-7154-4488-9891-0db2f46791e7,9,"These highlights do not include all the information needed to use EVENITY safely and effectively. See full prescribing information for EVENITY.  

   

EVENITY

®

 
(
romosozumab-aqqg
) 
injection, 
for
 
subcutaneous
 use

Initial U.S. Approval: 2019",2123126,romosozumab,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_8fa41f19-0b2b-4b6a-aa5f-d28f8213a6bc.json,8fa41f19-0b2b-4b6a-aa5f-d28f8213a6bc,3,"Amphetamine Sulfate Tablets, USP, CII",725,amphetamine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220727_551e43d5-f700-4d6e-8029-026f8a8932ff.json,551e43d5-f700-4d6e-8029-026f8a8932ff,14,These highlights do not include all the information needed to use SOLOSEC® safely and effectively. See full prescribing information for SOLOSEC.SOLOSEC® (secnidazole) oral granulesInitial U.S. Approval: 2017,36314,secnidazole,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220727_551e43d5-f700-4d6e-8029-026f8a8932ff.json,551e43d5-f700-4d6e-8029-026f8a8932ff,14,These highlights do not include all the information needed to use SOLOSEC® safely and effectively. See full prescribing information for SOLOSEC.SOLOSEC® (secnidazole) oral granulesInitial U.S. Approval: 2017,36314,secnidazole,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,d5929f91-6496-4c0e-97e8-0bd524e15763,3,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,d5929f91-6496-4c0e-97e8-0bd524e15763,3,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/train_xml/20240201_cc9e1c8c-0e2b-44e2-878b-27057f786be9.json,cc9e1c8c-0e2b-44e2-878b-27057f786be9,35,"These highlights do not include all the information needed to use GILENYA® safely and effectively. See full prescribing information for GILENYA.


GILENYA (fingolimod) capsules, for oral use

Initial U.S. Approval: 2010",1012892,fingolimod,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_49aa3d6d-2270-4615-aafa-b440859ab870.json,49aa3d6d-2270-4615-aafa-b440859ab870,4,Naltrexone Hydrochloride Tablets USP 50 mg,7243,naltrexone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240109_0c8dbbc9-6c85-4acd-a7bd-c55ec5829212.json,0c8dbbc9-6c85-4acd-a7bd-c55ec5829212,1,"These highlights do not include all the information needed to use ALOGLIPTIN TABLETS safely and effectively. See full prescribing information for ALOGLIPTIN TABLETS.
 

Alogliptin Tablets, for oral use
 
Initial U.S. Approval: 2013",1368001,alogliptin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/train_xml/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012",1302966,carfilzomib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012",1302966,carfilzomib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/gold_xml/20221103_da1c9f37-779e-4682-816f-93d0faa4cfc9.json,da1c9f37-779e-4682-816f-93d0faa4cfc9,16,"These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. 
OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014",1592737,nintedanib,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_106b33e3-b199-e555-e063-6294a90a5af5.json,106b33e3-b199-e555-e063-6294a90a5af5,1,"Diltiazem Hydrochloride Tablets, USP


Tablets",3443,diltiazem,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231121_1aa75a3a-18c9-49e1-91a6-293d0b7da756.json,1aa75a3a-18c9-49e1-91a6-293d0b7da756,8,"MATULANE 
  ®(procarbazine hydrochloride) Capsules",8702,procarbazine,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231216_3fc03452-cbfb-48a2-a747-45b03399741c.json,3fc03452-cbfb-48a2-a747-45b03399741c,8,"These highlights do not include all the information needed to use INVOKANA safely and effectively. See full prescribing information for INVOKANA.
 

INVOKANA 
 ®(canagliflozin) tablets, for oral use
 
Initial U.S. Approval: 2013",1373458,canagliflozin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/train_xml/20221214_8b6261f6-4bdc-462e-8af1-4064664c62f3.json,8b6261f6-4bdc-462e-8af1-4064664c62f3,2,"These highlights do not include all the information
needed to use JARDIANCE safely and effectively.  See full prescribing
information for JARDIANCE.
 JARDIANCE® (empagliflozin) tablets, for oral use Initial U.S. Approval: 2014",1545653,empagliflozin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/train_xml/20230105_b4c2c9dc-a0bb-4d64-a667-a67ebe88392d.json,b4c2c9dc-a0bb-4d64-a667-a67ebe88392d,37,"These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA.
 



CIMZIA (certolizumab pegol) for injection, for subcutaneous use
 

CIMZIA (certolizumab pegol) injection, for subcutaneous use
 

Initial U.S. Approval: 2008",709271,certolizumab pegol,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/train_xml/20230125_c16ac648-d5d2-9f7d-8637-e2328572754e.json,c16ac648-d5d2-9f7d-8637-e2328572754e,15,"These highlights do not include all the information needed to use NULOJIX safely and effectively. See full prescribing information for NULOJIX.
NULOJIX (belatacept) for injection, for intravenous useInitial U.S. Approval: 2011",1112973,belatacept,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_27f15fac-7d98-4114-a2ec-92494a91da98.json,27f15fac-7d98-4114-a2ec-92494a91da98,8,"These highlights do not include all the information needed to use RYBELSUS®
 safely and effectively.  See full prescribing information for RYBELSUS.
RYBELSUS (semaglutide) tablets, for oral use
Initial U.S. Approval: 2017",1991302,semaglutide,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230301_d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6.json,d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6,21,"Synarel®


(nafarelin acetate)

nasal solution",28656,nafarelin,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240124_d2daba09-f1c2-4764-a567-1291be4892b9.json,d2daba09-f1c2-4764-a567-1291be4892b9,100,"These highlights do not include all the information needed to use
POSACONAZOLE DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for

POSACONAZOLE

DELAYED-RELEASE TABLETS
.



POSACONAZOLE

delayed-release tablets, for oral use

Initial U.S. Approval: 2006",282446,posaconazole,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231223_ce167984-8b9d-40b7-84ce-d0f33fff1eaa.json,ce167984-8b9d-40b7-84ce-d0f33fff1eaa,9,"These highlights do not include all the information needed to use
OLINVYK® safely and effectively. See full prescribing information for
OLINVYK.OLINVYK (oliceridine) injection, for intravenous use, CIIInitial U.S. Approval: 2020",2392230,oliceridine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/gold_xml/20231201_38eea320-7e0c-485a-bc30-98c3c45e2763.json,38eea320-7e0c-485a-bc30-98c3c45e2763,24,"These highlights do not include all the information needed to use ZELBORAF safely and effectively. See full prescribing information for ZELBORAF. 
 ZELBORAF® (vemurafenib) tablet for oral use  Initial U.S. Approval: 2011",1147220,vemurafenib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231122_f86cb4a7-c358-4136-ae57-b32bda9bba00.json,f86cb4a7-c358-4136-ae57-b32bda9bba00,34,"These highlights do not include all the information needed to use SIMPONI safely and effectively. See full prescribing information for SIMPONI.
 



SIMPONI (golimumab) injection, for subcutaneous use
 

Initial U.S. Approval: 2009",819300,golimumab,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230516_2e8ef36b-71fa-4492-a16f-577d5f7d111d.json,2e8ef36b-71fa-4492-a16f-577d5f7d111d,7,"These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ.
 BELEODAQ® (belinostat) for injection, for intravenous use Initial U.S. Approval: 2014",1543543,belinostat,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231202_685eaf44-5944-4f38-afba-0a4fc0b3462b.json,685eaf44-5944-4f38-afba-0a4fc0b3462b,11,"These highlights do not include all the information needed to use SECUADO® (asenapine) transdermal system safely and effectively.  See full prescribing information for SECUADO®.
			
SECUADO® (asenapine) transdermal system
			Initial U.S. Approval: 2009",784649,asenapine,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230617_3423ac0f-9585-4abf-a8ba-a5123a8277ee.json,3423ac0f-9585-4abf-a8ba-a5123a8277ee,8,"These highlights do not include all the information needed to use AZEDRA safely and effectively.  See full prescribing information for AZEDRA. 		
AZEDRA® (iobenguane I 131) injection, for intravenous use 		Initial U.S. Approval: 2018",14448,3-iodobenzylguanidine,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,2265ef30-253e-11df-8a39-0800200c9a66,42,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011",1094833,ipilimumab,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_455892c3-d144-4ba8-9ab4-79cabff9876d.json,455892c3-d144-4ba8-9ab4-79cabff9876d,11,"These highlights do not include all the information needed to use TABRECTA safely and effectively. See full prescribing information for TABRECTA.
		
TABRECTA® (capmatinib) tablets, for oral use
		
		Initial U.S. Approval: 2020",2362165,capmatinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_81a33cfa-262f-4432-a05d-7dd260928437.json,81a33cfa-262f-4432-a05d-7dd260928437,7,"These highlights do not include all the information needed to use ABRILADA safely and effectively. See full prescribing information for ABRILADA.
ABRILADA™ (adalimumab-afzb) injection, for subcutaneous useInitial U.S. Approval: 2019
ABRILADA (adalimumab-afzb) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of ABRILADA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA (adalimumab).",797541,isopropyl alcohol,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/train_xml/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008",711942,eltrombopag,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_4034fb6d-f55d-4df0-b500-d6a413591f6e.json,4034fb6d-f55d-4df0-b500-d6a413591f6e,39,"These highlights do not include all the information needed to use DOXAZOSIN TABLETS safely and effectively. See full prescribing information for DOXAZOSIN TABLETS.




DOXAZOSIN tablets, for oral use 




Initial U.S. Approval: 1990",49276,doxazosin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/gold_xml/20230902_23f3c1f4-0fc8-4804-a9e3-04cf25dd302e.json,23f3c1f4-0fc8-4804-a9e3-04cf25dd302e,26,"These highlights do not include all the information needed to use KADCYLA safely and effectively.  See full prescribing information for KADCYLA. 
KADCYLA® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval:  2013",224905,trastuzumab,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,b6465b44-a6dd-f99c-d009-6851cf05169c,11,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab).",224905,trastuzumab,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230912_0002ad27-779d-42ab-83b5-bc65453412a1.json,0002ad27-779d-42ab-83b5-bc65453412a1,22,"These highlights do not include all the information needed to use MEKINIST safely and effectively. See full prescribing information for MEKINIST.
MEKINIST® (trametinib) tablets, for oral useMEKINIST® (trametinib) for oral solutionInitial U.S. Approval: 2013",1425099,trametinib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231122_2a51b0de-47d6-455e-a94c-d2c737b04ff7.json,2a51b0de-47d6-455e-a94c-d2c737b04ff7,43,"These highlights do not include all the information needed to use XALKORI® safely and effectively. See full prescribing information for XALKORI. 
XALKORI® (crizotinib) capsules, for oral useXALKORI® (crizotinib) oral pelletsInitial U.S. Approval: 2011",1148495,crizotinib,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231122_2a51b0de-47d6-455e-a94c-d2c737b04ff7.json,2a51b0de-47d6-455e-a94c-d2c737b04ff7,43,"These highlights do not include all the information needed to use XALKORI® safely and effectively. See full prescribing information for XALKORI. 
XALKORI® (crizotinib) capsules, for oral useXALKORI® (crizotinib) oral pelletsInitial U.S. Approval: 2011",1148495,crizotinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_c8b58efa-1820-48a4-b70d-62918fc4abfc.json,c8b58efa-1820-48a4-b70d-62918fc4abfc,6,"These highlights do not include all the information needed to use ONIVYDE® safely and effectively. See full prescribing information for ONIVYDE®
 ONIVYDE® (irinotecan liposome injection), for intravenous use Initial U.S. Approval: 1996",51499,irinotecan,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231020_0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.json,0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25,30,"These highlights do not include all the information needed to use KALYDECO safely and effectively. See full prescribing information for KALYDECO.
KALYDECO® (ivacaftor) tablets, for oral useKALYDECO® (ivacaftor) oral granulesInitial U.S. Approval: 2012",1243041,ivacaftor,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_4e8516dc-a3c6-4d8f-aa14-2c37c6c8f6e6.json,4e8516dc-a3c6-4d8f-aa14-2c37c6c8f6e6,1,"These highlights do not include all the information needed to use ISOTRETINOIN CAPSULES safely and effectively. See full prescribing information for ISOTRETINOIN CAPSULES.
 ISOTRETINOIN capsules, for oral use Initial U.S. Approval: 1982",6064,isotretinoin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20070914_6698bc44-b971-49cc-a5de-11e569493c59.json,6698bc44-b971-49cc-a5de-11e569493c59,2,SECONAL SODIUMSECOBARBITAL SODIUM CAPSULESCIIRx only,9624,secobarbital,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_1b8a4689-3916-4f4b-b54a-bbb4e322d79b.json,1b8a4689-3916-4f4b-b54a-bbb4e322d79b,13,"Atenolol Tablets, USP Rx only",1202,atenolol,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_0edeb103-5e94-4f42-828f-c7336486c784.json,0edeb103-5e94-4f42-828f-c7336486c784,3,These highlights do not include all the information needed to use CEPHALEXIN FOR ORAL SUSPENSION safely and effectively. See full prescribing information for CEPHALEXIN FOR ORAL SUSPENSION CEPHALEXIN for oral suspension Initial U.S. Approval: 1971,2231,cephalexin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_0be243c6-de02-45dd-8210-cab1bbc8dfa7.json,0be243c6-de02-45dd-8210-cab1bbc8dfa7,28,"These highlights do not include all the information needed to use CLARITHROMYCIN TABLETS safely and effectively. See full prescribing information for CLARITHROMYCIN TABLETS.
 

CLARITHROMYCIN tablets, for oral use
 
Initial U.S. Approval: 1991",21212,clarithromycin,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231221_8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb.json,8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb,19,Nisoldipine,7435,nisoldipine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_18fb1c2b-0c1e-436c-a5b6-d4840b5da228.json,18fb1c2b-0c1e-436c-a5b6-d4840b5da228,12,"These highlights do not include all the information needed to use NICARDIPINE HYDROCHLORIDE safely and effectively. See full prescribing information for NICARDIPINE HYDROCHLORIDE.
 NICARDIPINE 
HYDROCHLORIDE injection, for intravenous use

Initial U.S. Approval: 1988",7396,nicardipine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_fbac3b4f-dc23-4359-ac3f-2b3fdde41af2.json,fbac3b4f-dc23-4359-ac3f-2b3fdde41af2,32,"These highlights do not include all the information needed to use ALLOPURINOL TABLETS safely and effectively. See full prescribing information for ALLOPURINOL TABLETS.


ALLOPURINOL tablets for oral use 

Initial U.S. Approval:1966",519,allopurinol,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1167322,1,1
./data/2024_latest_labels/latest_labels_ingredients/20221228_39e62997-8781-449a-e054-00144ff88e88.json,39e62997-8781-449a-e054-00144ff88e88,7,"Nizatidine Oral Solution 

15 mg/mL 

 
Rx only",42319,nizatidine,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_51635427-fb13-45ee-813d-a40b0405d14f.json,51635427-fb13-45ee-813d-a40b0405d14f,7,"Diclofenac Sodium Extended-Release Tablets, USP, Tablets of 100 mg
  

Rx only
  

Prescribing Information",3355,diclofenac,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_1401d590-0967-4c6b-b52b-a83e9f6df097.json,1401d590-0967-4c6b-b52b-a83e9f6df097,34,DOXYCYCLINE HYCLATE TABLETS USP 100 mg,3640,doxycycline,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,7ee820e4-a479-4b7d-8730-101ac1f8015c,102,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982",8356,piroxicam,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1146810,1,1
./data/2024_latest_labels/train_xml/20231130_02c91fba-9c47-43ef-ac78-e82369798834.json,02c91fba-9c47-43ef-ac78-e82369798834,16,These highlights do not include all the information needed to use NATAZIA safely and effectively.  See full prescribing information for NATAZIA.NATAZIA (estradiol valerate and estradiol valerate/dienogest) tablets for oral useInitial U.S. Approval: 2010,4083,estradiol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1548195,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_6c5c47ab-28ee-11e1-bfc2-0800200c9a66.json,6c5c47ab-28ee-11e1-bfc2-0800200c9a66,19,"These highlights do not include all the information needed to use MINIVELLE safely and effectively. See full prescribing information for MINIVELLE.
         

MINIVELLE® (estradiol transdermal system) 
Initial U.S. Approval: 1975",4083,estradiol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1548195,1,1
./data/2024_latest_labels/latest_labels_ingredients/20100225_ef14122b-7fff-45fa-b13b-0ea9e48bd57d.json,ef14122b-7fff-45fa-b13b-0ea9e48bd57d,1,1  INDICATIONS AND USAGE,84108,rosiglitazone,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_9c9d9f5c-bfd1-4e2a-be4a-697344ca6833.json,9c9d9f5c-bfd1-4e2a-be4a-697344ca6833,11,"These highlights do not include all the information needed to use citalopram tablets safely and effectively. See full prescribing information for citalopram tablets.
 


CITALOPRAM (Citalopram) tablets, for oral use
 


Initial U.S. Approval: 1998",2556,citalopram,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_cee5b232-0464-4697-93ef-77e044c83776.json,cee5b232-0464-4697-93ef-77e044c83776,8,"These highlights do not include all the information needed to use CLOPIDOGREL TABLETS safely and effectively. See full prescribing information for CLOPIDOGREL TABLETS.
 



CLOPIDOGREL tablets, for oral use
 



Initial U.S. Approval: 1997",32968,clopidogrel,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1322184,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_0366164b-1846-443d-9564-dbe52d8d9b65.json,0366164b-1846-443d-9564-dbe52d8d9b65,11,"These highlights do not include all the information needed to use TOPIRAMATE safely and effectively. See full prescribing information for TOPIRAMATE.
 

TOPIRAMATE tablets, for oral use
 
TOPIRAMATE capsules, for oral use
 
Initial U.S. Approval-1996",38404,topiramate,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_806b3e38-3b2a-4aaa-973c-e2d921bb353e.json,806b3e38-3b2a-4aaa-973c-e2d921bb353e,10,"Venlafaxine Tablets, USP
 
Rx only",39786,venlafaxine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,ccd95dfc-9236-4707-a715-6a12c91519ff,6,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976",7258,naproxen,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1115008,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240202_c0d1c22b-566b-4776-bdbf-00f96dad0cae.json,c0d1c22b-566b-4776-bdbf-00f96dad0cae,9,"These highlights do not include all the information needed to use ZARXIO safely and effectively. See full prescribing information for ZARXIO.
ZARXIO® (filgrastim-sndz) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2015ZARXIO (filgrastim-sndz) is biosimilar* to NEUPOGEN (filgrastim).",68442,filgrastim,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_3a404db2-7a7d-476f-81cf-979a67d37f66.json,3a404db2-7a7d-476f-81cf-979a67d37f66,7,"These highlights do not include all the information needed to use ALYQ™ safely and effectively.  See full prescribing information for ALYQ™. 


ALYQ™ (tadalafil) tablets for oral administration

Initial U.S. Approval: 2003",358263,tadalafil,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_cf41a02d-c881-4b40-b99c-d5b79dbd645b.json,cf41a02d-c881-4b40-b99c-d5b79dbd645b,9,"Perphenazine Tablets, USP",8076,perphenazine,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240126_1fffe88d-50c8-45cf-ac7c-a62b665c89a8.json,1fffe88d-50c8-45cf-ac7c-a62b665c89a8,16,SULINDAC TABLETS USP,10237,sulindac,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/train_xml/20141007_144067b2-0532-476a-996e-e4a0a9d09b05.json,144067b2-0532-476a-996e-e4a0a9d09b05,1,"These highlights do not include all the information needed to use STRIBILD safely and effectively. See full prescribing information for STRIBILD.
 STRIBILD® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral useInitial U.S. Approval: 2012",300195,tenofovir disoproxil,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_d1f64796-6ba0-415c-a6a0-5456b21a7ed6.json,d1f64796-6ba0-415c-a6a0-5456b21a7ed6,5,"These highlights do not include all the information needed to use FENOFIBRATE TABLETS safely and effectively. See full prescribing information for FENOFIBRATE TABLETS.
 
FENOFIBRATE tablets, for oral use
 
Initial U.S. Approval: 1993",8703,fenofibrate,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_6fc9c8e2-6f34-aa43-e053-2a91aa0ac377.json,6fc9c8e2-6f34-aa43-e053-2a91aa0ac377,10,"QUETIAPINE TABLETS. These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.
 

Quetiapine tablets, for oral use
 

Initial U.S. Approval: 1997",51272,quetiapine,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231204_8bdb47c5-9d19-4d59-94c8-62c117525e7f.json,8bdb47c5-9d19-4d59-94c8-62c117525e7f,1,Zafirlukast Tablets Rx only,114970,zafirlukast,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1111706,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,76e1839b-7462-4344-b319-001a5f57d67a,12,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000",40790,pantoprazole,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240123_ed977166-7ac0-4a8c-a10c-4b19a69403c0.json,ed977166-7ac0-4a8c-a10c-4b19a69403c0,1,"These highlights do not include all the information needed to use DARUNAVIR TABLETS safely and effectively. See Full Prescribing Information for DARUNAVIR TABLETS.
DARUNAVIR tablets, for oral useInitial U.S. Approval: 2006",460132,darunavir,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,500000301,1756831,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240206_f47d4365-40a8-445b-99cd-49edad6a8ffc.json,f47d4365-40a8-445b-99cd-49edad6a8ffc,15,"Ketorolac Tromethamine Tablets USP, 10 mg 
 




Rx only",35827,ketorolac,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1136980,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240222_56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec.json,56e8d1f6-6dbf-4e11-a177-a56bbfb9f8ec,10,"These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PRAMIPEXOLE DIHYDROCHLORIDE TABLETS.
 PRAMIPEXOLE DIHYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1997",746741,pramipexole,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_51a88e8e-da02-4b97-9e7e-442fbffd908d.json,51a88e8e-da02-4b97-9e7e-442fbffd908d,8,"These highlights do not include all the information needed to use AMIODARONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for AMIODARONE HYDROCHLORIDE TABLETS.
 

AMIODARONE HYDROCHLORIDE tablets, for oral use
 
Initial U.S. Approval: 1985",703,amiodarone,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_9e5c0ef3-3179-4d7b-bc76-901473c73ce8.json,9e5c0ef3-3179-4d7b-bc76-901473c73ce8,20,"These highlights do not include all the information needed to use VARENICLINE TABLETS safely and effectively. See full prescribing information for VARENICLINE TABLETS.



VARENICLINE tablets, for oral use 

Initial U.S. Approval: 2006",591622,varenicline,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240220_9e5c0ef3-3179-4d7b-bc76-901473c73ce8.json,9e5c0ef3-3179-4d7b-bc76-901473c73ce8,20,"These highlights do not include all the information needed to use VARENICLINE TABLETS safely and effectively. See full prescribing information for VARENICLINE TABLETS.



VARENICLINE tablets, for oral use 

Initial U.S. Approval: 2006",591622,varenicline,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_4238a064-1bfd-4ce3-b9d9-12c96eee8af0.json,4238a064-1bfd-4ce3-b9d9-12c96eee8af0,2,"These highlights do not include all the information needed to use OLMESARTAN MEDOXOMIL TABLETS safely and effectively. See full prescribing information for OLMESARTAN MEDOXOMIL TABLETS.  OLMESARTAN MEDOXOMIL tablets, for oral use   Initial U.S. Approval: 2002",321064,olmesartan,10069339,acute kidney injury,500000401,acute kidney injury,6,1,500000401,1312742,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240220_0422fe47-c372-494f-bac2-612f550b44a4.json,0422fe47-c372-494f-bac2-612f550b44a4,12,"Cefazolin for Injection, USP",2180,cefazolin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_8e292a8d-9fd6-45fb-8fb5-d8cb25a4b46d.json,8e292a8d-9fd6-45fb-8fb5-d8cb25a4b46d,4,"",19552,cefprozil,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240119_3e4842ec-773b-4aeb-b37d-1c4e3cf53424.json,3e4842ec-773b-4aeb-b37d-1c4e3cf53424,102,"Dicloxacillin Sodium Capsules USP


Rx only",3356,dicloxacillin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,KIPROFEN™ Capsules,6142,ketoprofen,10018830,haematemesis,500001001,gi bleed,11,1,500001001,1185922,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240104_d72e0e10-4557-41b0-b65d-d395468cad19.json,d72e0e10-4557-41b0-b65d-d395468cad19,11,"These highlights do not include all the information needed to use APREPITANT CAPSULES safely and effectively. See full prescribing information for APREPITANT CAPSULES. 
APREPITANT capsules, for oral use Initial U.S. Approval: 2003",358255,aprepitant,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_58c4261e-e98f-4280-9562-2800956dff14.json,58c4261e-e98f-4280-9562-2800956dff14,16,"These highlights do not include all the information needed to use GLIMEPIRIDE TABLETS safely and effectively. See full prescribing information for GLIMEPIRIDE TABLETS.
 

GLIMEPIRIDE tablets for oral use
 

Initial U.S. Approval: 1995",25789,glimepiride,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240213_b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0.json,b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0,15,"Propylthiouracil Tablets, USP",8794,propylthiouracil,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1554072,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231210_7e659505-c902-4906-9461-1cc83e2236d2.json,7e659505-c902-4906-9461-1cc83e2236d2,25,"These highlights do not include all the information needed to use ISENTRESS safely and effectively. See full prescribing information for ISENTRESS. 
ISENTRESS® (raltegravir) film-coated tablets, for oral useISENTRESS® HD (raltegravir) film-coated tablets, for oral useISENTRESS® (raltegravir) chewable tablets, for oral useISENTRESS® (raltegravir) for oral suspensionInitial U.S. Approval: 2007",719872,raltegravir,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240124_c3658bc8-1524-43db-930e-66f9ac01b808.json,c3658bc8-1524-43db-930e-66f9ac01b808,11,"These highlights do not include all the information needed to use TELMISARTAN TABLETS safely and effectively. See full prescribing information for TELMISARTAN TABLETS.  TELMISARTAN tablets, for oral useInitial U.S. Approval: 1998",73494,telmisartan,10069339,acute kidney injury,500000401,acute kidney injury,6,1,500000401,1317640,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231230_cb960074-99c1-4a73-941f-f0644a7ec219.json,cb960074-99c1-4a73-941f-f0644a7ec219,40,"These highlights do not include all the information needed to use AGRYLIN safely and effectively. See full prescribing information for AGRYLIN.
AGRYLIN® (anagrelide) capsules, for oral useInitial U.S. Approval: 1997",596724,anagrelide,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20120511_ba1cca98-f350-4655-88e3-6ef990779fb9.json,ba1cca98-f350-4655-88e3-6ef990779fb9,1,"KETEK®
(telithromycin) Tablets",274786,telithromycin,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230223_4764f37b-c9e6-4ede-bcc2-8a03b7c521df.json,4764f37b-c9e6-4ede-bcc2-8a03b7c521df,46,"These highlights do not include all the information needed to use SPRYCEL® safely and effectively. See full prescribing information for SPRYCEL.

SPRYCEL (dasatinib) tablets, for oral useInitial U.S. Approval: 2006",475342,dasatinib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20121026_32d632f6-e7cc-455e-bd9a-3dcfc99a794f.json,32d632f6-e7cc-455e-bd9a-3dcfc99a794f,1,"These highlights do not include all the information needed to use PRISTIQ safely and effectively. See full prescribing information for PRISTIQ.
PRISTIQ® (desvenlafaxine) Extended-Release Tablets, oralInitial U.S. Approval: 2008",734064,desvenlafaxine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240202_e2e576e6-6181-4178-b989-61d0e795e559.json,e2e576e6-6181-4178-b989-61d0e795e559,13,"These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. 
JANUVIA® (sitagliptin) tablets, for oral useInitial U.S. Approval: 2006",593411,sitagliptin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac.json,3cf751f2-a0c9-45d7-8acb-2bc61db0e4ac,9,"Mesalamine Rectal Suspension Enema

4 grams/unit (60 mL)",52582,mesalamine,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd.json,3e43c17f-7e7e-4ccd-b321-1dd5e62cdafd,8,"These highlights do not include all the information needed to use LEVETIRACETAM INJECTION safely and effectively. See full prescribing information for LEVETIRACETAM INJECTION.
 LEVETIRACETAM injection, for intravenous use Initial U.S. Approval: 1999",114477,levetiracetam,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230620_20e5acf0-90b7-45c8-be78-91eaf77c9ac0.json,20e5acf0-90b7-45c8-be78-91eaf77c9ac0,2,"These highlights do not include all the information needed to use FLUDARABINE phosphate injection safely and effectively. See full prescribing information for FLUDARABINE phosphate injection.
FLUDARABINE phosphate injection, for intravenous use onlyInitial U.S. Approval: 1991",24698,fludarabine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_b856bfaf-ec6b-4171-81c4-b9b07f780084.json,b856bfaf-ec6b-4171-81c4-b9b07f780084,2,"These highlights do not include all the information needed to use VALGANCICLOVIR HYDROCHLORIDE FOR ORAL SOLUTION safely and effectively. See full prescribing information for VALGANCICLOVIR HYDROCHLORIDE FOR ORAL SOLUTION. VALGANCICLOVIR HYDROCHLORIDE, for oral solution Initial U.S. Approval: 2001",275891,valganciclovir,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_3495a71a-cc04-4776-851f-f185956f32af.json,3495a71a-cc04-4776-851f-f185956f32af,22,"These highlights do not include all the information needed to use VIDAZA safely and effectively. See full prescribing information for VIDAZA.
VIDAZA (azacitidine for injection), for subcutaneous or intravenous useInitial U.S. Approval: 2004",1251,azacitidine,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231228_755476e5-62a2-4f01-92a3-307e192ad42c.json,755476e5-62a2-4f01-92a3-307e192ad42c,5,"These highlights do not include all the information needed to use PARICALCITOL CAPSULES safely and effectively.
 
See full prescribing information for PARICALCITOL CAPSULES.
 

PARICALCITOL capsules, for oral use
 
Initial U.S. Approval: 1998",73710,paricalcitol,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/train_xml/20231004_63df5af3-b8ac-4e76-9830-2dbb340af922.json,63df5af3-b8ac-4e76-9830-2dbb340af922,27,"These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspensionInitial U.S. Approval: 2013",1433868,dolutegravir,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,a1787fad-3612-43e1-98fa-ce62361e0b3c,13,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001",282388,imatinib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240203_a1787fad-3612-43e1-98fa-ce62361e0b3c.json,a1787fad-3612-43e1-98fa-ce62361e0b3c,13,"These highlights do not include all the information needed to use IMATINIB MESYLATE TABLETS safely and effectively.  See full prescribing information for IMATINIB MESYLATE TABLETS. IMATINIB MESYLATE tablets, for oral useInitial U.S. Approval: 2001",282388,imatinib,10019692,hepatic necrosis,500000301,acute liver injury,15,1,500000301,1304107,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240217_413c645e-074d-4276-b39a-d83521077602.json,413c645e-074d-4276-b39a-d83521077602,14,"These highlights do not include all the information needed to use ABIRATERONE ACETATE TABLETS safely and effectively. See full prescribing information for ABIRATERONE ACETATE TABLETS.
  

ABIRATERONE ACETATE tablets,
 
for oral use 

Initial U.S. Approval: 2011",1100072,abiraterone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240201_b17679e8-88c8-4b8d-bfae-246fab6eead9.json,b17679e8-88c8-4b8d-bfae-246fab6eead9,13,"These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, for intravenous use
Initial U.S. Approval: 1996",72962,docetaxel,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_749e42fb-2fe0-45dd-9268-b43bb3f4081c.json,749e42fb-2fe0-45dd-9268-b43bb3f4081c,32,"These highlights do not include all the information needed to use TRACLEER safely and effectively. See full prescribing information for TRACLEER.
 



TRACLEER 
 ®(bosentan) tablets, for oral use
 

TRACLEER 
 ®(bosentan) tablets for oral suspension
 

Initial U.S. Approval: 2001",75207,bosentan,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1321636,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231208_de512e9b-444c-4ae4-8c6b-accd87a02021.json,de512e9b-444c-4ae4-8c6b-accd87a02021,5,"Chlorothiazide Sodium for Injection, USP",2396,chlorothiazide,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,992590,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240117_8c5d6067-16a1-43ab-9e52-a33c600a5c44.json,8c5d6067-16a1-43ab-9e52-a33c600a5c44,2,"These highlights do not include all the information needed to use DECITABINE FOR INJECTION safely and effectively. See full prescribing information for DECITABINE FOR INJECTION.
DECITABINE for injection, for intravenous useInitial U.S. Approval: 2006",15657,decitabine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240202_860c799c-5199-4f0c-b21b-9910273474d9.json,860c799c-5199-4f0c-b21b-9910273474d9,6,Pentamidine isethionate for injection,7994,pentamidine,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231229_4b4725eb-95f1-45cc-852f-152beb5f1e2c.json,4b4725eb-95f1-45cc-852f-152beb5f1e2c,4,"These highlights do not include all the information needed to use THIOTEPA FOR INJECTION safely and effectively. See full prescribing information for THIOTEPA FOR INJECTION.THIOTEPA for injection, for intravenous, intracavitary, or intravesical useInitial U.S. Approval: 1959",10473,thiotepa,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230321_f7573809-7741-04c9-e053-6294a90ab193.json,f7573809-7741-04c9-e053-6294a90ab193,1,"ZILEUTON EXTENDED-RELEASE TABLETS. These highlights do not include all the information needed to use ZILEUTON EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for ZILEUTON EXTENDED-RELEASE TABLETS.
 

ZILEUTON extended-release tablets, for oral use
 

Initial U.S. Approval: 1996",40575,zileuton,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240119_6d1c87df-b319-4c63-9f19-6584d7c4ff8e.json,6d1c87df-b319-4c63-9f19-6584d7c4ff8e,8,Rifampin Capsules USP,9384,rifampin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1763204,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_5198b1c8-8dd6-4b8f-bd85-294ac468af53.json,5198b1c8-8dd6-4b8f-bd85-294ac468af53,10,"These highlights do not include all the information needed to use FLUVOXAMINE MALEATE TABLETS safely and effectively. See full prescribing information for FLUVOXAMINE MALEATE TABLETS.
 

FLUVOXAMINE MALEATE tablets, for oral use
 
Initial U.S. Approval: 1994",42355,fluvoxamine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/train_xml/20211231_ca70b23e-6f02-43a8-9c88-9550c0d230cf.json,ca70b23e-6f02-43a8-9c88-9550c0d230cf,100,"These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.
ELIQUIS® (apixaban) tablets, for oral useInitial U.S. Approval: 2012",1364430,apixaban,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240126_2428969a-7431-4e94-9503-ad5c680e2ea4.json,2428969a-7431-4e94-9503-ad5c680e2ea4,9,"Corvert®


(ibutilide fumarate) injection",41289,ibutilide,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240106_bc9c338c-1fc7-4bc2-a357-a78e433cbe9d.json,bc9c338c-1fc7-4bc2-a357-a78e433cbe9d,6,"Cefpodoxime Proxetil Tablets, USP
 Rx only",20489,cefpodoxime,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_7731e46a-2121-441b-b090-12dcefe240f0.json,7731e46a-2121-441b-b090-12dcefe240f0,9,"These highlights do not include all the information needed to use TIROFIBAN HYDROCHLORIDE injection safely and effectively. See full prescribing information for TIROFIBAN HYDROCHLORIDE injection.
TIROFIBAN HYDROCHLORIDE injection, for intravenous use Initial U.S. Approval: 1998",73137,tirofiban,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_8849c8f9-ee41-4ccd-8a62-67b04e80a276.json,8849c8f9-ee41-4ccd-8a62-67b04e80a276,1,"These highlights do not include all the information needed to use ARSENIC TRIOXIDE INJECTION safely and effectively. See full prescribing information for ARSENIC TRIOXIDE INJECTION. ARSENIC TRIOXIDE injection, for intravenous use Initial U.S. Approval: 2000",18330,arsenic trioxide,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210630_c00d1607-ac36-457b-a34b-75ad74f9cf0a.json,c00d1607-ac36-457b-a34b-75ad74f9cf0a,32,"These highlights do not include all the information needed to use INVIRASE safely and effectively. See full prescribing information for INVIRASE. 
INVIRASE® (saquinavir mesylate) tablets, for oral use
 Initial U.S. Approval: 1995",83395,saquinavir,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230613_dd3dcc9a-e40c-4677-9ee6-f318e7c7d835.json,dd3dcc9a-e40c-4677-9ee6-f318e7c7d835,31,"These highlights do not include all the information needed to use VINORELBINE INJECTION safely and effectively. See full prescribing information for VINORELBINE INJECTION. 


VINORELBINE injection, for intravenous use 

Initial U.S. Approval: 1994",39541,vinorelbine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231222_674e0e6d-46ed-4868-9196-04019d667716.json,674e0e6d-46ed-4868-9196-04019d667716,24,"",8011,pentostatin,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231222_674e0e6d-46ed-4868-9196-04019d667716.json,674e0e6d-46ed-4868-9196-04019d667716,24,"",8011,pentostatin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/gold_xml/20211121_17f85d17-ab71-4f5b-9fe3-0b8c822f69ff.json,17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,19,"These highlights do not include all the information needed to use PERJETA safely and effectively.  See full prescribing information for PERJETA. 
PERJETA® (pertuzumab) injection, for intravenous use Initial U.S. Approval:  2012",1298944,pertuzumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,b6465b44-a6dd-f99c-d009-6851cf05169c,11,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab).",224905,trastuzumab,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,b6465b44-a6dd-f99c-d009-6851cf05169c,11,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab).",224905,trastuzumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_29ba0172-7ca3-4122-af1b-f0da522318cb.json,29ba0172-7ca3-4122-af1b-f0da522318cb,6,"These highlights do not include all the information needed to use HYDROXYCHLOROQUINE SULFATE TABLETS safely and effectively. See full prescribing information for HYDROXYCHLOROQUINE SULFATE TABLETS.
HYDROXYCHLOROQUINE SULFATE Tablets, for oral use
Initial U.S. Approval: 1955",5521,hydroxychloroquine,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240120_d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f.json,d15733a9-d5fd-4d5f-86ce-e7ed8c706c7f,8,Mefenamic Acid Capsules USPRx Only,257844,mefenamate,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240125_ca1d3449-ea29-49a4-8863-365ec95f1553.json,ca1d3449-ea29-49a4-8863-365ec95f1553,6,"SSKI® 
Potassium Iodide Oral Solution, USP (Saturated) 1 g/mL",8597,potassium iodide,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231115_fb77637a-88d9-4aea-958f-e270030ce30d.json,fb77637a-88d9-4aea-958f-e270030ce30d,18,"These highlights do not include all the information needed to use BAXDELA® safely and effectively. See full prescribing information for BAXDELA. 
BAXDELA (delafloxacin) tablets, for oral use BAXDELA (delafloxacin) for injection, for intravenous use Initial U.S. Approval: 2017",1927663,delafloxacin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,2150f73a-179b-4afc-b8ce-67c85cc72f04,60,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009",141704,everolimus,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_c7bb6ba1-9a7f-43f5-b058-ef26d4b59221.json,c7bb6ba1-9a7f-43f5-b058-ef26d4b59221,3,"These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS.
 EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009",141704,everolimus,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240112_ae77f00f-d43b-4b75-afd5-a2a9cb7138da.json,ae77f00f-d43b-4b75-afd5-a2a9cb7138da,9,"These highlights do not include all the information needed to use PEMETREXED FOR INJECTION safely and effectively. See full prescribing information for PEMETREXED FOR INJECTION.
PEMETREXED FOR INJECTION, for Intravenous Use Initial U.S. Approval: 2004",68446,pemetrexed,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231129_d1e41dcf-e82a-47c2-a0ad-6c6eef621834.json,d1e41dcf-e82a-47c2-a0ad-6c6eef621834,16,"These highlights do not include all the information needed to use NERLYNX safely and effectively. See full prescribing information for NERLYNX.
 



NERLYNX 
 ®(neratinib) tablets, for oral use
 

Initial U.S. Approval: 2017",1940643,neratinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240219_06f442d6-071e-4081-b7f7-40f3b803ab3f.json,06f442d6-071e-4081-b7f7-40f3b803ab3f,4,"These highlights do not include all the information needed to use SORAFENIB TABLETS safely and effectively.
 
See full prescribing information for SORAFENIB TABLETS.
 
Sorafenib tablets, for oral use
 
Initial U.S. Approval: 2005",495881,sorafenib,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220618_42c49deb-713b-427a-9670-08af08adcffb.json,42c49deb-713b-427a-9670-08af08adcffb,22,"These highlights do not include all the information needed to use ALECENSA safely and effectively. See full prescribing information for ALECENSA. 
ALECENSA® (alectinib) capsules, for oral useInitial U.S. Approval: 2015",1727455,alectinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220623_08982e49-d2eb-4b25-b01a-1be52fd669ef.json,08982e49-d2eb-4b25-b01a-1be52fd669ef,16,"These highlights do not include all the information needed to use APTIVUS safely and effectively.  See full prescribing information for APTIVUS. 
APTIVUS® (tipranavir) capsules, for oral use APTIVUS® (tipranavir) oral solution Initial U.S. Approval: 2005",190548,tipranavir,10024690,liver function test abnormal,500000301,acute liver injury,15,1,500000301,1736999,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231108_c01906fa-2c73-4c13-9765-2fd06628d263.json,c01906fa-2c73-4c13-9765-2fd06628d263,26,"Lincocin®


 lincomycin injection, USP",6398,lincomycin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/train_xml/20240220_4b4674d8-4d1e-4728-8465-d42ada33fa5c.json,4b4674d8-4d1e-4728-8465-d42ada33fa5c,23,"These highlights do not include all the information needed to use 
DALVANCE

®

 
safely and effectively.  
See full prescribing information for 
DALVANCE
.  

   

DALVANCE
 (
dalbavancin
)
 
for 
injection
,
 
for 
intravenous 
use 

Initial U.S. Approval: 
2014",1539239,dalbavancin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,d5929f91-6496-4c0e-97e8-0bd524e15763,3,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20220826_de77155c-ecf2-4f15-9758-21d271449d83.json,de77155c-ecf2-4f15-9758-21d271449d83,2,"These highlights do not include all the information needed to use FOTIVDA safely and effectively. See full prescribing information for FOTIVDA. 
FOTIVDA® (tivozanib) capsules, for oral use Initial U.S. Approval: 2021",2534233,tivozanib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221118_a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330.json,a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330,4,"These highlights do not include all the information needed to use Cleviprex safely and effectively. See full prescribing information for Cleviprex.
 



Cleviprex (clevidipine) injectable emulsion, for intravenous use
 

Initial U.S. Approval: 2008",233603,clevidipine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_49aa3d6d-2270-4615-aafa-b440859ab870.json,49aa3d6d-2270-4615-aafa-b440859ab870,4,Naltrexone Hydrochloride Tablets USP 50 mg,7243,naltrexone,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240109_0c8dbbc9-6c85-4acd-a7bd-c55ec5829212.json,0c8dbbc9-6c85-4acd-a7bd-c55ec5829212,1,"These highlights do not include all the information needed to use ALOGLIPTIN TABLETS safely and effectively. See full prescribing information for ALOGLIPTIN TABLETS.
 

Alogliptin Tablets, for oral use
 
Initial U.S. Approval: 2013",1368001,alogliptin,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/train_xml/20230811_a3768c7e-aa4c-44d3-bc53-43bb7346c0b0.json,a3768c7e-aa4c-44d3-bc53-43bb7346c0b0,21,"These highlights do not include all the information needed to use NESINA safely and effectively. See full prescribing information for NESINA. 
NESINA (alogliptin) tablets, for oral use Initial U.S. Approval: 2013",1368001,alogliptin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231130_7b0ec4bf-b2ac-49ee-96af-7740ad3f2e16.json,7b0ec4bf-b2ac-49ee-96af-7740ad3f2e16,4,"These highlights do not include all the information needed to use TURALIO safely and effectively. See full prescribing information for TURALIO.
 TURALIO® (pexidartinib) capsules, for oral use Initial U.S. Approval: 2019",2183102,pexidartinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230325_294b168b-6e5f-4db9-bf70-d599271458b3.json,294b168b-6e5f-4db9-bf70-d599271458b3,6,These highlights do not include all the information needed to use ZOLADEX safely and effectively. See full prescribing information for ZOLADEX.ZOLADEX® (goserelin implant) 3.6 mgInitial U.S. Approval: 1989,50610,goserelin,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/gold_xml/20221103_da1c9f37-779e-4682-816f-93d0faa4cfc9.json,da1c9f37-779e-4682-816f-93d0faa4cfc9,16,"These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. 
OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014",1592737,nintedanib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231117_a3e4c8e5-bff0-4a8f-8401-e9866c846ee2.json,a3e4c8e5-bff0-4a8f-8401-e9866c846ee2,3,"These highlights do not include all the information needed to use Suprane (desflurane, USP) safely and effectively. See full prescribing information for Suprane (desflurane, USP).Suprane (desflurane, USP) Volatile Liquid for InhalationInitial U.S. Approval:  1992",27340,desflurane,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/train_xml/20231216_8d5f892b-e4f3-4a9e-9a91-95e2fca34144.json,8d5f892b-e4f3-4a9e-9a91-95e2fca34144,9,"These highlights do not include all the information needed to use INVOKANA safely and effectively. See full prescribing information for INVOKANA.
 

INVOKANA 
 ®(canagliflozin) tablets, for oral use
 
Initial U.S. Approval: 2013",1373458,canagliflozin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221201_857e53aa-1098-4dad-b654-0276cdd43e03.json,857e53aa-1098-4dad-b654-0276cdd43e03,4,"These highlights do not include all the information needed to use RYLAZE safely and effectively. See full prescribing information for RYLAZE.
RYLAZE® (asparaginase erwinia chrysanthemi (recombinant)-rywn) injection, for intramuscular useInitial U.S. Approval: 2021",1156,asparaginase,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20231213_01f90c94-71cb-4a1f-81ff-8004b850529b.json,01f90c94-71cb-4a1f-81ff-8004b850529b,15,"These highlights do not include all the information needed to use FARXIGA safely and effectively.  See full prescribing information for FARXIGA.
FARXIGA® (dapagliflozin) tablets, for oral useInitial U.S. Approval: 2014",1488564,dapagliflozin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,2150f73a-179b-4afc-b8ce-67c85cc72f04,60,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009",141704,everolimus,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/gold_xml/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010",612865,tocilizumab,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010",612865,tocilizumab,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230106_74a611bc-9977-46bb-b626-0370b3031628.json,74a611bc-9977-46bb-b626-0370b3031628,8,"These highlights do not include all the information needed to use FEXINIDAZOLE TABLETS safely and effectively. See full prescribing information for FEXINIDAZOLE TABLETS.
 



FEXINIDAZOLE tablets, for oral use
 

Initial U.S. Approval: 2021",2564146,fexinidazole,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230107_626dc9e5-c6b4-4f9c-9bf4-774fd3ae619a.json,626dc9e5-c6b4-4f9c-9bf4-774fd3ae619a,43,"These highlights do not include all the information needed to use VENOFER ® safely and effectively. See full prescribing information for VENOFER.Venofer (iron sucrose) injection, for intravenous useInitial U.S. Approval:  2000",24909,iron sucrose,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_fee3bd4a-ade3-41fa-839a-48e9af69bcf4.json,fee3bd4a-ade3-41fa-839a-48e9af69bcf4,5,"Diprivan® (Propofol) Injectable Emulsion, USP",8782,propofol,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230202_241f0b1e-8b95-470d-876f-bf1804daaf18.json,241f0b1e-8b95-470d-876f-bf1804daaf18,11,"These highlights do not include all the information needed to use IXEMPRA 
 ® safely and effectively. See full prescribing information for IXEMPRA 
 ®.
 



IXEMPRA 
 ® 
Kit (ixabepilone) for Injection, for intravenous infusion only
 



Initial U.S. Approval: 2007",337523,ixabepilone,10000804,acute hepatic failure,500000301,acute liver injury,5,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230215_57a597d2-03f0-472e-b148-016d7169169d.json,57a597d2-03f0-472e-b148-016d7169169d,12,"These highlights do not include all the information needed to use TRODELVY safely and effectively. See full prescribing information for TRODELVY 
 TRODELVY® (sacituzumab govitecan-hziy) for injection, for intravenous use Initial U.S. Approval: 2020",2360231,sacituzumab,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230225_d7354af1-f304-f4d9-e053-2995a90ab219.json,d7354af1-f304-f4d9-e053-2995a90ab219,2,"These highlights do not include all the information needed to use FILSPARITM safely and effectively. See full prescribing information for FILSPARITM.
FILSPARITM (sparsentan) tablets, for oral useInitial U.S. Approval: 2023",2630535,sparsentan,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/gold_xml/20231201_38eea320-7e0c-485a-bc30-98c3c45e2763.json,38eea320-7e0c-485a-bc30-98c3c45e2763,24,"These highlights do not include all the information needed to use ZELBORAF safely and effectively. See full prescribing information for ZELBORAF. 
 ZELBORAF® (vemurafenib) tablet for oral use  Initial U.S. Approval: 2011",1147220,vemurafenib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231201_38eea320-7e0c-485a-bc30-98c3c45e2763.json,38eea320-7e0c-485a-bc30-98c3c45e2763,24,"These highlights do not include all the information needed to use ZELBORAF safely and effectively. See full prescribing information for ZELBORAF. 
 ZELBORAF® (vemurafenib) tablet for oral use  Initial U.S. Approval: 2011",1147220,vemurafenib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_d138ab10-1ed9-44be-8d81-49dda1e434ac.json,d138ab10-1ed9-44be-8d81-49dda1e434ac,2,"These highlights do not include all the information needed to use ERAXIS safely and effectively. See full prescribing information for ERAXIS. 
ERAXIS® (anidulafungin) for injection, for intravenous use Initial U.S. Approval: 2006",341018,anidulafungin,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230523_6fa682c9-a312-4932-9831-f286908660ee.json,6fa682c9-a312-4932-9831-f286908660ee,34,"These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. 
 TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016",1792776,atezolizumab,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230526_e5721cb8-4185-47b9-bbb3-1c587e558a03.json,e5721cb8-4185-47b9-bbb3-1c587e558a03,8,"These highlights do not include all the information needed to use CAPRELSA safely and effectively. See full prescribing information for CAPRELSA.CAPRELSA® (vandetanib) tablets, for oral useInitial U.S. Approval: 2011",1098413,vandetanib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230615_1e484a50-55db-4b85-8c57-6cd1b0353abd.json,1e484a50-55db-4b85-8c57-6cd1b0353abd,32,"These highlights do not include all the information needed to use OPSUMIT safely and effectively. See full prescribing information for OPSUMIT.
 



OPSUMIT 
 ® (macitentan) tablets, for oral use
 

Initial U.S. Approval: 2013",1442132,macitentan,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_0935cd31-3251-4a0a-ac23-25ca4be12be9.json,0935cd31-3251-4a0a-ac23-25ca4be12be9,2,"These highlights do not include all the information needed to use BYLVAY safely and effectively. See full prescribing information for BYLVAY. 
BYLVAY (odevixibat) capsules, for oral use BYLVAY (odevixibat) oral pellets Initial U.S. Approval: 2021",2563966,odevixibat,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230617_6a571038-1f6c-4e66-937c-ddf6e2a4e30a.json,6a571038-1f6c-4e66-937c-ddf6e2a4e30a,3,"",2639620,vilobelimab,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/train_xml/20230627_3904f8dd-1aef-3490-e48f-bd55f32ed67f.json,3904f8dd-1aef-3490-e48f-bd55f32ed67f,34,"These highlights do not include all the information needed to use ADCETRIS safely and effectively. See full prescribing information for ADCETRIS. 
ADCETRIS® (brentuximab vedotin) for injection, for intravenous use Initial U.S. approval: 2011",1147320,brentuximab vedotin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,2265ef30-253e-11df-8a39-0800200c9a66,42,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011",1094833,ipilimumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,6093952a-5248-45cb-ad17-33716a411146,37,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007",662281,nilotinib,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_6093952a-5248-45cb-ad17-33716a411146.json,6093952a-5248-45cb-ad17-33716a411146,37,"These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA.
TASIGNA® (nilotinib) capsules, for oral use
		Initial U.S. Approval: 2007",662281,nilotinib,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_72e6b33c-0351-4070-9172-eeaa186c01d2.json,72e6b33c-0351-4070-9172-eeaa186c01d2,14,"These highlights do not include all the information needed to use VEMLIDY safely and effectively. See full prescribing information for VEMLIDY. 
 VEMLIDY® (tenofovir alafenamide) tablets, for oral use  Initial U.S. Approval: 2015",1721603,tenofovir alafenamide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240217_fedbffa7-087d-4448-85c9-0350a3947080.json,fedbffa7-087d-4448-85c9-0350a3947080,10,"HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use LINEZOLID INJECTION safely and effectively. See full prescribing information for LINEZOLID INJECTION.




LINEZOLID injection, for intravenous use

Initial U.S. Approval: 2000",190376,linezolid,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231228_bcbc5d92-e022-4a0d-ab4d-2b0d7aa68c58.json,bcbc5d92-e022-4a0d-ab4d-2b0d7aa68c58,5,"These highlights do not include all the information needed to use LEVOMILNACIPRAN EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for LEVOMILNACIPRAN EXTENDED-RELEASE CAPSULES.
 


LEVOMILNACIPRAN extended-release capsules, for oral use 

Initial U.S. Approval: 2009 (milnacipran)",1433212,levomilnacipran,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240125_b6465b44-a6dd-f99c-d009-6851cf05169c.json,b6465b44-a6dd-f99c-d009-6851cf05169c,11,"These highlights do not include all the information needed to use OGIVRI safely and effectively.  See full prescribing information for OGIVRI. 
OGIVRI® (trastuzumab-dkst) for injection, for intravenous use
Initial U.S. Approval: 2017
 

OGIVRI® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab).",224905,trastuzumab,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230907_aaeaef94-f3f5-4367-8ea2-b181d7be2da8.json,aaeaef94-f3f5-4367-8ea2-b181d7be2da8,19,"These highlights do not include all the information needed to use KISQALI safely and effectively. See full prescribing information for KISQALI.
		
KISQALI® (ribociclib) tablets, for oral use
		Initial U.S. Approval: 2017",1873916,ribociclib,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230930_f1a91500-a944-4cb8-b4a8-ae278bcf728d.json,f1a91500-a944-4cb8-b4a8-ae278bcf728d,4,"These highlights do not include all the information needed to use EXKIVITY safely and effectively. See full prescribing information for EXKIVITY.
 EXKIVITY® (mobocertinib) capsules, for oral use Initial U.S. Approval: 2021",2570736,mobocertinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/train_xml/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,84137882-e000-47da-bd5b-fa76ab3c76f9,20,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012",1242999,axitinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_4f6848e5-35ed-4046-b13c-3032b5ba3232.json,4f6848e5-35ed-4046-b13c-3032b5ba3232,25,"These highlights do not include all the information needed to use (PROVAYBLUE) safely and effectively. See full prescribing information for (PROVAYBLUE). 
 PROVAYBLUE® (methylene blue) injection, USP for intravenous use 
 Initial U.S. Approval: 2016",6878,methylene blue,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_61c3d6c7-0d9c-4e46-b091-88d84893e14a.json,61c3d6c7-0d9c-4e46-b091-88d84893e14a,11,"These highlights do not include all the information needed to use ZOLPIDEM TARTRATE TABLETS safely and effectively. See full prescribing information for ZOLPIDEM TARTRATE TABLETS.
 



ZOLPIDEM TARTRATE tablets, for oral use, C-IV
 

Initial U.S. Approval: 1992",39993,zolpidem,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240221_8d5ace90-983b-48c4-baf1-b44f6af146de.json,8d5ace90-983b-48c4-baf1-b44f6af146de,2,"Carbamazepine Oral Suspension, USP
 
Rx only
 
Prescribing Information",2002,carbamazepine,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,740275,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240208_5c8cebcd-699f-4c4c-900b-94e0fe519345.json,5c8cebcd-699f-4c4c-900b-94e0fe519345,100,"These highlights do not include all the information needed to use PROPAFENONE HYDROCHLORIDE TABLETS safely and effectively.  See full prescribing information for PROPAFENONE HYDROCHLORIDE TABLETS.
PROPAFENONE HYDROCHLORIDE tablets, for oral useInitial U.S. Approval: 1989",8754,propafenone,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_74f84173-a43f-7788-e053-2991aa0a8fb2.json,74f84173-a43f-7788-e053-2991aa0a8fb2,6,SOLU-CORTEF® 100mg 2mL ACT-O-VIAL®,5492,hydrocortisone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231218_8edd78a9-d762-4578-a610-28d6595f4bf3.json,8edd78a9-d762-4578-a610-28d6595f4bf3,1,Melphalan Hydrochloride for Injection(For Intravenous Infusion),6718,melphalan,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20221228_39e62997-8781-449a-e054-00144ff88e88.json,39e62997-8781-449a-e054-00144ff88e88,7,"Nizatidine Oral Solution 

15 mg/mL 

 
Rx only",42319,nizatidine,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992",32613,oxaprozin,10038435,renal failure,500000401,acute kidney injury,20,1,500000401,1118045,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_76e1839b-7462-4344-b319-001a5f57d67a.json,76e1839b-7462-4344-b319-001a5f57d67a,12,"These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
 

PANTOPRAZOLE SODIUM delayed-release tablets, for oral use
 
Initial U.S. approval: 2000",40790,pantoprazole,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_726daf35-4c03-464f-a814-cc0a715d6031.json,726daf35-4c03-464f-a814-cc0a715d6031,1,"Fluconazole Tablets USP
 
Rx only",4450,fluconazole,10000804,acute hepatic failure,500000301,acute liver injury,5,1,500000301,1754994,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240209_d288e484-32fc-4b46-b504-d75a0fac8663.json,d288e484-32fc-4b46-b504-d75a0fac8663,11,"Azathioprine Tablets, USP
  
(50 mg)
 

Rx only",1256,azathioprine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230221_87768fbf-7c63-47da-8925-0316f343d6ef.json,87768fbf-7c63-47da-8925-0316f343d6ef,16,"These highlights do not include all the information needed to use PERINDOPRIL ERBUMINE TABLETS safely and effectively. See full prescribing information for PERINDOPRIL ERBUMINE TABLETS.
 PERINDOPRIL erbumine tablets, for oral use Initial U.S. Approval: 1993",54552,perindopril,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_ccd95dfc-9236-4707-a715-6a12c91519ff.json,ccd95dfc-9236-4707-a715-6a12c91519ff,6,"These highlights do not include all the information needed to use NAPROXEN TABLETS safely and effectively. See full prescribing information for NAPROXEN TABLETS.
 

NAPROXEN tablets, for oral use
 

Initial U.S. Approval: 1976",7258,naproxen,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1115008,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240224_24926986-7552-4f1a-8366-f035bbd07104.json,24926986-7552-4f1a-8366-f035bbd07104,7,"These highlights do not include all the information needed to use FLUOXETINE CAPSULES safely and effectively. See full prescribing information for FLUOXETINE CAPSULES.
 
FLUOXETINE capsules, for oral use
 
Initial U.S. Approval: 1987",4493,fluoxetine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240126_1fffe88d-50c8-45cf-ac7c-a62b665c89a8.json,1fffe88d-50c8-45cf-ac7c-a62b665c89a8,16,SULINDAC TABLETS USP,10237,sulindac,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1236607,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240222_bf93022c-a965-49c5-a852-c59e580d7d91.json,bf93022c-a965-49c5-a852-c59e580d7d91,14,"These highlights do not include all the information needed to use INDOMETHACIN CAPSULES safely and effectively. See full prescribing information for INDOMETHACIN CAPSULES.
 



INDOMETHACIN capsules, for oral use
 

Initial U.S. Approval: 1965",5781,indomethacin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240214_0653b873-b74b-4ec6-b112-675760703d91.json,0653b873-b74b-4ec6-b112-675760703d91,3,"Nabumetone Tablets, USP

Rx only

8463021/1223F",31448,nabumetone,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1113648,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240105_8345d55e-ad02-4726-a04b-1a46e3337a4b.json,8345d55e-ad02-4726-a04b-1a46e3337a4b,13,"These highlights do not include all the information needed to use CAPECITABINE TABLETS safely and effectively. See full prescribing information for CAPECITABINE TABLETS.
 







CAPECITABINE tablets, for oral use
 







Initial U.S. Approval: 1998",194000,capecitabine,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_246e0ed0-f8ca-483b-a1ce-91052f3f35f0.json,246e0ed0-f8ca-483b-a1ce-91052f3f35f0,9,"Enalapril Maleate Tablets, USP",3827,enalapril,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240110_48ffeac8-38e8-4007-903a-dbffce25d679.json,48ffeac8-38e8-4007-903a-dbffce25d679,2,"These highlights do not include all the information needed to use ETRAVIRINE TABLETS safely and effectively.See full prescribing information for ETRAVIRINE TABLETS.
ETRAVIRINE tablets, for oral useInitial U.S. Approval: 2008",475969,etravirine,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20120508_829e744d-7bd4-43dc-9b58-ffb016cb8e67.json,829e744d-7bd4-43dc-9b58-ffb016cb8e67,1,These highlights do not include all the information needed to use didanosine delayed-release capsules safely and effectively. See full prescribing information for didanosine delayed-release capsules. Initial U.S. Approval: 1991,3364,didanosine,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1724869,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240210_0d976866-81b3-5db8-e063-6294a90a39f9.json,0d976866-81b3-5db8-e063-6294a90a39f9,3,"",8727,progesterone,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4.json,b81c6495-8b30-41ef-8a0f-4cbfd87f1eb4,9,"IBUPROFEN Tablets, USP",5640,ibuprofen,10019663,hepatic failure,500000301,acute liver injury,45,1,500000301,1177480,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240206_35d0074e-212b-4a1f-9cd7-974ca08d2c95.json,35d0074e-212b-4a1f-9cd7-974ca08d2c95,21,"These highlights do not include all the information needed to use ROPINIROLE TABLETS safely and effectively. See full prescribing information for ROPINIROLE TABLETS.
ROPINIROLE tablets, for oral use Initial U.S. Approval: 1997",72302,ropinirole,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_1dbac120-d4e6-45a9-b950-3d82aa7a1271.json,1dbac120-d4e6-45a9-b950-3d82aa7a1271,10,"Labetalol Hydrochloride Tablets, USP
 

Rx only",6185,labetalol,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231227_8bf8e76c-27cb-42a4-aa9c-bdade68c463b.json,8bf8e76c-27cb-42a4-aa9c-bdade68c463b,4,These highlights do not include all the information needed to use RASAGILINE TABLETS safely and effectively. See full prescribing information for RASAGILINE TABLETS. RASAGILINE tablets for oral use Initial U.S. Approval: 2006,134748,rasagiline,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231220_fd427d2d-b78b-412a-9c80-606bc88ad112.json,fd427d2d-b78b-412a-9c80-606bc88ad112,10,"These highlights do not include all the information needed to use ELETRIPTAN HYDROBROMIDE TABLETS safely and effectively. See full prescribing information for ELETRIPTAN HYDROBROMIDE TABLETS.


ELETRIPTAN hydrobromide tablets, for oral use 

Initial U.S. Approval: 2002",231049,eletriptan,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240206_9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f.json,9bf86115-8c8d-48f4-9cbe-7709c5ca0d0f,6,KIPROFEN™ Capsules,6142,ketoprofen,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,500000801,1185922,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240131_14f80ad5-37cc-4672-9caa-2dd2f469af0a.json,14f80ad5-37cc-4672-9caa-2dd2f469af0a,2,"These highlights do not include all the information needed to use FEBUXOSTAT TABLETS safely and effectively. See full prescribing information for FEBUXOSTAT TABLETS.
 
FEBUXOSTAT tablets, for oral use
 
Initial U.S. Approval: 2009",73689,febuxostat,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240222_918d0e2a-3af3-46e8-ad06-528263e03ba0.json,918d0e2a-3af3-46e8-ad06-528263e03ba0,11,"These highlights do not include all the information needed to use fentanyl buccal tablet safely and effectively.  See full prescribing information for fentanyl buccal tablet. 
 Fentanyl Buccal Tablet, CII    Initial U.S. Approval: 1968",4337,fentanyl,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240117_c391fe11-fd47-4a35-af6d-c823ab7b8838.json,c391fe11-fd47-4a35-af6d-c823ab7b8838,11,"These highlights do not include all the information needed to use
letrozole tablets
safely and effectively. See full prescribing information for
letrozole tablets.








LETROZOLE tablets, for oral use








Initial U.S. Approval:
1997",72965,letrozole,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_11fad602-16c2-4c1f-bdf1-867d95f063ca.json,11fad602-16c2-4c1f-bdf1-867d95f063ca,10,"These highlights do not include all the information needed to use ROSUVASTATIN TABLETS safely and effectively. See full prescribing information for ROSUVASTATIN TABLETS.
 

ROSUVASTATIN tablets, for oral use
 
Initial U.S. Approval: 2003",301542,rosuvastatin,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_c36132b2-3ec7-4c43-a25e-75cbdbe3d88d.json,c36132b2-3ec7-4c43-a25e-75cbdbe3d88d,5,"CYCLOSPORINE, MODIFIED - cyclosporine capsule, liquid filledRx only Prescribing Information",3008,cyclosporine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240213_b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0.json,b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0,15,"Propylthiouracil Tablets, USP",8794,propylthiouracil,10067125,liver injury,500000301,acute liver injury,6,1,500000301,1554072,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240213_b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0.json,b0c23a2c-b250-4c0d-9b2a-c1483faa2ca0,15,"Propylthiouracil Tablets, USP",8794,propylthiouracil,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,c35e019d-ec34-4e61-9400-a7ae7913e025,3,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004",337525,erlotinib,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231011_c35e019d-ec34-4e61-9400-a7ae7913e025.json,c35e019d-ec34-4e61-9400-a7ae7913e025,3,"These highlights do not include all the information needed to use ERLOTINIB TABLETS safely and effectively. See full prescribing information for ERLOTINIB TABLETS.
ERLOTINIB tablets, for oral use Initial U.S. Approval: 2004",337525,erlotinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231111_57f8aac6-3bd3-4ae1-aab2-759c8bc23292.json,57f8aac6-3bd3-4ae1-aab2-759c8bc23292,4,Trandolapril Tablets USP Rx only,38454,trandolapril,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_b6737b25-0c4f-4131-ba23-b0f2252a18ea.json,b6737b25-0c4f-4131-ba23-b0f2252a18ea,9,"These highlights do not include all the information needed to use SIMVASTATIN TABLETS safely and effectively. See full prescribing information for SIMVASTATIN TABLETS.








SIMVASTATIN tablets, for oral use








Initial U.S. Approval:
1991",36567,simvastatin,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20120511_ba1cca98-f350-4655-88e3-6ef990779fb9.json,ba1cca98-f350-4655-88e3-6ef990779fb9,1,"KETEK®
(telithromycin) Tablets",274786,telithromycin,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231111_3c52dddd-0457-41cd-99e0-d30d4fd00ec5.json,3c52dddd-0457-41cd-99e0-d30d4fd00ec5,4,"These highlights do not include all the information needed to use SELZENTRY safely and effectively. See full prescribing information for SELZENTRY.
SELZENTRY (maraviroc) tablets, for oral useSELZENTRY (maraviroc) oral solutionInitial U.S. Approval: 2007",620216,maraviroc,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231111_3c52dddd-0457-41cd-99e0-d30d4fd00ec5.json,3c52dddd-0457-41cd-99e0-d30d4fd00ec5,4,"These highlights do not include all the information needed to use SELZENTRY safely and effectively. See full prescribing information for SELZENTRY.
SELZENTRY (maraviroc) tablets, for oral useSELZENTRY (maraviroc) oral solutionInitial U.S. Approval: 2007",620216,maraviroc,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240127_03af7d09-314a-fe85-e063-6294a90afa25.json,03af7d09-314a-fe85-e063-6294a90afa25,1,"These highlights do not include all the information needed to use VALSARTAN TABLETS safely and effectively. See full prescribing information for VALSARTAN TABLETS.
 

VALSARTAN tablets, for ORAL use
 
Initial U.S. Approval: 1996",69749,valsartan,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231221_645af8f4-0843-4afb-9ddc-f587f38adb68.json,645af8f4-0843-4afb-9ddc-f587f38adb68,8,"DEMECLOCYCLINE HYDROCHLORIDE TABLETS, USPRx only",3154,demeclocycline,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230115_35addab5-09db-4f8a-9c69-6fbce33ecc37.json,35addab5-09db-4f8a-9c69-6fbce33ecc37,5,"These highlights do not include all the information needed to use GANCICLOVIR FOR INJECTION safely and effectively. See full prescribing information for GANCICLOVIR FOR INJECTION.GANCICLOVIR FOR INJECTION, for intravenous useInitial U.S. Approval: 1989Rx only",4678,ganciclovir,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231231_b9bc3907-bfa7-4d9f-90d9-c2097230f7e4.json,b9bc3907-bfa7-4d9f-90d9-c2097230f7e4,5,"Ethacrynic Acid Tablets, USP 

(25 mg)


Rx Only",62349,ethacrynate,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_f299b2d2-86ed-4fb8-822e-65455a0bb75a.json,f299b2d2-86ed-4fb8-822e-65455a0bb75a,6,"These highlights do not include all the information needed to use OXALIPLATIN INJECTION safely and effectively. See full prescribing information for OXALIPLATIN INJECTION.OXALIPLATIN injection, for intravenous useInitial U.S. Approval: 2002",32592,oxaliplatin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240207_56d64558-1fad-420e-8fcd-7103cd073127.json,56d64558-1fad-420e-8fcd-7103cd073127,1,"These highlights do not include all the information needed to use CELECOXIB CAPSULES safely and effectively. See full prescribing information for CELECOXIB CAPSULES.
 

CELECOXIB capsules, for oral use
 

Initial U.S. Approval: 1998",140587,celecoxib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1118084,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231207_26eb95ba-1f77-4496-a6ea-92bd63a40a3e.json,26eb95ba-1f77-4496-a6ea-92bd63a40a3e,100,"These highlights do not include all the information needed to use OXAPROZIN TABLETS safely and effectively. See full prescribing information for OXAPROZIN TABLETS.
OXAPROZIN tablets, for oral useInitial U.S. Approval: 1992",32613,oxaprozin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,500000301,1118045,1,1
./data/2024_latest_labels/latest_labels_ingredients/20231208_fea50328-b3d5-4300-8c67-82cda0a975b7.json,fea50328-b3d5-4300-8c67-82cda0a975b7,6,"Triamterene Capsule, USP Potassium-Sparing Diuretic",10763,triamterene,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_c394914b-2334-418e-bf86-9f9100323717.json,c394914b-2334-418e-bf86-9f9100323717,6,KETOCONAZOLE CREAM 2%,6135,ketoconazole,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_1738a682-5903-b675-3a7a-61d299a6f248.json,1738a682-5903-b675-3a7a-61d299a6f248,19,"These highlights do not include all the information needed to use ZOLEDRONIC ACID INJECTION safely and effectively. See full prescribing information for ZOLEDRONIC ACID INJECTION. ZOLEDRONIC ACID injection, for intravenous use 
Initial U.S. Approval: 2001",77655,zoledronic acid,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240215_bda70104-d84b-4d3f-9ca0-5f4f1ca816ad.json,bda70104-d84b-4d3f-9ca0-5f4f1ca816ad,13,"These highlights do not include all the information needed to use VORICONAZOLE TABLETS safely and effectively. See full prescribing information for VORICONAZOLE TABLETS.VORICONAZOLE tablets, for oral useInitial U.S. Approval: 2002",121243,voriconazole,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,500000301,1714277,1,1
./data/2024_latest_labels/latest_labels_ingredients/20230916_2cab8dd1-3a10-48e6-86ce-0e5275ed49e5.json,2cab8dd1-3a10-48e6-86ce-0e5275ed49e5,10,"These highlights do not include all the information needed to use FARESTON® safely and effectively. See full prescribing information for FARESTON®.


FARESTON® (toremifene citrate) 60 mg Tablets oral administration

Initial U.S. Approval: 1997",38409,toremifene,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231004_63df5af3-b8ac-4e76-9830-2dbb340af922.json,63df5af3-b8ac-4e76-9830-2dbb340af922,27,"These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspensionInitial U.S. Approval: 2013",1433868,dolutegravir,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20211016_4e338e89-3cf2-48eb-b6e2-a06c608c6513.json,4e338e89-3cf2-48eb-b6e2-a06c608c6513,36,"These highlights do not include all the information needed to use ZYTIGA safely and effectively. See full prescribing information for ZYTIGA. 
ZYTIGA® (abiraterone acetate) tablets, for oral use Initial U.S. Approval: 2011",1100072,abiraterone,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20190522_a4f9f620-e6e4-4a03-a9a7-79007c8c2cfe.json,a4f9f620-e6e4-4a03-a9a7-79007c8c2cfe,6,"These highlights do not include all the information needed to use CNJ-016 (vaccinia immune globulin intravenous, human), VIGIV safely and effectively. See full prescribing information for VIGIV. VIGIV (vaccinia immune globulin, human), 5% sterile solution for intravenous use.Initial U.S. Approval: 2005",597392,human vaccinia immune globulin,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240208_f3c516ad-d405-4fbe-af6a-962080dbfa7d.json,f3c516ad-d405-4fbe-af6a-962080dbfa7d,3,"These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN. 
 PROLEUKIN (aldesleukin) for injection, for intravenous use  Initial U.S. Approval: 1992",70223,aldesleukin,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240201_b17679e8-88c8-4b8d-bfae-246fab6eead9.json,b17679e8-88c8-4b8d-bfae-246fab6eead9,13,"These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, for intravenous use
Initial U.S. Approval: 1996",72962,docetaxel,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240201_b17679e8-88c8-4b8d-bfae-246fab6eead9.json,b17679e8-88c8-4b8d-bfae-246fab6eead9,13,"These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.DOCETAXEL injection, for intravenous use
Initial U.S. Approval: 1996",72962,docetaxel,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_7ee820e4-a479-4b7d-8730-101ac1f8015c.json,7ee820e4-a479-4b7d-8730-101ac1f8015c,102,"These highlights do not include all the information needed to use PIROXICAM CAPSULES safely and effectively.  See full prescribing information for PIROXICAM CAPSULES.
PIROXICAM capsules, for oral useInitial U.S. Approval: 1982",8356,piroxicam,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,500001001,1146810,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240112_ce9f0ea6-69f9-6b68-2811-3b51e34acea6.json,ce9f0ea6-69f9-6b68-2811-3b51e34acea6,5,"",2051,carboprost,10018830,haematemesis,500001001,gi bleed,11,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210106_dd367eec-359a-4065-b5c3-7c0107c823fe.json,dd367eec-359a-4065-b5c3-7c0107c823fe,7,"Tolcapone Tablets

100 mg",72937,tolcapone,10000804,acute hepatic failure,500000301,acute liver injury,5,1,500000301,715727,1,1
./data/2024_latest_labels/latest_labels_ingredients/20240223_7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef.json,7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef,5,"These highlights do not include all the information needed to use DAPTOMYCIN IN SODIUM CHLORIDE INJECTION safely and effectively.  See full prescribing information for DAPTOMYCIN IN SODIUM CHLORIDE INJECTION.
DAPTOMYCIN IN SODIUM CHLORIDE injection, for intravenous use
Initial U.S. Approval: 2003",22299,daptomycin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240227_20293943-46ff-4345-1aa4-929b4e017a25.json,20293943-46ff-4345-1aa4-929b4e017a25,28,"These highlights do not include all the information needed to use SUFENTANIL CITRATE INJECTION, safely and effectively. See full prescribing information for SUFENTANIL CITRATE INJECTION.
Sufentanil Citrate Injection, for intravenous and epidural use, CIIInitial U.S. Approval: 1984",56795,sufentanil,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240124_00fd1905-27e4-420e-8dc5-a69e4ddc1526.json,00fd1905-27e4-420e-8dc5-a69e4ddc1526,11,"These highlights do not include all the information needed to use NITYR safely and effectively. See full prescribing information for NITYR.
NITYR® (nitisinone) tablets, for oral useInitial U.S. Approval: 2002",61805,nitisinone,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_3d30eb8d-a62e-475f-926b-78ba63bee9c8.json,3d30eb8d-a62e-475f-926b-78ba63bee9c8,11,"FORANE (isoflurane, USP) liquid for inhalation",6026,isoflurane,10019692,hepatic necrosis,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_246d42e5-5418-42ba-aff9-ae399b166c69.json,246d42e5-5418-42ba-aff9-ae399b166c69,4,"These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS.
 







TERIFLUNOMIDE tablets, for oral use
 



Initial U.S. Approval: 2012",1310520,teriflunomide,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240216_246d42e5-5418-42ba-aff9-ae399b166c69.json,246d42e5-5418-42ba-aff9-ae399b166c69,4,"These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS.
 







TERIFLUNOMIDE tablets, for oral use
 



Initial U.S. Approval: 2012",1310520,teriflunomide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240113_4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213.json,4ebe66e7-5e0d-41ff-8ef9-e4c30a65f213,6,"""These highlights do not include all the information needed to use CYCLOPHOSPHAMIDE CAPSULES safely and effectively"". ""See full prescribing information for CYCLOPHOSPHAMIDE CAPSULES.""
 



""CYCLOPHOSPHAMIDE capsules""
 

""Initial U.S. Approval: 1959""",3002,cyclophosphamide,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240118_b471eb51-488e-5312-e053-2a95a90a8116.json,b471eb51-488e-5312-e053-2a95a90a8116,5,"These highlights do not include all the information needed to use FULVESTRANT INJECTION safely and effectively. See full prescribing information for FULVESTRANT INJECTION.
 
FULVESTRANT injection, for intramuscular use
 
Initial U.S. Approval: 2002",282357,fulvestrant,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240106_bc9c338c-1fc7-4bc2-a357-a78e433cbe9d.json,bc9c338c-1fc7-4bc2-a357-a78e433cbe9d,6,"Cefpodoxime Proxetil Tablets, USP
 Rx only",20489,cefpodoxime,10067125,liver injury,500000301,acute liver injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210508_a20eb852-4c25-49f0-98bc-aed493336e75.json,a20eb852-4c25-49f0-98bc-aed493336e75,12,"These highlights do not include all the information needed to use PRALUENT safely and effectively.  See full prescribing information for PRALUENT. 
PRALUENT® (alirocumab) injection, for subcutaneous use Initial U.S. Approval:  2015",1659152,alirocumab,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231202_2c631ce7-ea15-4b51-b5bc-4962e3c315cd.json,2c631ce7-ea15-4b51-b5bc-4962e3c315cd,3,"FLUOROURACIL TOPICAL SOLUTION Rx only  FOR TOPICAL USE ONLY  NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE",4492,fluorouracil,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240119_08b7ee65-53a5-ffbb-e063-6294a90ad4ee.json,08b7ee65-53a5-ffbb-e063-6294a90ad4ee,9,Chlorthalidone Tablets USP 25mg and 50mg,2409,chlorthalidone,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230527_7974d4ad-c419-4c7f-bbd6-f631d53e30de.json,7974d4ad-c419-4c7f-bbd6-f631d53e30de,3,"These highlights do not include all the information needed to use TRANYLCYPROMINE SULFATE TABLETS safely and effectively. See full prescribing information for TRANYLCYPROMINE SULFATE TABLETS.TRANYLCYPROMINE SULFATE USP tablets, for oral useInitial U.S. Approval: 1961",10734,tranylcypromine,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20210905_32fd2bb2-1cfa-4250-feb8-d7956c794e05.json,32fd2bb2-1cfa-4250-feb8-d7956c794e05,16,"These highlights do not include all the information needed to use MYLOTARG safely and effectively. See full prescribing information for MYLOTARG.
 MYLOTARG™ (gemtuzumab ozogamicin) for injection, for intravenous use Initial U.S. Approval: 2000",1294580,gemtuzumab ozogamicin,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231012_0772eb61-ca42-39de-e063-6294a90a6632.json,0772eb61-ca42-39de-e063-6294a90a6632,1,"SUNITINIB MALATE
 

These highlights do not include all the information needed to use SUNITINIB MALATE CAPSULES safely and effectively. See full prescribing information for SUNITINIB MALATE CAPSULES.
 

Initial U.S. Approval: 2006",357977,sunitinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240130_a68d1eff-5cbb-4a6e-98e7-0fb6590ce2a0.json,a68d1eff-5cbb-4a6e-98e7-0fb6590ce2a0,13,"ADENOSINE INJECTION, USP",296,adenosine,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240223_cfeab9e3-58b9-4890-9185-11b62904e2af.json,cfeab9e3-58b9-4890-9185-11b62904e2af,13,Metronidazole Tablets USP,6922,metronidazole,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240124_0d6111be-aabe-88e2-e063-6394a90a3963.json,0d6111be-aabe-88e2-e063-6394a90a3963,2,"These highlights do not include all the information needed to use MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS.


MYCOPHENOLIC ACID delayed-release tablets, for oral use

Initial U.S. Approval: 2004",7145,mycophenolic acid,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231115_fb77637a-88d9-4aea-958f-e270030ce30d.json,fb77637a-88d9-4aea-958f-e270030ce30d,18,"These highlights do not include all the information needed to use BAXDELA® safely and effectively. See full prescribing information for BAXDELA. 
BAXDELA (delafloxacin) tablets, for oral use BAXDELA (delafloxacin) for injection, for intravenous use Initial U.S. Approval: 2017",1927663,delafloxacin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240126_55ad6325-16f6-4f0c-a1dc-734847052d0b.json,55ad6325-16f6-4f0c-a1dc-734847052d0b,2,"Danazol Capsules, USP
 

Rx only",3102,danazol,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/train_xml/20230802_2150f73a-179b-4afc-b8ce-67c85cc72f04.json,2150f73a-179b-4afc-b8ce-67c85cc72f04,60,"These highlights do not include all the information needed to use AFINITOR/AFINITOR DISPERZ safely and effectively. See full prescribing information for AFINITOR/AFINITOR DISPERZ.


AFINITOR® (everolimus) tablets, for oral use

AFINITOR DISPERZ® (everolimus tablets for oral suspension)

Initial U.S. Approval: 2009",141704,everolimus,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240219_06f442d6-071e-4081-b7f7-40f3b803ab3f.json,06f442d6-071e-4081-b7f7-40f3b803ab3f,4,"These highlights do not include all the information needed to use SORAFENIB TABLETS safely and effectively.
 
See full prescribing information for SORAFENIB TABLETS.
 
Sorafenib tablets, for oral use
 
Initial U.S. Approval: 2005",495881,sorafenib,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/gold_xml/20220916_c9a1d0a8-581f-4f91-a2b8-f419192d0ebf.json,c9a1d0a8-581f-4f91-a2b8-f419192d0ebf,12,"These highlights do not include all the information needed to use DALIRESP safely and effectively. See full prescribing information for DALIRESP.
DALIRESP® (roflumilast) tabletsInitial U.S. Approval: 2011",1091836,roflumilast,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,d5929f91-6496-4c0e-97e8-0bd524e15763,3,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240102_adc84ad5-a04d-4fee-9ba8-91f7abd928e3.json,adc84ad5-a04d-4fee-9ba8-91f7abd928e3,29,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. 
BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/train_xml/20220817_d5929f91-6496-4c0e-97e8-0bd524e15763.json,d5929f91-6496-4c0e-97e8-0bd524e15763,3,"These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF.
 BOSULIF® (bosutinib) tablets, for oral use Initial U.S. Approval: 2012",1307619,bosutinib,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/train_xml/20221118_a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330.json,a6826aa3-fabb-4ff1-a7a3-cd4c34e3a330,4,"These highlights do not include all the information needed to use Cleviprex safely and effectively. See full prescribing information for Cleviprex.
 



Cleviprex (clevidipine) injectable emulsion, for intravenous use
 

Initial U.S. Approval: 2008",233603,clevidipine,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240116_9583405d-53a0-49dc-88eb-5e6384ebabcb.json,9583405d-53a0-49dc-88eb-5e6384ebabcb,6,"These highlights do not include all the information needed to use BESREMi safely and effectively. See full prescribing information for BESREMi. BESREMI (ropeginterferon alfa-2b-njft) injection, for subcutaneous use Initial U.S. Approval: 2021",2587059,ropeginterferon alfa-2b,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230325_294b168b-6e5f-4db9-bf70-d599271458b3.json,294b168b-6e5f-4db9-bf70-d599271458b3,6,These highlights do not include all the information needed to use ZOLADEX safely and effectively. See full prescribing information for ZOLADEX.ZOLADEX® (goserelin implant) 3.6 mgInitial U.S. Approval: 1989,50610,goserelin,10038435,renal failure,500000401,acute kidney injury,20,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240224_88441a9f-b4f9-455d-a355-46fb30699a7b.json,88441a9f-b4f9-455d-a355-46fb30699a7b,10,"Sulfasalazine Tablets, USP",9524,sulfasalazine,10024690,liver function test abnormal,500000301,acute liver injury,15,1,,,,
./data/2024_latest_labels/train_xml/20221029_ea66eb30-e665-4693-99a1-a9d3b4bbe2d6.json,ea66eb30-e665-4693-99a1-a9d3b4bbe2d6,54,"These highlights do not include all the information needed to use KYPROLIS safely and effectively. See full prescribing information for KYPROLIS. 
KYPROLIS® (carfilzomib) for injection, for intravenous use Initial U.S. Approval: 2012",1302966,carfilzomib,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231005_499ab990-2b21-474f-aaba-d86388965f40.json,499ab990-2b21-474f-aaba-d86388965f40,9,"These highlights do not include all the information needed to use ARIKAYCE safely and effectively. See full prescribing information for ARIKAYCE. 
ARIKAYCE® (amikacin liposome inhalation suspension), for oral inhalation use Initial U.S. Approval: 2018 LIMITED POPULATION",641,amikacin,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/gold_xml/20221115_16d804b6-4957-43ee-b18c-3b36ec37c5ac.json,16d804b6-4957-43ee-b18c-3b36ec37c5ac,15,"These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. 
ICLUSIG® (ponatinib) tablets, for oral use Initial U.S. Approval: 2012",1364347,ponatinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230101_2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.json,2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13,46,"These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. 
 ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use  Initial U.S. Approval: 2010",612865,tocilizumab,10062685,hepatic enzyme abnormal,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_fedfd1db-7e32-44b2-89e9-7bb00ee6810d.json,fedfd1db-7e32-44b2-89e9-7bb00ee6810d,24,"Sojourn®
 
Sevoflurane, USP
 
Volatile Liquid for Inhalation",36453,sevoflurane,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230204_f27eb1b9-b7fc-424e-988f-84dd7bb195a3.json,f27eb1b9-b7fc-424e-988f-84dd7bb195a3,6,"These highlights do not include all the information needed to use TUKYSA safely and effectively. See full prescribing information for TUKYSA.
TUKYSA® (tucatinib) tablets, for oral use Initial U.S. Approval: 2020",2361285,tucatinib,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230406_2eda833b-1357-4ed4-a093-194524fcb061.json,2eda833b-1357-4ed4-a093-194524fcb061,25,"These highlights do not include all the information needed to use THALOMID® safely and effectively. See full prescribing information for THALOMID. 
THALOMID (thalidomide) capsules, for oral use Initial U.S. Approval: 1998",10432,thalidomide,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240210_9c44bd5b-4464-40a4-8933-8680950f00f2.json,9c44bd5b-4464-40a4-8933-8680950f00f2,29,"These highlights do not include all the information needed to use AMJEVITA™ safely and effectively. See full prescribing information for AMJEVITA. 
 AMJEVITA (adalimumab-atto) injection, for subcutaneous use    Initial U.S. Approval: 2016 
 AMJEVITA (adalimumab-atto) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of AMJEVITA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA® (adalimumab).",327361,adalimumab,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240118_d1cda4f7-cb33-46ea-b9ac-431f6452b1a5.json,d1cda4f7-cb33-46ea-b9ac-431f6452b1a5,23,"These highlights do not include all the information needed to use ERLEADA safely and effectively. See full prescribing information for ERLEADA.
 



ERLEADA 
 ®(apalutamide) tablets, for oral use
 

Initial U.S. Approval – 2018",1999574,apalutamide,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230803_cf94c7fc-13a0-4ac9-bb85-9c38aa704d35.json,cf94c7fc-13a0-4ac9-bb85-9c38aa704d35,5,"These highlights do not include all the information needed to use FERUMOXYTOL INJECTION safely and effectively. See full prescribing information for FERUMOXYTOL INJECTION. 
	FERUMOXYTOL injection, for intravenous use 	Initial U.S. Approval: 2009",473387,ferumoxytol,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/train_xml/20230516_2e8ef36b-71fa-4492-a16f-577d5f7d111d.json,2e8ef36b-71fa-4492-a16f-577d5f7d111d,7,"These highlights do not include all the information needed to use BELEODAQ safely and effectively. See full prescribing information for BELEODAQ.
 BELEODAQ® (belinostat) for injection, for intravenous use Initial U.S. Approval: 2014",1543543,belinostat,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230528_645c887c-8cd4-4623-8da9-ac223d71a8b9.json,645c887c-8cd4-4623-8da9-ac223d71a8b9,8,"These highlights do not include all the information needed to use AYVAKIT safely and effectively. See full prescribing information for AYVAKIT.
 AYVAKIT® (avapritinib) tablets, for oral use Initial U.S. Approval: 2020",2272107,avapritinib,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230613_90073508-6dca-4d27-aa5a-ed837737c35b.json,90073508-6dca-4d27-aa5a-ed837737c35b,1,"These highlights do not include all the information needed to use REZZAYO safely and effectively. See full prescribing information for REZZAYO.
 REZZAYO™ (rezafungin for injection), for intravenous useInitial U.S. Approval: 2023",2639155,rezafungin,10017955,gastrointestinal haemorrhage,500001001,gi bleed,21,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,2265ef30-253e-11df-8a39-0800200c9a66,42,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011",1094833,ipilimumab,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/train_xml/20230630_2265ef30-253e-11df-8a39-0800200c9a66.json,2265ef30-253e-11df-8a39-0800200c9a66,42,"These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. 
YERVOY® (ipilimumab) injection, for intravenous useInitial U.S. Approval: 2011",1094833,ipilimumab,10019837,hepatocellular injury,500000301,acute liver injury,3,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240112_7714a0ed-34bb-46e6-a0a5-b363908b22c2.json,7714a0ed-34bb-46e6-a0a5-b363908b22c2,25,"These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
PROMACTA® (eltrombopag) tablets, for oral usePROMACTA® (eltrombopag) for oral suspensionInitial U.S. Approval: 2008",711942,eltrombopag,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20230817_44492772-5aed-4627-bd85-e8e89f308bb3.json,44492772-5aed-4627-bd85-e8e89f308bb3,12,"These highlights do not include all the information needed to use MAYZENT safely and effectively. See full prescribing information for MAYZENT.


MAYZENT® (siponimod) tablets, for oral use

Initial U.S. Approval: 2019",2121085,siponimod,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/train_xml/20230910_fa7d93e3-b69b-4e02-8146-89760cd8e9d6.json,fa7d93e3-b69b-4e02-8146-89760cd8e9d6,6,"These highlights do not include all the information needed to use 
STENDRA
 safely and effectively.  See full prescribing information for 
STENDRA
.



STENDRA

®

 (avanafil) 
tablets, for oral use

Initial U.S. Approval:  
2012",1291301,avanafil,10028596,myocardial infarction,500000801,acute myocardial infarction,29,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231230_b5631d3e-4604-4363-8f20-11dfc5a4a8ed.json,b5631d3e-4604-4363-8f20-11dfc5a4a8ed,13,"These highlights do not include all the information needed to use PADCEV safely and effectively. See full prescribing information for PADCEV.
PADCEV® (enfortumab vedotin-ejfv) for injection, for intravenous useInitial U.S. Approval: 2019",2268307,enfortumab,10069339,acute kidney injury,500000401,acute kidney injury,6,1,,,,
./data/2024_latest_labels/train_xml/20230907_1a0c3bea-c87b-4d25-bb44-5f0174da6b34.json,1a0c3bea-c87b-4d25-bb44-5f0174da6b34,14,"These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.
COMETRIQ® (cabozantinib) capsules, for oral useInitial U.S. Approval: 2012",1363268,cabozantinib,10060795,hepatic enzyme increased,500000301,acute liver injury,14,1,,,,
./data/2024_latest_labels/train_xml/20231122_2a51b0de-47d6-455e-a94c-d2c737b04ff7.json,2a51b0de-47d6-455e-a94c-d2c737b04ff7,43,"These highlights do not include all the information needed to use XALKORI® safely and effectively. See full prescribing information for XALKORI. 
XALKORI® (crizotinib) capsules, for oral useXALKORI® (crizotinib) oral pelletsInitial U.S. Approval: 2011",1148495,crizotinib,10019663,hepatic failure,500000301,acute liver injury,45,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20240131_5cd725a1-2fa4-408a-a651-57a7b84b2118.json,5cd725a1-2fa4-408a-a651-57a7b84b2118,18,"These highlights do not include all the information needed to use BAVENCIO safely and effectively. See full prescribing information for BAVENCIO.
 BAVENCIO® (avelumab) injection, for intravenous use Initial U.S. Approval: 2017",1875534,avelumab,10062237,renal impairment,500000401,acute kidney injury,8,1,,,,
./data/2024_latest_labels/latest_labels_ingredients/20231020_84137882-e000-47da-bd5b-fa76ab3c76f9.json,84137882-e000-47da-bd5b-fa76ab3c76f9,20,"These highlights do not include all the information needed to use INLYTA safely and effectively. See full prescribing information for INLYTA. 
INLYTA® (axitinib) tablets, for oral administration Initial U.S. Approval: 2012",1242999,axitinib,10019851,hepatotoxicity,500000301,acute liver injury,28,1,,,,
